Spaces:
Sleeping
Sleeping
Upload 16 files
Browse files- MEDICINE_TXT/Chapter_01_Pain_Relievers_Analgesics.txt +190 -0
- MEDICINE_TXT/Chapter_02_NSAIDs.txt +147 -0
- MEDICINE_TXT/Chapter_03_Antipyretics.txt +98 -0
- MEDICINE_TXT/Chapter_04_Antacids.txt +115 -0
- MEDICINE_TXT/Chapter_05_Antihistamines.txt +183 -0
- MEDICINE_TXT/Chapter_06_Decongestants.txt +4851 -0
- MEDICINE_TXT/Chapter_07_Cough_Suppressants.txt +138 -0
- MEDICINE_TXT/Chapter_08_Expectorants.txt +150 -0
- MEDICINE_TXT/Chapter_09_Topical_Analgesics.txt +228 -0
- MEDICINE_TXT/Chapter_10_Laxatives.txt +315 -0
- MEDICINE_TXT/Chapter_11_Antifungals.txt +242 -0
- MEDICINE_TXT/Chapter_12_Acne_Medications.txt +264 -0
- MEDICINE_TXT/Chapter_13_Motion_Sickness_Medications.txt +233 -0
- MEDICINE_TXT/Chapter_14_Anti_Diarrheals.txt +183 -0
- MEDICINE_TXT/Chapter_15_Oral_Rehydration_Solutions.txt +242 -0
- MEDICINE_TXT/Chapter_16_Sleep_Aids.txt +251 -0
MEDICINE_TXT/Chapter_01_Pain_Relievers_Analgesics.txt
ADDED
|
@@ -0,0 +1,190 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
1
|
| 3 |
+
|
| 4 |
+
Pain Relievers / Analgesics
|
| 5 |
+
Dr. Girish Kumar Vyas
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Analgesics, often known as painkillers or relievers, are the mainstay of over-the-counter (OTC)
|
| 9 |
+
medication for easing pain without making you fall asleep or cause unconsciousness. This type of
|
| 10 |
+
over-the-counter drugs comes in convenient formats such liquids for easy administration, oral pills,
|
| 11 |
+
and capsules to accommodate a range of preferences. Additionally, suppositories give an alternate
|
| 12 |
+
mode of delivery, while topical treatments like lotions, gels, and ointments offer localized relief. The
|
| 13 |
+
kind and length of use of over-the-counter analgesics might affect their negative effects, just like with
|
| 14 |
+
any medication. Potential adverse effects that users can experience include constipation, sleepiness, or
|
| 15 |
+
dizziness.
|
| 16 |
+
Several analgesic medications are available over-the-counter (OTC) for pain relief. Here are some
|
| 17 |
+
common OTC analgesics:
|
| 18 |
+
1. Acetaminophen (Tylenol):- Acetaminophen is widely used for relieving mild to moderate pain
|
| 19 |
+
and reducing fever. It's often recommended for individuals who cannot take NSAIDs (Non-
|
| 20 |
+
Steroidal Anti-Inflammatory Drugs).
|
| 21 |
+
2. Ibuprofen (Advil, Motrin):- Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that
|
| 22 |
+
helps reduce pain, inflammation, and fever. It is commonly used for various types of pain,
|
| 23 |
+
including headaches, muscle aches, and menstrual pain.
|
| 24 |
+
3. Naproxen (Aleve):- Naproxen is another NSAID that provides pain relief and reduces
|
| 25 |
+
inflammation. It has a longer duration of action compared to ibuprofen, allowing for less
|
| 26 |
+
frequent dosing.
|
| 27 |
+
4. Aspirin:- Aspirin, also an NSAID, is known for its pain-relieving and anti-inflammatory
|
| 28 |
+
properties. It is often used to relieve minor aches and pains and reduce the risk of heart attacks
|
| 29 |
+
or strokes.
|
| 30 |
+
|
| 31 |
+
|
| 32 |
+
Pain Relievers / Analgesics | 1
|
| 33 |
+
|
| 34 |
+
--- End of Page 1 ---
|
| 35 |
+
|
| 36 |
+
Paracetamol:
|
| 37 |
+
Acetaminophen, a commonly utilized over-the-counter analgesic and antipyretic, is frequently
|
| 38 |
+
employed for managing mild-to-moderate pain and fever. While generally considered safe at
|
| 39 |
+
recommended doses, the potential for hepatotoxicity escalates significantly in cases of overdose,
|
| 40 |
+
leading to acute liver injury and, in severe instances, acute liver failure resulting in fatality.
|
| 41 |
+
Derived from p-aminophenol, acetaminophen exhibits analgesic and antipyretic properties. Although
|
| 42 |
+
the precise mechanism of action remains incompletely understood, acetaminophen is thought to
|
| 43 |
+
modulate the nitric oxide (NO) pathway. This modulation occurs through the inhibition of various
|
| 44 |
+
neurotransmitter receptors, including N-methyl-D-aspartate (NMDA) and substance P. Ultimately, this
|
| 45 |
+
process leads to an increased pain threshold.
|
| 46 |
+
|
| 47 |
+
[Chapter_01_Pain_Relievers_Analgesics_page2_img1.png]
|
| 48 |
+
|
| 49 |
+
|
| 50 |
+
Chemical Information:
|
| 51 |
+
- Chemical Name: N-(4-hydroxyphenyl) acetamide
|
| 52 |
+
- Chemical Structure:
|
| 53 |
+
|
| 54 |
+
[Chapter_01_Pain_Relievers_Analgesics_page2_img2.png]
|
| 55 |
+
|
| 56 |
+
|
| 57 |
+
Uses:
|
| 58 |
+
• Paracetamol encompasses anti-inflammatory, antipyretic, and analgesic properties.
|
| 59 |
+
• Widely utilized as a pain-relieving medication.
|
| 60 |
+
• Categorized under NSAIDs.
|
| 61 |
+
• Commonly used for conditions such as backache, headache, arthritis, and toothache.
|
| 62 |
+
Stability and Storage Conditions:Stored at 40°C +/- 2 degrees and Relative Humidity (RH) of 75%
|
| 63 |
+
+/- 5%, with the long-term stability storage condition specified at 25°C +/- 2 degrees and RH of 60%
|
| 64 |
+
+/- 5%.
|
| 65 |
+
2 | Pain Relievers / Analgesics
|
| 66 |
+
|
| 67 |
+
--- End of Page 2 ---
|
| 68 |
+
|
| 69 |
+
Safe and Unsafe Doses:
|
| 70 |
+
The safe and unsafe doses of paracetamol (acetaminophen) can vary based on factors such as age,
|
| 71 |
+
weight, and individual health conditions. It's essential to follow recommended guidelines and consult
|
| 72 |
+
with a healthcare professional for personalized advice. GenerallySafe Dose of Paracetamol:
|
| 73 |
+
● For adults: Typically, the standard dose is 500 mg to 1000 mg every 4-6 hours, not exceeding
|
| 74 |
+
4000 mg (4 grams) per day.
|
| 75 |
+
● For children: Dosing is weight-dependent. Pediatric formulations provide specific instructions
|
| 76 |
+
based on age and weight.
|
| 77 |
+
Marketed Brands:
|
| 78 |
+
● Crocin
|
| 79 |
+
● Metacin
|
| 80 |
+
● Calpol
|
| 81 |
+
● Dolo
|
| 82 |
+
● Sumo
|
| 83 |
+
● Kabimol
|
| 84 |
+
● Pyrigesic
|
| 85 |
+
Ibuprofen
|
| 86 |
+
Ibuprofen, a propionic acid derivative, is a non-steroidal anti-inflammatory drug (NSAID) with
|
| 87 |
+
analgesic, antipyretic, and anti-inflammatory properties. Developed in 1960 as the inaugural propionic
|
| 88 |
+
acid, it emerged as a safer alternative to aspirin. Ibuprofen's chemical structure involves propionic acid
|
| 89 |
+
with a substitution at position 2 by a 4-(2-methylpropyl) phenyl group. It acts as a cyclooxygenase
|
| 90 |
+
inhibitor, a xenobiotic, an environmental contaminant, and possesses roles as a radical scavenger, drug
|
| 91 |
+
allergen, and geroprotector.
|
| 92 |
+
|
| 93 |
+
[Chapter_01_Pain_Relievers_Analgesics_page3_img1.png]
|
| 94 |
+
|
| 95 |
+
|
| 96 |
+
Pain Relievers / Analgesics | 3
|
| 97 |
+
|
| 98 |
+
--- End of Page 3 ---
|
| 99 |
+
|
| 100 |
+
Chemical Information:
|
| 101 |
+
● Chemical Name: 2-[4-(2-methylpropyl) phenyl] propanoic acid
|
| 102 |
+
● Chemical Structure:
|
| 103 |
+
|
| 104 |
+
[Chapter_01_Pain_Relievers_Analgesics_page4_img1.png]
|
| 105 |
+
|
| 106 |
+
|
| 107 |
+
Uses:
|
| 108 |
+
• Utilized for pain relief.
|
| 109 |
+
• Effective in reducing fever.
|
| 110 |
+
Stability and Storage Conditions:Undiluted ibuprofen (5 mg/mL) stored in glass vials and ibuprofen
|
| 111 |
+
diluted to 2.5 mg/mL with either NS or D5W and stored in polypropylene syringes will maintain more
|
| 112 |
+
than 92% of its initial concentration with storage for up to 14 days at 4°C.
|
| 113 |
+
Safe and Unsafe Doses:
|
| 114 |
+
The safe dose of ibuprofen can vary depending on factors such as age, weight, and individual health
|
| 115 |
+
conditions. It's important to follow recommended guidelines and consult with a healthcare professional
|
| 116 |
+
for personalized advice. Generally, Safe Dose of Ibuprofen:
|
| 117 |
+
● For adults: The typical dose is 200 mg to 400 mg every 4-6 hours, not exceeding 1200 mg in a
|
| 118 |
+
24-hour period. However, lower doses are often effective for certain conditions.
|
| 119 |
+
● For children: Dosing is weight-dependent, and pediatric formulations provide specific
|
| 120 |
+
instructions based on age and weight.
|
| 121 |
+
Marketed Brands:
|
| 122 |
+
• Brufen
|
| 123 |
+
• Ibugesic
|
| 124 |
+
• Ximafen
|
| 125 |
+
• Icparil
|
| 126 |
+
FREQUENTLY ASKED QUESTION
|
| 127 |
+
Question: What is the recommended dosage for ibuprofen?
|
| 128 |
+
Answer: The recommended dosage of ibuprofen for adults is typically 200-400 milligrams every 4-6
|
| 129 |
+
hours as needed for pain relief. However, it's important to follow the instructions on the medication
|
| 130 |
+
label and consult with a healthcare professional for personalized dosing recommendations.
|
| 131 |
+
Question: Can I take acetaminophen if I have a history of liver problems?
|
| 132 |
+
Answer: Individuals with a history of liver problems should use acetaminophen with caution and
|
| 133 |
+
under the guidance of a healthcare professional. Excessive or prolonged use of acetaminophen can lead
|
| 134 |
+
to liver damage, especially when combined with alcohol or other medications that affect the liver. It's
|
| 135 |
+
essential to adhere to the recommended dosage and avoid exceeding the maximum daily limit.
|
| 136 |
+
4 | Pain Relievers / Analgesics
|
| 137 |
+
|
| 138 |
+
--- End of Page 4 ---
|
| 139 |
+
|
| 140 |
+
Question: What are some signs of opioid overdose?
|
| 141 |
+
Answer: Signs of opioid overdose include slowed or shallow breathing, extreme drowsiness or
|
| 142 |
+
difficulty waking up, confusion, pinpoint pupils, bluish lips or fingertips, and loss of consciousness. If
|
| 143 |
+
you suspect someone is experiencing an opioid overdose, call emergency services immediately and
|
| 144 |
+
administer naloxone if available.
|
| 145 |
+
Question: Is it safe to take NSAIDs on an empty stomach?
|
| 146 |
+
Answer: NSAIDs can irritate the stomach lining and increase the risk of gastrointestinal side effects,
|
| 147 |
+
such as ulcers and bleeding, especially when taken on an empty stomach. It's generally recommended
|
| 148 |
+
to take NSAIDs with food or milk to help reduce stomach upset and protect the digestive tract.
|
| 149 |
+
Question: Can I drive or operate machinery while taking opioid pain medication?
|
| 150 |
+
Answer: Opioid pain medications can cause drowsiness, dizziness, and impaired judgment, which can
|
| 151 |
+
affect your ability to drive or operate machinery safely. It's important to avoid driving or engaging in
|
| 152 |
+
activities that require mental alertness until you know how the medication affects you. Be sure to read
|
| 153 |
+
the medication label for specific warnings and precautions.
|
| 154 |
+
Question: What is the difference between NSAIDs and acetaminophen in terms of pain relief?
|
| 155 |
+
Answer: NSAIDs (nonsteroidal anti-inflammatory drugs) such as ibuprofen and naproxen work by
|
| 156 |
+
reducing inflammation, which can help alleviate pain associated with conditions like arthritis and
|
| 157 |
+
muscle strains. Acetaminophen, on the other hand, primarily works as a pain reliever and fever reducer
|
| 158 |
+
but does not have anti-inflammatory effects. It is often used to manage mild to moderate pain and is
|
| 159 |
+
less likely to cause stomach irritation compared to NSAIDs.
|
| 160 |
+
Question: How do opioid analgesics work to relieve pain?
|
| 161 |
+
Answer: Opioid analgesics, such as oxycodone, hydrocodone, and codeine, work by binding to opioid
|
| 162 |
+
receptors in the brain and spinal cord, blocking pain signals and producing feelings of euphoria and
|
| 163 |
+
relaxation. While effective for managing severe pain, opioids carry a risk of addiction, tolerance, and
|
| 164 |
+
overdose, so they are typically reserved for short-term use or severe pain that does not respond to other
|
| 165 |
+
treatments.
|
| 166 |
+
Question: What are some common side effects of NSAIDs?
|
| 167 |
+
Answer: Common side effects of NSAIDs include stomach upset, heartburn, nausea, vomiting,
|
| 168 |
+
diarrhea, and bloating. Long-term use of NSAIDs can also increase the risk of gastrointestinal
|
| 169 |
+
bleeding, ulcers, kidney damage, and cardiovascular events such as heart attack and stroke. It's
|
| 170 |
+
important to take NSAIDs as directed and to avoid using them for extended periods without medical
|
| 171 |
+
supervision.
|
| 172 |
+
Pain Relievers / Analgesics | 5
|
| 173 |
+
|
| 174 |
+
--- End of Page 5 ---
|
| 175 |
+
|
| 176 |
+
Question: Can acetaminophen be used in combination with NSAIDs?
|
| 177 |
+
Answer: Yes, acetaminophen can often be used in combination with NSAIDs for enhanced pain relief,
|
| 178 |
+
as they work through different mechanisms. However, it's important to avoid exceeding the
|
| 179 |
+
recommended dosage of either medication and to be cautious of potential interactions or side effects,
|
| 180 |
+
especially if you have underlying health conditions or are taking other medications.
|
| 181 |
+
Question: When should I seek medical attention for pain relief?
|
| 182 |
+
Answer: It's essential to seek medical attention if you experience severe or persistent pain that does not
|
| 183 |
+
respond to over-the-counter pain medications, as it may be a sign of a more serious underlying
|
| 184 |
+
condition. Additionally, if you experience adverse reactions or side effects from pain medications, such
|
| 185 |
+
as allergic reactions, difficulty breathing, or changes in mental status, seek medical help immediately.
|
| 186 |
+
|
| 187 |
+
6 | Pain Relievers / Analgesics
|
| 188 |
+
|
| 189 |
+
--- End of Page 6 ---
|
| 190 |
+
|
MEDICINE_TXT/Chapter_02_NSAIDs.txt
ADDED
|
@@ -0,0 +1,147 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
2
|
| 3 |
+
|
| 4 |
+
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
|
| 5 |
+
Dr. Nitin Nama
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) constitute a widely used class of medications
|
| 9 |
+
known for their ability to alleviate pain, reduce inflammation, and lower fever. Commonly available
|
| 10 |
+
over-the-counter or through prescription, NSAIDs function by inhibiting enzymes involved in the
|
| 11 |
+
production of prostaglandins, substances that play a key role in the inflammatory response. These
|
| 12 |
+
drugs are frequently employed to manage conditions such as arthritis, muscle aches, and headaches.
|
| 13 |
+
While NSAIDs provide effective relief for various ailments, it is essential to use them judiciously,
|
| 14 |
+
considering potential side effects and individual health factors. Consulting with a healthcare
|
| 15 |
+
professional ensures safe and appropriate use of NSAIDs for optimal therapeutic benefits.
|
| 16 |
+
Over-the-Counter (OTC) NSAIDs, available without a prescription, mainly fall into the category of
|
| 17 |
+
traditional NSAIDs. A simplified classification is given below:
|
| 18 |
+
1. Non-Selective COX Inhibitors:
|
| 19 |
+
● Ibuprofen: Widely used for pain relief and fever reduction. Brands include Advil and Motrin.
|
| 20 |
+
(Explained in Analgesics Category)
|
| 21 |
+
● Naproxen: Commonly used for various types of pain. Brands include Aleve.
|
| 22 |
+
2. Acetylsalicylic Acid (Aspirin):
|
| 23 |
+
● Though not exclusively OTC, aspirin is widely available without a prescription. It has analgesic,
|
| 24 |
+
anti-inflammatory, and antipyretic properties. Brands include Bayer and Bufferin.
|
| 25 |
+
It is crucial to follow recommended dosages and usage instructions when using OTC NSAIDs.
|
| 26 |
+
Individuals with specific health conditions or those taking other medications should consult a
|
| 27 |
+
healthcare professional before using these medications.
|
| 28 |
+
Aspirin
|
| 29 |
+
Aspirin, or acetylsalicylic acid, is a widely used analgesic and antipyretic with over a century of
|
| 30 |
+
clinical history. However, caution is warranted, as high doses may cause liver injury, occasionally
|
| 31 |
+
resulting in jaundice or dysfunction. Administered in lower doses to susceptible children with a febrile
|
| 32 |
+
illness, it can contribute to Reye syndrome. As a non-steroidal anti-inflammatory agent, aspirin
|
| 33 |
+
decreases prostaglandin synthesis, platelet aggregation, and inflammation, offering analgesic,
|
| 34 |
+
antipyretic, and anticoagulant properties.
|
| 35 |
+
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | 7
|
| 36 |
+
|
| 37 |
+
--- End of Page 1 ---
|
| 38 |
+
|
| 39 |
+
Chemical Information:
|
| 40 |
+
● Chemical Name: 2-acetyloxybenzoic acid
|
| 41 |
+
● Chemical Structure:
|
| 42 |
+
|
| 43 |
+
[Chapter_02_NSAIDs_page2_img1.png]
|
| 44 |
+
|
| 45 |
+
|
| 46 |
+
Applications:
|
| 47 |
+
• Used for angina (heart-related chest pain).
|
| 48 |
+
• Employed in the treatment of heart attacks and strokes.
|
| 49 |
+
Stability and Storage Conditions:Commonly stored at 40°C +/- 2 degrees and Relative Humidity
|
| 50 |
+
(RH) of 75% +/- 5%. Long-term stability storage condition for the product is 25°C +/- 2 degrees and
|
| 51 |
+
RH of 60% +/- 5%.
|
| 52 |
+
Safe dose of Aspirin:The safe dose of aspirin for adults can vary based on individual health conditions
|
| 53 |
+
and the reason for use.
|
| 54 |
+
|
| 55 |
+
[Chapter_02_NSAIDs_page2_img2.png]
|
| 56 |
+
|
| 57 |
+
|
| 58 |
+
It is important to follow the guidance of a healthcare professional or the specific instructions provided
|
| 59 |
+
on the medication packaging. However, for general reference:
|
| 60 |
+
- Pain Relief and Fever:
|
| 61 |
+
● Standard dose: 325 mg to 650 mg every 4-6 hours as needed.
|
| 62 |
+
● Maximum dose: Up to 4,000 mg (4 grams) per day.
|
| 63 |
+
Cardiovascular Protection:- For individuals using aspirin for cardiovascular protection (such as
|
| 64 |
+
preventing heart attacks or strokes), the recommended dose is often lower and typically determined by
|
| 65 |
+
a healthcare provider.
|
| 66 |
+
It is crucial to adhere to the recommended dosage and not exceed the maximum daily limit without
|
| 67 |
+
consulting a healthcare professional. Aspirin should be taken with food or a glass of milk to minimize
|
| 68 |
+
the risk of gastrointestinal irritation. Additionally, individuals with specific health conditions or those
|
| 69 |
+
taking other medications should consult their healthcare provider before using aspirin to ensure its
|
| 70 |
+
safety and effectiveness for their situation.
|
| 71 |
+
8 | Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
|
| 72 |
+
|
| 73 |
+
--- End of Page 2 ---
|
| 74 |
+
|
| 75 |
+
Marketed Brands:
|
| 76 |
+
• Ecosprin
|
| 77 |
+
• Loprin
|
| 78 |
+
• Delisprin
|
| 79 |
+
• Aspeeday
|
| 80 |
+
Naproxen
|
| 81 |
+
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), is widely utilized for its analgesic and
|
| 82 |
+
anti-inflammatory properties. It functions by inhibiting the production of prostaglandins, substances in
|
| 83 |
+
the body that contribute to pain and inflammation.
|
| 84 |
+
|
| 85 |
+
[Chapter_02_NSAIDs_page3_img1.png]
|
| 86 |
+
|
| 87 |
+
|
| 88 |
+
Typically prescribed for conditions like arthritis, menstrual cramps, and various inflammatory
|
| 89 |
+
conditions, naproxen provides relief by reducing pain, swelling, and stiffness. Available in different
|
| 90 |
+
formulations.
|
| 91 |
+
Chemical Name: (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
|
| 92 |
+
Chemical Structure:
|
| 93 |
+
|
| 94 |
+
[Chapter_02_NSAIDs_page3_img2.png]
|
| 95 |
+
|
| 96 |
+
|
| 97 |
+
Uses:
|
| 98 |
+
● Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) used primarily for relieving pain
|
| 99 |
+
and reducing inflammation.
|
| 100 |
+
● It is commonly prescribed for conditions such as arthritis, menstrual cramps, and inflammatory
|
| 101 |
+
disorders.
|
| 102 |
+
Stability and Storage Conditions:
|
| 103 |
+
● Typically stored at room temperature, away from light and moisture.
|
| 104 |
+
● Specific storage conditions may vary by formulation and manufacturer.
|
| 105 |
+
Safe Dose for Adults:
|
| 106 |
+
● The typical dose for pain relief ranges from 250 mg to 500 mg twice daily.
|
| 107 |
+
● For chronic conditions like arthritis, the dosage may be higher, up to 1,500 mg per day.
|
| 108 |
+
Marketed Brands:
|
| 109 |
+
Naproxen is available under various brand names, including Aleve, Naprosyn, Anaprox.
|
| 110 |
+
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | 9
|
| 111 |
+
|
| 112 |
+
--- End of Page 3 ---
|
| 113 |
+
|
| 114 |
+
FREQUENTLY ASKED QUESTIONS
|
| 115 |
+
Question: What are NSAIDs?
|
| 116 |
+
Answer: NSAIDs (nonsteroidal anti-inflammatory drugs) are a class of medications commonly used to
|
| 117 |
+
relieve pain, reduce inflammation, and lower fever.
|
| 118 |
+
Question: How do NSAIDs work?
|
| 119 |
+
Answer: NSAIDs work by inhibiting the enzymes COX-1 and COX-2, which are involved in the
|
| 120 |
+
production of prostaglandins, substances that promote inflammation, pain, and fever.
|
| 121 |
+
Question: What conditions are NSAIDs commonly used to treat?
|
| 122 |
+
Answer: NSAIDs are commonly used to treat conditions such as arthritis, menstrual cramps,
|
| 123 |
+
headaches, muscle aches, dental pain, and minor injuries like sprains and strains.
|
| 124 |
+
Question: What are some common examples of NSAIDs?
|
| 125 |
+
Answer: Common examples of NSAIDs include ibuprofen (Advil, Motrin), naproxen (Aleve), aspirin,
|
| 126 |
+
diclofenac (Voltaren), and celecoxib (Celebrex).
|
| 127 |
+
Question: What are some potential side effects of NSAIDs?
|
| 128 |
+
Answer: Potential side effects of NSAIDs include stomach upset, heartburn, nausea, vomiting,
|
| 129 |
+
diarrhea, gastrointestinal ulcers or bleeding, kidney damage, and increased risk of cardiovascular
|
| 130 |
+
events like heart attack and stroke.
|
| 131 |
+
Question: Can NSAIDs be taken with food?
|
| 132 |
+
Answer: Yes, taking NSAIDs with food or milk can help reduce the risk of stomach upset and
|
| 133 |
+
gastrointestinal side effects.
|
| 134 |
+
Question: Are NSAIDs safe for everyone to take?
|
| 135 |
+
Answer: While NSAIDs are generally safe for most people when used as directed, they may not be
|
| 136 |
+
suitable for individuals with certain health conditions such as kidney disease, gastrointestinal ulcers, or
|
| 137 |
+
a history of heart disease. It's important to consult with a healthcare professional before using NSAIDs,
|
| 138 |
+
especially on a long-term basis or in high doses.
|
| 139 |
+
Question: Can NSAIDs be used to treat COVID-19?
|
| 140 |
+
Answer: While some initial studies suggested that NSAIDs might worsen outcomes in COVID-19
|
| 141 |
+
patients, more recent evidence suggests that NSAIDs can be safely used to manage symptoms such as
|
| 142 |
+
fever and body aches in individuals with COVID-19. However, it's essential to follow the advice of
|
| 143 |
+
healthcare professionals and adhere to treatment guidelines.
|
| 144 |
+
10 | Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
|
| 145 |
+
|
| 146 |
+
--- End of Page 4 ---
|
| 147 |
+
|
MEDICINE_TXT/Chapter_03_Antipyretics.txt
ADDED
|
@@ -0,0 +1,98 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
3
|
| 3 |
+
|
| 4 |
+
Antipyretics
|
| 5 |
+
Dr. Harshita Jain
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Antipyretics are a class of medications or substances that are primarily used to reduce fever (pyrexia).
|
| 9 |
+
They work by lowering the body's temperature, which is elevated during fever episodes typically
|
| 10 |
+
caused by infections or inflammatory conditions. Antipyretics help alleviate discomfort associated with
|
| 11 |
+
fever and may also relieve other symptoms such as headaches and muscle aches. Common antipyretics
|
| 12 |
+
include acetaminophen (Tylenol), ibuprofen (Advil, Motrin), aspirin, and naproxen (Aleve). These
|
| 13 |
+
medications are available over-the-counter and are often used to manage fevers in both adults and
|
| 14 |
+
children.
|
| 15 |
+
Acetaminophen, commonly known by its brand name Tylenol, is a widely used over-the-counter
|
| 16 |
+
analgesic (pain reliever) and antipyretic (fever reducer). It is considered one of the safest and most
|
| 17 |
+
effective medications for mild to moderate pain and fever. Acetaminophen is available in various
|
| 18 |
+
forms, including tablets, capsules, liquid suspension, and suppositories, making it convenient for
|
| 19 |
+
different age groups and medical conditions.
|
| 20 |
+
Chemical Information:
|
| 21 |
+
● Chemical Name: Acetaminophen
|
| 22 |
+
● Chemical Structure: Acetaminophen has the chemical formula C8H9NO2.
|
| 23 |
+
● Its chemical structure is:
|
| 24 |
+
|
| 25 |
+
[Chapter_03_Antipyretics_page1_img1.png]
|
| 26 |
+
|
| 27 |
+
|
| 28 |
+
Uses:
|
| 29 |
+
● Pain Relief: Acetaminophen is commonly used to relieve mild to moderate pain caused by
|
| 30 |
+
conditions such as headaches, muscle aches, arthritis, toothaches, backaches, menstrual cramps,
|
| 31 |
+
and colds.
|
| 32 |
+
● Fever Reduction: It is also effective in reducing fever associated with various illnesses, including
|
| 33 |
+
the common cold, flu, and other infections.
|
| 34 |
+
● Combination Therapies: Acetaminophen is often combined with other medications, such as
|
| 35 |
+
opioids (e.g., codeine) or nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, to
|
| 36 |
+
enhance pain relief.
|
| 37 |
+
Antipyretics | 11
|
| 38 |
+
|
| 39 |
+
--- End of Page 1 ---
|
| 40 |
+
|
| 41 |
+
Stability and Storage Conditions:
|
| 42 |
+
● Stability: Acetaminophen is generally stable when stored properly as per the standard
|
| 43 |
+
mentioned conditions.
|
| 44 |
+
● Storage Conditions: It should be stored at room temperature, away from moisture and heat.
|
| 45 |
+
Avoid storing it in the bathroom or kitchen, where moisture and temperature fluctuations can
|
| 46 |
+
affect its stability. Keep it out of reach of children and pets to prevent accidental ingestion.
|
| 47 |
+
Safe Dose for Adults:
|
| 48 |
+
The recommended adult dose of acetaminophen varies depending on the formulation and strength.
|
| 49 |
+
However, the typical maximum daily dose for adults is 4,000 milligrams (mg) or 4 grams. It's
|
| 50 |
+
important to follow the dosing instructions on the product label or as directed by a healthcare
|
| 51 |
+
professional to avoid overdose and potential liver damage.
|
| 52 |
+
Marketed Brands:
|
| 53 |
+
Apart from the brand name, acetaminophen is available under various other brand names worldwide.
|
| 54 |
+
Some of the commonly marketed brands include:
|
| 55 |
+
● Tylenol
|
| 56 |
+
● Panadol
|
| 57 |
+
● Anacin-3
|
| 58 |
+
● Feverall
|
| 59 |
+
● Mapap
|
| 60 |
+
● Tempra
|
| 61 |
+
Note:Always consult a healthcare professional before using acetaminophen, especially if you have any
|
| 62 |
+
pre-existing medical conditions or are taking other medications, to ensure its safety and effectiveness
|
| 63 |
+
for your specific situation.
|
| 64 |
+
FREQUENTLY ASKED QUESTIONS
|
| 65 |
+
Question: What are antipyretics?
|
| 66 |
+
Answer: Antipyretics are medications used to lower fever by reducing body temperature.
|
| 67 |
+
Question: How do antipyretics work?
|
| 68 |
+
Answer: Antipyretics work by acting on the hypothalamus in the brain, which regulates body
|
| 69 |
+
temperature, to lower fever.
|
| 70 |
+
Question: What are some common examples of antipyretics?
|
| 71 |
+
Answer: Common examples of antipyretics include acetaminophen (Tylenol) and nonsteroidal anti-
|
| 72 |
+
inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin) and aspirin.
|
| 73 |
+
12 | Antipyretics
|
| 74 |
+
|
| 75 |
+
--- End of Page 2 ---
|
| 76 |
+
|
| 77 |
+
Question: When should antipyretics be used?
|
| 78 |
+
Answer: Antipyretics should be used when fever is causing discomfort or distress, especially in
|
| 79 |
+
children, or when fever is accompanied by other symptoms such as headache, muscle aches, or chills.
|
| 80 |
+
Question: Can antipyretics cure the underlying cause of fever?
|
| 81 |
+
Answer: No, antipyretics do not cure the underlying cause of fever but rather help manage the
|
| 82 |
+
symptoms of fever by lowering body temperature.
|
| 83 |
+
Question: Are antipyretics safe for everyone to take?
|
| 84 |
+
Answer: While antipyretics are generally safe for most people when used as directed, they may not be
|
| 85 |
+
suitable for individuals with certain health conditions or allergies. It's important to consult with a
|
| 86 |
+
healthcare professional before using antipyretics, especially in children or during pregnancy.
|
| 87 |
+
Question: What are the potential side effects of antipyretics?
|
| 88 |
+
Answer: Potential side effects of antipyretics may include stomach upset, nausea, vomiting, allergic
|
| 89 |
+
reactions, and in the case of NSAIDs, gastrointestinal bleeding or kidney damage if used excessively
|
| 90 |
+
or for prolonged periods.
|
| 91 |
+
Question: Can antipyretics be used to treat COVID-19?
|
| 92 |
+
Answer: Antipyretics can be used to manage fever in individuals with COVID-19, but they do not
|
| 93 |
+
treat the underlying viral infection. It's essential to follow healthcare professionals' advice and adhere
|
| 94 |
+
to treatment guidelines for managing COVID-19 symptoms.
|
| 95 |
+
Antipyretics | 13
|
| 96 |
+
|
| 97 |
+
--- End of Page 3 ---
|
| 98 |
+
|
MEDICINE_TXT/Chapter_04_Antacids.txt
ADDED
|
@@ -0,0 +1,115 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
4
|
| 3 |
+
|
| 4 |
+
Antacids
|
| 5 |
+
Mr. Rahul Kumar Ancheria
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Antacids are a class of medications designed to neutralize excess stomach acid, providing relief from
|
| 9 |
+
conditions such as heartburn, indigestion, and acid reflux. They work by raising the pH of the stomach
|
| 10 |
+
contents, reducing acidity and the associated discomfort. Antacids often contain various compounds
|
| 11 |
+
like aluminum hydroxide, magnesium carbonate, and calcium carbonate. This class of medications is
|
| 12 |
+
commonly used for the symptomatic relief of gastrointestinal issues caused by an imbalance in
|
| 13 |
+
stomach acid levels.
|
| 14 |
+
Antacids, designed to neutralize excess stomach acid, alleviate symptoms of heartburn, indigestion,
|
| 15 |
+
and acid reflux. They act by raising stomach pH, providing relief from gastrointestinal discomfort.
|
| 16 |
+
OTC Classification:
|
| 17 |
+
1. Calcium Carbonate-based Antacids:
|
| 18 |
+
● Example: Tums
|
| 19 |
+
● Mechanism: Neutralizes stomach acid, providing rapid relief.
|
| 20 |
+
● Safe Dose: Follow recommended dosage to avoid hypercalcemia.
|
| 21 |
+
● Contraindications: Avoid in hypercalcemia, kidney stones, or renal impairment.
|
| 22 |
+
|
| 23 |
+
[Chapter_04_Antacids_page1_img1.png]
|
| 24 |
+
|
| 25 |
+
|
| 26 |
+
|
| 27 |
+
14 | Antacids
|
| 28 |
+
|
| 29 |
+
--- End of Page 1 ---
|
| 30 |
+
|
| 31 |
+
2. Aluminum and Magnesium-based Antacids:
|
| 32 |
+
● Example: Maalox
|
| 33 |
+
● Mechanism: Combines aluminum and magnesium to neutralize acid and balance effects.
|
| 34 |
+
● Safe Dose: Use as directed; excessive intake may lead to electrolyte imbalance.
|
| 35 |
+
● Contraindications: Caution in renal impairment, avoid in severe kidney disease.
|
| 36 |
+
|
| 37 |
+
[Chapter_04_Antacids_page2_img1.png]
|
| 38 |
+
|
| 39 |
+
|
| 40 |
+
3. Sodium Bicarbonate-based Antacids:
|
| 41 |
+
● Example: Alka-Seltzer
|
| 42 |
+
● Mechanism: Contains sodium bicarbonate for quick relief and effervescence.
|
| 43 |
+
● Safe Dose: Use with caution due to sodium content; follow instructions.
|
| 44 |
+
● Contraindications: Avoid in hypertension, heart failure, or edema.
|
| 45 |
+
|
| 46 |
+
[Chapter_04_Antacids_page2_img2.png]
|
| 47 |
+
|
| 48 |
+
|
| 49 |
+
4. Combination Antacids:
|
| 50 |
+
● Example: Rolaids
|
| 51 |
+
|
| 52 |
+
[Chapter_04_Antacids_page2_img3.png]
|
| 53 |
+
|
| 54 |
+
|
| 55 |
+
Antacids | 15
|
| 56 |
+
|
| 57 |
+
--- End of Page 2 ---
|
| 58 |
+
|
| 59 |
+
● Mechanism: Blend of calcium carbonate and magnesium hydroxide for dual-action relief.
|
| 60 |
+
● Safe Dose: Follow recommended dosage; excessive use may lead to magnesium toxicity.
|
| 61 |
+
● Contraindications: Caution in renal impairment; avoid in severe kidney disease.
|
| 62 |
+
5. Foaming Agents:
|
| 63 |
+
● Example: Gaviscon
|
| 64 |
+
● Mechanism: Creates a foam barrier to block stomach acid from entering the esophagus.
|
| 65 |
+
● Safe Dose: Follow recommended dosage; excessive use may lead to gas and bloating.
|
| 66 |
+
● Contraindications: Caution in respiratory conditions; avoid if sensitive to ingredients.
|
| 67 |
+
|
| 68 |
+
[Chapter_04_Antacids_page3_img1.png]
|
| 69 |
+
|
| 70 |
+
|
| 71 |
+
Antacids in these categories are available over-the-counter, offering consumers a range of choices for
|
| 72 |
+
rapid relief from mild digestive issues. Always follow dosage instructions and seek professional advice
|
| 73 |
+
for prolonged symptoms or interactions.
|
| 74 |
+
FREQUENTLY ASKED QUESTIONS
|
| 75 |
+
Question: What are antacids?
|
| 76 |
+
Answer: Antacids are medications that help neutralize stomach acid, providing relief from heartburn,
|
| 77 |
+
indigestion, and acid reflux.
|
| 78 |
+
Question: How do antacids work?
|
| 79 |
+
Answer: Antacids work by increasing the pH of the stomach contents, which reduces acidity and helps
|
| 80 |
+
alleviate symptoms of acid-related disorders.
|
| 81 |
+
Question: What are some common ingredients found in antacids?
|
| 82 |
+
Answer: Common ingredients found in antacids include calcium carbonate, magnesium hydroxide,
|
| 83 |
+
aluminum hydroxide, and sodium bicarbonate.
|
| 84 |
+
16 | Antacids
|
| 85 |
+
|
| 86 |
+
--- End of Page 3 ---
|
| 87 |
+
|
| 88 |
+
Question: When should antacids be taken?
|
| 89 |
+
Answer: Antacids should be taken as needed, typically after meals or when symptoms of heartburn or
|
| 90 |
+
indigestion occur.
|
| 91 |
+
Question: How quickly do antacids work?
|
| 92 |
+
Answer: Antacids usually work within minutes to provide relief from symptoms of heartburn or
|
| 93 |
+
indigestion.
|
| 94 |
+
Question: Can antacids be taken with other medications?
|
| 95 |
+
Answer: Yes, antacids can generally be taken with other medications, but it's essential to consult with
|
| 96 |
+
a healthcare professional or pharmacist to avoid potential interactions.
|
| 97 |
+
Question: Are there any side effects associated with antacids?
|
| 98 |
+
Answer: Side effects of antacids may include constipation or diarrhea, depending on the specific
|
| 99 |
+
ingredients, as well as rare occurrences of kidney stones or rebound acidity with prolonged use.
|
| 100 |
+
Question: Can antacids be taken during pregnancy?
|
| 101 |
+
Answer: Many antacids are considered safe for use during pregnancy, but it's important to consult with
|
| 102 |
+
a healthcare professional before using any medication during pregnancy.
|
| 103 |
+
Question: Can antacids be used to treat ulcers?
|
| 104 |
+
Answer: While antacids can provide temporary relief from ulcer symptoms such as heartburn, they do
|
| 105 |
+
not treat the underlying cause of ulcers, such as infection with H. pylori bacteria or long-term use of
|
| 106 |
+
NSAIDs.
|
| 107 |
+
Question: Are there any lifestyle changes that can help reduce the need for antacids?
|
| 108 |
+
Answer: Yes, lifestyle changes such as avoiding trigger foods, eating smaller meals, avoiding lying
|
| 109 |
+
down after eating, and maintaining a healthy weight can help reduce the frequency of heartburn and
|
| 110 |
+
indigestion, reducing the need for antacids.
|
| 111 |
+
|
| 112 |
+
Antacids | 17
|
| 113 |
+
|
| 114 |
+
--- End of Page 4 ---
|
| 115 |
+
|
MEDICINE_TXT/Chapter_05_Antihistamines.txt
ADDED
|
@@ -0,0 +1,183 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
5
|
| 3 |
+
|
| 4 |
+
Antihistamines
|
| 5 |
+
Dr. Girish Kumar Vyas
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Antihistamines are a class of medications that are primarily used to counteract the effects of histamine,
|
| 9 |
+
a natural substance released by the body during allergic reactions. Histamine is responsible for
|
| 10 |
+
symptoms such as itching, sneezing, runny nose, watery eyes, and hives. Antihistamines work by
|
| 11 |
+
blocking the action of histamine on certain cells, thereby reducing or preventing these allergic
|
| 12 |
+
symptoms. They are commonly used to treat allergic rhinitis (hay fever), allergic conjunctivitis,
|
| 13 |
+
allergic skin conditions (such as eczema and urticaria), and allergic reactions to insect bites or stings.
|
| 14 |
+
Antihistamines can be categorized into two main types: first-generation antihistamines, which tend to
|
| 15 |
+
cause drowsiness as a side effect, and second-generation antihistamines, which are less sedating and
|
| 16 |
+
are often preferred for daytime use. Examples of antihistamines include diphenhydramine (Benadryl),
|
| 17 |
+
cetirizine (Zyrtec), loratadine (Claritin), fexofenadine (Allegra), and desloratadine (Clarinex).
|
| 18 |
+
Antihistamines can be classified into two main generations based on their development and
|
| 19 |
+
characteristics:
|
| 20 |
+
1. First-generation antihistamines:
|
| 21 |
+
● These antihistamines were among the earliest developed and have been in use for several
|
| 22 |
+
decades.
|
| 23 |
+
● They are effective in treating allergic symptoms but are often associated with sedative side
|
| 24 |
+
effects, causing drowsiness and impairing cognitive function.
|
| 25 |
+
● First-generation antihistamines are also known to have anticholinergic effects, leading to
|
| 26 |
+
dry mouth, blurred vision, constipation, and urinary retention.
|
| 27 |
+
● Examples include diphenhydramine (Benadryl), chlorpheniramine (Chlor-Trimeton),
|
| 28 |
+
brompheniramine (Dimetapp), and hydroxyzine (Atarax).
|
| 29 |
+
2. Second-generation antihistamines:
|
| 30 |
+
● These antihistamines were developed later and were designed to be more selective in their
|
| 31 |
+
action, targeting histamine receptors more specifically.
|
| 32 |
+
● Second-generation antihistamines have reduced penetration of the blood-brain barrier
|
| 33 |
+
compared to first-generation ones, leading to decreased sedative effects.
|
| 34 |
+
18 | Antihistamines
|
| 35 |
+
|
| 36 |
+
--- End of Page 1 ---
|
| 37 |
+
|
| 38 |
+
● They are generally preferred for daytime use due to their lower propensity to cause
|
| 39 |
+
drowsiness and other central nervous system side effects.
|
| 40 |
+
● Second-generation antihistamines are less likely to cause anticholinergic effects compared
|
| 41 |
+
to first-generation ones.
|
| 42 |
+
● Examples include cetirizine (Zyrtec), loratadine (Claritin), fexofenadine (Allegra),
|
| 43 |
+
desloratadine (Clarinex), levocetirizine (Xyzal), and bilastine (Blexten).
|
| 44 |
+
Additionally, antihistamines can be further categorized based on their duration of action:
|
| 45 |
+
1. Short-acting antihistamines:
|
| 46 |
+
● These antihistamines have a relatively rapid onset of action but may require multiple doses
|
| 47 |
+
throughout the day to maintain their effectiveness.
|
| 48 |
+
● Examples include diphenhydramine and chlorpheniramine.
|
| 49 |
+
2. Long-acting antihistamines:
|
| 50 |
+
● These antihistamines provide symptom relief for a longer duration, often allowing for once-
|
| 51 |
+
daily dosing.
|
| 52 |
+
● Examples include cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine, and
|
| 53 |
+
bilastine.
|
| 54 |
+
This classification is very useful for antihistamine therapy based on factors such as the severity of
|
| 55 |
+
symptoms, the time of administration (day or night), and the individual's tolerance for sedation.
|
| 56 |
+
First Generation Antihistamine Diphenhydramine (Benadryl):
|
| 57 |
+
Diphenhydramine, marketed under the brand name Benadryl among others, is a first-generation
|
| 58 |
+
antihistamine medication. It is commonly used to relieve symptoms of allergies, hay fever, and the
|
| 59 |
+
common cold, as well as to alleviate itching due to allergic reactions and skin irritations.
|
| 60 |
+
Diphenhydramine is also utilized as a mild sedative and sleep aid due to its ability to induce
|
| 61 |
+
drowsiness.
|
| 62 |
+
|
| 63 |
+
[Chapter_05_Antihistamines_page2_img1.png]
|
| 64 |
+
|
| 65 |
+
|
| 66 |
+
|
| 67 |
+
Antihistamines | 19
|
| 68 |
+
|
| 69 |
+
--- End of Page 2 ---
|
| 70 |
+
|
| 71 |
+
Chemical Information:
|
| 72 |
+
● Chemical Name: Diphenhydramine
|
| 73 |
+
● Chemical Structure: Diphenhydramine has the chemical formula C17H21NO.
|
| 74 |
+
● Its chemical structure is:
|
| 75 |
+
|
| 76 |
+
[Chapter_05_Antihistamines_page3_img1.png]
|
| 77 |
+
|
| 78 |
+
|
| 79 |
+
Uses:
|
| 80 |
+
● Allergy Relief: Diphenhydramine is effective in relieving symptoms of allergic reactions,
|
| 81 |
+
including sneezing, itching, watery eyes, and runny nose.
|
| 82 |
+
● Sedation: Due to its sedative properties, diphenhydramine is often used as a mild sleep aid
|
| 83 |
+
to promote sleep onset and improve sleep quality.
|
| 84 |
+
● Itch Relief: It is also used to alleviate itching associated with allergic skin conditions,
|
| 85 |
+
insect bites, and various dermatological conditions.
|
| 86 |
+
Stability and Storage Conditions:
|
| 87 |
+
● Stability: Diphenhydramine is generally stable when stored properly.
|
| 88 |
+
● Storage Conditions: It should be stored at room temperature, away from moisture and heat.
|
| 89 |
+
Avoid storing it in the bathroom or kitchen, where moisture and temperature fluctuations
|
| 90 |
+
can affect its stability. Keep it out of reach of children and pets to prevent accidental
|
| 91 |
+
ingestion.
|
| 92 |
+
Safe Dose for Adults:
|
| 93 |
+
● The recommended adult dose of diphenhydramine varies depending on the formulation and
|
| 94 |
+
strength. However, for allergic symptoms, the typical adult dose is 25 to 50 milligrams
|
| 95 |
+
every 4 to 6 hours, with a maximum daily dose of 300 milligrams.
|
| 96 |
+
● For sleep aid purposes, a dose of 50 milligrams taken 30 minutes before bedtime is
|
| 97 |
+
commonly recommended.
|
| 98 |
+
Marketed Brands:
|
| 99 |
+
● Benadryl,
|
| 100 |
+
● Diphenhydramine
|
| 101 |
+
● Nytol
|
| 102 |
+
● Sominex
|
| 103 |
+
● Unisom
|
| 104 |
+
20 | Antihistamines
|
| 105 |
+
|
| 106 |
+
--- End of Page 3 ---
|
| 107 |
+
|
| 108 |
+
Second Generation Antihistamine Cetirizine:
|
| 109 |
+
Cetirizine is a second-generation antihistamine medication commonly used to treat allergic
|
| 110 |
+
conditions such as allergic rhinitis (hay fever), allergic conjunctivitis, allergic skin reactions like
|
| 111 |
+
chronic urticaria (hives), and other allergy-related symptoms. It belongs to the class of drugs
|
| 112 |
+
known as selective histamine H1 receptor antagonists, which work by blocking the action of
|
| 113 |
+
histamine, thereby alleviating allergy symptoms.
|
| 114 |
+
Chemical Information:
|
| 115 |
+
● Chemical Name: Cetirizine
|
| 116 |
+
● Chemical Structure: Cetirizine has the chemical formula C21H25ClN2O3.
|
| 117 |
+
● Its chemical structure is:
|
| 118 |
+
|
| 119 |
+
[Chapter_05_Antihistamines_page4_img1.png]
|
| 120 |
+
|
| 121 |
+
|
| 122 |
+
Uses:
|
| 123 |
+
1. Allergic Rhinitis: Cetirizine is effective in relieving symptoms of allergic rhinitis, including
|
| 124 |
+
sneezing, runny or itchy nose, and nasal congestion.
|
| 125 |
+
2. Allergic Conjunctivitis: It can also alleviate symptoms of allergic conjunctivitis, such as itchy,
|
| 126 |
+
watery eyes.
|
| 127 |
+
3. Chronic Urticaria: Cetirizine is commonly used to treat chronic urticaria (hives), reducing
|
| 128 |
+
itching and the appearance of hives on the skin.
|
| 129 |
+
4. Other Allergic Symptoms: It may also be used to relieve itching and other allergy-related
|
| 130 |
+
symptoms associated with insect bites, allergic reactions to food or medications, and other
|
| 131 |
+
allergens.
|
| 132 |
+
Stability/Storage Conditions:
|
| 133 |
+
● Stability: Cetirizine is generally stable when stored properly.
|
| 134 |
+
● Storage Conditions: It should be stored at room temperature, away from moisture and heat.
|
| 135 |
+
Avoid storing it in the bathroom or kitchen, where moisture and temperature fluctuations can
|
| 136 |
+
affect its stability. Keep it out of reach of children and pets to prevent accidental ingestion.
|
| 137 |
+
Antihistamines | 21
|
| 138 |
+
|
| 139 |
+
--- End of Page 4 ---
|
| 140 |
+
|
| 141 |
+
Safe Dose for Adults:
|
| 142 |
+
● The recommended adult dose of cetirizine is typically 5 to 10 milligrams (mg) once daily,
|
| 143 |
+
depending on the severity of symptoms and individual response to the medication.
|
| 144 |
+
● For individuals with impaired renal function, a lower dose may be recommended to prevent the
|
| 145 |
+
accumulation of the drug in the body.
|
| 146 |
+
Marketed Brands:
|
| 147 |
+
● Zyrtec
|
| 148 |
+
● Reactine
|
| 149 |
+
● Aller-Tec
|
| 150 |
+
● Cetzine
|
| 151 |
+
FREQUENTLY ASKED QUESTIONS
|
| 152 |
+
Question: What are antihistamines?
|
| 153 |
+
Answer: Antihistamines are medications that help alleviate allergy symptoms by blocking the action
|
| 154 |
+
of histamine, a substance in the body that triggers allergic reactions.
|
| 155 |
+
Question: How do antihistamines work?
|
| 156 |
+
Answer: Antihistamines work by blocking histamine receptors, which prevents histamine from
|
| 157 |
+
binding to these receptors and causing allergy symptoms such as sneezing, itching, and runny nose.
|
| 158 |
+
Question: What are some common examples of antihistamines?
|
| 159 |
+
Answer: Common examples of antihistamines include diphenhydramine (Benadryl), loratadine
|
| 160 |
+
(Claritin), cetirizine (Zyrtec), and fexofenadine (Allegra).
|
| 161 |
+
Question: When should antihistamines be taken?
|
| 162 |
+
Answer: Antihistamines are typically taken as needed to relieve allergy symptoms such as hay fever,
|
| 163 |
+
allergic rhinitis, or hives. Some antihistamines may cause drowsiness and are often taken at bedtime to
|
| 164 |
+
minimize this side effect.
|
| 165 |
+
Question: Can antihistamines be taken with other medications?
|
| 166 |
+
Answer: Antihistamines can generally be taken with other medications, but it's important to consult
|
| 167 |
+
with a healthcare professional or pharmacist to avoid potential interactions, especially with sedating
|
| 168 |
+
antihistamines.
|
| 169 |
+
Question: Do antihistamines have any side effects?
|
| 170 |
+
Answer: Common side effects of antihistamines may include drowsiness, dry mouth, dizziness,
|
| 171 |
+
blurred vision, and constipation. Sedating antihistamines are more likely to cause drowsiness than non-
|
| 172 |
+
sedating ones.
|
| 173 |
+
Question: Can antihistamines be used to treat conditions other than allergies?
|
| 174 |
+
Answer: Yes, antihistamines can also be used to relieve symptoms of motion sickness, insomnia, and
|
| 175 |
+
certain skin conditions such as itching associated with eczema or dermatitis.
|
| 176 |
+
Question: Are there any lifestyle changes that can help reduce the need for antihistamines?
|
| 177 |
+
Answer: Yes, avoiding known allergens, such as pollen, dust mites, or pet dander, practicing good
|
| 178 |
+
hygiene, using air purifiers, and keeping windows closed during peak pollen seasons can help reduce
|
| 179 |
+
allergy symptoms and the need for antihistamines.
|
| 180 |
+
22 | Antihistamines
|
| 181 |
+
|
| 182 |
+
--- End of Page 5 ---
|
| 183 |
+
|
MEDICINE_TXT/Chapter_06_Decongestants.txt
ADDED
|
@@ -0,0 +1,4851 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
6
|
| 3 |
+
|
| 4 |
+
Decongestants
|
| 5 |
+
Dr. Nitin Nama
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Decongestants are a class of medications commonly used to alleviate nasal congestion by reducing
|
| 9 |
+
swelling of the nasal passages and promoting drainage of mucus. They work by constricting the
|
| 10 |
+
blood vessels in the nasal mucosa, which decreases blood flow to the nasal tissues and reduces
|
| 11 |
+
swelling. This action helps to relieve symptoms such as stuffy or blocked nose, sinus pressure, and
|
| 12 |
+
difficulty breathing through the nose. Decongestants are commonly used to provide temporary
|
| 13 |
+
relief from symptoms associated with the common cold, flu, sinusitis, allergic rhinitis, and other
|
| 14 |
+
respiratory conditions. They are available in various formulations, including oral tablets or
|
| 15 |
+
capsules, nasal sprays, and nasal drops. It's important to use decongestants according to the
|
| 16 |
+
recommended dosage and duration to avoid potential side effects such as rebound congestion or
|
| 17 |
+
increased blood pressure. Always consult a healthcare professional before using decongestants,
|
| 18 |
+
especially if you have any underlying medical conditions or are taking other medications.
|
| 19 |
+
Classification of marketed drugs of decongestant:
|
| 20 |
+
1. Systemic Decongestants:
|
| 21 |
+
● Pseudoephedrine: Marketed under various brand names such as Sudafed, Sudafed PE, and
|
| 22 |
+
Afrinol, pseudoephedrine is a commonly used oral decongestant. It is available in different
|
| 23 |
+
formulations, including tablets and extended-release capsules.
|
| 24 |
+
● Phenylephrine: Another oral decongestant, phenylephrine is available under brand names
|
| 25 |
+
like Sudafed PE and PE Congestion. It is commonly found in tablets and liquid
|
| 26 |
+
formulations.
|
| 27 |
+
2. Topical Decongestants:
|
| 28 |
+
● Oxymetazoline: Marketed under brand names such as Afrin, Neo-Synephrine, and Vicks
|
| 29 |
+
Sinex, oxymetazoline is a popular nasal spray decongestant. It provides rapid relief from
|
| 30 |
+
nasal congestion and is available in various strengths.
|
| 31 |
+
● Phenylephrine (Nasal Spray): Phenylephrine is also available as a nasal spray, marketed
|
| 32 |
+
under brand names like Sudafed PE Nasal Decongestant Spray and Neo-Synephrine Nasal
|
| 33 |
+
Spray. It works locally to relieve nasal congestion.
|
| 34 |
+
These examples represent commonly used decongestants available in the market, but there are
|
| 35 |
+
other formulations and brands as well. It's essential to read the product labels and consult
|
| 36 |
+
healthcare professionals for proper usage instructions and to determine the most suitable
|
| 37 |
+
decongestant for individual needs.
|
| 38 |
+
Decongestants | 23
|
| 39 |
+
|
| 40 |
+
--- End of Page 1 ---
|
| 41 |
+
|
| 42 |
+
Introduction to Pseudoephedrine:
|
| 43 |
+
Pseudoephedrine is a systemic decongestant commonly used to relieve nasal and sinus congestion
|
| 44 |
+
caused by conditions such as the common cold, allergies, or sinusitis. It belongs to the class of
|
| 45 |
+
drugs known as sympathomimetic amines, which work by constricting blood vessels in the nasal
|
| 46 |
+
passages, thereby reducing swelling and congestion. Pseudoephedrine is available over-the-counter
|
| 47 |
+
in many countries but may also be regulated due to its potential for misuse in the production of
|
| 48 |
+
methamphetamine.
|
| 49 |
+
Chemical Information:
|
| 50 |
+
- Chemical Name: Pseudoephedrine
|
| 51 |
+
- Chemical Structure:
|
| 52 |
+
- Pseudoephedrine has the chemical formula C10H15NO.
|
| 53 |
+
- Its chemical structure is:
|
| 54 |
+
|
| 55 |
+
[Chapter_06_Decongestants_page2_img1.png]
|
| 56 |
+
|
| 57 |
+
|
| 58 |
+
[Chapter_06_Decongestants_page2_img2.png]
|
| 59 |
+
|
| 60 |
+
|
| 61 |
+
[Chapter_06_Decongestants_page2_img3.png]
|
| 62 |
+
|
| 63 |
+
|
| 64 |
+
[Chapter_06_Decongestants_page2_img4.png]
|
| 65 |
+
|
| 66 |
+
|
| 67 |
+
[Chapter_06_Decongestants_page2_img5.png]
|
| 68 |
+
|
| 69 |
+
|
| 70 |
+
[Chapter_06_Decongestants_page2_img6.png]
|
| 71 |
+
|
| 72 |
+
|
| 73 |
+
[Chapter_06_Decongestants_page2_img7.png]
|
| 74 |
+
|
| 75 |
+
|
| 76 |
+
[Chapter_06_Decongestants_page2_img8.png]
|
| 77 |
+
|
| 78 |
+
|
| 79 |
+
[Chapter_06_Decongestants_page2_img9.png]
|
| 80 |
+
|
| 81 |
+
|
| 82 |
+
[Chapter_06_Decongestants_page2_img10.png]
|
| 83 |
+
|
| 84 |
+
|
| 85 |
+
[Chapter_06_Decongestants_page2_img11.png]
|
| 86 |
+
|
| 87 |
+
|
| 88 |
+
[Chapter_06_Decongestants_page2_img12.png]
|
| 89 |
+
|
| 90 |
+
|
| 91 |
+
[Chapter_06_Decongestants_page2_img13.png]
|
| 92 |
+
|
| 93 |
+
|
| 94 |
+
[Chapter_06_Decongestants_page2_img14.png]
|
| 95 |
+
|
| 96 |
+
|
| 97 |
+
[Chapter_06_Decongestants_page2_img15.png]
|
| 98 |
+
|
| 99 |
+
|
| 100 |
+
[Chapter_06_Decongestants_page2_img16.png]
|
| 101 |
+
|
| 102 |
+
|
| 103 |
+
[Chapter_06_Decongestants_page2_img17.png]
|
| 104 |
+
|
| 105 |
+
|
| 106 |
+
[Chapter_06_Decongestants_page2_img18.png]
|
| 107 |
+
|
| 108 |
+
|
| 109 |
+
[Chapter_06_Decongestants_page2_img19.png]
|
| 110 |
+
|
| 111 |
+
|
| 112 |
+
[Chapter_06_Decongestants_page2_img20.png]
|
| 113 |
+
|
| 114 |
+
|
| 115 |
+
[Chapter_06_Decongestants_page2_img21.png]
|
| 116 |
+
|
| 117 |
+
|
| 118 |
+
[Chapter_06_Decongestants_page2_img22.png]
|
| 119 |
+
|
| 120 |
+
|
| 121 |
+
[Chapter_06_Decongestants_page2_img23.png]
|
| 122 |
+
|
| 123 |
+
|
| 124 |
+
[Chapter_06_Decongestants_page2_img24.png]
|
| 125 |
+
|
| 126 |
+
|
| 127 |
+
[Chapter_06_Decongestants_page2_img25.png]
|
| 128 |
+
|
| 129 |
+
|
| 130 |
+
[Chapter_06_Decongestants_page2_img26.png]
|
| 131 |
+
|
| 132 |
+
|
| 133 |
+
[Chapter_06_Decongestants_page2_img27.png]
|
| 134 |
+
|
| 135 |
+
|
| 136 |
+
[Chapter_06_Decongestants_page2_img28.png]
|
| 137 |
+
|
| 138 |
+
|
| 139 |
+
[Chapter_06_Decongestants_page2_img29.png]
|
| 140 |
+
|
| 141 |
+
|
| 142 |
+
[Chapter_06_Decongestants_page2_img30.png]
|
| 143 |
+
|
| 144 |
+
|
| 145 |
+
[Chapter_06_Decongestants_page2_img31.png]
|
| 146 |
+
|
| 147 |
+
|
| 148 |
+
[Chapter_06_Decongestants_page2_img32.png]
|
| 149 |
+
|
| 150 |
+
|
| 151 |
+
[Chapter_06_Decongestants_page2_img33.png]
|
| 152 |
+
|
| 153 |
+
|
| 154 |
+
[Chapter_06_Decongestants_page2_img34.png]
|
| 155 |
+
|
| 156 |
+
|
| 157 |
+
[Chapter_06_Decongestants_page2_img35.png]
|
| 158 |
+
|
| 159 |
+
|
| 160 |
+
[Chapter_06_Decongestants_page2_img36.png]
|
| 161 |
+
|
| 162 |
+
|
| 163 |
+
[Chapter_06_Decongestants_page2_img37.png]
|
| 164 |
+
|
| 165 |
+
|
| 166 |
+
[Chapter_06_Decongestants_page2_img38.png]
|
| 167 |
+
|
| 168 |
+
|
| 169 |
+
[Chapter_06_Decongestants_page2_img39.png]
|
| 170 |
+
|
| 171 |
+
|
| 172 |
+
[Chapter_06_Decongestants_page2_img40.png]
|
| 173 |
+
|
| 174 |
+
|
| 175 |
+
[Chapter_06_Decongestants_page2_img41.png]
|
| 176 |
+
|
| 177 |
+
|
| 178 |
+
[Chapter_06_Decongestants_page2_img42.png]
|
| 179 |
+
|
| 180 |
+
|
| 181 |
+
[Chapter_06_Decongestants_page2_img43.png]
|
| 182 |
+
|
| 183 |
+
|
| 184 |
+
[Chapter_06_Decongestants_page2_img44.png]
|
| 185 |
+
|
| 186 |
+
|
| 187 |
+
[Chapter_06_Decongestants_page2_img45.png]
|
| 188 |
+
|
| 189 |
+
|
| 190 |
+
[Chapter_06_Decongestants_page2_img46.png]
|
| 191 |
+
|
| 192 |
+
|
| 193 |
+
[Chapter_06_Decongestants_page2_img47.png]
|
| 194 |
+
|
| 195 |
+
|
| 196 |
+
[Chapter_06_Decongestants_page2_img48.png]
|
| 197 |
+
|
| 198 |
+
|
| 199 |
+
[Chapter_06_Decongestants_page2_img49.png]
|
| 200 |
+
|
| 201 |
+
|
| 202 |
+
[Chapter_06_Decongestants_page2_img50.png]
|
| 203 |
+
|
| 204 |
+
|
| 205 |
+
[Chapter_06_Decongestants_page2_img51.png]
|
| 206 |
+
|
| 207 |
+
|
| 208 |
+
[Chapter_06_Decongestants_page2_img52.png]
|
| 209 |
+
|
| 210 |
+
|
| 211 |
+
[Chapter_06_Decongestants_page2_img53.png]
|
| 212 |
+
|
| 213 |
+
|
| 214 |
+
[Chapter_06_Decongestants_page2_img54.png]
|
| 215 |
+
|
| 216 |
+
|
| 217 |
+
[Chapter_06_Decongestants_page2_img55.png]
|
| 218 |
+
|
| 219 |
+
|
| 220 |
+
[Chapter_06_Decongestants_page2_img56.png]
|
| 221 |
+
|
| 222 |
+
|
| 223 |
+
[Chapter_06_Decongestants_page2_img57.png]
|
| 224 |
+
|
| 225 |
+
|
| 226 |
+
[Chapter_06_Decongestants_page2_img58.png]
|
| 227 |
+
|
| 228 |
+
|
| 229 |
+
[Chapter_06_Decongestants_page2_img59.png]
|
| 230 |
+
|
| 231 |
+
|
| 232 |
+
[Chapter_06_Decongestants_page2_img60.png]
|
| 233 |
+
|
| 234 |
+
|
| 235 |
+
[Chapter_06_Decongestants_page2_img61.png]
|
| 236 |
+
|
| 237 |
+
|
| 238 |
+
[Chapter_06_Decongestants_page2_img62.png]
|
| 239 |
+
|
| 240 |
+
|
| 241 |
+
[Chapter_06_Decongestants_page2_img63.png]
|
| 242 |
+
|
| 243 |
+
|
| 244 |
+
[Chapter_06_Decongestants_page2_img64.png]
|
| 245 |
+
|
| 246 |
+
|
| 247 |
+
[Chapter_06_Decongestants_page2_img65.png]
|
| 248 |
+
|
| 249 |
+
|
| 250 |
+
[Chapter_06_Decongestants_page2_img66.png]
|
| 251 |
+
|
| 252 |
+
|
| 253 |
+
[Chapter_06_Decongestants_page2_img67.png]
|
| 254 |
+
|
| 255 |
+
|
| 256 |
+
[Chapter_06_Decongestants_page2_img68.png]
|
| 257 |
+
|
| 258 |
+
|
| 259 |
+
[Chapter_06_Decongestants_page2_img69.png]
|
| 260 |
+
|
| 261 |
+
|
| 262 |
+
[Chapter_06_Decongestants_page2_img70.png]
|
| 263 |
+
|
| 264 |
+
|
| 265 |
+
[Chapter_06_Decongestants_page2_img71.png]
|
| 266 |
+
|
| 267 |
+
|
| 268 |
+
[Chapter_06_Decongestants_page2_img72.png]
|
| 269 |
+
|
| 270 |
+
|
| 271 |
+
[Chapter_06_Decongestants_page2_img73.png]
|
| 272 |
+
|
| 273 |
+
|
| 274 |
+
[Chapter_06_Decongestants_page2_img74.png]
|
| 275 |
+
|
| 276 |
+
|
| 277 |
+
[Chapter_06_Decongestants_page2_img75.png]
|
| 278 |
+
|
| 279 |
+
|
| 280 |
+
[Chapter_06_Decongestants_page2_img76.png]
|
| 281 |
+
|
| 282 |
+
|
| 283 |
+
[Chapter_06_Decongestants_page2_img77.png]
|
| 284 |
+
|
| 285 |
+
|
| 286 |
+
[Chapter_06_Decongestants_page2_img78.png]
|
| 287 |
+
|
| 288 |
+
|
| 289 |
+
[Chapter_06_Decongestants_page2_img79.png]
|
| 290 |
+
|
| 291 |
+
|
| 292 |
+
[Chapter_06_Decongestants_page2_img80.png]
|
| 293 |
+
|
| 294 |
+
|
| 295 |
+
[Chapter_06_Decongestants_page2_img81.png]
|
| 296 |
+
|
| 297 |
+
|
| 298 |
+
[Chapter_06_Decongestants_page2_img82.png]
|
| 299 |
+
|
| 300 |
+
|
| 301 |
+
[Chapter_06_Decongestants_page2_img83.png]
|
| 302 |
+
|
| 303 |
+
|
| 304 |
+
[Chapter_06_Decongestants_page2_img84.png]
|
| 305 |
+
|
| 306 |
+
|
| 307 |
+
[Chapter_06_Decongestants_page2_img85.png]
|
| 308 |
+
|
| 309 |
+
|
| 310 |
+
[Chapter_06_Decongestants_page2_img86.png]
|
| 311 |
+
|
| 312 |
+
|
| 313 |
+
[Chapter_06_Decongestants_page2_img87.png]
|
| 314 |
+
|
| 315 |
+
|
| 316 |
+
[Chapter_06_Decongestants_page2_img88.png]
|
| 317 |
+
|
| 318 |
+
|
| 319 |
+
[Chapter_06_Decongestants_page2_img89.png]
|
| 320 |
+
|
| 321 |
+
|
| 322 |
+
[Chapter_06_Decongestants_page2_img90.png]
|
| 323 |
+
|
| 324 |
+
|
| 325 |
+
[Chapter_06_Decongestants_page2_img91.png]
|
| 326 |
+
|
| 327 |
+
|
| 328 |
+
[Chapter_06_Decongestants_page2_img92.png]
|
| 329 |
+
|
| 330 |
+
|
| 331 |
+
[Chapter_06_Decongestants_page2_img93.png]
|
| 332 |
+
|
| 333 |
+
|
| 334 |
+
[Chapter_06_Decongestants_page2_img94.png]
|
| 335 |
+
|
| 336 |
+
|
| 337 |
+
[Chapter_06_Decongestants_page2_img95.png]
|
| 338 |
+
|
| 339 |
+
|
| 340 |
+
[Chapter_06_Decongestants_page2_img96.png]
|
| 341 |
+
|
| 342 |
+
|
| 343 |
+
[Chapter_06_Decongestants_page2_img97.png]
|
| 344 |
+
|
| 345 |
+
|
| 346 |
+
[Chapter_06_Decongestants_page2_img98.png]
|
| 347 |
+
|
| 348 |
+
|
| 349 |
+
[Chapter_06_Decongestants_page2_img99.png]
|
| 350 |
+
|
| 351 |
+
|
| 352 |
+
[Chapter_06_Decongestants_page2_img100.png]
|
| 353 |
+
|
| 354 |
+
|
| 355 |
+
[Chapter_06_Decongestants_page2_img101.png]
|
| 356 |
+
|
| 357 |
+
|
| 358 |
+
[Chapter_06_Decongestants_page2_img102.png]
|
| 359 |
+
|
| 360 |
+
|
| 361 |
+
[Chapter_06_Decongestants_page2_img103.png]
|
| 362 |
+
|
| 363 |
+
|
| 364 |
+
[Chapter_06_Decongestants_page2_img104.png]
|
| 365 |
+
|
| 366 |
+
|
| 367 |
+
[Chapter_06_Decongestants_page2_img105.png]
|
| 368 |
+
|
| 369 |
+
|
| 370 |
+
[Chapter_06_Decongestants_page2_img106.png]
|
| 371 |
+
|
| 372 |
+
|
| 373 |
+
[Chapter_06_Decongestants_page2_img107.png]
|
| 374 |
+
|
| 375 |
+
|
| 376 |
+
[Chapter_06_Decongestants_page2_img108.png]
|
| 377 |
+
|
| 378 |
+
|
| 379 |
+
[Chapter_06_Decongestants_page2_img109.png]
|
| 380 |
+
|
| 381 |
+
|
| 382 |
+
[Chapter_06_Decongestants_page2_img110.png]
|
| 383 |
+
|
| 384 |
+
|
| 385 |
+
[Chapter_06_Decongestants_page2_img111.png]
|
| 386 |
+
|
| 387 |
+
|
| 388 |
+
[Chapter_06_Decongestants_page2_img112.png]
|
| 389 |
+
|
| 390 |
+
|
| 391 |
+
[Chapter_06_Decongestants_page2_img113.png]
|
| 392 |
+
|
| 393 |
+
|
| 394 |
+
[Chapter_06_Decongestants_page2_img114.png]
|
| 395 |
+
|
| 396 |
+
|
| 397 |
+
[Chapter_06_Decongestants_page2_img115.png]
|
| 398 |
+
|
| 399 |
+
|
| 400 |
+
[Chapter_06_Decongestants_page2_img116.png]
|
| 401 |
+
|
| 402 |
+
|
| 403 |
+
[Chapter_06_Decongestants_page2_img117.png]
|
| 404 |
+
|
| 405 |
+
|
| 406 |
+
[Chapter_06_Decongestants_page2_img118.png]
|
| 407 |
+
|
| 408 |
+
|
| 409 |
+
[Chapter_06_Decongestants_page2_img119.png]
|
| 410 |
+
|
| 411 |
+
|
| 412 |
+
[Chapter_06_Decongestants_page2_img120.png]
|
| 413 |
+
|
| 414 |
+
|
| 415 |
+
[Chapter_06_Decongestants_page2_img121.png]
|
| 416 |
+
|
| 417 |
+
|
| 418 |
+
[Chapter_06_Decongestants_page2_img122.png]
|
| 419 |
+
|
| 420 |
+
|
| 421 |
+
[Chapter_06_Decongestants_page2_img123.png]
|
| 422 |
+
|
| 423 |
+
|
| 424 |
+
[Chapter_06_Decongestants_page2_img124.png]
|
| 425 |
+
|
| 426 |
+
|
| 427 |
+
[Chapter_06_Decongestants_page2_img125.png]
|
| 428 |
+
|
| 429 |
+
|
| 430 |
+
[Chapter_06_Decongestants_page2_img126.png]
|
| 431 |
+
|
| 432 |
+
|
| 433 |
+
[Chapter_06_Decongestants_page2_img127.png]
|
| 434 |
+
|
| 435 |
+
|
| 436 |
+
[Chapter_06_Decongestants_page2_img128.png]
|
| 437 |
+
|
| 438 |
+
|
| 439 |
+
[Chapter_06_Decongestants_page2_img129.png]
|
| 440 |
+
|
| 441 |
+
|
| 442 |
+
[Chapter_06_Decongestants_page2_img130.png]
|
| 443 |
+
|
| 444 |
+
|
| 445 |
+
[Chapter_06_Decongestants_page2_img131.png]
|
| 446 |
+
|
| 447 |
+
|
| 448 |
+
[Chapter_06_Decongestants_page2_img132.png]
|
| 449 |
+
|
| 450 |
+
|
| 451 |
+
[Chapter_06_Decongestants_page2_img133.png]
|
| 452 |
+
|
| 453 |
+
|
| 454 |
+
[Chapter_06_Decongestants_page2_img134.png]
|
| 455 |
+
|
| 456 |
+
|
| 457 |
+
[Chapter_06_Decongestants_page2_img135.png]
|
| 458 |
+
|
| 459 |
+
|
| 460 |
+
[Chapter_06_Decongestants_page2_img136.png]
|
| 461 |
+
|
| 462 |
+
|
| 463 |
+
[Chapter_06_Decongestants_page2_img137.png]
|
| 464 |
+
|
| 465 |
+
|
| 466 |
+
[Chapter_06_Decongestants_page2_img138.png]
|
| 467 |
+
|
| 468 |
+
|
| 469 |
+
[Chapter_06_Decongestants_page2_img139.png]
|
| 470 |
+
|
| 471 |
+
|
| 472 |
+
[Chapter_06_Decongestants_page2_img140.png]
|
| 473 |
+
|
| 474 |
+
|
| 475 |
+
[Chapter_06_Decongestants_page2_img141.png]
|
| 476 |
+
|
| 477 |
+
|
| 478 |
+
[Chapter_06_Decongestants_page2_img142.png]
|
| 479 |
+
|
| 480 |
+
|
| 481 |
+
[Chapter_06_Decongestants_page2_img143.png]
|
| 482 |
+
|
| 483 |
+
|
| 484 |
+
[Chapter_06_Decongestants_page2_img144.png]
|
| 485 |
+
|
| 486 |
+
|
| 487 |
+
[Chapter_06_Decongestants_page2_img145.png]
|
| 488 |
+
|
| 489 |
+
|
| 490 |
+
[Chapter_06_Decongestants_page2_img146.png]
|
| 491 |
+
|
| 492 |
+
|
| 493 |
+
[Chapter_06_Decongestants_page2_img147.png]
|
| 494 |
+
|
| 495 |
+
|
| 496 |
+
[Chapter_06_Decongestants_page2_img148.png]
|
| 497 |
+
|
| 498 |
+
|
| 499 |
+
[Chapter_06_Decongestants_page2_img149.png]
|
| 500 |
+
|
| 501 |
+
|
| 502 |
+
[Chapter_06_Decongestants_page2_img150.png]
|
| 503 |
+
|
| 504 |
+
|
| 505 |
+
[Chapter_06_Decongestants_page2_img151.png]
|
| 506 |
+
|
| 507 |
+
|
| 508 |
+
[Chapter_06_Decongestants_page2_img152.png]
|
| 509 |
+
|
| 510 |
+
|
| 511 |
+
[Chapter_06_Decongestants_page2_img153.png]
|
| 512 |
+
|
| 513 |
+
|
| 514 |
+
[Chapter_06_Decongestants_page2_img154.png]
|
| 515 |
+
|
| 516 |
+
|
| 517 |
+
[Chapter_06_Decongestants_page2_img155.png]
|
| 518 |
+
|
| 519 |
+
|
| 520 |
+
[Chapter_06_Decongestants_page2_img156.png]
|
| 521 |
+
|
| 522 |
+
|
| 523 |
+
[Chapter_06_Decongestants_page2_img157.png]
|
| 524 |
+
|
| 525 |
+
|
| 526 |
+
[Chapter_06_Decongestants_page2_img158.png]
|
| 527 |
+
|
| 528 |
+
|
| 529 |
+
[Chapter_06_Decongestants_page2_img159.png]
|
| 530 |
+
|
| 531 |
+
|
| 532 |
+
[Chapter_06_Decongestants_page2_img160.png]
|
| 533 |
+
|
| 534 |
+
|
| 535 |
+
[Chapter_06_Decongestants_page2_img161.png]
|
| 536 |
+
|
| 537 |
+
|
| 538 |
+
[Chapter_06_Decongestants_page2_img162.png]
|
| 539 |
+
|
| 540 |
+
|
| 541 |
+
[Chapter_06_Decongestants_page2_img163.png]
|
| 542 |
+
|
| 543 |
+
|
| 544 |
+
[Chapter_06_Decongestants_page2_img164.png]
|
| 545 |
+
|
| 546 |
+
|
| 547 |
+
[Chapter_06_Decongestants_page2_img165.png]
|
| 548 |
+
|
| 549 |
+
|
| 550 |
+
[Chapter_06_Decongestants_page2_img166.png]
|
| 551 |
+
|
| 552 |
+
|
| 553 |
+
[Chapter_06_Decongestants_page2_img167.png]
|
| 554 |
+
|
| 555 |
+
|
| 556 |
+
[Chapter_06_Decongestants_page2_img168.png]
|
| 557 |
+
|
| 558 |
+
|
| 559 |
+
[Chapter_06_Decongestants_page2_img169.png]
|
| 560 |
+
|
| 561 |
+
|
| 562 |
+
[Chapter_06_Decongestants_page2_img170.png]
|
| 563 |
+
|
| 564 |
+
|
| 565 |
+
[Chapter_06_Decongestants_page2_img171.png]
|
| 566 |
+
|
| 567 |
+
|
| 568 |
+
[Chapter_06_Decongestants_page2_img172.png]
|
| 569 |
+
|
| 570 |
+
|
| 571 |
+
[Chapter_06_Decongestants_page2_img173.png]
|
| 572 |
+
|
| 573 |
+
|
| 574 |
+
[Chapter_06_Decongestants_page2_img174.png]
|
| 575 |
+
|
| 576 |
+
|
| 577 |
+
[Chapter_06_Decongestants_page2_img175.png]
|
| 578 |
+
|
| 579 |
+
|
| 580 |
+
[Chapter_06_Decongestants_page2_img176.png]
|
| 581 |
+
|
| 582 |
+
|
| 583 |
+
[Chapter_06_Decongestants_page2_img177.png]
|
| 584 |
+
|
| 585 |
+
|
| 586 |
+
[Chapter_06_Decongestants_page2_img178.png]
|
| 587 |
+
|
| 588 |
+
|
| 589 |
+
[Chapter_06_Decongestants_page2_img179.png]
|
| 590 |
+
|
| 591 |
+
|
| 592 |
+
[Chapter_06_Decongestants_page2_img180.png]
|
| 593 |
+
|
| 594 |
+
|
| 595 |
+
[Chapter_06_Decongestants_page2_img181.png]
|
| 596 |
+
|
| 597 |
+
|
| 598 |
+
[Chapter_06_Decongestants_page2_img182.png]
|
| 599 |
+
|
| 600 |
+
|
| 601 |
+
[Chapter_06_Decongestants_page2_img183.png]
|
| 602 |
+
|
| 603 |
+
|
| 604 |
+
[Chapter_06_Decongestants_page2_img184.png]
|
| 605 |
+
|
| 606 |
+
|
| 607 |
+
[Chapter_06_Decongestants_page2_img185.png]
|
| 608 |
+
|
| 609 |
+
|
| 610 |
+
[Chapter_06_Decongestants_page2_img186.png]
|
| 611 |
+
|
| 612 |
+
|
| 613 |
+
[Chapter_06_Decongestants_page2_img187.png]
|
| 614 |
+
|
| 615 |
+
|
| 616 |
+
[Chapter_06_Decongestants_page2_img188.png]
|
| 617 |
+
|
| 618 |
+
|
| 619 |
+
[Chapter_06_Decongestants_page2_img189.png]
|
| 620 |
+
|
| 621 |
+
|
| 622 |
+
[Chapter_06_Decongestants_page2_img190.png]
|
| 623 |
+
|
| 624 |
+
|
| 625 |
+
[Chapter_06_Decongestants_page2_img191.png]
|
| 626 |
+
|
| 627 |
+
|
| 628 |
+
[Chapter_06_Decongestants_page2_img192.png]
|
| 629 |
+
|
| 630 |
+
|
| 631 |
+
[Chapter_06_Decongestants_page2_img193.png]
|
| 632 |
+
|
| 633 |
+
|
| 634 |
+
[Chapter_06_Decongestants_page2_img194.png]
|
| 635 |
+
|
| 636 |
+
|
| 637 |
+
[Chapter_06_Decongestants_page2_img195.png]
|
| 638 |
+
|
| 639 |
+
|
| 640 |
+
[Chapter_06_Decongestants_page2_img196.png]
|
| 641 |
+
|
| 642 |
+
|
| 643 |
+
[Chapter_06_Decongestants_page2_img197.png]
|
| 644 |
+
|
| 645 |
+
|
| 646 |
+
[Chapter_06_Decongestants_page2_img198.png]
|
| 647 |
+
|
| 648 |
+
|
| 649 |
+
[Chapter_06_Decongestants_page2_img199.png]
|
| 650 |
+
|
| 651 |
+
|
| 652 |
+
[Chapter_06_Decongestants_page2_img200.png]
|
| 653 |
+
|
| 654 |
+
|
| 655 |
+
[Chapter_06_Decongestants_page2_img201.png]
|
| 656 |
+
|
| 657 |
+
|
| 658 |
+
[Chapter_06_Decongestants_page2_img202.png]
|
| 659 |
+
|
| 660 |
+
|
| 661 |
+
[Chapter_06_Decongestants_page2_img203.png]
|
| 662 |
+
|
| 663 |
+
|
| 664 |
+
[Chapter_06_Decongestants_page2_img204.png]
|
| 665 |
+
|
| 666 |
+
|
| 667 |
+
[Chapter_06_Decongestants_page2_img205.png]
|
| 668 |
+
|
| 669 |
+
|
| 670 |
+
[Chapter_06_Decongestants_page2_img206.png]
|
| 671 |
+
|
| 672 |
+
|
| 673 |
+
[Chapter_06_Decongestants_page2_img207.png]
|
| 674 |
+
|
| 675 |
+
|
| 676 |
+
[Chapter_06_Decongestants_page2_img208.png]
|
| 677 |
+
|
| 678 |
+
|
| 679 |
+
[Chapter_06_Decongestants_page2_img209.png]
|
| 680 |
+
|
| 681 |
+
|
| 682 |
+
[Chapter_06_Decongestants_page2_img210.png]
|
| 683 |
+
|
| 684 |
+
|
| 685 |
+
[Chapter_06_Decongestants_page2_img211.png]
|
| 686 |
+
|
| 687 |
+
|
| 688 |
+
[Chapter_06_Decongestants_page2_img212.png]
|
| 689 |
+
|
| 690 |
+
|
| 691 |
+
[Chapter_06_Decongestants_page2_img213.png]
|
| 692 |
+
|
| 693 |
+
|
| 694 |
+
[Chapter_06_Decongestants_page2_img214.png]
|
| 695 |
+
|
| 696 |
+
|
| 697 |
+
[Chapter_06_Decongestants_page2_img215.png]
|
| 698 |
+
|
| 699 |
+
|
| 700 |
+
[Chapter_06_Decongestants_page2_img216.png]
|
| 701 |
+
|
| 702 |
+
|
| 703 |
+
[Chapter_06_Decongestants_page2_img217.png]
|
| 704 |
+
|
| 705 |
+
|
| 706 |
+
[Chapter_06_Decongestants_page2_img218.png]
|
| 707 |
+
|
| 708 |
+
|
| 709 |
+
[Chapter_06_Decongestants_page2_img219.png]
|
| 710 |
+
|
| 711 |
+
|
| 712 |
+
[Chapter_06_Decongestants_page2_img220.png]
|
| 713 |
+
|
| 714 |
+
|
| 715 |
+
[Chapter_06_Decongestants_page2_img221.png]
|
| 716 |
+
|
| 717 |
+
|
| 718 |
+
[Chapter_06_Decongestants_page2_img222.png]
|
| 719 |
+
|
| 720 |
+
|
| 721 |
+
[Chapter_06_Decongestants_page2_img223.png]
|
| 722 |
+
|
| 723 |
+
|
| 724 |
+
[Chapter_06_Decongestants_page2_img224.png]
|
| 725 |
+
|
| 726 |
+
|
| 727 |
+
[Chapter_06_Decongestants_page2_img225.png]
|
| 728 |
+
|
| 729 |
+
|
| 730 |
+
[Chapter_06_Decongestants_page2_img226.png]
|
| 731 |
+
|
| 732 |
+
|
| 733 |
+
[Chapter_06_Decongestants_page2_img227.png]
|
| 734 |
+
|
| 735 |
+
|
| 736 |
+
[Chapter_06_Decongestants_page2_img228.png]
|
| 737 |
+
|
| 738 |
+
|
| 739 |
+
[Chapter_06_Decongestants_page2_img229.png]
|
| 740 |
+
|
| 741 |
+
|
| 742 |
+
[Chapter_06_Decongestants_page2_img230.png]
|
| 743 |
+
|
| 744 |
+
|
| 745 |
+
[Chapter_06_Decongestants_page2_img231.png]
|
| 746 |
+
|
| 747 |
+
|
| 748 |
+
[Chapter_06_Decongestants_page2_img232.png]
|
| 749 |
+
|
| 750 |
+
|
| 751 |
+
[Chapter_06_Decongestants_page2_img233.png]
|
| 752 |
+
|
| 753 |
+
|
| 754 |
+
[Chapter_06_Decongestants_page2_img234.png]
|
| 755 |
+
|
| 756 |
+
|
| 757 |
+
[Chapter_06_Decongestants_page2_img235.png]
|
| 758 |
+
|
| 759 |
+
|
| 760 |
+
[Chapter_06_Decongestants_page2_img236.png]
|
| 761 |
+
|
| 762 |
+
|
| 763 |
+
[Chapter_06_Decongestants_page2_img237.png]
|
| 764 |
+
|
| 765 |
+
|
| 766 |
+
[Chapter_06_Decongestants_page2_img238.png]
|
| 767 |
+
|
| 768 |
+
|
| 769 |
+
[Chapter_06_Decongestants_page2_img239.png]
|
| 770 |
+
|
| 771 |
+
|
| 772 |
+
[Chapter_06_Decongestants_page2_img240.png]
|
| 773 |
+
|
| 774 |
+
|
| 775 |
+
[Chapter_06_Decongestants_page2_img241.png]
|
| 776 |
+
|
| 777 |
+
|
| 778 |
+
[Chapter_06_Decongestants_page2_img242.png]
|
| 779 |
+
|
| 780 |
+
|
| 781 |
+
[Chapter_06_Decongestants_page2_img243.png]
|
| 782 |
+
|
| 783 |
+
|
| 784 |
+
[Chapter_06_Decongestants_page2_img244.png]
|
| 785 |
+
|
| 786 |
+
|
| 787 |
+
[Chapter_06_Decongestants_page2_img245.png]
|
| 788 |
+
|
| 789 |
+
|
| 790 |
+
[Chapter_06_Decongestants_page2_img246.png]
|
| 791 |
+
|
| 792 |
+
|
| 793 |
+
[Chapter_06_Decongestants_page2_img247.png]
|
| 794 |
+
|
| 795 |
+
|
| 796 |
+
[Chapter_06_Decongestants_page2_img248.png]
|
| 797 |
+
|
| 798 |
+
|
| 799 |
+
[Chapter_06_Decongestants_page2_img249.png]
|
| 800 |
+
|
| 801 |
+
|
| 802 |
+
[Chapter_06_Decongestants_page2_img250.png]
|
| 803 |
+
|
| 804 |
+
|
| 805 |
+
[Chapter_06_Decongestants_page2_img251.png]
|
| 806 |
+
|
| 807 |
+
|
| 808 |
+
[Chapter_06_Decongestants_page2_img252.png]
|
| 809 |
+
|
| 810 |
+
|
| 811 |
+
[Chapter_06_Decongestants_page2_img253.png]
|
| 812 |
+
|
| 813 |
+
|
| 814 |
+
[Chapter_06_Decongestants_page2_img254.png]
|
| 815 |
+
|
| 816 |
+
|
| 817 |
+
[Chapter_06_Decongestants_page2_img255.png]
|
| 818 |
+
|
| 819 |
+
|
| 820 |
+
[Chapter_06_Decongestants_page2_img256.png]
|
| 821 |
+
|
| 822 |
+
|
| 823 |
+
[Chapter_06_Decongestants_page2_img257.png]
|
| 824 |
+
|
| 825 |
+
|
| 826 |
+
[Chapter_06_Decongestants_page2_img258.png]
|
| 827 |
+
|
| 828 |
+
|
| 829 |
+
[Chapter_06_Decongestants_page2_img259.png]
|
| 830 |
+
|
| 831 |
+
|
| 832 |
+
[Chapter_06_Decongestants_page2_img260.png]
|
| 833 |
+
|
| 834 |
+
|
| 835 |
+
[Chapter_06_Decongestants_page2_img261.png]
|
| 836 |
+
|
| 837 |
+
|
| 838 |
+
[Chapter_06_Decongestants_page2_img262.png]
|
| 839 |
+
|
| 840 |
+
|
| 841 |
+
[Chapter_06_Decongestants_page2_img263.png]
|
| 842 |
+
|
| 843 |
+
|
| 844 |
+
[Chapter_06_Decongestants_page2_img264.png]
|
| 845 |
+
|
| 846 |
+
|
| 847 |
+
[Chapter_06_Decongestants_page2_img265.png]
|
| 848 |
+
|
| 849 |
+
|
| 850 |
+
[Chapter_06_Decongestants_page2_img266.png]
|
| 851 |
+
|
| 852 |
+
|
| 853 |
+
[Chapter_06_Decongestants_page2_img267.png]
|
| 854 |
+
|
| 855 |
+
|
| 856 |
+
[Chapter_06_Decongestants_page2_img268.png]
|
| 857 |
+
|
| 858 |
+
|
| 859 |
+
[Chapter_06_Decongestants_page2_img269.png]
|
| 860 |
+
|
| 861 |
+
|
| 862 |
+
[Chapter_06_Decongestants_page2_img270.png]
|
| 863 |
+
|
| 864 |
+
|
| 865 |
+
[Chapter_06_Decongestants_page2_img271.png]
|
| 866 |
+
|
| 867 |
+
|
| 868 |
+
[Chapter_06_Decongestants_page2_img272.png]
|
| 869 |
+
|
| 870 |
+
|
| 871 |
+
[Chapter_06_Decongestants_page2_img273.png]
|
| 872 |
+
|
| 873 |
+
|
| 874 |
+
[Chapter_06_Decongestants_page2_img274.png]
|
| 875 |
+
|
| 876 |
+
|
| 877 |
+
[Chapter_06_Decongestants_page2_img275.png]
|
| 878 |
+
|
| 879 |
+
|
| 880 |
+
[Chapter_06_Decongestants_page2_img276.png]
|
| 881 |
+
|
| 882 |
+
|
| 883 |
+
[Chapter_06_Decongestants_page2_img277.png]
|
| 884 |
+
|
| 885 |
+
|
| 886 |
+
[Chapter_06_Decongestants_page2_img278.png]
|
| 887 |
+
|
| 888 |
+
|
| 889 |
+
[Chapter_06_Decongestants_page2_img279.png]
|
| 890 |
+
|
| 891 |
+
|
| 892 |
+
[Chapter_06_Decongestants_page2_img280.png]
|
| 893 |
+
|
| 894 |
+
|
| 895 |
+
[Chapter_06_Decongestants_page2_img281.png]
|
| 896 |
+
|
| 897 |
+
|
| 898 |
+
[Chapter_06_Decongestants_page2_img282.png]
|
| 899 |
+
|
| 900 |
+
|
| 901 |
+
[Chapter_06_Decongestants_page2_img283.png]
|
| 902 |
+
|
| 903 |
+
|
| 904 |
+
[Chapter_06_Decongestants_page2_img284.png]
|
| 905 |
+
|
| 906 |
+
|
| 907 |
+
[Chapter_06_Decongestants_page2_img285.png]
|
| 908 |
+
|
| 909 |
+
|
| 910 |
+
[Chapter_06_Decongestants_page2_img286.png]
|
| 911 |
+
|
| 912 |
+
|
| 913 |
+
[Chapter_06_Decongestants_page2_img287.png]
|
| 914 |
+
|
| 915 |
+
|
| 916 |
+
[Chapter_06_Decongestants_page2_img288.png]
|
| 917 |
+
|
| 918 |
+
|
| 919 |
+
[Chapter_06_Decongestants_page2_img289.png]
|
| 920 |
+
|
| 921 |
+
|
| 922 |
+
[Chapter_06_Decongestants_page2_img290.png]
|
| 923 |
+
|
| 924 |
+
|
| 925 |
+
[Chapter_06_Decongestants_page2_img291.png]
|
| 926 |
+
|
| 927 |
+
|
| 928 |
+
[Chapter_06_Decongestants_page2_img292.png]
|
| 929 |
+
|
| 930 |
+
|
| 931 |
+
[Chapter_06_Decongestants_page2_img293.png]
|
| 932 |
+
|
| 933 |
+
|
| 934 |
+
[Chapter_06_Decongestants_page2_img294.png]
|
| 935 |
+
|
| 936 |
+
|
| 937 |
+
[Chapter_06_Decongestants_page2_img295.png]
|
| 938 |
+
|
| 939 |
+
|
| 940 |
+
[Chapter_06_Decongestants_page2_img296.png]
|
| 941 |
+
|
| 942 |
+
|
| 943 |
+
[Chapter_06_Decongestants_page2_img297.png]
|
| 944 |
+
|
| 945 |
+
|
| 946 |
+
[Chapter_06_Decongestants_page2_img298.png]
|
| 947 |
+
|
| 948 |
+
|
| 949 |
+
[Chapter_06_Decongestants_page2_img299.png]
|
| 950 |
+
|
| 951 |
+
|
| 952 |
+
[Chapter_06_Decongestants_page2_img300.png]
|
| 953 |
+
|
| 954 |
+
|
| 955 |
+
[Chapter_06_Decongestants_page2_img301.png]
|
| 956 |
+
|
| 957 |
+
|
| 958 |
+
[Chapter_06_Decongestants_page2_img302.png]
|
| 959 |
+
|
| 960 |
+
|
| 961 |
+
[Chapter_06_Decongestants_page2_img303.png]
|
| 962 |
+
|
| 963 |
+
|
| 964 |
+
[Chapter_06_Decongestants_page2_img304.png]
|
| 965 |
+
|
| 966 |
+
|
| 967 |
+
[Chapter_06_Decongestants_page2_img305.png]
|
| 968 |
+
|
| 969 |
+
|
| 970 |
+
[Chapter_06_Decongestants_page2_img306.png]
|
| 971 |
+
|
| 972 |
+
|
| 973 |
+
[Chapter_06_Decongestants_page2_img307.png]
|
| 974 |
+
|
| 975 |
+
|
| 976 |
+
[Chapter_06_Decongestants_page2_img308.png]
|
| 977 |
+
|
| 978 |
+
|
| 979 |
+
[Chapter_06_Decongestants_page2_img309.png]
|
| 980 |
+
|
| 981 |
+
|
| 982 |
+
[Chapter_06_Decongestants_page2_img310.png]
|
| 983 |
+
|
| 984 |
+
|
| 985 |
+
[Chapter_06_Decongestants_page2_img311.png]
|
| 986 |
+
|
| 987 |
+
|
| 988 |
+
[Chapter_06_Decongestants_page2_img312.png]
|
| 989 |
+
|
| 990 |
+
|
| 991 |
+
[Chapter_06_Decongestants_page2_img313.png]
|
| 992 |
+
|
| 993 |
+
|
| 994 |
+
[Chapter_06_Decongestants_page2_img314.png]
|
| 995 |
+
|
| 996 |
+
|
| 997 |
+
[Chapter_06_Decongestants_page2_img315.png]
|
| 998 |
+
|
| 999 |
+
|
| 1000 |
+
[Chapter_06_Decongestants_page2_img316.png]
|
| 1001 |
+
|
| 1002 |
+
|
| 1003 |
+
[Chapter_06_Decongestants_page2_img317.png]
|
| 1004 |
+
|
| 1005 |
+
|
| 1006 |
+
[Chapter_06_Decongestants_page2_img318.png]
|
| 1007 |
+
|
| 1008 |
+
|
| 1009 |
+
[Chapter_06_Decongestants_page2_img319.png]
|
| 1010 |
+
|
| 1011 |
+
|
| 1012 |
+
[Chapter_06_Decongestants_page2_img320.png]
|
| 1013 |
+
|
| 1014 |
+
|
| 1015 |
+
[Chapter_06_Decongestants_page2_img321.png]
|
| 1016 |
+
|
| 1017 |
+
|
| 1018 |
+
[Chapter_06_Decongestants_page2_img322.png]
|
| 1019 |
+
|
| 1020 |
+
|
| 1021 |
+
[Chapter_06_Decongestants_page2_img323.png]
|
| 1022 |
+
|
| 1023 |
+
|
| 1024 |
+
[Chapter_06_Decongestants_page2_img324.png]
|
| 1025 |
+
|
| 1026 |
+
|
| 1027 |
+
[Chapter_06_Decongestants_page2_img325.png]
|
| 1028 |
+
|
| 1029 |
+
|
| 1030 |
+
[Chapter_06_Decongestants_page2_img326.png]
|
| 1031 |
+
|
| 1032 |
+
|
| 1033 |
+
[Chapter_06_Decongestants_page2_img327.png]
|
| 1034 |
+
|
| 1035 |
+
|
| 1036 |
+
[Chapter_06_Decongestants_page2_img328.png]
|
| 1037 |
+
|
| 1038 |
+
|
| 1039 |
+
[Chapter_06_Decongestants_page2_img329.png]
|
| 1040 |
+
|
| 1041 |
+
|
| 1042 |
+
[Chapter_06_Decongestants_page2_img330.png]
|
| 1043 |
+
|
| 1044 |
+
|
| 1045 |
+
[Chapter_06_Decongestants_page2_img331.png]
|
| 1046 |
+
|
| 1047 |
+
|
| 1048 |
+
[Chapter_06_Decongestants_page2_img332.png]
|
| 1049 |
+
|
| 1050 |
+
|
| 1051 |
+
[Chapter_06_Decongestants_page2_img333.png]
|
| 1052 |
+
|
| 1053 |
+
|
| 1054 |
+
[Chapter_06_Decongestants_page2_img334.png]
|
| 1055 |
+
|
| 1056 |
+
|
| 1057 |
+
[Chapter_06_Decongestants_page2_img335.png]
|
| 1058 |
+
|
| 1059 |
+
|
| 1060 |
+
[Chapter_06_Decongestants_page2_img336.png]
|
| 1061 |
+
|
| 1062 |
+
|
| 1063 |
+
[Chapter_06_Decongestants_page2_img337.png]
|
| 1064 |
+
|
| 1065 |
+
|
| 1066 |
+
[Chapter_06_Decongestants_page2_img338.png]
|
| 1067 |
+
|
| 1068 |
+
|
| 1069 |
+
[Chapter_06_Decongestants_page2_img339.png]
|
| 1070 |
+
|
| 1071 |
+
|
| 1072 |
+
[Chapter_06_Decongestants_page2_img340.png]
|
| 1073 |
+
|
| 1074 |
+
|
| 1075 |
+
[Chapter_06_Decongestants_page2_img341.png]
|
| 1076 |
+
|
| 1077 |
+
|
| 1078 |
+
[Chapter_06_Decongestants_page2_img342.png]
|
| 1079 |
+
|
| 1080 |
+
|
| 1081 |
+
[Chapter_06_Decongestants_page2_img343.png]
|
| 1082 |
+
|
| 1083 |
+
|
| 1084 |
+
[Chapter_06_Decongestants_page2_img344.png]
|
| 1085 |
+
|
| 1086 |
+
|
| 1087 |
+
[Chapter_06_Decongestants_page2_img345.png]
|
| 1088 |
+
|
| 1089 |
+
|
| 1090 |
+
[Chapter_06_Decongestants_page2_img346.png]
|
| 1091 |
+
|
| 1092 |
+
|
| 1093 |
+
[Chapter_06_Decongestants_page2_img347.png]
|
| 1094 |
+
|
| 1095 |
+
|
| 1096 |
+
[Chapter_06_Decongestants_page2_img348.png]
|
| 1097 |
+
|
| 1098 |
+
|
| 1099 |
+
[Chapter_06_Decongestants_page2_img349.png]
|
| 1100 |
+
|
| 1101 |
+
|
| 1102 |
+
[Chapter_06_Decongestants_page2_img350.png]
|
| 1103 |
+
|
| 1104 |
+
|
| 1105 |
+
[Chapter_06_Decongestants_page2_img351.png]
|
| 1106 |
+
|
| 1107 |
+
|
| 1108 |
+
[Chapter_06_Decongestants_page2_img352.png]
|
| 1109 |
+
|
| 1110 |
+
|
| 1111 |
+
[Chapter_06_Decongestants_page2_img353.png]
|
| 1112 |
+
|
| 1113 |
+
|
| 1114 |
+
[Chapter_06_Decongestants_page2_img354.png]
|
| 1115 |
+
|
| 1116 |
+
|
| 1117 |
+
[Chapter_06_Decongestants_page2_img355.png]
|
| 1118 |
+
|
| 1119 |
+
|
| 1120 |
+
[Chapter_06_Decongestants_page2_img356.png]
|
| 1121 |
+
|
| 1122 |
+
|
| 1123 |
+
[Chapter_06_Decongestants_page2_img357.png]
|
| 1124 |
+
|
| 1125 |
+
|
| 1126 |
+
[Chapter_06_Decongestants_page2_img358.png]
|
| 1127 |
+
|
| 1128 |
+
|
| 1129 |
+
[Chapter_06_Decongestants_page2_img359.png]
|
| 1130 |
+
|
| 1131 |
+
|
| 1132 |
+
[Chapter_06_Decongestants_page2_img360.png]
|
| 1133 |
+
|
| 1134 |
+
|
| 1135 |
+
[Chapter_06_Decongestants_page2_img361.png]
|
| 1136 |
+
|
| 1137 |
+
|
| 1138 |
+
[Chapter_06_Decongestants_page2_img362.png]
|
| 1139 |
+
|
| 1140 |
+
|
| 1141 |
+
[Chapter_06_Decongestants_page2_img363.png]
|
| 1142 |
+
|
| 1143 |
+
|
| 1144 |
+
[Chapter_06_Decongestants_page2_img364.png]
|
| 1145 |
+
|
| 1146 |
+
|
| 1147 |
+
[Chapter_06_Decongestants_page2_img365.png]
|
| 1148 |
+
|
| 1149 |
+
|
| 1150 |
+
[Chapter_06_Decongestants_page2_img366.png]
|
| 1151 |
+
|
| 1152 |
+
|
| 1153 |
+
[Chapter_06_Decongestants_page2_img367.png]
|
| 1154 |
+
|
| 1155 |
+
|
| 1156 |
+
[Chapter_06_Decongestants_page2_img368.png]
|
| 1157 |
+
|
| 1158 |
+
|
| 1159 |
+
[Chapter_06_Decongestants_page2_img369.png]
|
| 1160 |
+
|
| 1161 |
+
|
| 1162 |
+
[Chapter_06_Decongestants_page2_img370.png]
|
| 1163 |
+
|
| 1164 |
+
|
| 1165 |
+
[Chapter_06_Decongestants_page2_img371.png]
|
| 1166 |
+
|
| 1167 |
+
|
| 1168 |
+
[Chapter_06_Decongestants_page2_img372.png]
|
| 1169 |
+
|
| 1170 |
+
|
| 1171 |
+
[Chapter_06_Decongestants_page2_img373.png]
|
| 1172 |
+
|
| 1173 |
+
|
| 1174 |
+
[Chapter_06_Decongestants_page2_img374.png]
|
| 1175 |
+
|
| 1176 |
+
|
| 1177 |
+
[Chapter_06_Decongestants_page2_img375.png]
|
| 1178 |
+
|
| 1179 |
+
|
| 1180 |
+
[Chapter_06_Decongestants_page2_img376.png]
|
| 1181 |
+
|
| 1182 |
+
|
| 1183 |
+
[Chapter_06_Decongestants_page2_img377.png]
|
| 1184 |
+
|
| 1185 |
+
|
| 1186 |
+
[Chapter_06_Decongestants_page2_img378.png]
|
| 1187 |
+
|
| 1188 |
+
|
| 1189 |
+
[Chapter_06_Decongestants_page2_img379.png]
|
| 1190 |
+
|
| 1191 |
+
|
| 1192 |
+
[Chapter_06_Decongestants_page2_img380.png]
|
| 1193 |
+
|
| 1194 |
+
|
| 1195 |
+
[Chapter_06_Decongestants_page2_img381.png]
|
| 1196 |
+
|
| 1197 |
+
|
| 1198 |
+
[Chapter_06_Decongestants_page2_img382.png]
|
| 1199 |
+
|
| 1200 |
+
|
| 1201 |
+
[Chapter_06_Decongestants_page2_img383.png]
|
| 1202 |
+
|
| 1203 |
+
|
| 1204 |
+
[Chapter_06_Decongestants_page2_img384.png]
|
| 1205 |
+
|
| 1206 |
+
|
| 1207 |
+
[Chapter_06_Decongestants_page2_img385.png]
|
| 1208 |
+
|
| 1209 |
+
|
| 1210 |
+
[Chapter_06_Decongestants_page2_img386.png]
|
| 1211 |
+
|
| 1212 |
+
|
| 1213 |
+
[Chapter_06_Decongestants_page2_img387.png]
|
| 1214 |
+
|
| 1215 |
+
|
| 1216 |
+
[Chapter_06_Decongestants_page2_img388.png]
|
| 1217 |
+
|
| 1218 |
+
|
| 1219 |
+
[Chapter_06_Decongestants_page2_img389.png]
|
| 1220 |
+
|
| 1221 |
+
|
| 1222 |
+
[Chapter_06_Decongestants_page2_img390.png]
|
| 1223 |
+
|
| 1224 |
+
|
| 1225 |
+
[Chapter_06_Decongestants_page2_img391.png]
|
| 1226 |
+
|
| 1227 |
+
|
| 1228 |
+
[Chapter_06_Decongestants_page2_img392.png]
|
| 1229 |
+
|
| 1230 |
+
|
| 1231 |
+
[Chapter_06_Decongestants_page2_img393.png]
|
| 1232 |
+
|
| 1233 |
+
|
| 1234 |
+
[Chapter_06_Decongestants_page2_img394.png]
|
| 1235 |
+
|
| 1236 |
+
|
| 1237 |
+
[Chapter_06_Decongestants_page2_img395.png]
|
| 1238 |
+
|
| 1239 |
+
|
| 1240 |
+
[Chapter_06_Decongestants_page2_img396.png]
|
| 1241 |
+
|
| 1242 |
+
|
| 1243 |
+
[Chapter_06_Decongestants_page2_img397.png]
|
| 1244 |
+
|
| 1245 |
+
|
| 1246 |
+
[Chapter_06_Decongestants_page2_img398.png]
|
| 1247 |
+
|
| 1248 |
+
|
| 1249 |
+
[Chapter_06_Decongestants_page2_img399.png]
|
| 1250 |
+
|
| 1251 |
+
|
| 1252 |
+
[Chapter_06_Decongestants_page2_img400.png]
|
| 1253 |
+
|
| 1254 |
+
|
| 1255 |
+
[Chapter_06_Decongestants_page2_img401.png]
|
| 1256 |
+
|
| 1257 |
+
|
| 1258 |
+
[Chapter_06_Decongestants_page2_img402.png]
|
| 1259 |
+
|
| 1260 |
+
|
| 1261 |
+
[Chapter_06_Decongestants_page2_img403.png]
|
| 1262 |
+
|
| 1263 |
+
|
| 1264 |
+
[Chapter_06_Decongestants_page2_img404.png]
|
| 1265 |
+
|
| 1266 |
+
|
| 1267 |
+
[Chapter_06_Decongestants_page2_img405.png]
|
| 1268 |
+
|
| 1269 |
+
|
| 1270 |
+
[Chapter_06_Decongestants_page2_img406.png]
|
| 1271 |
+
|
| 1272 |
+
|
| 1273 |
+
[Chapter_06_Decongestants_page2_img407.png]
|
| 1274 |
+
|
| 1275 |
+
|
| 1276 |
+
[Chapter_06_Decongestants_page2_img408.png]
|
| 1277 |
+
|
| 1278 |
+
|
| 1279 |
+
[Chapter_06_Decongestants_page2_img409.png]
|
| 1280 |
+
|
| 1281 |
+
|
| 1282 |
+
[Chapter_06_Decongestants_page2_img410.png]
|
| 1283 |
+
|
| 1284 |
+
|
| 1285 |
+
[Chapter_06_Decongestants_page2_img411.png]
|
| 1286 |
+
|
| 1287 |
+
|
| 1288 |
+
[Chapter_06_Decongestants_page2_img412.png]
|
| 1289 |
+
|
| 1290 |
+
|
| 1291 |
+
[Chapter_06_Decongestants_page2_img413.png]
|
| 1292 |
+
|
| 1293 |
+
|
| 1294 |
+
[Chapter_06_Decongestants_page2_img414.png]
|
| 1295 |
+
|
| 1296 |
+
|
| 1297 |
+
[Chapter_06_Decongestants_page2_img415.png]
|
| 1298 |
+
|
| 1299 |
+
|
| 1300 |
+
[Chapter_06_Decongestants_page2_img416.png]
|
| 1301 |
+
|
| 1302 |
+
|
| 1303 |
+
[Chapter_06_Decongestants_page2_img417.png]
|
| 1304 |
+
|
| 1305 |
+
|
| 1306 |
+
[Chapter_06_Decongestants_page2_img418.png]
|
| 1307 |
+
|
| 1308 |
+
|
| 1309 |
+
[Chapter_06_Decongestants_page2_img419.png]
|
| 1310 |
+
|
| 1311 |
+
|
| 1312 |
+
[Chapter_06_Decongestants_page2_img420.png]
|
| 1313 |
+
|
| 1314 |
+
|
| 1315 |
+
[Chapter_06_Decongestants_page2_img421.png]
|
| 1316 |
+
|
| 1317 |
+
|
| 1318 |
+
[Chapter_06_Decongestants_page2_img422.png]
|
| 1319 |
+
|
| 1320 |
+
|
| 1321 |
+
[Chapter_06_Decongestants_page2_img423.png]
|
| 1322 |
+
|
| 1323 |
+
|
| 1324 |
+
[Chapter_06_Decongestants_page2_img424.png]
|
| 1325 |
+
|
| 1326 |
+
|
| 1327 |
+
[Chapter_06_Decongestants_page2_img425.png]
|
| 1328 |
+
|
| 1329 |
+
|
| 1330 |
+
[Chapter_06_Decongestants_page2_img426.png]
|
| 1331 |
+
|
| 1332 |
+
|
| 1333 |
+
[Chapter_06_Decongestants_page2_img427.png]
|
| 1334 |
+
|
| 1335 |
+
|
| 1336 |
+
[Chapter_06_Decongestants_page2_img428.png]
|
| 1337 |
+
|
| 1338 |
+
|
| 1339 |
+
[Chapter_06_Decongestants_page2_img429.png]
|
| 1340 |
+
|
| 1341 |
+
|
| 1342 |
+
[Chapter_06_Decongestants_page2_img430.png]
|
| 1343 |
+
|
| 1344 |
+
|
| 1345 |
+
[Chapter_06_Decongestants_page2_img431.png]
|
| 1346 |
+
|
| 1347 |
+
|
| 1348 |
+
[Chapter_06_Decongestants_page2_img432.png]
|
| 1349 |
+
|
| 1350 |
+
|
| 1351 |
+
[Chapter_06_Decongestants_page2_img433.png]
|
| 1352 |
+
|
| 1353 |
+
|
| 1354 |
+
[Chapter_06_Decongestants_page2_img434.png]
|
| 1355 |
+
|
| 1356 |
+
|
| 1357 |
+
[Chapter_06_Decongestants_page2_img435.png]
|
| 1358 |
+
|
| 1359 |
+
|
| 1360 |
+
[Chapter_06_Decongestants_page2_img436.png]
|
| 1361 |
+
|
| 1362 |
+
|
| 1363 |
+
[Chapter_06_Decongestants_page2_img437.png]
|
| 1364 |
+
|
| 1365 |
+
|
| 1366 |
+
[Chapter_06_Decongestants_page2_img438.png]
|
| 1367 |
+
|
| 1368 |
+
|
| 1369 |
+
[Chapter_06_Decongestants_page2_img439.png]
|
| 1370 |
+
|
| 1371 |
+
|
| 1372 |
+
[Chapter_06_Decongestants_page2_img440.png]
|
| 1373 |
+
|
| 1374 |
+
|
| 1375 |
+
[Chapter_06_Decongestants_page2_img441.png]
|
| 1376 |
+
|
| 1377 |
+
|
| 1378 |
+
[Chapter_06_Decongestants_page2_img442.png]
|
| 1379 |
+
|
| 1380 |
+
|
| 1381 |
+
[Chapter_06_Decongestants_page2_img443.png]
|
| 1382 |
+
|
| 1383 |
+
|
| 1384 |
+
[Chapter_06_Decongestants_page2_img444.png]
|
| 1385 |
+
|
| 1386 |
+
|
| 1387 |
+
[Chapter_06_Decongestants_page2_img445.png]
|
| 1388 |
+
|
| 1389 |
+
|
| 1390 |
+
[Chapter_06_Decongestants_page2_img446.png]
|
| 1391 |
+
|
| 1392 |
+
|
| 1393 |
+
[Chapter_06_Decongestants_page2_img447.png]
|
| 1394 |
+
|
| 1395 |
+
|
| 1396 |
+
[Chapter_06_Decongestants_page2_img448.png]
|
| 1397 |
+
|
| 1398 |
+
|
| 1399 |
+
[Chapter_06_Decongestants_page2_img449.png]
|
| 1400 |
+
|
| 1401 |
+
|
| 1402 |
+
[Chapter_06_Decongestants_page2_img450.png]
|
| 1403 |
+
|
| 1404 |
+
|
| 1405 |
+
[Chapter_06_Decongestants_page2_img451.png]
|
| 1406 |
+
|
| 1407 |
+
|
| 1408 |
+
[Chapter_06_Decongestants_page2_img452.png]
|
| 1409 |
+
|
| 1410 |
+
|
| 1411 |
+
[Chapter_06_Decongestants_page2_img453.png]
|
| 1412 |
+
|
| 1413 |
+
|
| 1414 |
+
[Chapter_06_Decongestants_page2_img454.png]
|
| 1415 |
+
|
| 1416 |
+
|
| 1417 |
+
[Chapter_06_Decongestants_page2_img455.png]
|
| 1418 |
+
|
| 1419 |
+
|
| 1420 |
+
[Chapter_06_Decongestants_page2_img456.png]
|
| 1421 |
+
|
| 1422 |
+
|
| 1423 |
+
[Chapter_06_Decongestants_page2_img457.png]
|
| 1424 |
+
|
| 1425 |
+
|
| 1426 |
+
[Chapter_06_Decongestants_page2_img458.png]
|
| 1427 |
+
|
| 1428 |
+
|
| 1429 |
+
[Chapter_06_Decongestants_page2_img459.png]
|
| 1430 |
+
|
| 1431 |
+
|
| 1432 |
+
[Chapter_06_Decongestants_page2_img460.png]
|
| 1433 |
+
|
| 1434 |
+
|
| 1435 |
+
[Chapter_06_Decongestants_page2_img461.png]
|
| 1436 |
+
|
| 1437 |
+
|
| 1438 |
+
[Chapter_06_Decongestants_page2_img462.png]
|
| 1439 |
+
|
| 1440 |
+
|
| 1441 |
+
[Chapter_06_Decongestants_page2_img463.png]
|
| 1442 |
+
|
| 1443 |
+
|
| 1444 |
+
[Chapter_06_Decongestants_page2_img464.png]
|
| 1445 |
+
|
| 1446 |
+
|
| 1447 |
+
[Chapter_06_Decongestants_page2_img465.png]
|
| 1448 |
+
|
| 1449 |
+
|
| 1450 |
+
[Chapter_06_Decongestants_page2_img466.png]
|
| 1451 |
+
|
| 1452 |
+
|
| 1453 |
+
[Chapter_06_Decongestants_page2_img467.png]
|
| 1454 |
+
|
| 1455 |
+
|
| 1456 |
+
[Chapter_06_Decongestants_page2_img468.png]
|
| 1457 |
+
|
| 1458 |
+
|
| 1459 |
+
[Chapter_06_Decongestants_page2_img469.png]
|
| 1460 |
+
|
| 1461 |
+
|
| 1462 |
+
[Chapter_06_Decongestants_page2_img470.png]
|
| 1463 |
+
|
| 1464 |
+
|
| 1465 |
+
[Chapter_06_Decongestants_page2_img471.png]
|
| 1466 |
+
|
| 1467 |
+
|
| 1468 |
+
[Chapter_06_Decongestants_page2_img472.png]
|
| 1469 |
+
|
| 1470 |
+
|
| 1471 |
+
[Chapter_06_Decongestants_page2_img473.png]
|
| 1472 |
+
|
| 1473 |
+
|
| 1474 |
+
[Chapter_06_Decongestants_page2_img474.png]
|
| 1475 |
+
|
| 1476 |
+
|
| 1477 |
+
[Chapter_06_Decongestants_page2_img475.png]
|
| 1478 |
+
|
| 1479 |
+
|
| 1480 |
+
[Chapter_06_Decongestants_page2_img476.png]
|
| 1481 |
+
|
| 1482 |
+
|
| 1483 |
+
[Chapter_06_Decongestants_page2_img477.png]
|
| 1484 |
+
|
| 1485 |
+
|
| 1486 |
+
[Chapter_06_Decongestants_page2_img478.png]
|
| 1487 |
+
|
| 1488 |
+
|
| 1489 |
+
[Chapter_06_Decongestants_page2_img479.png]
|
| 1490 |
+
|
| 1491 |
+
|
| 1492 |
+
[Chapter_06_Decongestants_page2_img480.png]
|
| 1493 |
+
|
| 1494 |
+
|
| 1495 |
+
[Chapter_06_Decongestants_page2_img481.png]
|
| 1496 |
+
|
| 1497 |
+
|
| 1498 |
+
[Chapter_06_Decongestants_page2_img482.png]
|
| 1499 |
+
|
| 1500 |
+
|
| 1501 |
+
[Chapter_06_Decongestants_page2_img483.png]
|
| 1502 |
+
|
| 1503 |
+
|
| 1504 |
+
[Chapter_06_Decongestants_page2_img484.png]
|
| 1505 |
+
|
| 1506 |
+
|
| 1507 |
+
[Chapter_06_Decongestants_page2_img485.png]
|
| 1508 |
+
|
| 1509 |
+
|
| 1510 |
+
[Chapter_06_Decongestants_page2_img486.png]
|
| 1511 |
+
|
| 1512 |
+
|
| 1513 |
+
[Chapter_06_Decongestants_page2_img487.png]
|
| 1514 |
+
|
| 1515 |
+
|
| 1516 |
+
[Chapter_06_Decongestants_page2_img488.png]
|
| 1517 |
+
|
| 1518 |
+
|
| 1519 |
+
[Chapter_06_Decongestants_page2_img489.png]
|
| 1520 |
+
|
| 1521 |
+
|
| 1522 |
+
[Chapter_06_Decongestants_page2_img490.png]
|
| 1523 |
+
|
| 1524 |
+
|
| 1525 |
+
[Chapter_06_Decongestants_page2_img491.png]
|
| 1526 |
+
|
| 1527 |
+
|
| 1528 |
+
[Chapter_06_Decongestants_page2_img492.png]
|
| 1529 |
+
|
| 1530 |
+
|
| 1531 |
+
[Chapter_06_Decongestants_page2_img493.png]
|
| 1532 |
+
|
| 1533 |
+
|
| 1534 |
+
[Chapter_06_Decongestants_page2_img494.png]
|
| 1535 |
+
|
| 1536 |
+
|
| 1537 |
+
[Chapter_06_Decongestants_page2_img495.png]
|
| 1538 |
+
|
| 1539 |
+
|
| 1540 |
+
[Chapter_06_Decongestants_page2_img496.png]
|
| 1541 |
+
|
| 1542 |
+
|
| 1543 |
+
[Chapter_06_Decongestants_page2_img497.png]
|
| 1544 |
+
|
| 1545 |
+
|
| 1546 |
+
[Chapter_06_Decongestants_page2_img498.png]
|
| 1547 |
+
|
| 1548 |
+
|
| 1549 |
+
[Chapter_06_Decongestants_page2_img499.png]
|
| 1550 |
+
|
| 1551 |
+
|
| 1552 |
+
[Chapter_06_Decongestants_page2_img500.png]
|
| 1553 |
+
|
| 1554 |
+
|
| 1555 |
+
[Chapter_06_Decongestants_page2_img501.png]
|
| 1556 |
+
|
| 1557 |
+
|
| 1558 |
+
[Chapter_06_Decongestants_page2_img502.png]
|
| 1559 |
+
|
| 1560 |
+
|
| 1561 |
+
[Chapter_06_Decongestants_page2_img503.png]
|
| 1562 |
+
|
| 1563 |
+
|
| 1564 |
+
[Chapter_06_Decongestants_page2_img504.png]
|
| 1565 |
+
|
| 1566 |
+
|
| 1567 |
+
[Chapter_06_Decongestants_page2_img505.png]
|
| 1568 |
+
|
| 1569 |
+
|
| 1570 |
+
[Chapter_06_Decongestants_page2_img506.png]
|
| 1571 |
+
|
| 1572 |
+
|
| 1573 |
+
[Chapter_06_Decongestants_page2_img507.png]
|
| 1574 |
+
|
| 1575 |
+
|
| 1576 |
+
[Chapter_06_Decongestants_page2_img508.png]
|
| 1577 |
+
|
| 1578 |
+
|
| 1579 |
+
[Chapter_06_Decongestants_page2_img509.png]
|
| 1580 |
+
|
| 1581 |
+
|
| 1582 |
+
[Chapter_06_Decongestants_page2_img510.png]
|
| 1583 |
+
|
| 1584 |
+
|
| 1585 |
+
[Chapter_06_Decongestants_page2_img511.png]
|
| 1586 |
+
|
| 1587 |
+
|
| 1588 |
+
[Chapter_06_Decongestants_page2_img512.png]
|
| 1589 |
+
|
| 1590 |
+
|
| 1591 |
+
[Chapter_06_Decongestants_page2_img513.png]
|
| 1592 |
+
|
| 1593 |
+
|
| 1594 |
+
[Chapter_06_Decongestants_page2_img514.png]
|
| 1595 |
+
|
| 1596 |
+
|
| 1597 |
+
[Chapter_06_Decongestants_page2_img515.png]
|
| 1598 |
+
|
| 1599 |
+
|
| 1600 |
+
[Chapter_06_Decongestants_page2_img516.png]
|
| 1601 |
+
|
| 1602 |
+
|
| 1603 |
+
[Chapter_06_Decongestants_page2_img517.png]
|
| 1604 |
+
|
| 1605 |
+
|
| 1606 |
+
[Chapter_06_Decongestants_page2_img518.png]
|
| 1607 |
+
|
| 1608 |
+
|
| 1609 |
+
[Chapter_06_Decongestants_page2_img519.png]
|
| 1610 |
+
|
| 1611 |
+
|
| 1612 |
+
[Chapter_06_Decongestants_page2_img520.png]
|
| 1613 |
+
|
| 1614 |
+
|
| 1615 |
+
[Chapter_06_Decongestants_page2_img521.png]
|
| 1616 |
+
|
| 1617 |
+
|
| 1618 |
+
[Chapter_06_Decongestants_page2_img522.png]
|
| 1619 |
+
|
| 1620 |
+
|
| 1621 |
+
[Chapter_06_Decongestants_page2_img523.png]
|
| 1622 |
+
|
| 1623 |
+
|
| 1624 |
+
[Chapter_06_Decongestants_page2_img524.png]
|
| 1625 |
+
|
| 1626 |
+
|
| 1627 |
+
[Chapter_06_Decongestants_page2_img525.png]
|
| 1628 |
+
|
| 1629 |
+
|
| 1630 |
+
[Chapter_06_Decongestants_page2_img526.png]
|
| 1631 |
+
|
| 1632 |
+
|
| 1633 |
+
[Chapter_06_Decongestants_page2_img527.png]
|
| 1634 |
+
|
| 1635 |
+
|
| 1636 |
+
[Chapter_06_Decongestants_page2_img528.png]
|
| 1637 |
+
|
| 1638 |
+
|
| 1639 |
+
[Chapter_06_Decongestants_page2_img529.png]
|
| 1640 |
+
|
| 1641 |
+
|
| 1642 |
+
[Chapter_06_Decongestants_page2_img530.png]
|
| 1643 |
+
|
| 1644 |
+
|
| 1645 |
+
[Chapter_06_Decongestants_page2_img531.png]
|
| 1646 |
+
|
| 1647 |
+
|
| 1648 |
+
[Chapter_06_Decongestants_page2_img532.png]
|
| 1649 |
+
|
| 1650 |
+
|
| 1651 |
+
[Chapter_06_Decongestants_page2_img533.png]
|
| 1652 |
+
|
| 1653 |
+
|
| 1654 |
+
[Chapter_06_Decongestants_page2_img534.png]
|
| 1655 |
+
|
| 1656 |
+
|
| 1657 |
+
[Chapter_06_Decongestants_page2_img535.png]
|
| 1658 |
+
|
| 1659 |
+
|
| 1660 |
+
[Chapter_06_Decongestants_page2_img536.png]
|
| 1661 |
+
|
| 1662 |
+
|
| 1663 |
+
[Chapter_06_Decongestants_page2_img537.png]
|
| 1664 |
+
|
| 1665 |
+
|
| 1666 |
+
[Chapter_06_Decongestants_page2_img538.png]
|
| 1667 |
+
|
| 1668 |
+
|
| 1669 |
+
[Chapter_06_Decongestants_page2_img539.png]
|
| 1670 |
+
|
| 1671 |
+
|
| 1672 |
+
[Chapter_06_Decongestants_page2_img540.png]
|
| 1673 |
+
|
| 1674 |
+
|
| 1675 |
+
[Chapter_06_Decongestants_page2_img541.png]
|
| 1676 |
+
|
| 1677 |
+
|
| 1678 |
+
[Chapter_06_Decongestants_page2_img542.png]
|
| 1679 |
+
|
| 1680 |
+
|
| 1681 |
+
[Chapter_06_Decongestants_page2_img543.png]
|
| 1682 |
+
|
| 1683 |
+
|
| 1684 |
+
[Chapter_06_Decongestants_page2_img544.png]
|
| 1685 |
+
|
| 1686 |
+
|
| 1687 |
+
[Chapter_06_Decongestants_page2_img545.png]
|
| 1688 |
+
|
| 1689 |
+
|
| 1690 |
+
[Chapter_06_Decongestants_page2_img546.png]
|
| 1691 |
+
|
| 1692 |
+
|
| 1693 |
+
[Chapter_06_Decongestants_page2_img547.png]
|
| 1694 |
+
|
| 1695 |
+
|
| 1696 |
+
[Chapter_06_Decongestants_page2_img548.png]
|
| 1697 |
+
|
| 1698 |
+
|
| 1699 |
+
[Chapter_06_Decongestants_page2_img549.png]
|
| 1700 |
+
|
| 1701 |
+
|
| 1702 |
+
[Chapter_06_Decongestants_page2_img550.png]
|
| 1703 |
+
|
| 1704 |
+
|
| 1705 |
+
[Chapter_06_Decongestants_page2_img551.png]
|
| 1706 |
+
|
| 1707 |
+
|
| 1708 |
+
[Chapter_06_Decongestants_page2_img552.png]
|
| 1709 |
+
|
| 1710 |
+
|
| 1711 |
+
[Chapter_06_Decongestants_page2_img553.png]
|
| 1712 |
+
|
| 1713 |
+
|
| 1714 |
+
[Chapter_06_Decongestants_page2_img554.png]
|
| 1715 |
+
|
| 1716 |
+
|
| 1717 |
+
[Chapter_06_Decongestants_page2_img555.png]
|
| 1718 |
+
|
| 1719 |
+
|
| 1720 |
+
[Chapter_06_Decongestants_page2_img556.png]
|
| 1721 |
+
|
| 1722 |
+
|
| 1723 |
+
[Chapter_06_Decongestants_page2_img557.png]
|
| 1724 |
+
|
| 1725 |
+
|
| 1726 |
+
[Chapter_06_Decongestants_page2_img558.png]
|
| 1727 |
+
|
| 1728 |
+
|
| 1729 |
+
[Chapter_06_Decongestants_page2_img559.png]
|
| 1730 |
+
|
| 1731 |
+
|
| 1732 |
+
[Chapter_06_Decongestants_page2_img560.png]
|
| 1733 |
+
|
| 1734 |
+
|
| 1735 |
+
[Chapter_06_Decongestants_page2_img561.png]
|
| 1736 |
+
|
| 1737 |
+
|
| 1738 |
+
[Chapter_06_Decongestants_page2_img562.png]
|
| 1739 |
+
|
| 1740 |
+
|
| 1741 |
+
[Chapter_06_Decongestants_page2_img563.png]
|
| 1742 |
+
|
| 1743 |
+
|
| 1744 |
+
[Chapter_06_Decongestants_page2_img564.png]
|
| 1745 |
+
|
| 1746 |
+
|
| 1747 |
+
[Chapter_06_Decongestants_page2_img565.png]
|
| 1748 |
+
|
| 1749 |
+
|
| 1750 |
+
[Chapter_06_Decongestants_page2_img566.png]
|
| 1751 |
+
|
| 1752 |
+
|
| 1753 |
+
[Chapter_06_Decongestants_page2_img567.png]
|
| 1754 |
+
|
| 1755 |
+
|
| 1756 |
+
[Chapter_06_Decongestants_page2_img568.png]
|
| 1757 |
+
|
| 1758 |
+
|
| 1759 |
+
[Chapter_06_Decongestants_page2_img569.png]
|
| 1760 |
+
|
| 1761 |
+
|
| 1762 |
+
[Chapter_06_Decongestants_page2_img570.png]
|
| 1763 |
+
|
| 1764 |
+
|
| 1765 |
+
[Chapter_06_Decongestants_page2_img571.png]
|
| 1766 |
+
|
| 1767 |
+
|
| 1768 |
+
[Chapter_06_Decongestants_page2_img572.png]
|
| 1769 |
+
|
| 1770 |
+
|
| 1771 |
+
[Chapter_06_Decongestants_page2_img573.png]
|
| 1772 |
+
|
| 1773 |
+
|
| 1774 |
+
[Chapter_06_Decongestants_page2_img574.png]
|
| 1775 |
+
|
| 1776 |
+
|
| 1777 |
+
[Chapter_06_Decongestants_page2_img575.png]
|
| 1778 |
+
|
| 1779 |
+
|
| 1780 |
+
[Chapter_06_Decongestants_page2_img576.png]
|
| 1781 |
+
|
| 1782 |
+
|
| 1783 |
+
[Chapter_06_Decongestants_page2_img577.png]
|
| 1784 |
+
|
| 1785 |
+
|
| 1786 |
+
[Chapter_06_Decongestants_page2_img578.png]
|
| 1787 |
+
|
| 1788 |
+
|
| 1789 |
+
[Chapter_06_Decongestants_page2_img579.png]
|
| 1790 |
+
|
| 1791 |
+
|
| 1792 |
+
[Chapter_06_Decongestants_page2_img580.png]
|
| 1793 |
+
|
| 1794 |
+
|
| 1795 |
+
[Chapter_06_Decongestants_page2_img581.png]
|
| 1796 |
+
|
| 1797 |
+
|
| 1798 |
+
[Chapter_06_Decongestants_page2_img582.png]
|
| 1799 |
+
|
| 1800 |
+
|
| 1801 |
+
[Chapter_06_Decongestants_page2_img583.png]
|
| 1802 |
+
|
| 1803 |
+
|
| 1804 |
+
[Chapter_06_Decongestants_page2_img584.png]
|
| 1805 |
+
|
| 1806 |
+
|
| 1807 |
+
[Chapter_06_Decongestants_page2_img585.png]
|
| 1808 |
+
|
| 1809 |
+
|
| 1810 |
+
[Chapter_06_Decongestants_page2_img586.png]
|
| 1811 |
+
|
| 1812 |
+
|
| 1813 |
+
[Chapter_06_Decongestants_page2_img587.png]
|
| 1814 |
+
|
| 1815 |
+
|
| 1816 |
+
[Chapter_06_Decongestants_page2_img588.png]
|
| 1817 |
+
|
| 1818 |
+
|
| 1819 |
+
[Chapter_06_Decongestants_page2_img589.png]
|
| 1820 |
+
|
| 1821 |
+
|
| 1822 |
+
[Chapter_06_Decongestants_page2_img590.png]
|
| 1823 |
+
|
| 1824 |
+
|
| 1825 |
+
[Chapter_06_Decongestants_page2_img591.png]
|
| 1826 |
+
|
| 1827 |
+
|
| 1828 |
+
[Chapter_06_Decongestants_page2_img592.png]
|
| 1829 |
+
|
| 1830 |
+
|
| 1831 |
+
[Chapter_06_Decongestants_page2_img593.png]
|
| 1832 |
+
|
| 1833 |
+
|
| 1834 |
+
[Chapter_06_Decongestants_page2_img594.png]
|
| 1835 |
+
|
| 1836 |
+
|
| 1837 |
+
[Chapter_06_Decongestants_page2_img595.png]
|
| 1838 |
+
|
| 1839 |
+
|
| 1840 |
+
[Chapter_06_Decongestants_page2_img596.png]
|
| 1841 |
+
|
| 1842 |
+
|
| 1843 |
+
[Chapter_06_Decongestants_page2_img597.png]
|
| 1844 |
+
|
| 1845 |
+
|
| 1846 |
+
[Chapter_06_Decongestants_page2_img598.png]
|
| 1847 |
+
|
| 1848 |
+
|
| 1849 |
+
[Chapter_06_Decongestants_page2_img599.png]
|
| 1850 |
+
|
| 1851 |
+
|
| 1852 |
+
[Chapter_06_Decongestants_page2_img600.png]
|
| 1853 |
+
|
| 1854 |
+
|
| 1855 |
+
[Chapter_06_Decongestants_page2_img601.png]
|
| 1856 |
+
|
| 1857 |
+
|
| 1858 |
+
[Chapter_06_Decongestants_page2_img602.png]
|
| 1859 |
+
|
| 1860 |
+
|
| 1861 |
+
[Chapter_06_Decongestants_page2_img603.png]
|
| 1862 |
+
|
| 1863 |
+
|
| 1864 |
+
[Chapter_06_Decongestants_page2_img604.png]
|
| 1865 |
+
|
| 1866 |
+
|
| 1867 |
+
[Chapter_06_Decongestants_page2_img605.png]
|
| 1868 |
+
|
| 1869 |
+
|
| 1870 |
+
[Chapter_06_Decongestants_page2_img606.png]
|
| 1871 |
+
|
| 1872 |
+
|
| 1873 |
+
[Chapter_06_Decongestants_page2_img607.png]
|
| 1874 |
+
|
| 1875 |
+
|
| 1876 |
+
[Chapter_06_Decongestants_page2_img608.png]
|
| 1877 |
+
|
| 1878 |
+
|
| 1879 |
+
[Chapter_06_Decongestants_page2_img609.png]
|
| 1880 |
+
|
| 1881 |
+
|
| 1882 |
+
[Chapter_06_Decongestants_page2_img610.png]
|
| 1883 |
+
|
| 1884 |
+
|
| 1885 |
+
[Chapter_06_Decongestants_page2_img611.png]
|
| 1886 |
+
|
| 1887 |
+
|
| 1888 |
+
[Chapter_06_Decongestants_page2_img612.png]
|
| 1889 |
+
|
| 1890 |
+
|
| 1891 |
+
[Chapter_06_Decongestants_page2_img613.png]
|
| 1892 |
+
|
| 1893 |
+
|
| 1894 |
+
[Chapter_06_Decongestants_page2_img614.png]
|
| 1895 |
+
|
| 1896 |
+
|
| 1897 |
+
[Chapter_06_Decongestants_page2_img615.png]
|
| 1898 |
+
|
| 1899 |
+
|
| 1900 |
+
[Chapter_06_Decongestants_page2_img616.png]
|
| 1901 |
+
|
| 1902 |
+
|
| 1903 |
+
[Chapter_06_Decongestants_page2_img617.png]
|
| 1904 |
+
|
| 1905 |
+
|
| 1906 |
+
[Chapter_06_Decongestants_page2_img618.png]
|
| 1907 |
+
|
| 1908 |
+
|
| 1909 |
+
[Chapter_06_Decongestants_page2_img619.png]
|
| 1910 |
+
|
| 1911 |
+
|
| 1912 |
+
[Chapter_06_Decongestants_page2_img620.png]
|
| 1913 |
+
|
| 1914 |
+
|
| 1915 |
+
[Chapter_06_Decongestants_page2_img621.png]
|
| 1916 |
+
|
| 1917 |
+
|
| 1918 |
+
[Chapter_06_Decongestants_page2_img622.png]
|
| 1919 |
+
|
| 1920 |
+
|
| 1921 |
+
[Chapter_06_Decongestants_page2_img623.png]
|
| 1922 |
+
|
| 1923 |
+
|
| 1924 |
+
[Chapter_06_Decongestants_page2_img624.png]
|
| 1925 |
+
|
| 1926 |
+
|
| 1927 |
+
[Chapter_06_Decongestants_page2_img625.png]
|
| 1928 |
+
|
| 1929 |
+
|
| 1930 |
+
[Chapter_06_Decongestants_page2_img626.png]
|
| 1931 |
+
|
| 1932 |
+
|
| 1933 |
+
[Chapter_06_Decongestants_page2_img627.png]
|
| 1934 |
+
|
| 1935 |
+
|
| 1936 |
+
[Chapter_06_Decongestants_page2_img628.png]
|
| 1937 |
+
|
| 1938 |
+
|
| 1939 |
+
[Chapter_06_Decongestants_page2_img629.png]
|
| 1940 |
+
|
| 1941 |
+
|
| 1942 |
+
[Chapter_06_Decongestants_page2_img630.png]
|
| 1943 |
+
|
| 1944 |
+
|
| 1945 |
+
[Chapter_06_Decongestants_page2_img631.png]
|
| 1946 |
+
|
| 1947 |
+
|
| 1948 |
+
[Chapter_06_Decongestants_page2_img632.png]
|
| 1949 |
+
|
| 1950 |
+
|
| 1951 |
+
[Chapter_06_Decongestants_page2_img633.png]
|
| 1952 |
+
|
| 1953 |
+
|
| 1954 |
+
[Chapter_06_Decongestants_page2_img634.png]
|
| 1955 |
+
|
| 1956 |
+
|
| 1957 |
+
[Chapter_06_Decongestants_page2_img635.png]
|
| 1958 |
+
|
| 1959 |
+
|
| 1960 |
+
[Chapter_06_Decongestants_page2_img636.png]
|
| 1961 |
+
|
| 1962 |
+
|
| 1963 |
+
[Chapter_06_Decongestants_page2_img637.png]
|
| 1964 |
+
|
| 1965 |
+
|
| 1966 |
+
[Chapter_06_Decongestants_page2_img638.png]
|
| 1967 |
+
|
| 1968 |
+
|
| 1969 |
+
[Chapter_06_Decongestants_page2_img639.png]
|
| 1970 |
+
|
| 1971 |
+
|
| 1972 |
+
[Chapter_06_Decongestants_page2_img640.png]
|
| 1973 |
+
|
| 1974 |
+
|
| 1975 |
+
[Chapter_06_Decongestants_page2_img641.png]
|
| 1976 |
+
|
| 1977 |
+
|
| 1978 |
+
[Chapter_06_Decongestants_page2_img642.png]
|
| 1979 |
+
|
| 1980 |
+
|
| 1981 |
+
[Chapter_06_Decongestants_page2_img643.png]
|
| 1982 |
+
|
| 1983 |
+
|
| 1984 |
+
[Chapter_06_Decongestants_page2_img644.png]
|
| 1985 |
+
|
| 1986 |
+
|
| 1987 |
+
[Chapter_06_Decongestants_page2_img645.png]
|
| 1988 |
+
|
| 1989 |
+
|
| 1990 |
+
[Chapter_06_Decongestants_page2_img646.png]
|
| 1991 |
+
|
| 1992 |
+
|
| 1993 |
+
[Chapter_06_Decongestants_page2_img647.png]
|
| 1994 |
+
|
| 1995 |
+
|
| 1996 |
+
[Chapter_06_Decongestants_page2_img648.png]
|
| 1997 |
+
|
| 1998 |
+
|
| 1999 |
+
[Chapter_06_Decongestants_page2_img649.png]
|
| 2000 |
+
|
| 2001 |
+
|
| 2002 |
+
[Chapter_06_Decongestants_page2_img650.png]
|
| 2003 |
+
|
| 2004 |
+
|
| 2005 |
+
[Chapter_06_Decongestants_page2_img651.png]
|
| 2006 |
+
|
| 2007 |
+
|
| 2008 |
+
[Chapter_06_Decongestants_page2_img652.png]
|
| 2009 |
+
|
| 2010 |
+
|
| 2011 |
+
[Chapter_06_Decongestants_page2_img653.png]
|
| 2012 |
+
|
| 2013 |
+
|
| 2014 |
+
[Chapter_06_Decongestants_page2_img654.png]
|
| 2015 |
+
|
| 2016 |
+
|
| 2017 |
+
[Chapter_06_Decongestants_page2_img655.png]
|
| 2018 |
+
|
| 2019 |
+
|
| 2020 |
+
[Chapter_06_Decongestants_page2_img656.png]
|
| 2021 |
+
|
| 2022 |
+
|
| 2023 |
+
[Chapter_06_Decongestants_page2_img657.png]
|
| 2024 |
+
|
| 2025 |
+
|
| 2026 |
+
[Chapter_06_Decongestants_page2_img658.png]
|
| 2027 |
+
|
| 2028 |
+
|
| 2029 |
+
[Chapter_06_Decongestants_page2_img659.png]
|
| 2030 |
+
|
| 2031 |
+
|
| 2032 |
+
[Chapter_06_Decongestants_page2_img660.png]
|
| 2033 |
+
|
| 2034 |
+
|
| 2035 |
+
[Chapter_06_Decongestants_page2_img661.png]
|
| 2036 |
+
|
| 2037 |
+
|
| 2038 |
+
[Chapter_06_Decongestants_page2_img662.png]
|
| 2039 |
+
|
| 2040 |
+
|
| 2041 |
+
[Chapter_06_Decongestants_page2_img663.png]
|
| 2042 |
+
|
| 2043 |
+
|
| 2044 |
+
[Chapter_06_Decongestants_page2_img664.png]
|
| 2045 |
+
|
| 2046 |
+
|
| 2047 |
+
[Chapter_06_Decongestants_page2_img665.png]
|
| 2048 |
+
|
| 2049 |
+
|
| 2050 |
+
[Chapter_06_Decongestants_page2_img666.png]
|
| 2051 |
+
|
| 2052 |
+
|
| 2053 |
+
[Chapter_06_Decongestants_page2_img667.png]
|
| 2054 |
+
|
| 2055 |
+
|
| 2056 |
+
[Chapter_06_Decongestants_page2_img668.png]
|
| 2057 |
+
|
| 2058 |
+
|
| 2059 |
+
[Chapter_06_Decongestants_page2_img669.png]
|
| 2060 |
+
|
| 2061 |
+
|
| 2062 |
+
[Chapter_06_Decongestants_page2_img670.png]
|
| 2063 |
+
|
| 2064 |
+
|
| 2065 |
+
[Chapter_06_Decongestants_page2_img671.png]
|
| 2066 |
+
|
| 2067 |
+
|
| 2068 |
+
[Chapter_06_Decongestants_page2_img672.png]
|
| 2069 |
+
|
| 2070 |
+
|
| 2071 |
+
[Chapter_06_Decongestants_page2_img673.png]
|
| 2072 |
+
|
| 2073 |
+
|
| 2074 |
+
[Chapter_06_Decongestants_page2_img674.png]
|
| 2075 |
+
|
| 2076 |
+
|
| 2077 |
+
[Chapter_06_Decongestants_page2_img675.png]
|
| 2078 |
+
|
| 2079 |
+
|
| 2080 |
+
[Chapter_06_Decongestants_page2_img676.png]
|
| 2081 |
+
|
| 2082 |
+
|
| 2083 |
+
[Chapter_06_Decongestants_page2_img677.png]
|
| 2084 |
+
|
| 2085 |
+
|
| 2086 |
+
[Chapter_06_Decongestants_page2_img678.png]
|
| 2087 |
+
|
| 2088 |
+
|
| 2089 |
+
[Chapter_06_Decongestants_page2_img679.png]
|
| 2090 |
+
|
| 2091 |
+
|
| 2092 |
+
[Chapter_06_Decongestants_page2_img680.png]
|
| 2093 |
+
|
| 2094 |
+
|
| 2095 |
+
[Chapter_06_Decongestants_page2_img681.png]
|
| 2096 |
+
|
| 2097 |
+
|
| 2098 |
+
[Chapter_06_Decongestants_page2_img682.png]
|
| 2099 |
+
|
| 2100 |
+
|
| 2101 |
+
[Chapter_06_Decongestants_page2_img683.png]
|
| 2102 |
+
|
| 2103 |
+
|
| 2104 |
+
[Chapter_06_Decongestants_page2_img684.png]
|
| 2105 |
+
|
| 2106 |
+
|
| 2107 |
+
[Chapter_06_Decongestants_page2_img685.png]
|
| 2108 |
+
|
| 2109 |
+
|
| 2110 |
+
[Chapter_06_Decongestants_page2_img686.png]
|
| 2111 |
+
|
| 2112 |
+
|
| 2113 |
+
[Chapter_06_Decongestants_page2_img687.png]
|
| 2114 |
+
|
| 2115 |
+
|
| 2116 |
+
[Chapter_06_Decongestants_page2_img688.png]
|
| 2117 |
+
|
| 2118 |
+
|
| 2119 |
+
[Chapter_06_Decongestants_page2_img689.png]
|
| 2120 |
+
|
| 2121 |
+
|
| 2122 |
+
[Chapter_06_Decongestants_page2_img690.png]
|
| 2123 |
+
|
| 2124 |
+
|
| 2125 |
+
[Chapter_06_Decongestants_page2_img691.png]
|
| 2126 |
+
|
| 2127 |
+
|
| 2128 |
+
[Chapter_06_Decongestants_page2_img692.png]
|
| 2129 |
+
|
| 2130 |
+
|
| 2131 |
+
[Chapter_06_Decongestants_page2_img693.png]
|
| 2132 |
+
|
| 2133 |
+
|
| 2134 |
+
[Chapter_06_Decongestants_page2_img694.png]
|
| 2135 |
+
|
| 2136 |
+
|
| 2137 |
+
[Chapter_06_Decongestants_page2_img695.png]
|
| 2138 |
+
|
| 2139 |
+
|
| 2140 |
+
[Chapter_06_Decongestants_page2_img696.png]
|
| 2141 |
+
|
| 2142 |
+
|
| 2143 |
+
[Chapter_06_Decongestants_page2_img697.png]
|
| 2144 |
+
|
| 2145 |
+
|
| 2146 |
+
[Chapter_06_Decongestants_page2_img698.png]
|
| 2147 |
+
|
| 2148 |
+
|
| 2149 |
+
[Chapter_06_Decongestants_page2_img699.png]
|
| 2150 |
+
|
| 2151 |
+
|
| 2152 |
+
[Chapter_06_Decongestants_page2_img700.png]
|
| 2153 |
+
|
| 2154 |
+
|
| 2155 |
+
[Chapter_06_Decongestants_page2_img701.png]
|
| 2156 |
+
|
| 2157 |
+
|
| 2158 |
+
[Chapter_06_Decongestants_page2_img702.png]
|
| 2159 |
+
|
| 2160 |
+
|
| 2161 |
+
[Chapter_06_Decongestants_page2_img703.png]
|
| 2162 |
+
|
| 2163 |
+
|
| 2164 |
+
[Chapter_06_Decongestants_page2_img704.png]
|
| 2165 |
+
|
| 2166 |
+
|
| 2167 |
+
[Chapter_06_Decongestants_page2_img705.png]
|
| 2168 |
+
|
| 2169 |
+
|
| 2170 |
+
[Chapter_06_Decongestants_page2_img706.png]
|
| 2171 |
+
|
| 2172 |
+
|
| 2173 |
+
[Chapter_06_Decongestants_page2_img707.png]
|
| 2174 |
+
|
| 2175 |
+
|
| 2176 |
+
[Chapter_06_Decongestants_page2_img708.png]
|
| 2177 |
+
|
| 2178 |
+
|
| 2179 |
+
[Chapter_06_Decongestants_page2_img709.png]
|
| 2180 |
+
|
| 2181 |
+
|
| 2182 |
+
[Chapter_06_Decongestants_page2_img710.png]
|
| 2183 |
+
|
| 2184 |
+
|
| 2185 |
+
[Chapter_06_Decongestants_page2_img711.png]
|
| 2186 |
+
|
| 2187 |
+
|
| 2188 |
+
[Chapter_06_Decongestants_page2_img712.png]
|
| 2189 |
+
|
| 2190 |
+
|
| 2191 |
+
[Chapter_06_Decongestants_page2_img713.png]
|
| 2192 |
+
|
| 2193 |
+
|
| 2194 |
+
[Chapter_06_Decongestants_page2_img714.png]
|
| 2195 |
+
|
| 2196 |
+
|
| 2197 |
+
[Chapter_06_Decongestants_page2_img715.png]
|
| 2198 |
+
|
| 2199 |
+
|
| 2200 |
+
[Chapter_06_Decongestants_page2_img716.png]
|
| 2201 |
+
|
| 2202 |
+
|
| 2203 |
+
[Chapter_06_Decongestants_page2_img717.png]
|
| 2204 |
+
|
| 2205 |
+
|
| 2206 |
+
[Chapter_06_Decongestants_page2_img718.png]
|
| 2207 |
+
|
| 2208 |
+
|
| 2209 |
+
[Chapter_06_Decongestants_page2_img719.png]
|
| 2210 |
+
|
| 2211 |
+
|
| 2212 |
+
[Chapter_06_Decongestants_page2_img720.png]
|
| 2213 |
+
|
| 2214 |
+
|
| 2215 |
+
[Chapter_06_Decongestants_page2_img721.png]
|
| 2216 |
+
|
| 2217 |
+
|
| 2218 |
+
[Chapter_06_Decongestants_page2_img722.png]
|
| 2219 |
+
|
| 2220 |
+
|
| 2221 |
+
[Chapter_06_Decongestants_page2_img723.png]
|
| 2222 |
+
|
| 2223 |
+
|
| 2224 |
+
[Chapter_06_Decongestants_page2_img724.png]
|
| 2225 |
+
|
| 2226 |
+
|
| 2227 |
+
[Chapter_06_Decongestants_page2_img725.png]
|
| 2228 |
+
|
| 2229 |
+
|
| 2230 |
+
[Chapter_06_Decongestants_page2_img726.png]
|
| 2231 |
+
|
| 2232 |
+
|
| 2233 |
+
[Chapter_06_Decongestants_page2_img727.png]
|
| 2234 |
+
|
| 2235 |
+
|
| 2236 |
+
[Chapter_06_Decongestants_page2_img728.png]
|
| 2237 |
+
|
| 2238 |
+
|
| 2239 |
+
[Chapter_06_Decongestants_page2_img729.png]
|
| 2240 |
+
|
| 2241 |
+
|
| 2242 |
+
[Chapter_06_Decongestants_page2_img730.png]
|
| 2243 |
+
|
| 2244 |
+
|
| 2245 |
+
[Chapter_06_Decongestants_page2_img731.png]
|
| 2246 |
+
|
| 2247 |
+
|
| 2248 |
+
[Chapter_06_Decongestants_page2_img732.png]
|
| 2249 |
+
|
| 2250 |
+
|
| 2251 |
+
[Chapter_06_Decongestants_page2_img733.png]
|
| 2252 |
+
|
| 2253 |
+
|
| 2254 |
+
[Chapter_06_Decongestants_page2_img734.png]
|
| 2255 |
+
|
| 2256 |
+
|
| 2257 |
+
[Chapter_06_Decongestants_page2_img735.png]
|
| 2258 |
+
|
| 2259 |
+
|
| 2260 |
+
[Chapter_06_Decongestants_page2_img736.png]
|
| 2261 |
+
|
| 2262 |
+
|
| 2263 |
+
[Chapter_06_Decongestants_page2_img737.png]
|
| 2264 |
+
|
| 2265 |
+
|
| 2266 |
+
[Chapter_06_Decongestants_page2_img738.png]
|
| 2267 |
+
|
| 2268 |
+
|
| 2269 |
+
[Chapter_06_Decongestants_page2_img739.png]
|
| 2270 |
+
|
| 2271 |
+
|
| 2272 |
+
[Chapter_06_Decongestants_page2_img740.png]
|
| 2273 |
+
|
| 2274 |
+
|
| 2275 |
+
[Chapter_06_Decongestants_page2_img741.png]
|
| 2276 |
+
|
| 2277 |
+
|
| 2278 |
+
[Chapter_06_Decongestants_page2_img742.png]
|
| 2279 |
+
|
| 2280 |
+
|
| 2281 |
+
[Chapter_06_Decongestants_page2_img743.png]
|
| 2282 |
+
|
| 2283 |
+
|
| 2284 |
+
[Chapter_06_Decongestants_page2_img744.png]
|
| 2285 |
+
|
| 2286 |
+
|
| 2287 |
+
[Chapter_06_Decongestants_page2_img745.png]
|
| 2288 |
+
|
| 2289 |
+
|
| 2290 |
+
[Chapter_06_Decongestants_page2_img746.png]
|
| 2291 |
+
|
| 2292 |
+
|
| 2293 |
+
[Chapter_06_Decongestants_page2_img747.png]
|
| 2294 |
+
|
| 2295 |
+
|
| 2296 |
+
[Chapter_06_Decongestants_page2_img748.png]
|
| 2297 |
+
|
| 2298 |
+
|
| 2299 |
+
[Chapter_06_Decongestants_page2_img749.png]
|
| 2300 |
+
|
| 2301 |
+
|
| 2302 |
+
[Chapter_06_Decongestants_page2_img750.png]
|
| 2303 |
+
|
| 2304 |
+
|
| 2305 |
+
[Chapter_06_Decongestants_page2_img751.png]
|
| 2306 |
+
|
| 2307 |
+
|
| 2308 |
+
[Chapter_06_Decongestants_page2_img752.png]
|
| 2309 |
+
|
| 2310 |
+
|
| 2311 |
+
[Chapter_06_Decongestants_page2_img753.png]
|
| 2312 |
+
|
| 2313 |
+
|
| 2314 |
+
[Chapter_06_Decongestants_page2_img754.png]
|
| 2315 |
+
|
| 2316 |
+
|
| 2317 |
+
[Chapter_06_Decongestants_page2_img755.png]
|
| 2318 |
+
|
| 2319 |
+
|
| 2320 |
+
[Chapter_06_Decongestants_page2_img756.png]
|
| 2321 |
+
|
| 2322 |
+
|
| 2323 |
+
[Chapter_06_Decongestants_page2_img757.png]
|
| 2324 |
+
|
| 2325 |
+
|
| 2326 |
+
[Chapter_06_Decongestants_page2_img758.png]
|
| 2327 |
+
|
| 2328 |
+
|
| 2329 |
+
[Chapter_06_Decongestants_page2_img759.png]
|
| 2330 |
+
|
| 2331 |
+
|
| 2332 |
+
[Chapter_06_Decongestants_page2_img760.png]
|
| 2333 |
+
|
| 2334 |
+
|
| 2335 |
+
[Chapter_06_Decongestants_page2_img761.png]
|
| 2336 |
+
|
| 2337 |
+
|
| 2338 |
+
[Chapter_06_Decongestants_page2_img762.png]
|
| 2339 |
+
|
| 2340 |
+
|
| 2341 |
+
[Chapter_06_Decongestants_page2_img763.png]
|
| 2342 |
+
|
| 2343 |
+
|
| 2344 |
+
[Chapter_06_Decongestants_page2_img764.png]
|
| 2345 |
+
|
| 2346 |
+
|
| 2347 |
+
[Chapter_06_Decongestants_page2_img765.png]
|
| 2348 |
+
|
| 2349 |
+
|
| 2350 |
+
[Chapter_06_Decongestants_page2_img766.png]
|
| 2351 |
+
|
| 2352 |
+
|
| 2353 |
+
[Chapter_06_Decongestants_page2_img767.png]
|
| 2354 |
+
|
| 2355 |
+
|
| 2356 |
+
[Chapter_06_Decongestants_page2_img768.png]
|
| 2357 |
+
|
| 2358 |
+
|
| 2359 |
+
[Chapter_06_Decongestants_page2_img769.png]
|
| 2360 |
+
|
| 2361 |
+
|
| 2362 |
+
[Chapter_06_Decongestants_page2_img770.png]
|
| 2363 |
+
|
| 2364 |
+
|
| 2365 |
+
[Chapter_06_Decongestants_page2_img771.png]
|
| 2366 |
+
|
| 2367 |
+
|
| 2368 |
+
[Chapter_06_Decongestants_page2_img772.png]
|
| 2369 |
+
|
| 2370 |
+
|
| 2371 |
+
[Chapter_06_Decongestants_page2_img773.png]
|
| 2372 |
+
|
| 2373 |
+
|
| 2374 |
+
[Chapter_06_Decongestants_page2_img774.png]
|
| 2375 |
+
|
| 2376 |
+
|
| 2377 |
+
[Chapter_06_Decongestants_page2_img775.png]
|
| 2378 |
+
|
| 2379 |
+
|
| 2380 |
+
[Chapter_06_Decongestants_page2_img776.png]
|
| 2381 |
+
|
| 2382 |
+
|
| 2383 |
+
[Chapter_06_Decongestants_page2_img777.png]
|
| 2384 |
+
|
| 2385 |
+
|
| 2386 |
+
[Chapter_06_Decongestants_page2_img778.png]
|
| 2387 |
+
|
| 2388 |
+
|
| 2389 |
+
[Chapter_06_Decongestants_page2_img779.png]
|
| 2390 |
+
|
| 2391 |
+
|
| 2392 |
+
[Chapter_06_Decongestants_page2_img780.png]
|
| 2393 |
+
|
| 2394 |
+
|
| 2395 |
+
[Chapter_06_Decongestants_page2_img781.png]
|
| 2396 |
+
|
| 2397 |
+
|
| 2398 |
+
[Chapter_06_Decongestants_page2_img782.png]
|
| 2399 |
+
|
| 2400 |
+
|
| 2401 |
+
[Chapter_06_Decongestants_page2_img783.png]
|
| 2402 |
+
|
| 2403 |
+
|
| 2404 |
+
[Chapter_06_Decongestants_page2_img784.png]
|
| 2405 |
+
|
| 2406 |
+
|
| 2407 |
+
[Chapter_06_Decongestants_page2_img785.png]
|
| 2408 |
+
|
| 2409 |
+
|
| 2410 |
+
[Chapter_06_Decongestants_page2_img786.png]
|
| 2411 |
+
|
| 2412 |
+
|
| 2413 |
+
[Chapter_06_Decongestants_page2_img787.png]
|
| 2414 |
+
|
| 2415 |
+
|
| 2416 |
+
[Chapter_06_Decongestants_page2_img788.png]
|
| 2417 |
+
|
| 2418 |
+
|
| 2419 |
+
[Chapter_06_Decongestants_page2_img789.png]
|
| 2420 |
+
|
| 2421 |
+
|
| 2422 |
+
[Chapter_06_Decongestants_page2_img790.png]
|
| 2423 |
+
|
| 2424 |
+
|
| 2425 |
+
[Chapter_06_Decongestants_page2_img791.png]
|
| 2426 |
+
|
| 2427 |
+
|
| 2428 |
+
[Chapter_06_Decongestants_page2_img792.png]
|
| 2429 |
+
|
| 2430 |
+
|
| 2431 |
+
[Chapter_06_Decongestants_page2_img793.png]
|
| 2432 |
+
|
| 2433 |
+
|
| 2434 |
+
[Chapter_06_Decongestants_page2_img794.png]
|
| 2435 |
+
|
| 2436 |
+
|
| 2437 |
+
[Chapter_06_Decongestants_page2_img795.png]
|
| 2438 |
+
|
| 2439 |
+
|
| 2440 |
+
[Chapter_06_Decongestants_page2_img796.png]
|
| 2441 |
+
|
| 2442 |
+
|
| 2443 |
+
[Chapter_06_Decongestants_page2_img797.png]
|
| 2444 |
+
|
| 2445 |
+
|
| 2446 |
+
[Chapter_06_Decongestants_page2_img798.png]
|
| 2447 |
+
|
| 2448 |
+
|
| 2449 |
+
[Chapter_06_Decongestants_page2_img799.png]
|
| 2450 |
+
|
| 2451 |
+
|
| 2452 |
+
[Chapter_06_Decongestants_page2_img800.png]
|
| 2453 |
+
|
| 2454 |
+
|
| 2455 |
+
[Chapter_06_Decongestants_page2_img801.png]
|
| 2456 |
+
|
| 2457 |
+
|
| 2458 |
+
[Chapter_06_Decongestants_page2_img802.png]
|
| 2459 |
+
|
| 2460 |
+
|
| 2461 |
+
[Chapter_06_Decongestants_page2_img803.png]
|
| 2462 |
+
|
| 2463 |
+
|
| 2464 |
+
[Chapter_06_Decongestants_page2_img804.png]
|
| 2465 |
+
|
| 2466 |
+
|
| 2467 |
+
[Chapter_06_Decongestants_page2_img805.png]
|
| 2468 |
+
|
| 2469 |
+
|
| 2470 |
+
[Chapter_06_Decongestants_page2_img806.png]
|
| 2471 |
+
|
| 2472 |
+
|
| 2473 |
+
[Chapter_06_Decongestants_page2_img807.png]
|
| 2474 |
+
|
| 2475 |
+
|
| 2476 |
+
[Chapter_06_Decongestants_page2_img808.png]
|
| 2477 |
+
|
| 2478 |
+
|
| 2479 |
+
[Chapter_06_Decongestants_page2_img809.png]
|
| 2480 |
+
|
| 2481 |
+
|
| 2482 |
+
[Chapter_06_Decongestants_page2_img810.png]
|
| 2483 |
+
|
| 2484 |
+
|
| 2485 |
+
[Chapter_06_Decongestants_page2_img811.png]
|
| 2486 |
+
|
| 2487 |
+
|
| 2488 |
+
[Chapter_06_Decongestants_page2_img812.png]
|
| 2489 |
+
|
| 2490 |
+
|
| 2491 |
+
[Chapter_06_Decongestants_page2_img813.png]
|
| 2492 |
+
|
| 2493 |
+
|
| 2494 |
+
[Chapter_06_Decongestants_page2_img814.png]
|
| 2495 |
+
|
| 2496 |
+
|
| 2497 |
+
[Chapter_06_Decongestants_page2_img815.png]
|
| 2498 |
+
|
| 2499 |
+
|
| 2500 |
+
[Chapter_06_Decongestants_page2_img816.png]
|
| 2501 |
+
|
| 2502 |
+
|
| 2503 |
+
[Chapter_06_Decongestants_page2_img817.png]
|
| 2504 |
+
|
| 2505 |
+
|
| 2506 |
+
[Chapter_06_Decongestants_page2_img818.png]
|
| 2507 |
+
|
| 2508 |
+
|
| 2509 |
+
[Chapter_06_Decongestants_page2_img819.png]
|
| 2510 |
+
|
| 2511 |
+
|
| 2512 |
+
[Chapter_06_Decongestants_page2_img820.png]
|
| 2513 |
+
|
| 2514 |
+
|
| 2515 |
+
[Chapter_06_Decongestants_page2_img821.png]
|
| 2516 |
+
|
| 2517 |
+
|
| 2518 |
+
[Chapter_06_Decongestants_page2_img822.png]
|
| 2519 |
+
|
| 2520 |
+
|
| 2521 |
+
[Chapter_06_Decongestants_page2_img823.png]
|
| 2522 |
+
|
| 2523 |
+
|
| 2524 |
+
[Chapter_06_Decongestants_page2_img824.png]
|
| 2525 |
+
|
| 2526 |
+
|
| 2527 |
+
[Chapter_06_Decongestants_page2_img825.png]
|
| 2528 |
+
|
| 2529 |
+
|
| 2530 |
+
[Chapter_06_Decongestants_page2_img826.png]
|
| 2531 |
+
|
| 2532 |
+
|
| 2533 |
+
[Chapter_06_Decongestants_page2_img827.png]
|
| 2534 |
+
|
| 2535 |
+
|
| 2536 |
+
[Chapter_06_Decongestants_page2_img828.png]
|
| 2537 |
+
|
| 2538 |
+
|
| 2539 |
+
[Chapter_06_Decongestants_page2_img829.png]
|
| 2540 |
+
|
| 2541 |
+
|
| 2542 |
+
[Chapter_06_Decongestants_page2_img830.png]
|
| 2543 |
+
|
| 2544 |
+
|
| 2545 |
+
[Chapter_06_Decongestants_page2_img831.png]
|
| 2546 |
+
|
| 2547 |
+
|
| 2548 |
+
[Chapter_06_Decongestants_page2_img832.png]
|
| 2549 |
+
|
| 2550 |
+
|
| 2551 |
+
[Chapter_06_Decongestants_page2_img833.png]
|
| 2552 |
+
|
| 2553 |
+
|
| 2554 |
+
[Chapter_06_Decongestants_page2_img834.png]
|
| 2555 |
+
|
| 2556 |
+
|
| 2557 |
+
[Chapter_06_Decongestants_page2_img835.png]
|
| 2558 |
+
|
| 2559 |
+
|
| 2560 |
+
[Chapter_06_Decongestants_page2_img836.png]
|
| 2561 |
+
|
| 2562 |
+
|
| 2563 |
+
[Chapter_06_Decongestants_page2_img837.png]
|
| 2564 |
+
|
| 2565 |
+
|
| 2566 |
+
[Chapter_06_Decongestants_page2_img838.png]
|
| 2567 |
+
|
| 2568 |
+
|
| 2569 |
+
[Chapter_06_Decongestants_page2_img839.png]
|
| 2570 |
+
|
| 2571 |
+
|
| 2572 |
+
[Chapter_06_Decongestants_page2_img840.png]
|
| 2573 |
+
|
| 2574 |
+
|
| 2575 |
+
[Chapter_06_Decongestants_page2_img841.png]
|
| 2576 |
+
|
| 2577 |
+
|
| 2578 |
+
[Chapter_06_Decongestants_page2_img842.png]
|
| 2579 |
+
|
| 2580 |
+
|
| 2581 |
+
[Chapter_06_Decongestants_page2_img843.png]
|
| 2582 |
+
|
| 2583 |
+
|
| 2584 |
+
[Chapter_06_Decongestants_page2_img844.png]
|
| 2585 |
+
|
| 2586 |
+
|
| 2587 |
+
[Chapter_06_Decongestants_page2_img845.png]
|
| 2588 |
+
|
| 2589 |
+
|
| 2590 |
+
[Chapter_06_Decongestants_page2_img846.png]
|
| 2591 |
+
|
| 2592 |
+
|
| 2593 |
+
[Chapter_06_Decongestants_page2_img847.png]
|
| 2594 |
+
|
| 2595 |
+
|
| 2596 |
+
[Chapter_06_Decongestants_page2_img848.png]
|
| 2597 |
+
|
| 2598 |
+
|
| 2599 |
+
[Chapter_06_Decongestants_page2_img849.png]
|
| 2600 |
+
|
| 2601 |
+
|
| 2602 |
+
[Chapter_06_Decongestants_page2_img850.png]
|
| 2603 |
+
|
| 2604 |
+
|
| 2605 |
+
[Chapter_06_Decongestants_page2_img851.png]
|
| 2606 |
+
|
| 2607 |
+
|
| 2608 |
+
[Chapter_06_Decongestants_page2_img852.png]
|
| 2609 |
+
|
| 2610 |
+
|
| 2611 |
+
[Chapter_06_Decongestants_page2_img853.png]
|
| 2612 |
+
|
| 2613 |
+
|
| 2614 |
+
[Chapter_06_Decongestants_page2_img854.png]
|
| 2615 |
+
|
| 2616 |
+
|
| 2617 |
+
[Chapter_06_Decongestants_page2_img855.png]
|
| 2618 |
+
|
| 2619 |
+
|
| 2620 |
+
[Chapter_06_Decongestants_page2_img856.png]
|
| 2621 |
+
|
| 2622 |
+
|
| 2623 |
+
[Chapter_06_Decongestants_page2_img857.png]
|
| 2624 |
+
|
| 2625 |
+
|
| 2626 |
+
[Chapter_06_Decongestants_page2_img858.png]
|
| 2627 |
+
|
| 2628 |
+
|
| 2629 |
+
[Chapter_06_Decongestants_page2_img859.png]
|
| 2630 |
+
|
| 2631 |
+
|
| 2632 |
+
[Chapter_06_Decongestants_page2_img860.png]
|
| 2633 |
+
|
| 2634 |
+
|
| 2635 |
+
[Chapter_06_Decongestants_page2_img861.png]
|
| 2636 |
+
|
| 2637 |
+
|
| 2638 |
+
[Chapter_06_Decongestants_page2_img862.png]
|
| 2639 |
+
|
| 2640 |
+
|
| 2641 |
+
[Chapter_06_Decongestants_page2_img863.png]
|
| 2642 |
+
|
| 2643 |
+
|
| 2644 |
+
[Chapter_06_Decongestants_page2_img864.png]
|
| 2645 |
+
|
| 2646 |
+
|
| 2647 |
+
[Chapter_06_Decongestants_page2_img865.png]
|
| 2648 |
+
|
| 2649 |
+
|
| 2650 |
+
[Chapter_06_Decongestants_page2_img866.png]
|
| 2651 |
+
|
| 2652 |
+
|
| 2653 |
+
[Chapter_06_Decongestants_page2_img867.png]
|
| 2654 |
+
|
| 2655 |
+
|
| 2656 |
+
[Chapter_06_Decongestants_page2_img868.png]
|
| 2657 |
+
|
| 2658 |
+
|
| 2659 |
+
[Chapter_06_Decongestants_page2_img869.png]
|
| 2660 |
+
|
| 2661 |
+
|
| 2662 |
+
[Chapter_06_Decongestants_page2_img870.png]
|
| 2663 |
+
|
| 2664 |
+
|
| 2665 |
+
[Chapter_06_Decongestants_page2_img871.png]
|
| 2666 |
+
|
| 2667 |
+
|
| 2668 |
+
[Chapter_06_Decongestants_page2_img872.png]
|
| 2669 |
+
|
| 2670 |
+
|
| 2671 |
+
[Chapter_06_Decongestants_page2_img873.png]
|
| 2672 |
+
|
| 2673 |
+
|
| 2674 |
+
[Chapter_06_Decongestants_page2_img874.png]
|
| 2675 |
+
|
| 2676 |
+
|
| 2677 |
+
[Chapter_06_Decongestants_page2_img875.png]
|
| 2678 |
+
|
| 2679 |
+
|
| 2680 |
+
[Chapter_06_Decongestants_page2_img876.png]
|
| 2681 |
+
|
| 2682 |
+
|
| 2683 |
+
[Chapter_06_Decongestants_page2_img877.png]
|
| 2684 |
+
|
| 2685 |
+
|
| 2686 |
+
[Chapter_06_Decongestants_page2_img878.png]
|
| 2687 |
+
|
| 2688 |
+
|
| 2689 |
+
[Chapter_06_Decongestants_page2_img879.png]
|
| 2690 |
+
|
| 2691 |
+
|
| 2692 |
+
[Chapter_06_Decongestants_page2_img880.png]
|
| 2693 |
+
|
| 2694 |
+
|
| 2695 |
+
[Chapter_06_Decongestants_page2_img881.png]
|
| 2696 |
+
|
| 2697 |
+
|
| 2698 |
+
[Chapter_06_Decongestants_page2_img882.png]
|
| 2699 |
+
|
| 2700 |
+
|
| 2701 |
+
[Chapter_06_Decongestants_page2_img883.png]
|
| 2702 |
+
|
| 2703 |
+
|
| 2704 |
+
[Chapter_06_Decongestants_page2_img884.png]
|
| 2705 |
+
|
| 2706 |
+
|
| 2707 |
+
[Chapter_06_Decongestants_page2_img885.png]
|
| 2708 |
+
|
| 2709 |
+
|
| 2710 |
+
[Chapter_06_Decongestants_page2_img886.png]
|
| 2711 |
+
|
| 2712 |
+
|
| 2713 |
+
[Chapter_06_Decongestants_page2_img887.png]
|
| 2714 |
+
|
| 2715 |
+
|
| 2716 |
+
[Chapter_06_Decongestants_page2_img888.png]
|
| 2717 |
+
|
| 2718 |
+
|
| 2719 |
+
[Chapter_06_Decongestants_page2_img889.png]
|
| 2720 |
+
|
| 2721 |
+
|
| 2722 |
+
[Chapter_06_Decongestants_page2_img890.png]
|
| 2723 |
+
|
| 2724 |
+
|
| 2725 |
+
[Chapter_06_Decongestants_page2_img891.png]
|
| 2726 |
+
|
| 2727 |
+
|
| 2728 |
+
[Chapter_06_Decongestants_page2_img892.png]
|
| 2729 |
+
|
| 2730 |
+
|
| 2731 |
+
[Chapter_06_Decongestants_page2_img893.png]
|
| 2732 |
+
|
| 2733 |
+
|
| 2734 |
+
[Chapter_06_Decongestants_page2_img894.png]
|
| 2735 |
+
|
| 2736 |
+
|
| 2737 |
+
[Chapter_06_Decongestants_page2_img895.png]
|
| 2738 |
+
|
| 2739 |
+
|
| 2740 |
+
[Chapter_06_Decongestants_page2_img896.png]
|
| 2741 |
+
|
| 2742 |
+
|
| 2743 |
+
[Chapter_06_Decongestants_page2_img897.png]
|
| 2744 |
+
|
| 2745 |
+
|
| 2746 |
+
[Chapter_06_Decongestants_page2_img898.png]
|
| 2747 |
+
|
| 2748 |
+
|
| 2749 |
+
[Chapter_06_Decongestants_page2_img899.png]
|
| 2750 |
+
|
| 2751 |
+
|
| 2752 |
+
[Chapter_06_Decongestants_page2_img900.png]
|
| 2753 |
+
|
| 2754 |
+
|
| 2755 |
+
[Chapter_06_Decongestants_page2_img901.png]
|
| 2756 |
+
|
| 2757 |
+
|
| 2758 |
+
[Chapter_06_Decongestants_page2_img902.png]
|
| 2759 |
+
|
| 2760 |
+
|
| 2761 |
+
[Chapter_06_Decongestants_page2_img903.png]
|
| 2762 |
+
|
| 2763 |
+
|
| 2764 |
+
[Chapter_06_Decongestants_page2_img904.png]
|
| 2765 |
+
|
| 2766 |
+
|
| 2767 |
+
[Chapter_06_Decongestants_page2_img905.png]
|
| 2768 |
+
|
| 2769 |
+
|
| 2770 |
+
[Chapter_06_Decongestants_page2_img906.png]
|
| 2771 |
+
|
| 2772 |
+
|
| 2773 |
+
[Chapter_06_Decongestants_page2_img907.png]
|
| 2774 |
+
|
| 2775 |
+
|
| 2776 |
+
[Chapter_06_Decongestants_page2_img908.png]
|
| 2777 |
+
|
| 2778 |
+
|
| 2779 |
+
[Chapter_06_Decongestants_page2_img909.png]
|
| 2780 |
+
|
| 2781 |
+
|
| 2782 |
+
[Chapter_06_Decongestants_page2_img910.png]
|
| 2783 |
+
|
| 2784 |
+
|
| 2785 |
+
[Chapter_06_Decongestants_page2_img911.png]
|
| 2786 |
+
|
| 2787 |
+
|
| 2788 |
+
[Chapter_06_Decongestants_page2_img912.png]
|
| 2789 |
+
|
| 2790 |
+
|
| 2791 |
+
[Chapter_06_Decongestants_page2_img913.png]
|
| 2792 |
+
|
| 2793 |
+
|
| 2794 |
+
[Chapter_06_Decongestants_page2_img914.png]
|
| 2795 |
+
|
| 2796 |
+
|
| 2797 |
+
[Chapter_06_Decongestants_page2_img915.png]
|
| 2798 |
+
|
| 2799 |
+
|
| 2800 |
+
[Chapter_06_Decongestants_page2_img916.png]
|
| 2801 |
+
|
| 2802 |
+
|
| 2803 |
+
[Chapter_06_Decongestants_page2_img917.png]
|
| 2804 |
+
|
| 2805 |
+
|
| 2806 |
+
[Chapter_06_Decongestants_page2_img918.png]
|
| 2807 |
+
|
| 2808 |
+
|
| 2809 |
+
[Chapter_06_Decongestants_page2_img919.png]
|
| 2810 |
+
|
| 2811 |
+
|
| 2812 |
+
[Chapter_06_Decongestants_page2_img920.png]
|
| 2813 |
+
|
| 2814 |
+
|
| 2815 |
+
[Chapter_06_Decongestants_page2_img921.png]
|
| 2816 |
+
|
| 2817 |
+
|
| 2818 |
+
[Chapter_06_Decongestants_page2_img922.png]
|
| 2819 |
+
|
| 2820 |
+
|
| 2821 |
+
[Chapter_06_Decongestants_page2_img923.png]
|
| 2822 |
+
|
| 2823 |
+
|
| 2824 |
+
[Chapter_06_Decongestants_page2_img924.png]
|
| 2825 |
+
|
| 2826 |
+
|
| 2827 |
+
[Chapter_06_Decongestants_page2_img925.png]
|
| 2828 |
+
|
| 2829 |
+
|
| 2830 |
+
[Chapter_06_Decongestants_page2_img926.png]
|
| 2831 |
+
|
| 2832 |
+
|
| 2833 |
+
[Chapter_06_Decongestants_page2_img927.png]
|
| 2834 |
+
|
| 2835 |
+
|
| 2836 |
+
[Chapter_06_Decongestants_page2_img928.png]
|
| 2837 |
+
|
| 2838 |
+
|
| 2839 |
+
[Chapter_06_Decongestants_page2_img929.png]
|
| 2840 |
+
|
| 2841 |
+
|
| 2842 |
+
[Chapter_06_Decongestants_page2_img930.png]
|
| 2843 |
+
|
| 2844 |
+
|
| 2845 |
+
[Chapter_06_Decongestants_page2_img931.png]
|
| 2846 |
+
|
| 2847 |
+
|
| 2848 |
+
[Chapter_06_Decongestants_page2_img932.png]
|
| 2849 |
+
|
| 2850 |
+
|
| 2851 |
+
[Chapter_06_Decongestants_page2_img933.png]
|
| 2852 |
+
|
| 2853 |
+
|
| 2854 |
+
[Chapter_06_Decongestants_page2_img934.png]
|
| 2855 |
+
|
| 2856 |
+
|
| 2857 |
+
[Chapter_06_Decongestants_page2_img935.png]
|
| 2858 |
+
|
| 2859 |
+
|
| 2860 |
+
[Chapter_06_Decongestants_page2_img936.png]
|
| 2861 |
+
|
| 2862 |
+
|
| 2863 |
+
[Chapter_06_Decongestants_page2_img937.png]
|
| 2864 |
+
|
| 2865 |
+
|
| 2866 |
+
[Chapter_06_Decongestants_page2_img938.png]
|
| 2867 |
+
|
| 2868 |
+
|
| 2869 |
+
[Chapter_06_Decongestants_page2_img939.png]
|
| 2870 |
+
|
| 2871 |
+
|
| 2872 |
+
[Chapter_06_Decongestants_page2_img940.png]
|
| 2873 |
+
|
| 2874 |
+
|
| 2875 |
+
[Chapter_06_Decongestants_page2_img941.png]
|
| 2876 |
+
|
| 2877 |
+
|
| 2878 |
+
[Chapter_06_Decongestants_page2_img942.png]
|
| 2879 |
+
|
| 2880 |
+
|
| 2881 |
+
[Chapter_06_Decongestants_page2_img943.png]
|
| 2882 |
+
|
| 2883 |
+
|
| 2884 |
+
[Chapter_06_Decongestants_page2_img944.png]
|
| 2885 |
+
|
| 2886 |
+
|
| 2887 |
+
[Chapter_06_Decongestants_page2_img945.png]
|
| 2888 |
+
|
| 2889 |
+
|
| 2890 |
+
[Chapter_06_Decongestants_page2_img946.png]
|
| 2891 |
+
|
| 2892 |
+
|
| 2893 |
+
[Chapter_06_Decongestants_page2_img947.png]
|
| 2894 |
+
|
| 2895 |
+
|
| 2896 |
+
[Chapter_06_Decongestants_page2_img948.png]
|
| 2897 |
+
|
| 2898 |
+
|
| 2899 |
+
[Chapter_06_Decongestants_page2_img949.png]
|
| 2900 |
+
|
| 2901 |
+
|
| 2902 |
+
[Chapter_06_Decongestants_page2_img950.png]
|
| 2903 |
+
|
| 2904 |
+
|
| 2905 |
+
[Chapter_06_Decongestants_page2_img951.png]
|
| 2906 |
+
|
| 2907 |
+
|
| 2908 |
+
[Chapter_06_Decongestants_page2_img952.png]
|
| 2909 |
+
|
| 2910 |
+
|
| 2911 |
+
[Chapter_06_Decongestants_page2_img953.png]
|
| 2912 |
+
|
| 2913 |
+
|
| 2914 |
+
[Chapter_06_Decongestants_page2_img954.png]
|
| 2915 |
+
|
| 2916 |
+
|
| 2917 |
+
[Chapter_06_Decongestants_page2_img955.png]
|
| 2918 |
+
|
| 2919 |
+
|
| 2920 |
+
[Chapter_06_Decongestants_page2_img956.png]
|
| 2921 |
+
|
| 2922 |
+
|
| 2923 |
+
[Chapter_06_Decongestants_page2_img957.png]
|
| 2924 |
+
|
| 2925 |
+
|
| 2926 |
+
[Chapter_06_Decongestants_page2_img958.png]
|
| 2927 |
+
|
| 2928 |
+
|
| 2929 |
+
[Chapter_06_Decongestants_page2_img959.png]
|
| 2930 |
+
|
| 2931 |
+
|
| 2932 |
+
[Chapter_06_Decongestants_page2_img960.png]
|
| 2933 |
+
|
| 2934 |
+
|
| 2935 |
+
[Chapter_06_Decongestants_page2_img961.png]
|
| 2936 |
+
|
| 2937 |
+
|
| 2938 |
+
[Chapter_06_Decongestants_page2_img962.png]
|
| 2939 |
+
|
| 2940 |
+
|
| 2941 |
+
[Chapter_06_Decongestants_page2_img963.png]
|
| 2942 |
+
|
| 2943 |
+
|
| 2944 |
+
[Chapter_06_Decongestants_page2_img964.png]
|
| 2945 |
+
|
| 2946 |
+
|
| 2947 |
+
[Chapter_06_Decongestants_page2_img965.png]
|
| 2948 |
+
|
| 2949 |
+
|
| 2950 |
+
[Chapter_06_Decongestants_page2_img966.png]
|
| 2951 |
+
|
| 2952 |
+
|
| 2953 |
+
[Chapter_06_Decongestants_page2_img967.png]
|
| 2954 |
+
|
| 2955 |
+
|
| 2956 |
+
[Chapter_06_Decongestants_page2_img968.png]
|
| 2957 |
+
|
| 2958 |
+
|
| 2959 |
+
[Chapter_06_Decongestants_page2_img969.png]
|
| 2960 |
+
|
| 2961 |
+
|
| 2962 |
+
[Chapter_06_Decongestants_page2_img970.png]
|
| 2963 |
+
|
| 2964 |
+
|
| 2965 |
+
[Chapter_06_Decongestants_page2_img971.png]
|
| 2966 |
+
|
| 2967 |
+
|
| 2968 |
+
[Chapter_06_Decongestants_page2_img972.png]
|
| 2969 |
+
|
| 2970 |
+
|
| 2971 |
+
[Chapter_06_Decongestants_page2_img973.png]
|
| 2972 |
+
|
| 2973 |
+
|
| 2974 |
+
[Chapter_06_Decongestants_page2_img974.png]
|
| 2975 |
+
|
| 2976 |
+
|
| 2977 |
+
[Chapter_06_Decongestants_page2_img975.png]
|
| 2978 |
+
|
| 2979 |
+
|
| 2980 |
+
[Chapter_06_Decongestants_page2_img976.png]
|
| 2981 |
+
|
| 2982 |
+
|
| 2983 |
+
[Chapter_06_Decongestants_page2_img977.png]
|
| 2984 |
+
|
| 2985 |
+
|
| 2986 |
+
[Chapter_06_Decongestants_page2_img978.png]
|
| 2987 |
+
|
| 2988 |
+
|
| 2989 |
+
[Chapter_06_Decongestants_page2_img979.png]
|
| 2990 |
+
|
| 2991 |
+
|
| 2992 |
+
[Chapter_06_Decongestants_page2_img980.png]
|
| 2993 |
+
|
| 2994 |
+
|
| 2995 |
+
[Chapter_06_Decongestants_page2_img981.png]
|
| 2996 |
+
|
| 2997 |
+
|
| 2998 |
+
[Chapter_06_Decongestants_page2_img982.png]
|
| 2999 |
+
|
| 3000 |
+
|
| 3001 |
+
[Chapter_06_Decongestants_page2_img983.png]
|
| 3002 |
+
|
| 3003 |
+
|
| 3004 |
+
[Chapter_06_Decongestants_page2_img984.png]
|
| 3005 |
+
|
| 3006 |
+
|
| 3007 |
+
[Chapter_06_Decongestants_page2_img985.png]
|
| 3008 |
+
|
| 3009 |
+
|
| 3010 |
+
[Chapter_06_Decongestants_page2_img986.png]
|
| 3011 |
+
|
| 3012 |
+
|
| 3013 |
+
[Chapter_06_Decongestants_page2_img987.png]
|
| 3014 |
+
|
| 3015 |
+
|
| 3016 |
+
[Chapter_06_Decongestants_page2_img988.png]
|
| 3017 |
+
|
| 3018 |
+
|
| 3019 |
+
[Chapter_06_Decongestants_page2_img989.png]
|
| 3020 |
+
|
| 3021 |
+
|
| 3022 |
+
[Chapter_06_Decongestants_page2_img990.png]
|
| 3023 |
+
|
| 3024 |
+
|
| 3025 |
+
[Chapter_06_Decongestants_page2_img991.png]
|
| 3026 |
+
|
| 3027 |
+
|
| 3028 |
+
[Chapter_06_Decongestants_page2_img992.png]
|
| 3029 |
+
|
| 3030 |
+
|
| 3031 |
+
[Chapter_06_Decongestants_page2_img993.png]
|
| 3032 |
+
|
| 3033 |
+
|
| 3034 |
+
[Chapter_06_Decongestants_page2_img994.png]
|
| 3035 |
+
|
| 3036 |
+
|
| 3037 |
+
[Chapter_06_Decongestants_page2_img995.png]
|
| 3038 |
+
|
| 3039 |
+
|
| 3040 |
+
[Chapter_06_Decongestants_page2_img996.png]
|
| 3041 |
+
|
| 3042 |
+
|
| 3043 |
+
[Chapter_06_Decongestants_page2_img997.png]
|
| 3044 |
+
|
| 3045 |
+
|
| 3046 |
+
[Chapter_06_Decongestants_page2_img998.png]
|
| 3047 |
+
|
| 3048 |
+
|
| 3049 |
+
[Chapter_06_Decongestants_page2_img999.png]
|
| 3050 |
+
|
| 3051 |
+
|
| 3052 |
+
[Chapter_06_Decongestants_page2_img1000.png]
|
| 3053 |
+
|
| 3054 |
+
|
| 3055 |
+
[Chapter_06_Decongestants_page2_img1001.png]
|
| 3056 |
+
|
| 3057 |
+
|
| 3058 |
+
[Chapter_06_Decongestants_page2_img1002.png]
|
| 3059 |
+
|
| 3060 |
+
|
| 3061 |
+
[Chapter_06_Decongestants_page2_img1003.png]
|
| 3062 |
+
|
| 3063 |
+
|
| 3064 |
+
[Chapter_06_Decongestants_page2_img1004.png]
|
| 3065 |
+
|
| 3066 |
+
|
| 3067 |
+
[Chapter_06_Decongestants_page2_img1005.png]
|
| 3068 |
+
|
| 3069 |
+
|
| 3070 |
+
[Chapter_06_Decongestants_page2_img1006.png]
|
| 3071 |
+
|
| 3072 |
+
|
| 3073 |
+
[Chapter_06_Decongestants_page2_img1007.png]
|
| 3074 |
+
|
| 3075 |
+
|
| 3076 |
+
[Chapter_06_Decongestants_page2_img1008.png]
|
| 3077 |
+
|
| 3078 |
+
|
| 3079 |
+
[Chapter_06_Decongestants_page2_img1009.png]
|
| 3080 |
+
|
| 3081 |
+
|
| 3082 |
+
[Chapter_06_Decongestants_page2_img1010.png]
|
| 3083 |
+
|
| 3084 |
+
|
| 3085 |
+
[Chapter_06_Decongestants_page2_img1011.png]
|
| 3086 |
+
|
| 3087 |
+
|
| 3088 |
+
[Chapter_06_Decongestants_page2_img1012.png]
|
| 3089 |
+
|
| 3090 |
+
|
| 3091 |
+
[Chapter_06_Decongestants_page2_img1013.png]
|
| 3092 |
+
|
| 3093 |
+
|
| 3094 |
+
[Chapter_06_Decongestants_page2_img1014.png]
|
| 3095 |
+
|
| 3096 |
+
|
| 3097 |
+
[Chapter_06_Decongestants_page2_img1015.png]
|
| 3098 |
+
|
| 3099 |
+
|
| 3100 |
+
[Chapter_06_Decongestants_page2_img1016.png]
|
| 3101 |
+
|
| 3102 |
+
|
| 3103 |
+
[Chapter_06_Decongestants_page2_img1017.png]
|
| 3104 |
+
|
| 3105 |
+
|
| 3106 |
+
[Chapter_06_Decongestants_page2_img1018.png]
|
| 3107 |
+
|
| 3108 |
+
|
| 3109 |
+
[Chapter_06_Decongestants_page2_img1019.png]
|
| 3110 |
+
|
| 3111 |
+
|
| 3112 |
+
[Chapter_06_Decongestants_page2_img1020.png]
|
| 3113 |
+
|
| 3114 |
+
|
| 3115 |
+
[Chapter_06_Decongestants_page2_img1021.png]
|
| 3116 |
+
|
| 3117 |
+
|
| 3118 |
+
[Chapter_06_Decongestants_page2_img1022.png]
|
| 3119 |
+
|
| 3120 |
+
|
| 3121 |
+
[Chapter_06_Decongestants_page2_img1023.png]
|
| 3122 |
+
|
| 3123 |
+
|
| 3124 |
+
[Chapter_06_Decongestants_page2_img1024.png]
|
| 3125 |
+
|
| 3126 |
+
|
| 3127 |
+
[Chapter_06_Decongestants_page2_img1025.png]
|
| 3128 |
+
|
| 3129 |
+
|
| 3130 |
+
[Chapter_06_Decongestants_page2_img1026.png]
|
| 3131 |
+
|
| 3132 |
+
|
| 3133 |
+
[Chapter_06_Decongestants_page2_img1027.png]
|
| 3134 |
+
|
| 3135 |
+
|
| 3136 |
+
[Chapter_06_Decongestants_page2_img1028.png]
|
| 3137 |
+
|
| 3138 |
+
|
| 3139 |
+
[Chapter_06_Decongestants_page2_img1029.png]
|
| 3140 |
+
|
| 3141 |
+
|
| 3142 |
+
[Chapter_06_Decongestants_page2_img1030.png]
|
| 3143 |
+
|
| 3144 |
+
|
| 3145 |
+
[Chapter_06_Decongestants_page2_img1031.png]
|
| 3146 |
+
|
| 3147 |
+
|
| 3148 |
+
[Chapter_06_Decongestants_page2_img1032.png]
|
| 3149 |
+
|
| 3150 |
+
|
| 3151 |
+
[Chapter_06_Decongestants_page2_img1033.png]
|
| 3152 |
+
|
| 3153 |
+
|
| 3154 |
+
[Chapter_06_Decongestants_page2_img1034.png]
|
| 3155 |
+
|
| 3156 |
+
|
| 3157 |
+
[Chapter_06_Decongestants_page2_img1035.png]
|
| 3158 |
+
|
| 3159 |
+
|
| 3160 |
+
[Chapter_06_Decongestants_page2_img1036.png]
|
| 3161 |
+
|
| 3162 |
+
|
| 3163 |
+
[Chapter_06_Decongestants_page2_img1037.png]
|
| 3164 |
+
|
| 3165 |
+
|
| 3166 |
+
[Chapter_06_Decongestants_page2_img1038.png]
|
| 3167 |
+
|
| 3168 |
+
|
| 3169 |
+
[Chapter_06_Decongestants_page2_img1039.png]
|
| 3170 |
+
|
| 3171 |
+
|
| 3172 |
+
[Chapter_06_Decongestants_page2_img1040.png]
|
| 3173 |
+
|
| 3174 |
+
|
| 3175 |
+
[Chapter_06_Decongestants_page2_img1041.png]
|
| 3176 |
+
|
| 3177 |
+
|
| 3178 |
+
[Chapter_06_Decongestants_page2_img1042.png]
|
| 3179 |
+
|
| 3180 |
+
|
| 3181 |
+
[Chapter_06_Decongestants_page2_img1043.png]
|
| 3182 |
+
|
| 3183 |
+
|
| 3184 |
+
[Chapter_06_Decongestants_page2_img1044.png]
|
| 3185 |
+
|
| 3186 |
+
|
| 3187 |
+
[Chapter_06_Decongestants_page2_img1045.png]
|
| 3188 |
+
|
| 3189 |
+
|
| 3190 |
+
[Chapter_06_Decongestants_page2_img1046.png]
|
| 3191 |
+
|
| 3192 |
+
|
| 3193 |
+
[Chapter_06_Decongestants_page2_img1047.png]
|
| 3194 |
+
|
| 3195 |
+
|
| 3196 |
+
[Chapter_06_Decongestants_page2_img1048.png]
|
| 3197 |
+
|
| 3198 |
+
|
| 3199 |
+
[Chapter_06_Decongestants_page2_img1049.png]
|
| 3200 |
+
|
| 3201 |
+
|
| 3202 |
+
[Chapter_06_Decongestants_page2_img1050.png]
|
| 3203 |
+
|
| 3204 |
+
|
| 3205 |
+
[Chapter_06_Decongestants_page2_img1051.png]
|
| 3206 |
+
|
| 3207 |
+
|
| 3208 |
+
[Chapter_06_Decongestants_page2_img1052.png]
|
| 3209 |
+
|
| 3210 |
+
|
| 3211 |
+
[Chapter_06_Decongestants_page2_img1053.png]
|
| 3212 |
+
|
| 3213 |
+
|
| 3214 |
+
[Chapter_06_Decongestants_page2_img1054.png]
|
| 3215 |
+
|
| 3216 |
+
|
| 3217 |
+
[Chapter_06_Decongestants_page2_img1055.png]
|
| 3218 |
+
|
| 3219 |
+
|
| 3220 |
+
[Chapter_06_Decongestants_page2_img1056.png]
|
| 3221 |
+
|
| 3222 |
+
|
| 3223 |
+
[Chapter_06_Decongestants_page2_img1057.png]
|
| 3224 |
+
|
| 3225 |
+
|
| 3226 |
+
[Chapter_06_Decongestants_page2_img1058.png]
|
| 3227 |
+
|
| 3228 |
+
|
| 3229 |
+
[Chapter_06_Decongestants_page2_img1059.png]
|
| 3230 |
+
|
| 3231 |
+
|
| 3232 |
+
[Chapter_06_Decongestants_page2_img1060.png]
|
| 3233 |
+
|
| 3234 |
+
|
| 3235 |
+
[Chapter_06_Decongestants_page2_img1061.png]
|
| 3236 |
+
|
| 3237 |
+
|
| 3238 |
+
[Chapter_06_Decongestants_page2_img1062.png]
|
| 3239 |
+
|
| 3240 |
+
|
| 3241 |
+
[Chapter_06_Decongestants_page2_img1063.png]
|
| 3242 |
+
|
| 3243 |
+
|
| 3244 |
+
[Chapter_06_Decongestants_page2_img1064.png]
|
| 3245 |
+
|
| 3246 |
+
|
| 3247 |
+
[Chapter_06_Decongestants_page2_img1065.png]
|
| 3248 |
+
|
| 3249 |
+
|
| 3250 |
+
[Chapter_06_Decongestants_page2_img1066.png]
|
| 3251 |
+
|
| 3252 |
+
|
| 3253 |
+
[Chapter_06_Decongestants_page2_img1067.png]
|
| 3254 |
+
|
| 3255 |
+
|
| 3256 |
+
[Chapter_06_Decongestants_page2_img1068.png]
|
| 3257 |
+
|
| 3258 |
+
|
| 3259 |
+
[Chapter_06_Decongestants_page2_img1069.png]
|
| 3260 |
+
|
| 3261 |
+
|
| 3262 |
+
[Chapter_06_Decongestants_page2_img1070.png]
|
| 3263 |
+
|
| 3264 |
+
|
| 3265 |
+
[Chapter_06_Decongestants_page2_img1071.png]
|
| 3266 |
+
|
| 3267 |
+
|
| 3268 |
+
[Chapter_06_Decongestants_page2_img1072.png]
|
| 3269 |
+
|
| 3270 |
+
|
| 3271 |
+
[Chapter_06_Decongestants_page2_img1073.png]
|
| 3272 |
+
|
| 3273 |
+
|
| 3274 |
+
[Chapter_06_Decongestants_page2_img1074.png]
|
| 3275 |
+
|
| 3276 |
+
|
| 3277 |
+
[Chapter_06_Decongestants_page2_img1075.png]
|
| 3278 |
+
|
| 3279 |
+
|
| 3280 |
+
[Chapter_06_Decongestants_page2_img1076.png]
|
| 3281 |
+
|
| 3282 |
+
|
| 3283 |
+
[Chapter_06_Decongestants_page2_img1077.png]
|
| 3284 |
+
|
| 3285 |
+
|
| 3286 |
+
[Chapter_06_Decongestants_page2_img1078.png]
|
| 3287 |
+
|
| 3288 |
+
|
| 3289 |
+
[Chapter_06_Decongestants_page2_img1079.png]
|
| 3290 |
+
|
| 3291 |
+
|
| 3292 |
+
[Chapter_06_Decongestants_page2_img1080.png]
|
| 3293 |
+
|
| 3294 |
+
|
| 3295 |
+
[Chapter_06_Decongestants_page2_img1081.png]
|
| 3296 |
+
|
| 3297 |
+
|
| 3298 |
+
[Chapter_06_Decongestants_page2_img1082.png]
|
| 3299 |
+
|
| 3300 |
+
|
| 3301 |
+
[Chapter_06_Decongestants_page2_img1083.png]
|
| 3302 |
+
|
| 3303 |
+
|
| 3304 |
+
[Chapter_06_Decongestants_page2_img1084.png]
|
| 3305 |
+
|
| 3306 |
+
|
| 3307 |
+
[Chapter_06_Decongestants_page2_img1085.png]
|
| 3308 |
+
|
| 3309 |
+
|
| 3310 |
+
[Chapter_06_Decongestants_page2_img1086.png]
|
| 3311 |
+
|
| 3312 |
+
|
| 3313 |
+
[Chapter_06_Decongestants_page2_img1087.png]
|
| 3314 |
+
|
| 3315 |
+
|
| 3316 |
+
[Chapter_06_Decongestants_page2_img1088.png]
|
| 3317 |
+
|
| 3318 |
+
|
| 3319 |
+
[Chapter_06_Decongestants_page2_img1089.png]
|
| 3320 |
+
|
| 3321 |
+
|
| 3322 |
+
[Chapter_06_Decongestants_page2_img1090.png]
|
| 3323 |
+
|
| 3324 |
+
|
| 3325 |
+
[Chapter_06_Decongestants_page2_img1091.png]
|
| 3326 |
+
|
| 3327 |
+
|
| 3328 |
+
[Chapter_06_Decongestants_page2_img1092.png]
|
| 3329 |
+
|
| 3330 |
+
|
| 3331 |
+
[Chapter_06_Decongestants_page2_img1093.png]
|
| 3332 |
+
|
| 3333 |
+
|
| 3334 |
+
[Chapter_06_Decongestants_page2_img1094.png]
|
| 3335 |
+
|
| 3336 |
+
|
| 3337 |
+
[Chapter_06_Decongestants_page2_img1095.png]
|
| 3338 |
+
|
| 3339 |
+
|
| 3340 |
+
[Chapter_06_Decongestants_page2_img1096.png]
|
| 3341 |
+
|
| 3342 |
+
|
| 3343 |
+
[Chapter_06_Decongestants_page2_img1097.png]
|
| 3344 |
+
|
| 3345 |
+
|
| 3346 |
+
[Chapter_06_Decongestants_page2_img1098.png]
|
| 3347 |
+
|
| 3348 |
+
|
| 3349 |
+
[Chapter_06_Decongestants_page2_img1099.png]
|
| 3350 |
+
|
| 3351 |
+
|
| 3352 |
+
[Chapter_06_Decongestants_page2_img1100.png]
|
| 3353 |
+
|
| 3354 |
+
|
| 3355 |
+
[Chapter_06_Decongestants_page2_img1101.png]
|
| 3356 |
+
|
| 3357 |
+
|
| 3358 |
+
[Chapter_06_Decongestants_page2_img1102.png]
|
| 3359 |
+
|
| 3360 |
+
|
| 3361 |
+
[Chapter_06_Decongestants_page2_img1103.png]
|
| 3362 |
+
|
| 3363 |
+
|
| 3364 |
+
[Chapter_06_Decongestants_page2_img1104.png]
|
| 3365 |
+
|
| 3366 |
+
|
| 3367 |
+
[Chapter_06_Decongestants_page2_img1105.png]
|
| 3368 |
+
|
| 3369 |
+
|
| 3370 |
+
[Chapter_06_Decongestants_page2_img1106.png]
|
| 3371 |
+
|
| 3372 |
+
|
| 3373 |
+
[Chapter_06_Decongestants_page2_img1107.png]
|
| 3374 |
+
|
| 3375 |
+
|
| 3376 |
+
[Chapter_06_Decongestants_page2_img1108.png]
|
| 3377 |
+
|
| 3378 |
+
|
| 3379 |
+
[Chapter_06_Decongestants_page2_img1109.png]
|
| 3380 |
+
|
| 3381 |
+
|
| 3382 |
+
[Chapter_06_Decongestants_page2_img1110.png]
|
| 3383 |
+
|
| 3384 |
+
|
| 3385 |
+
[Chapter_06_Decongestants_page2_img1111.png]
|
| 3386 |
+
|
| 3387 |
+
|
| 3388 |
+
[Chapter_06_Decongestants_page2_img1112.png]
|
| 3389 |
+
|
| 3390 |
+
|
| 3391 |
+
[Chapter_06_Decongestants_page2_img1113.png]
|
| 3392 |
+
|
| 3393 |
+
|
| 3394 |
+
[Chapter_06_Decongestants_page2_img1114.png]
|
| 3395 |
+
|
| 3396 |
+
|
| 3397 |
+
[Chapter_06_Decongestants_page2_img1115.png]
|
| 3398 |
+
|
| 3399 |
+
|
| 3400 |
+
[Chapter_06_Decongestants_page2_img1116.png]
|
| 3401 |
+
|
| 3402 |
+
|
| 3403 |
+
[Chapter_06_Decongestants_page2_img1117.png]
|
| 3404 |
+
|
| 3405 |
+
|
| 3406 |
+
[Chapter_06_Decongestants_page2_img1118.png]
|
| 3407 |
+
|
| 3408 |
+
|
| 3409 |
+
[Chapter_06_Decongestants_page2_img1119.png]
|
| 3410 |
+
|
| 3411 |
+
|
| 3412 |
+
[Chapter_06_Decongestants_page2_img1120.png]
|
| 3413 |
+
|
| 3414 |
+
|
| 3415 |
+
[Chapter_06_Decongestants_page2_img1121.png]
|
| 3416 |
+
|
| 3417 |
+
|
| 3418 |
+
[Chapter_06_Decongestants_page2_img1122.png]
|
| 3419 |
+
|
| 3420 |
+
|
| 3421 |
+
[Chapter_06_Decongestants_page2_img1123.png]
|
| 3422 |
+
|
| 3423 |
+
|
| 3424 |
+
[Chapter_06_Decongestants_page2_img1124.png]
|
| 3425 |
+
|
| 3426 |
+
|
| 3427 |
+
[Chapter_06_Decongestants_page2_img1125.png]
|
| 3428 |
+
|
| 3429 |
+
|
| 3430 |
+
[Chapter_06_Decongestants_page2_img1126.png]
|
| 3431 |
+
|
| 3432 |
+
|
| 3433 |
+
[Chapter_06_Decongestants_page2_img1127.png]
|
| 3434 |
+
|
| 3435 |
+
|
| 3436 |
+
[Chapter_06_Decongestants_page2_img1128.png]
|
| 3437 |
+
|
| 3438 |
+
|
| 3439 |
+
[Chapter_06_Decongestants_page2_img1129.png]
|
| 3440 |
+
|
| 3441 |
+
|
| 3442 |
+
[Chapter_06_Decongestants_page2_img1130.png]
|
| 3443 |
+
|
| 3444 |
+
|
| 3445 |
+
[Chapter_06_Decongestants_page2_img1131.png]
|
| 3446 |
+
|
| 3447 |
+
|
| 3448 |
+
[Chapter_06_Decongestants_page2_img1132.png]
|
| 3449 |
+
|
| 3450 |
+
|
| 3451 |
+
[Chapter_06_Decongestants_page2_img1133.png]
|
| 3452 |
+
|
| 3453 |
+
|
| 3454 |
+
[Chapter_06_Decongestants_page2_img1134.png]
|
| 3455 |
+
|
| 3456 |
+
|
| 3457 |
+
[Chapter_06_Decongestants_page2_img1135.png]
|
| 3458 |
+
|
| 3459 |
+
|
| 3460 |
+
[Chapter_06_Decongestants_page2_img1136.png]
|
| 3461 |
+
|
| 3462 |
+
|
| 3463 |
+
[Chapter_06_Decongestants_page2_img1137.png]
|
| 3464 |
+
|
| 3465 |
+
|
| 3466 |
+
[Chapter_06_Decongestants_page2_img1138.png]
|
| 3467 |
+
|
| 3468 |
+
|
| 3469 |
+
[Chapter_06_Decongestants_page2_img1139.png]
|
| 3470 |
+
|
| 3471 |
+
|
| 3472 |
+
[Chapter_06_Decongestants_page2_img1140.png]
|
| 3473 |
+
|
| 3474 |
+
|
| 3475 |
+
[Chapter_06_Decongestants_page2_img1141.png]
|
| 3476 |
+
|
| 3477 |
+
|
| 3478 |
+
[Chapter_06_Decongestants_page2_img1142.png]
|
| 3479 |
+
|
| 3480 |
+
|
| 3481 |
+
[Chapter_06_Decongestants_page2_img1143.png]
|
| 3482 |
+
|
| 3483 |
+
|
| 3484 |
+
[Chapter_06_Decongestants_page2_img1144.png]
|
| 3485 |
+
|
| 3486 |
+
|
| 3487 |
+
[Chapter_06_Decongestants_page2_img1145.png]
|
| 3488 |
+
|
| 3489 |
+
|
| 3490 |
+
[Chapter_06_Decongestants_page2_img1146.png]
|
| 3491 |
+
|
| 3492 |
+
|
| 3493 |
+
[Chapter_06_Decongestants_page2_img1147.png]
|
| 3494 |
+
|
| 3495 |
+
|
| 3496 |
+
[Chapter_06_Decongestants_page2_img1148.png]
|
| 3497 |
+
|
| 3498 |
+
|
| 3499 |
+
[Chapter_06_Decongestants_page2_img1149.png]
|
| 3500 |
+
|
| 3501 |
+
|
| 3502 |
+
[Chapter_06_Decongestants_page2_img1150.png]
|
| 3503 |
+
|
| 3504 |
+
|
| 3505 |
+
[Chapter_06_Decongestants_page2_img1151.png]
|
| 3506 |
+
|
| 3507 |
+
|
| 3508 |
+
[Chapter_06_Decongestants_page2_img1152.png]
|
| 3509 |
+
|
| 3510 |
+
|
| 3511 |
+
[Chapter_06_Decongestants_page2_img1153.png]
|
| 3512 |
+
|
| 3513 |
+
|
| 3514 |
+
[Chapter_06_Decongestants_page2_img1154.png]
|
| 3515 |
+
|
| 3516 |
+
|
| 3517 |
+
[Chapter_06_Decongestants_page2_img1155.png]
|
| 3518 |
+
|
| 3519 |
+
|
| 3520 |
+
[Chapter_06_Decongestants_page2_img1156.png]
|
| 3521 |
+
|
| 3522 |
+
|
| 3523 |
+
[Chapter_06_Decongestants_page2_img1157.png]
|
| 3524 |
+
|
| 3525 |
+
|
| 3526 |
+
[Chapter_06_Decongestants_page2_img1158.png]
|
| 3527 |
+
|
| 3528 |
+
|
| 3529 |
+
[Chapter_06_Decongestants_page2_img1159.png]
|
| 3530 |
+
|
| 3531 |
+
|
| 3532 |
+
[Chapter_06_Decongestants_page2_img1160.png]
|
| 3533 |
+
|
| 3534 |
+
|
| 3535 |
+
[Chapter_06_Decongestants_page2_img1161.png]
|
| 3536 |
+
|
| 3537 |
+
|
| 3538 |
+
[Chapter_06_Decongestants_page2_img1162.png]
|
| 3539 |
+
|
| 3540 |
+
|
| 3541 |
+
[Chapter_06_Decongestants_page2_img1163.png]
|
| 3542 |
+
|
| 3543 |
+
|
| 3544 |
+
[Chapter_06_Decongestants_page2_img1164.png]
|
| 3545 |
+
|
| 3546 |
+
|
| 3547 |
+
[Chapter_06_Decongestants_page2_img1165.png]
|
| 3548 |
+
|
| 3549 |
+
|
| 3550 |
+
[Chapter_06_Decongestants_page2_img1166.png]
|
| 3551 |
+
|
| 3552 |
+
|
| 3553 |
+
[Chapter_06_Decongestants_page2_img1167.png]
|
| 3554 |
+
|
| 3555 |
+
|
| 3556 |
+
[Chapter_06_Decongestants_page2_img1168.png]
|
| 3557 |
+
|
| 3558 |
+
|
| 3559 |
+
[Chapter_06_Decongestants_page2_img1169.png]
|
| 3560 |
+
|
| 3561 |
+
|
| 3562 |
+
[Chapter_06_Decongestants_page2_img1170.png]
|
| 3563 |
+
|
| 3564 |
+
|
| 3565 |
+
[Chapter_06_Decongestants_page2_img1171.png]
|
| 3566 |
+
|
| 3567 |
+
|
| 3568 |
+
[Chapter_06_Decongestants_page2_img1172.png]
|
| 3569 |
+
|
| 3570 |
+
|
| 3571 |
+
[Chapter_06_Decongestants_page2_img1173.png]
|
| 3572 |
+
|
| 3573 |
+
|
| 3574 |
+
[Chapter_06_Decongestants_page2_img1174.png]
|
| 3575 |
+
|
| 3576 |
+
|
| 3577 |
+
[Chapter_06_Decongestants_page2_img1175.png]
|
| 3578 |
+
|
| 3579 |
+
|
| 3580 |
+
[Chapter_06_Decongestants_page2_img1176.png]
|
| 3581 |
+
|
| 3582 |
+
|
| 3583 |
+
[Chapter_06_Decongestants_page2_img1177.png]
|
| 3584 |
+
|
| 3585 |
+
|
| 3586 |
+
[Chapter_06_Decongestants_page2_img1178.png]
|
| 3587 |
+
|
| 3588 |
+
|
| 3589 |
+
[Chapter_06_Decongestants_page2_img1179.png]
|
| 3590 |
+
|
| 3591 |
+
|
| 3592 |
+
[Chapter_06_Decongestants_page2_img1180.png]
|
| 3593 |
+
|
| 3594 |
+
|
| 3595 |
+
[Chapter_06_Decongestants_page2_img1181.png]
|
| 3596 |
+
|
| 3597 |
+
|
| 3598 |
+
[Chapter_06_Decongestants_page2_img1182.png]
|
| 3599 |
+
|
| 3600 |
+
|
| 3601 |
+
[Chapter_06_Decongestants_page2_img1183.png]
|
| 3602 |
+
|
| 3603 |
+
|
| 3604 |
+
[Chapter_06_Decongestants_page2_img1184.png]
|
| 3605 |
+
|
| 3606 |
+
|
| 3607 |
+
[Chapter_06_Decongestants_page2_img1185.png]
|
| 3608 |
+
|
| 3609 |
+
|
| 3610 |
+
[Chapter_06_Decongestants_page2_img1186.png]
|
| 3611 |
+
|
| 3612 |
+
|
| 3613 |
+
[Chapter_06_Decongestants_page2_img1187.png]
|
| 3614 |
+
|
| 3615 |
+
|
| 3616 |
+
[Chapter_06_Decongestants_page2_img1188.png]
|
| 3617 |
+
|
| 3618 |
+
|
| 3619 |
+
[Chapter_06_Decongestants_page2_img1189.png]
|
| 3620 |
+
|
| 3621 |
+
|
| 3622 |
+
[Chapter_06_Decongestants_page2_img1190.png]
|
| 3623 |
+
|
| 3624 |
+
|
| 3625 |
+
[Chapter_06_Decongestants_page2_img1191.png]
|
| 3626 |
+
|
| 3627 |
+
|
| 3628 |
+
[Chapter_06_Decongestants_page2_img1192.png]
|
| 3629 |
+
|
| 3630 |
+
|
| 3631 |
+
[Chapter_06_Decongestants_page2_img1193.png]
|
| 3632 |
+
|
| 3633 |
+
|
| 3634 |
+
[Chapter_06_Decongestants_page2_img1194.png]
|
| 3635 |
+
|
| 3636 |
+
|
| 3637 |
+
[Chapter_06_Decongestants_page2_img1195.png]
|
| 3638 |
+
|
| 3639 |
+
|
| 3640 |
+
[Chapter_06_Decongestants_page2_img1196.png]
|
| 3641 |
+
|
| 3642 |
+
|
| 3643 |
+
[Chapter_06_Decongestants_page2_img1197.png]
|
| 3644 |
+
|
| 3645 |
+
|
| 3646 |
+
[Chapter_06_Decongestants_page2_img1198.png]
|
| 3647 |
+
|
| 3648 |
+
|
| 3649 |
+
[Chapter_06_Decongestants_page2_img1199.png]
|
| 3650 |
+
|
| 3651 |
+
|
| 3652 |
+
[Chapter_06_Decongestants_page2_img1200.png]
|
| 3653 |
+
|
| 3654 |
+
|
| 3655 |
+
[Chapter_06_Decongestants_page2_img1201.png]
|
| 3656 |
+
|
| 3657 |
+
|
| 3658 |
+
[Chapter_06_Decongestants_page2_img1202.png]
|
| 3659 |
+
|
| 3660 |
+
|
| 3661 |
+
[Chapter_06_Decongestants_page2_img1203.png]
|
| 3662 |
+
|
| 3663 |
+
|
| 3664 |
+
[Chapter_06_Decongestants_page2_img1204.png]
|
| 3665 |
+
|
| 3666 |
+
|
| 3667 |
+
[Chapter_06_Decongestants_page2_img1205.png]
|
| 3668 |
+
|
| 3669 |
+
|
| 3670 |
+
[Chapter_06_Decongestants_page2_img1206.png]
|
| 3671 |
+
|
| 3672 |
+
|
| 3673 |
+
[Chapter_06_Decongestants_page2_img1207.png]
|
| 3674 |
+
|
| 3675 |
+
|
| 3676 |
+
[Chapter_06_Decongestants_page2_img1208.png]
|
| 3677 |
+
|
| 3678 |
+
|
| 3679 |
+
[Chapter_06_Decongestants_page2_img1209.png]
|
| 3680 |
+
|
| 3681 |
+
|
| 3682 |
+
[Chapter_06_Decongestants_page2_img1210.png]
|
| 3683 |
+
|
| 3684 |
+
|
| 3685 |
+
[Chapter_06_Decongestants_page2_img1211.png]
|
| 3686 |
+
|
| 3687 |
+
|
| 3688 |
+
[Chapter_06_Decongestants_page2_img1212.png]
|
| 3689 |
+
|
| 3690 |
+
|
| 3691 |
+
[Chapter_06_Decongestants_page2_img1213.png]
|
| 3692 |
+
|
| 3693 |
+
|
| 3694 |
+
[Chapter_06_Decongestants_page2_img1214.png]
|
| 3695 |
+
|
| 3696 |
+
|
| 3697 |
+
[Chapter_06_Decongestants_page2_img1215.png]
|
| 3698 |
+
|
| 3699 |
+
|
| 3700 |
+
[Chapter_06_Decongestants_page2_img1216.png]
|
| 3701 |
+
|
| 3702 |
+
|
| 3703 |
+
[Chapter_06_Decongestants_page2_img1217.png]
|
| 3704 |
+
|
| 3705 |
+
|
| 3706 |
+
[Chapter_06_Decongestants_page2_img1218.png]
|
| 3707 |
+
|
| 3708 |
+
|
| 3709 |
+
[Chapter_06_Decongestants_page2_img1219.png]
|
| 3710 |
+
|
| 3711 |
+
|
| 3712 |
+
[Chapter_06_Decongestants_page2_img1220.png]
|
| 3713 |
+
|
| 3714 |
+
|
| 3715 |
+
[Chapter_06_Decongestants_page2_img1221.png]
|
| 3716 |
+
|
| 3717 |
+
|
| 3718 |
+
[Chapter_06_Decongestants_page2_img1222.png]
|
| 3719 |
+
|
| 3720 |
+
|
| 3721 |
+
[Chapter_06_Decongestants_page2_img1223.png]
|
| 3722 |
+
|
| 3723 |
+
|
| 3724 |
+
[Chapter_06_Decongestants_page2_img1224.png]
|
| 3725 |
+
|
| 3726 |
+
|
| 3727 |
+
[Chapter_06_Decongestants_page2_img1225.png]
|
| 3728 |
+
|
| 3729 |
+
|
| 3730 |
+
[Chapter_06_Decongestants_page2_img1226.png]
|
| 3731 |
+
|
| 3732 |
+
|
| 3733 |
+
[Chapter_06_Decongestants_page2_img1227.png]
|
| 3734 |
+
|
| 3735 |
+
|
| 3736 |
+
[Chapter_06_Decongestants_page2_img1228.png]
|
| 3737 |
+
|
| 3738 |
+
|
| 3739 |
+
[Chapter_06_Decongestants_page2_img1229.png]
|
| 3740 |
+
|
| 3741 |
+
|
| 3742 |
+
[Chapter_06_Decongestants_page2_img1230.png]
|
| 3743 |
+
|
| 3744 |
+
|
| 3745 |
+
[Chapter_06_Decongestants_page2_img1231.png]
|
| 3746 |
+
|
| 3747 |
+
|
| 3748 |
+
[Chapter_06_Decongestants_page2_img1232.png]
|
| 3749 |
+
|
| 3750 |
+
|
| 3751 |
+
[Chapter_06_Decongestants_page2_img1233.png]
|
| 3752 |
+
|
| 3753 |
+
|
| 3754 |
+
[Chapter_06_Decongestants_page2_img1234.png]
|
| 3755 |
+
|
| 3756 |
+
|
| 3757 |
+
[Chapter_06_Decongestants_page2_img1235.png]
|
| 3758 |
+
|
| 3759 |
+
|
| 3760 |
+
[Chapter_06_Decongestants_page2_img1236.png]
|
| 3761 |
+
|
| 3762 |
+
|
| 3763 |
+
[Chapter_06_Decongestants_page2_img1237.png]
|
| 3764 |
+
|
| 3765 |
+
|
| 3766 |
+
[Chapter_06_Decongestants_page2_img1238.png]
|
| 3767 |
+
|
| 3768 |
+
|
| 3769 |
+
[Chapter_06_Decongestants_page2_img1239.png]
|
| 3770 |
+
|
| 3771 |
+
|
| 3772 |
+
[Chapter_06_Decongestants_page2_img1240.png]
|
| 3773 |
+
|
| 3774 |
+
|
| 3775 |
+
[Chapter_06_Decongestants_page2_img1241.png]
|
| 3776 |
+
|
| 3777 |
+
|
| 3778 |
+
[Chapter_06_Decongestants_page2_img1242.png]
|
| 3779 |
+
|
| 3780 |
+
|
| 3781 |
+
[Chapter_06_Decongestants_page2_img1243.png]
|
| 3782 |
+
|
| 3783 |
+
|
| 3784 |
+
[Chapter_06_Decongestants_page2_img1244.png]
|
| 3785 |
+
|
| 3786 |
+
|
| 3787 |
+
[Chapter_06_Decongestants_page2_img1245.png]
|
| 3788 |
+
|
| 3789 |
+
|
| 3790 |
+
[Chapter_06_Decongestants_page2_img1246.png]
|
| 3791 |
+
|
| 3792 |
+
|
| 3793 |
+
[Chapter_06_Decongestants_page2_img1247.png]
|
| 3794 |
+
|
| 3795 |
+
|
| 3796 |
+
[Chapter_06_Decongestants_page2_img1248.png]
|
| 3797 |
+
|
| 3798 |
+
|
| 3799 |
+
[Chapter_06_Decongestants_page2_img1249.png]
|
| 3800 |
+
|
| 3801 |
+
|
| 3802 |
+
[Chapter_06_Decongestants_page2_img1250.png]
|
| 3803 |
+
|
| 3804 |
+
|
| 3805 |
+
[Chapter_06_Decongestants_page2_img1251.png]
|
| 3806 |
+
|
| 3807 |
+
|
| 3808 |
+
[Chapter_06_Decongestants_page2_img1252.png]
|
| 3809 |
+
|
| 3810 |
+
|
| 3811 |
+
[Chapter_06_Decongestants_page2_img1253.png]
|
| 3812 |
+
|
| 3813 |
+
|
| 3814 |
+
[Chapter_06_Decongestants_page2_img1254.png]
|
| 3815 |
+
|
| 3816 |
+
|
| 3817 |
+
[Chapter_06_Decongestants_page2_img1255.png]
|
| 3818 |
+
|
| 3819 |
+
|
| 3820 |
+
[Chapter_06_Decongestants_page2_img1256.png]
|
| 3821 |
+
|
| 3822 |
+
|
| 3823 |
+
[Chapter_06_Decongestants_page2_img1257.png]
|
| 3824 |
+
|
| 3825 |
+
|
| 3826 |
+
[Chapter_06_Decongestants_page2_img1258.png]
|
| 3827 |
+
|
| 3828 |
+
|
| 3829 |
+
[Chapter_06_Decongestants_page2_img1259.png]
|
| 3830 |
+
|
| 3831 |
+
|
| 3832 |
+
[Chapter_06_Decongestants_page2_img1260.png]
|
| 3833 |
+
|
| 3834 |
+
|
| 3835 |
+
[Chapter_06_Decongestants_page2_img1261.png]
|
| 3836 |
+
|
| 3837 |
+
|
| 3838 |
+
[Chapter_06_Decongestants_page2_img1262.png]
|
| 3839 |
+
|
| 3840 |
+
|
| 3841 |
+
[Chapter_06_Decongestants_page2_img1263.png]
|
| 3842 |
+
|
| 3843 |
+
|
| 3844 |
+
[Chapter_06_Decongestants_page2_img1264.png]
|
| 3845 |
+
|
| 3846 |
+
|
| 3847 |
+
[Chapter_06_Decongestants_page2_img1265.png]
|
| 3848 |
+
|
| 3849 |
+
|
| 3850 |
+
[Chapter_06_Decongestants_page2_img1266.png]
|
| 3851 |
+
|
| 3852 |
+
|
| 3853 |
+
[Chapter_06_Decongestants_page2_img1267.png]
|
| 3854 |
+
|
| 3855 |
+
|
| 3856 |
+
[Chapter_06_Decongestants_page2_img1268.png]
|
| 3857 |
+
|
| 3858 |
+
|
| 3859 |
+
[Chapter_06_Decongestants_page2_img1269.png]
|
| 3860 |
+
|
| 3861 |
+
|
| 3862 |
+
[Chapter_06_Decongestants_page2_img1270.png]
|
| 3863 |
+
|
| 3864 |
+
|
| 3865 |
+
[Chapter_06_Decongestants_page2_img1271.png]
|
| 3866 |
+
|
| 3867 |
+
|
| 3868 |
+
[Chapter_06_Decongestants_page2_img1272.png]
|
| 3869 |
+
|
| 3870 |
+
|
| 3871 |
+
[Chapter_06_Decongestants_page2_img1273.png]
|
| 3872 |
+
|
| 3873 |
+
|
| 3874 |
+
[Chapter_06_Decongestants_page2_img1274.png]
|
| 3875 |
+
|
| 3876 |
+
|
| 3877 |
+
[Chapter_06_Decongestants_page2_img1275.png]
|
| 3878 |
+
|
| 3879 |
+
|
| 3880 |
+
[Chapter_06_Decongestants_page2_img1276.png]
|
| 3881 |
+
|
| 3882 |
+
|
| 3883 |
+
[Chapter_06_Decongestants_page2_img1277.png]
|
| 3884 |
+
|
| 3885 |
+
|
| 3886 |
+
[Chapter_06_Decongestants_page2_img1278.png]
|
| 3887 |
+
|
| 3888 |
+
|
| 3889 |
+
[Chapter_06_Decongestants_page2_img1279.png]
|
| 3890 |
+
|
| 3891 |
+
|
| 3892 |
+
[Chapter_06_Decongestants_page2_img1280.png]
|
| 3893 |
+
|
| 3894 |
+
|
| 3895 |
+
[Chapter_06_Decongestants_page2_img1281.png]
|
| 3896 |
+
|
| 3897 |
+
|
| 3898 |
+
[Chapter_06_Decongestants_page2_img1282.png]
|
| 3899 |
+
|
| 3900 |
+
|
| 3901 |
+
[Chapter_06_Decongestants_page2_img1283.png]
|
| 3902 |
+
|
| 3903 |
+
|
| 3904 |
+
[Chapter_06_Decongestants_page2_img1284.png]
|
| 3905 |
+
|
| 3906 |
+
|
| 3907 |
+
[Chapter_06_Decongestants_page2_img1285.png]
|
| 3908 |
+
|
| 3909 |
+
|
| 3910 |
+
[Chapter_06_Decongestants_page2_img1286.png]
|
| 3911 |
+
|
| 3912 |
+
|
| 3913 |
+
[Chapter_06_Decongestants_page2_img1287.png]
|
| 3914 |
+
|
| 3915 |
+
|
| 3916 |
+
[Chapter_06_Decongestants_page2_img1288.png]
|
| 3917 |
+
|
| 3918 |
+
|
| 3919 |
+
[Chapter_06_Decongestants_page2_img1289.png]
|
| 3920 |
+
|
| 3921 |
+
|
| 3922 |
+
[Chapter_06_Decongestants_page2_img1290.png]
|
| 3923 |
+
|
| 3924 |
+
|
| 3925 |
+
[Chapter_06_Decongestants_page2_img1291.png]
|
| 3926 |
+
|
| 3927 |
+
|
| 3928 |
+
[Chapter_06_Decongestants_page2_img1292.png]
|
| 3929 |
+
|
| 3930 |
+
|
| 3931 |
+
[Chapter_06_Decongestants_page2_img1293.png]
|
| 3932 |
+
|
| 3933 |
+
|
| 3934 |
+
[Chapter_06_Decongestants_page2_img1294.png]
|
| 3935 |
+
|
| 3936 |
+
|
| 3937 |
+
[Chapter_06_Decongestants_page2_img1295.png]
|
| 3938 |
+
|
| 3939 |
+
|
| 3940 |
+
[Chapter_06_Decongestants_page2_img1296.png]
|
| 3941 |
+
|
| 3942 |
+
|
| 3943 |
+
[Chapter_06_Decongestants_page2_img1297.png]
|
| 3944 |
+
|
| 3945 |
+
|
| 3946 |
+
[Chapter_06_Decongestants_page2_img1298.png]
|
| 3947 |
+
|
| 3948 |
+
|
| 3949 |
+
[Chapter_06_Decongestants_page2_img1299.png]
|
| 3950 |
+
|
| 3951 |
+
|
| 3952 |
+
[Chapter_06_Decongestants_page2_img1300.png]
|
| 3953 |
+
|
| 3954 |
+
|
| 3955 |
+
[Chapter_06_Decongestants_page2_img1301.png]
|
| 3956 |
+
|
| 3957 |
+
|
| 3958 |
+
[Chapter_06_Decongestants_page2_img1302.png]
|
| 3959 |
+
|
| 3960 |
+
|
| 3961 |
+
[Chapter_06_Decongestants_page2_img1303.png]
|
| 3962 |
+
|
| 3963 |
+
|
| 3964 |
+
[Chapter_06_Decongestants_page2_img1304.png]
|
| 3965 |
+
|
| 3966 |
+
|
| 3967 |
+
[Chapter_06_Decongestants_page2_img1305.png]
|
| 3968 |
+
|
| 3969 |
+
|
| 3970 |
+
[Chapter_06_Decongestants_page2_img1306.png]
|
| 3971 |
+
|
| 3972 |
+
|
| 3973 |
+
[Chapter_06_Decongestants_page2_img1307.png]
|
| 3974 |
+
|
| 3975 |
+
|
| 3976 |
+
[Chapter_06_Decongestants_page2_img1308.png]
|
| 3977 |
+
|
| 3978 |
+
|
| 3979 |
+
[Chapter_06_Decongestants_page2_img1309.png]
|
| 3980 |
+
|
| 3981 |
+
|
| 3982 |
+
[Chapter_06_Decongestants_page2_img1310.png]
|
| 3983 |
+
|
| 3984 |
+
|
| 3985 |
+
[Chapter_06_Decongestants_page2_img1311.png]
|
| 3986 |
+
|
| 3987 |
+
|
| 3988 |
+
[Chapter_06_Decongestants_page2_img1312.png]
|
| 3989 |
+
|
| 3990 |
+
|
| 3991 |
+
[Chapter_06_Decongestants_page2_img1313.png]
|
| 3992 |
+
|
| 3993 |
+
|
| 3994 |
+
[Chapter_06_Decongestants_page2_img1314.png]
|
| 3995 |
+
|
| 3996 |
+
|
| 3997 |
+
[Chapter_06_Decongestants_page2_img1315.png]
|
| 3998 |
+
|
| 3999 |
+
|
| 4000 |
+
[Chapter_06_Decongestants_page2_img1316.png]
|
| 4001 |
+
|
| 4002 |
+
|
| 4003 |
+
[Chapter_06_Decongestants_page2_img1317.png]
|
| 4004 |
+
|
| 4005 |
+
|
| 4006 |
+
[Chapter_06_Decongestants_page2_img1318.png]
|
| 4007 |
+
|
| 4008 |
+
|
| 4009 |
+
[Chapter_06_Decongestants_page2_img1319.png]
|
| 4010 |
+
|
| 4011 |
+
|
| 4012 |
+
[Chapter_06_Decongestants_page2_img1320.png]
|
| 4013 |
+
|
| 4014 |
+
|
| 4015 |
+
[Chapter_06_Decongestants_page2_img1321.png]
|
| 4016 |
+
|
| 4017 |
+
|
| 4018 |
+
[Chapter_06_Decongestants_page2_img1322.png]
|
| 4019 |
+
|
| 4020 |
+
|
| 4021 |
+
[Chapter_06_Decongestants_page2_img1323.png]
|
| 4022 |
+
|
| 4023 |
+
|
| 4024 |
+
[Chapter_06_Decongestants_page2_img1324.png]
|
| 4025 |
+
|
| 4026 |
+
|
| 4027 |
+
[Chapter_06_Decongestants_page2_img1325.png]
|
| 4028 |
+
|
| 4029 |
+
|
| 4030 |
+
[Chapter_06_Decongestants_page2_img1326.png]
|
| 4031 |
+
|
| 4032 |
+
|
| 4033 |
+
[Chapter_06_Decongestants_page2_img1327.png]
|
| 4034 |
+
|
| 4035 |
+
|
| 4036 |
+
[Chapter_06_Decongestants_page2_img1328.png]
|
| 4037 |
+
|
| 4038 |
+
|
| 4039 |
+
[Chapter_06_Decongestants_page2_img1329.png]
|
| 4040 |
+
|
| 4041 |
+
|
| 4042 |
+
[Chapter_06_Decongestants_page2_img1330.png]
|
| 4043 |
+
|
| 4044 |
+
|
| 4045 |
+
[Chapter_06_Decongestants_page2_img1331.png]
|
| 4046 |
+
|
| 4047 |
+
|
| 4048 |
+
[Chapter_06_Decongestants_page2_img1332.png]
|
| 4049 |
+
|
| 4050 |
+
|
| 4051 |
+
[Chapter_06_Decongestants_page2_img1333.png]
|
| 4052 |
+
|
| 4053 |
+
|
| 4054 |
+
[Chapter_06_Decongestants_page2_img1334.png]
|
| 4055 |
+
|
| 4056 |
+
|
| 4057 |
+
[Chapter_06_Decongestants_page2_img1335.png]
|
| 4058 |
+
|
| 4059 |
+
|
| 4060 |
+
[Chapter_06_Decongestants_page2_img1336.png]
|
| 4061 |
+
|
| 4062 |
+
|
| 4063 |
+
[Chapter_06_Decongestants_page2_img1337.png]
|
| 4064 |
+
|
| 4065 |
+
|
| 4066 |
+
[Chapter_06_Decongestants_page2_img1338.png]
|
| 4067 |
+
|
| 4068 |
+
|
| 4069 |
+
[Chapter_06_Decongestants_page2_img1339.png]
|
| 4070 |
+
|
| 4071 |
+
|
| 4072 |
+
[Chapter_06_Decongestants_page2_img1340.png]
|
| 4073 |
+
|
| 4074 |
+
|
| 4075 |
+
[Chapter_06_Decongestants_page2_img1341.png]
|
| 4076 |
+
|
| 4077 |
+
|
| 4078 |
+
[Chapter_06_Decongestants_page2_img1342.png]
|
| 4079 |
+
|
| 4080 |
+
|
| 4081 |
+
[Chapter_06_Decongestants_page2_img1343.png]
|
| 4082 |
+
|
| 4083 |
+
|
| 4084 |
+
[Chapter_06_Decongestants_page2_img1344.png]
|
| 4085 |
+
|
| 4086 |
+
|
| 4087 |
+
[Chapter_06_Decongestants_page2_img1345.png]
|
| 4088 |
+
|
| 4089 |
+
|
| 4090 |
+
[Chapter_06_Decongestants_page2_img1346.png]
|
| 4091 |
+
|
| 4092 |
+
|
| 4093 |
+
[Chapter_06_Decongestants_page2_img1347.png]
|
| 4094 |
+
|
| 4095 |
+
|
| 4096 |
+
[Chapter_06_Decongestants_page2_img1348.png]
|
| 4097 |
+
|
| 4098 |
+
|
| 4099 |
+
[Chapter_06_Decongestants_page2_img1349.png]
|
| 4100 |
+
|
| 4101 |
+
|
| 4102 |
+
[Chapter_06_Decongestants_page2_img1350.png]
|
| 4103 |
+
|
| 4104 |
+
|
| 4105 |
+
[Chapter_06_Decongestants_page2_img1351.png]
|
| 4106 |
+
|
| 4107 |
+
|
| 4108 |
+
[Chapter_06_Decongestants_page2_img1352.png]
|
| 4109 |
+
|
| 4110 |
+
|
| 4111 |
+
[Chapter_06_Decongestants_page2_img1353.png]
|
| 4112 |
+
|
| 4113 |
+
|
| 4114 |
+
[Chapter_06_Decongestants_page2_img1354.png]
|
| 4115 |
+
|
| 4116 |
+
|
| 4117 |
+
[Chapter_06_Decongestants_page2_img1355.png]
|
| 4118 |
+
|
| 4119 |
+
|
| 4120 |
+
[Chapter_06_Decongestants_page2_img1356.png]
|
| 4121 |
+
|
| 4122 |
+
|
| 4123 |
+
[Chapter_06_Decongestants_page2_img1357.png]
|
| 4124 |
+
|
| 4125 |
+
|
| 4126 |
+
[Chapter_06_Decongestants_page2_img1358.png]
|
| 4127 |
+
|
| 4128 |
+
|
| 4129 |
+
[Chapter_06_Decongestants_page2_img1359.png]
|
| 4130 |
+
|
| 4131 |
+
|
| 4132 |
+
[Chapter_06_Decongestants_page2_img1360.png]
|
| 4133 |
+
|
| 4134 |
+
|
| 4135 |
+
[Chapter_06_Decongestants_page2_img1361.png]
|
| 4136 |
+
|
| 4137 |
+
|
| 4138 |
+
[Chapter_06_Decongestants_page2_img1362.png]
|
| 4139 |
+
|
| 4140 |
+
|
| 4141 |
+
[Chapter_06_Decongestants_page2_img1363.png]
|
| 4142 |
+
|
| 4143 |
+
|
| 4144 |
+
[Chapter_06_Decongestants_page2_img1364.png]
|
| 4145 |
+
|
| 4146 |
+
|
| 4147 |
+
[Chapter_06_Decongestants_page2_img1365.png]
|
| 4148 |
+
|
| 4149 |
+
|
| 4150 |
+
[Chapter_06_Decongestants_page2_img1366.png]
|
| 4151 |
+
|
| 4152 |
+
|
| 4153 |
+
[Chapter_06_Decongestants_page2_img1367.png]
|
| 4154 |
+
|
| 4155 |
+
|
| 4156 |
+
[Chapter_06_Decongestants_page2_img1368.png]
|
| 4157 |
+
|
| 4158 |
+
|
| 4159 |
+
[Chapter_06_Decongestants_page2_img1369.png]
|
| 4160 |
+
|
| 4161 |
+
|
| 4162 |
+
[Chapter_06_Decongestants_page2_img1370.png]
|
| 4163 |
+
|
| 4164 |
+
|
| 4165 |
+
[Chapter_06_Decongestants_page2_img1371.png]
|
| 4166 |
+
|
| 4167 |
+
|
| 4168 |
+
[Chapter_06_Decongestants_page2_img1372.png]
|
| 4169 |
+
|
| 4170 |
+
|
| 4171 |
+
[Chapter_06_Decongestants_page2_img1373.png]
|
| 4172 |
+
|
| 4173 |
+
|
| 4174 |
+
[Chapter_06_Decongestants_page2_img1374.png]
|
| 4175 |
+
|
| 4176 |
+
|
| 4177 |
+
[Chapter_06_Decongestants_page2_img1375.png]
|
| 4178 |
+
|
| 4179 |
+
|
| 4180 |
+
[Chapter_06_Decongestants_page2_img1376.png]
|
| 4181 |
+
|
| 4182 |
+
|
| 4183 |
+
[Chapter_06_Decongestants_page2_img1377.png]
|
| 4184 |
+
|
| 4185 |
+
|
| 4186 |
+
[Chapter_06_Decongestants_page2_img1378.png]
|
| 4187 |
+
|
| 4188 |
+
|
| 4189 |
+
[Chapter_06_Decongestants_page2_img1379.png]
|
| 4190 |
+
|
| 4191 |
+
|
| 4192 |
+
[Chapter_06_Decongestants_page2_img1380.png]
|
| 4193 |
+
|
| 4194 |
+
|
| 4195 |
+
[Chapter_06_Decongestants_page2_img1381.png]
|
| 4196 |
+
|
| 4197 |
+
|
| 4198 |
+
[Chapter_06_Decongestants_page2_img1382.png]
|
| 4199 |
+
|
| 4200 |
+
|
| 4201 |
+
[Chapter_06_Decongestants_page2_img1383.png]
|
| 4202 |
+
|
| 4203 |
+
|
| 4204 |
+
[Chapter_06_Decongestants_page2_img1384.png]
|
| 4205 |
+
|
| 4206 |
+
|
| 4207 |
+
[Chapter_06_Decongestants_page2_img1385.png]
|
| 4208 |
+
|
| 4209 |
+
|
| 4210 |
+
[Chapter_06_Decongestants_page2_img1386.png]
|
| 4211 |
+
|
| 4212 |
+
|
| 4213 |
+
[Chapter_06_Decongestants_page2_img1387.png]
|
| 4214 |
+
|
| 4215 |
+
|
| 4216 |
+
[Chapter_06_Decongestants_page2_img1388.png]
|
| 4217 |
+
|
| 4218 |
+
|
| 4219 |
+
[Chapter_06_Decongestants_page2_img1389.png]
|
| 4220 |
+
|
| 4221 |
+
|
| 4222 |
+
[Chapter_06_Decongestants_page2_img1390.png]
|
| 4223 |
+
|
| 4224 |
+
|
| 4225 |
+
[Chapter_06_Decongestants_page2_img1391.png]
|
| 4226 |
+
|
| 4227 |
+
|
| 4228 |
+
[Chapter_06_Decongestants_page2_img1392.png]
|
| 4229 |
+
|
| 4230 |
+
|
| 4231 |
+
[Chapter_06_Decongestants_page2_img1393.png]
|
| 4232 |
+
|
| 4233 |
+
|
| 4234 |
+
[Chapter_06_Decongestants_page2_img1394.png]
|
| 4235 |
+
|
| 4236 |
+
|
| 4237 |
+
[Chapter_06_Decongestants_page2_img1395.png]
|
| 4238 |
+
|
| 4239 |
+
|
| 4240 |
+
[Chapter_06_Decongestants_page2_img1396.png]
|
| 4241 |
+
|
| 4242 |
+
|
| 4243 |
+
[Chapter_06_Decongestants_page2_img1397.png]
|
| 4244 |
+
|
| 4245 |
+
|
| 4246 |
+
[Chapter_06_Decongestants_page2_img1398.png]
|
| 4247 |
+
|
| 4248 |
+
|
| 4249 |
+
[Chapter_06_Decongestants_page2_img1399.png]
|
| 4250 |
+
|
| 4251 |
+
|
| 4252 |
+
[Chapter_06_Decongestants_page2_img1400.png]
|
| 4253 |
+
|
| 4254 |
+
|
| 4255 |
+
[Chapter_06_Decongestants_page2_img1401.png]
|
| 4256 |
+
|
| 4257 |
+
|
| 4258 |
+
[Chapter_06_Decongestants_page2_img1402.png]
|
| 4259 |
+
|
| 4260 |
+
|
| 4261 |
+
[Chapter_06_Decongestants_page2_img1403.png]
|
| 4262 |
+
|
| 4263 |
+
|
| 4264 |
+
[Chapter_06_Decongestants_page2_img1404.png]
|
| 4265 |
+
|
| 4266 |
+
|
| 4267 |
+
[Chapter_06_Decongestants_page2_img1405.png]
|
| 4268 |
+
|
| 4269 |
+
|
| 4270 |
+
[Chapter_06_Decongestants_page2_img1406.png]
|
| 4271 |
+
|
| 4272 |
+
|
| 4273 |
+
[Chapter_06_Decongestants_page2_img1407.png]
|
| 4274 |
+
|
| 4275 |
+
|
| 4276 |
+
[Chapter_06_Decongestants_page2_img1408.png]
|
| 4277 |
+
|
| 4278 |
+
|
| 4279 |
+
[Chapter_06_Decongestants_page2_img1409.png]
|
| 4280 |
+
|
| 4281 |
+
|
| 4282 |
+
[Chapter_06_Decongestants_page2_img1410.png]
|
| 4283 |
+
|
| 4284 |
+
|
| 4285 |
+
[Chapter_06_Decongestants_page2_img1411.png]
|
| 4286 |
+
|
| 4287 |
+
|
| 4288 |
+
[Chapter_06_Decongestants_page2_img1412.png]
|
| 4289 |
+
|
| 4290 |
+
|
| 4291 |
+
[Chapter_06_Decongestants_page2_img1413.png]
|
| 4292 |
+
|
| 4293 |
+
|
| 4294 |
+
[Chapter_06_Decongestants_page2_img1414.png]
|
| 4295 |
+
|
| 4296 |
+
|
| 4297 |
+
[Chapter_06_Decongestants_page2_img1415.png]
|
| 4298 |
+
|
| 4299 |
+
|
| 4300 |
+
[Chapter_06_Decongestants_page2_img1416.png]
|
| 4301 |
+
|
| 4302 |
+
|
| 4303 |
+
[Chapter_06_Decongestants_page2_img1417.png]
|
| 4304 |
+
|
| 4305 |
+
|
| 4306 |
+
[Chapter_06_Decongestants_page2_img1418.png]
|
| 4307 |
+
|
| 4308 |
+
|
| 4309 |
+
[Chapter_06_Decongestants_page2_img1419.png]
|
| 4310 |
+
|
| 4311 |
+
|
| 4312 |
+
[Chapter_06_Decongestants_page2_img1420.png]
|
| 4313 |
+
|
| 4314 |
+
|
| 4315 |
+
[Chapter_06_Decongestants_page2_img1421.png]
|
| 4316 |
+
|
| 4317 |
+
|
| 4318 |
+
[Chapter_06_Decongestants_page2_img1422.png]
|
| 4319 |
+
|
| 4320 |
+
|
| 4321 |
+
[Chapter_06_Decongestants_page2_img1423.png]
|
| 4322 |
+
|
| 4323 |
+
|
| 4324 |
+
[Chapter_06_Decongestants_page2_img1424.png]
|
| 4325 |
+
|
| 4326 |
+
|
| 4327 |
+
[Chapter_06_Decongestants_page2_img1425.png]
|
| 4328 |
+
|
| 4329 |
+
|
| 4330 |
+
[Chapter_06_Decongestants_page2_img1426.png]
|
| 4331 |
+
|
| 4332 |
+
|
| 4333 |
+
[Chapter_06_Decongestants_page2_img1427.png]
|
| 4334 |
+
|
| 4335 |
+
|
| 4336 |
+
[Chapter_06_Decongestants_page2_img1428.png]
|
| 4337 |
+
|
| 4338 |
+
|
| 4339 |
+
[Chapter_06_Decongestants_page2_img1429.png]
|
| 4340 |
+
|
| 4341 |
+
|
| 4342 |
+
[Chapter_06_Decongestants_page2_img1430.png]
|
| 4343 |
+
|
| 4344 |
+
|
| 4345 |
+
[Chapter_06_Decongestants_page2_img1431.png]
|
| 4346 |
+
|
| 4347 |
+
|
| 4348 |
+
[Chapter_06_Decongestants_page2_img1432.png]
|
| 4349 |
+
|
| 4350 |
+
|
| 4351 |
+
[Chapter_06_Decongestants_page2_img1433.png]
|
| 4352 |
+
|
| 4353 |
+
|
| 4354 |
+
[Chapter_06_Decongestants_page2_img1434.png]
|
| 4355 |
+
|
| 4356 |
+
|
| 4357 |
+
[Chapter_06_Decongestants_page2_img1435.png]
|
| 4358 |
+
|
| 4359 |
+
|
| 4360 |
+
[Chapter_06_Decongestants_page2_img1436.png]
|
| 4361 |
+
|
| 4362 |
+
|
| 4363 |
+
[Chapter_06_Decongestants_page2_img1437.png]
|
| 4364 |
+
|
| 4365 |
+
|
| 4366 |
+
[Chapter_06_Decongestants_page2_img1438.png]
|
| 4367 |
+
|
| 4368 |
+
|
| 4369 |
+
[Chapter_06_Decongestants_page2_img1439.png]
|
| 4370 |
+
|
| 4371 |
+
|
| 4372 |
+
[Chapter_06_Decongestants_page2_img1440.png]
|
| 4373 |
+
|
| 4374 |
+
|
| 4375 |
+
[Chapter_06_Decongestants_page2_img1441.png]
|
| 4376 |
+
|
| 4377 |
+
|
| 4378 |
+
[Chapter_06_Decongestants_page2_img1442.png]
|
| 4379 |
+
|
| 4380 |
+
|
| 4381 |
+
[Chapter_06_Decongestants_page2_img1443.png]
|
| 4382 |
+
|
| 4383 |
+
|
| 4384 |
+
[Chapter_06_Decongestants_page2_img1444.png]
|
| 4385 |
+
|
| 4386 |
+
|
| 4387 |
+
[Chapter_06_Decongestants_page2_img1445.png]
|
| 4388 |
+
|
| 4389 |
+
|
| 4390 |
+
[Chapter_06_Decongestants_page2_img1446.png]
|
| 4391 |
+
|
| 4392 |
+
|
| 4393 |
+
[Chapter_06_Decongestants_page2_img1447.png]
|
| 4394 |
+
|
| 4395 |
+
|
| 4396 |
+
[Chapter_06_Decongestants_page2_img1448.png]
|
| 4397 |
+
|
| 4398 |
+
|
| 4399 |
+
[Chapter_06_Decongestants_page2_img1449.png]
|
| 4400 |
+
|
| 4401 |
+
|
| 4402 |
+
[Chapter_06_Decongestants_page2_img1450.png]
|
| 4403 |
+
|
| 4404 |
+
|
| 4405 |
+
[Chapter_06_Decongestants_page2_img1451.png]
|
| 4406 |
+
|
| 4407 |
+
|
| 4408 |
+
[Chapter_06_Decongestants_page2_img1452.png]
|
| 4409 |
+
|
| 4410 |
+
|
| 4411 |
+
[Chapter_06_Decongestants_page2_img1453.png]
|
| 4412 |
+
|
| 4413 |
+
|
| 4414 |
+
[Chapter_06_Decongestants_page2_img1454.png]
|
| 4415 |
+
|
| 4416 |
+
|
| 4417 |
+
[Chapter_06_Decongestants_page2_img1455.png]
|
| 4418 |
+
|
| 4419 |
+
|
| 4420 |
+
[Chapter_06_Decongestants_page2_img1456.png]
|
| 4421 |
+
|
| 4422 |
+
|
| 4423 |
+
[Chapter_06_Decongestants_page2_img1457.png]
|
| 4424 |
+
|
| 4425 |
+
|
| 4426 |
+
[Chapter_06_Decongestants_page2_img1458.png]
|
| 4427 |
+
|
| 4428 |
+
|
| 4429 |
+
[Chapter_06_Decongestants_page2_img1459.png]
|
| 4430 |
+
|
| 4431 |
+
|
| 4432 |
+
[Chapter_06_Decongestants_page2_img1460.png]
|
| 4433 |
+
|
| 4434 |
+
|
| 4435 |
+
[Chapter_06_Decongestants_page2_img1461.png]
|
| 4436 |
+
|
| 4437 |
+
|
| 4438 |
+
[Chapter_06_Decongestants_page2_img1462.png]
|
| 4439 |
+
|
| 4440 |
+
|
| 4441 |
+
[Chapter_06_Decongestants_page2_img1463.png]
|
| 4442 |
+
|
| 4443 |
+
|
| 4444 |
+
[Chapter_06_Decongestants_page2_img1464.png]
|
| 4445 |
+
|
| 4446 |
+
|
| 4447 |
+
[Chapter_06_Decongestants_page2_img1465.png]
|
| 4448 |
+
|
| 4449 |
+
|
| 4450 |
+
[Chapter_06_Decongestants_page2_img1466.png]
|
| 4451 |
+
|
| 4452 |
+
|
| 4453 |
+
[Chapter_06_Decongestants_page2_img1467.png]
|
| 4454 |
+
|
| 4455 |
+
|
| 4456 |
+
[Chapter_06_Decongestants_page2_img1468.png]
|
| 4457 |
+
|
| 4458 |
+
|
| 4459 |
+
[Chapter_06_Decongestants_page2_img1469.png]
|
| 4460 |
+
|
| 4461 |
+
|
| 4462 |
+
[Chapter_06_Decongestants_page2_img1470.png]
|
| 4463 |
+
|
| 4464 |
+
|
| 4465 |
+
[Chapter_06_Decongestants_page2_img1471.png]
|
| 4466 |
+
|
| 4467 |
+
|
| 4468 |
+
[Chapter_06_Decongestants_page2_img1472.png]
|
| 4469 |
+
|
| 4470 |
+
|
| 4471 |
+
[Chapter_06_Decongestants_page2_img1473.png]
|
| 4472 |
+
|
| 4473 |
+
|
| 4474 |
+
[Chapter_06_Decongestants_page2_img1474.png]
|
| 4475 |
+
|
| 4476 |
+
|
| 4477 |
+
[Chapter_06_Decongestants_page2_img1475.png]
|
| 4478 |
+
|
| 4479 |
+
|
| 4480 |
+
[Chapter_06_Decongestants_page2_img1476.png]
|
| 4481 |
+
|
| 4482 |
+
|
| 4483 |
+
[Chapter_06_Decongestants_page2_img1477.png]
|
| 4484 |
+
|
| 4485 |
+
|
| 4486 |
+
[Chapter_06_Decongestants_page2_img1478.png]
|
| 4487 |
+
|
| 4488 |
+
|
| 4489 |
+
[Chapter_06_Decongestants_page2_img1479.png]
|
| 4490 |
+
|
| 4491 |
+
|
| 4492 |
+
[Chapter_06_Decongestants_page2_img1480.png]
|
| 4493 |
+
|
| 4494 |
+
|
| 4495 |
+
[Chapter_06_Decongestants_page2_img1481.png]
|
| 4496 |
+
|
| 4497 |
+
|
| 4498 |
+
[Chapter_06_Decongestants_page2_img1482.png]
|
| 4499 |
+
|
| 4500 |
+
|
| 4501 |
+
[Chapter_06_Decongestants_page2_img1483.png]
|
| 4502 |
+
|
| 4503 |
+
|
| 4504 |
+
[Chapter_06_Decongestants_page2_img1484.png]
|
| 4505 |
+
|
| 4506 |
+
|
| 4507 |
+
[Chapter_06_Decongestants_page2_img1485.png]
|
| 4508 |
+
|
| 4509 |
+
|
| 4510 |
+
[Chapter_06_Decongestants_page2_img1486.png]
|
| 4511 |
+
|
| 4512 |
+
|
| 4513 |
+
[Chapter_06_Decongestants_page2_img1487.png]
|
| 4514 |
+
|
| 4515 |
+
|
| 4516 |
+
[Chapter_06_Decongestants_page2_img1488.png]
|
| 4517 |
+
|
| 4518 |
+
|
| 4519 |
+
[Chapter_06_Decongestants_page2_img1489.png]
|
| 4520 |
+
|
| 4521 |
+
|
| 4522 |
+
[Chapter_06_Decongestants_page2_img1490.png]
|
| 4523 |
+
|
| 4524 |
+
|
| 4525 |
+
[Chapter_06_Decongestants_page2_img1491.png]
|
| 4526 |
+
|
| 4527 |
+
|
| 4528 |
+
[Chapter_06_Decongestants_page2_img1492.png]
|
| 4529 |
+
|
| 4530 |
+
|
| 4531 |
+
[Chapter_06_Decongestants_page2_img1493.png]
|
| 4532 |
+
|
| 4533 |
+
|
| 4534 |
+
[Chapter_06_Decongestants_page2_img1494.png]
|
| 4535 |
+
|
| 4536 |
+
|
| 4537 |
+
[Chapter_06_Decongestants_page2_img1495.png]
|
| 4538 |
+
|
| 4539 |
+
|
| 4540 |
+
[Chapter_06_Decongestants_page2_img1496.png]
|
| 4541 |
+
|
| 4542 |
+
|
| 4543 |
+
[Chapter_06_Decongestants_page2_img1497.png]
|
| 4544 |
+
|
| 4545 |
+
|
| 4546 |
+
[Chapter_06_Decongestants_page2_img1498.png]
|
| 4547 |
+
|
| 4548 |
+
|
| 4549 |
+
[Chapter_06_Decongestants_page2_img1499.png]
|
| 4550 |
+
|
| 4551 |
+
|
| 4552 |
+
[Chapter_06_Decongestants_page2_img1500.png]
|
| 4553 |
+
|
| 4554 |
+
|
| 4555 |
+
[Chapter_06_Decongestants_page2_img1501.png]
|
| 4556 |
+
|
| 4557 |
+
|
| 4558 |
+
[Chapter_06_Decongestants_page2_img1502.png]
|
| 4559 |
+
|
| 4560 |
+
|
| 4561 |
+
[Chapter_06_Decongestants_page2_img1503.png]
|
| 4562 |
+
|
| 4563 |
+
|
| 4564 |
+
[Chapter_06_Decongestants_page2_img1504.png]
|
| 4565 |
+
|
| 4566 |
+
|
| 4567 |
+
[Chapter_06_Decongestants_page2_img1505.png]
|
| 4568 |
+
|
| 4569 |
+
|
| 4570 |
+
[Chapter_06_Decongestants_page2_img1506.png]
|
| 4571 |
+
|
| 4572 |
+
|
| 4573 |
+
[Chapter_06_Decongestants_page2_img1507.png]
|
| 4574 |
+
|
| 4575 |
+
|
| 4576 |
+
[Chapter_06_Decongestants_page2_img1508.png]
|
| 4577 |
+
|
| 4578 |
+
|
| 4579 |
+
[Chapter_06_Decongestants_page2_img1509.png]
|
| 4580 |
+
|
| 4581 |
+
|
| 4582 |
+
[Chapter_06_Decongestants_page2_img1510.png]
|
| 4583 |
+
|
| 4584 |
+
|
| 4585 |
+
[Chapter_06_Decongestants_page2_img1511.png]
|
| 4586 |
+
|
| 4587 |
+
|
| 4588 |
+
[Chapter_06_Decongestants_page2_img1512.png]
|
| 4589 |
+
|
| 4590 |
+
|
| 4591 |
+
[Chapter_06_Decongestants_page2_img1513.png]
|
| 4592 |
+
|
| 4593 |
+
|
| 4594 |
+
[Chapter_06_Decongestants_page2_img1514.png]
|
| 4595 |
+
|
| 4596 |
+
|
| 4597 |
+
[Chapter_06_Decongestants_page2_img1515.png]
|
| 4598 |
+
|
| 4599 |
+
|
| 4600 |
+
[Chapter_06_Decongestants_page2_img1516.png]
|
| 4601 |
+
|
| 4602 |
+
|
| 4603 |
+
[Chapter_06_Decongestants_page2_img1517.png]
|
| 4604 |
+
|
| 4605 |
+
|
| 4606 |
+
[Chapter_06_Decongestants_page2_img1518.png]
|
| 4607 |
+
|
| 4608 |
+
|
| 4609 |
+
[Chapter_06_Decongestants_page2_img1519.png]
|
| 4610 |
+
|
| 4611 |
+
|
| 4612 |
+
[Chapter_06_Decongestants_page2_img1520.png]
|
| 4613 |
+
|
| 4614 |
+
|
| 4615 |
+
[Chapter_06_Decongestants_page2_img1521.png]
|
| 4616 |
+
|
| 4617 |
+
|
| 4618 |
+
[Chapter_06_Decongestants_page2_img1522.png]
|
| 4619 |
+
|
| 4620 |
+
|
| 4621 |
+
[Chapter_06_Decongestants_page2_img1523.png]
|
| 4622 |
+
|
| 4623 |
+
|
| 4624 |
+
[Chapter_06_Decongestants_page2_img1524.png]
|
| 4625 |
+
|
| 4626 |
+
|
| 4627 |
+
[Chapter_06_Decongestants_page2_img1525.png]
|
| 4628 |
+
|
| 4629 |
+
|
| 4630 |
+
[Chapter_06_Decongestants_page2_img1526.png]
|
| 4631 |
+
|
| 4632 |
+
|
| 4633 |
+
[Chapter_06_Decongestants_page2_img1527.png]
|
| 4634 |
+
|
| 4635 |
+
|
| 4636 |
+
[Chapter_06_Decongestants_page2_img1528.png]
|
| 4637 |
+
|
| 4638 |
+
|
| 4639 |
+
[Chapter_06_Decongestants_page2_img1529.png]
|
| 4640 |
+
|
| 4641 |
+
|
| 4642 |
+
[Chapter_06_Decongestants_page2_img1530.png]
|
| 4643 |
+
|
| 4644 |
+
|
| 4645 |
+
[Chapter_06_Decongestants_page2_img1531.png]
|
| 4646 |
+
|
| 4647 |
+
|
| 4648 |
+
[Chapter_06_Decongestants_page2_img1532.png]
|
| 4649 |
+
|
| 4650 |
+
|
| 4651 |
+
[Chapter_06_Decongestants_page2_img1533.png]
|
| 4652 |
+
|
| 4653 |
+
|
| 4654 |
+
[Chapter_06_Decongestants_page2_img1534.png]
|
| 4655 |
+
|
| 4656 |
+
|
| 4657 |
+
[Chapter_06_Decongestants_page2_img1535.png]
|
| 4658 |
+
|
| 4659 |
+
|
| 4660 |
+
[Chapter_06_Decongestants_page2_img1536.png]
|
| 4661 |
+
|
| 4662 |
+
|
| 4663 |
+
[Chapter_06_Decongestants_page2_img1537.png]
|
| 4664 |
+
|
| 4665 |
+
|
| 4666 |
+
[Chapter_06_Decongestants_page2_img1538.png]
|
| 4667 |
+
|
| 4668 |
+
|
| 4669 |
+
Uses:
|
| 4670 |
+
● Nasal Congestion: Pseudoephedrine is primarily used to relieve nasal and sinus congestion
|
| 4671 |
+
associated with the common cold, allergies, sinusitis, and other upper respiratory tract
|
| 4672 |
+
infections.
|
| 4673 |
+
● Sinus Pressure: It may also help alleviate sinus pressure and discomfort caused by
|
| 4674 |
+
congestion.
|
| 4675 |
+
Stability/Storage Conditions:
|
| 4676 |
+
● Stability: Pseudoephedrine is generally stable when stored properly.
|
| 4677 |
+
● Storage Conditions: It should be stored at room temperature, away from moisture, heat, and
|
| 4678 |
+
direct sunlight. Keep it out of reach of children and pets. Avoid storing it in the bathroom or
|
| 4679 |
+
kitchen, where moisture levels may be high.
|
| 4680 |
+
Safe Dose for Adults:
|
| 4681 |
+
● The recommended adult dose of pseudoephedrine is typically 60 milligrams (mg) every 4 to
|
| 4682 |
+
6 hours, not to exceed 240 mg in 24 hours.
|
| 4683 |
+
● It's essential to follow the dosage instructions provided by a healthcare professional or as
|
| 4684 |
+
indicated on the product label to avoid potential side effects or adverse reactions.
|
| 4685 |
+
24 | Decongestants
|
| 4686 |
+
|
| 4687 |
+
--- End of Page 2 ---
|
| 4688 |
+
|
| 4689 |
+
Marketed Brands:
|
| 4690 |
+
● Sudafed: Trusted for years, clears congestion fast; Relieves sinus pressure, helps you
|
| 4691 |
+
breathe at last.
|
| 4692 |
+
|
| 4693 |
+
[Chapter_06_Decongestants_page3_img1.png]
|
| 4694 |
+
|
| 4695 |
+
|
| 4696 |
+
● Sudafed PE: Non-drowsy formula, tackles cold symptoms with ease; Clears stuffy nose, so
|
| 4697 |
+
you can find some peace.
|
| 4698 |
+
|
| 4699 |
+
[Chapter_06_Decongestants_page3_img2.png]
|
| 4700 |
+
|
| 4701 |
+
|
| 4702 |
+
● Afrinol: Nasal relief in a powerful dose; Congestion gone, with Afrinol close.
|
| 4703 |
+
|
| 4704 |
+
[Chapter_06_Decongestants_page3_img3.png]
|
| 4705 |
+
|
| 4706 |
+
|
| 4707 |
+
● Contac Cold: Multi-symptom relief, fights colds at their core; Clears head and chest, so you
|
| 4708 |
+
can conquer more.
|
| 4709 |
+
|
| 4710 |
+
[Chapter_06_Decongestants_page3_img4.png]
|
| 4711 |
+
|
| 4712 |
+
|
| 4713 |
+
Always consult a healthcare professional before using pseudoephedrine, especially if you have any
|
| 4714 |
+
underlying medical conditions, such as high blood pressure or heart disease, or are taking other
|
| 4715 |
+
medications, to ensure its safety and effectiveness for your specific situation. Additionally, be
|
| 4716 |
+
aware of any regulations or restrictions regarding the purchase and use of pseudoephedrine in your
|
| 4717 |
+
country.
|
| 4718 |
+
Decongestants | 25
|
| 4719 |
+
|
| 4720 |
+
--- End of Page 3 ---
|
| 4721 |
+
|
| 4722 |
+
Introduction to Oxymetazoline:
|
| 4723 |
+
Oxymetazoline is a topical decongestant used to relieve nasal congestion caused by conditions such
|
| 4724 |
+
as the common cold, allergies, or sinusitis. It belongs to the class of drugs known as alpha-
|
| 4725 |
+
adrenergic agonists, which work by constricting blood vessels in the nasal passages, thereby
|
| 4726 |
+
reducing swelling and congestion. Oxymetazoline is available over-the-counter in nasal spray or
|
| 4727 |
+
drop formulations and provides rapid relief from nasal congestion.
|
| 4728 |
+
Chemical Information:
|
| 4729 |
+
- Chemical Name: Oxymetazoline
|
| 4730 |
+
- Chemical Structure:
|
| 4731 |
+
- Oxymetazoline has the chemical formula C16H24N2O.
|
| 4732 |
+
- Its chemical structure is:
|
| 4733 |
+
|
| 4734 |
+
[Chapter_06_Decongestants_page4_img1.png]
|
| 4735 |
+
|
| 4736 |
+
|
| 4737 |
+
Uses:
|
| 4738 |
+
Nasal Congestion: Oxymetazoline is primarily used to relieve nasal congestion associated with the
|
| 4739 |
+
common cold, allergies, sinusitis, and other upper respiratory tract infections.
|
| 4740 |
+
Sinus Pressure: It may also help alleviate sinus pressure and discomfort caused by congestion.
|
| 4741 |
+
Stability/Storage Conditions:
|
| 4742 |
+
● Stability: Oxymetazoline is generally stable when stored properly.
|
| 4743 |
+
● Storage Conditions: It should be stored at room temperature, away from moisture, heat, and
|
| 4744 |
+
direct sunlight. Keep it out of reach of children and pets. Avoid storing it in the bathroom or
|
| 4745 |
+
kitchen, where moisture levels may be high.
|
| 4746 |
+
Safe Dose for Adults:
|
| 4747 |
+
● The recommended adult dose of oxymetazoline nasal spray is typically 1 to 2 sprays into
|
| 4748 |
+
each nostril every 10 to 12 hours, not to exceed 2 doses in 24 hours.
|
| 4749 |
+
● It's essential to follow the dosage instructions provided by a healthcare professional or as
|
| 4750 |
+
indicated on the product label to avoid potential side effects or adverse reactions.
|
| 4751 |
+
26 | Decongestants
|
| 4752 |
+
|
| 4753 |
+
--- End of Page 4 ---
|
| 4754 |
+
|
| 4755 |
+
Marketed Brands:
|
| 4756 |
+
- Afrin
|
| 4757 |
+
- Neo-Synephrine
|
| 4758 |
+
- Vicks Sinex
|
| 4759 |
+
- Dristan Nasal Spray
|
| 4760 |
+
|
| 4761 |
+
[Chapter_06_Decongestants_page5_img1.png]
|
| 4762 |
+
|
| 4763 |
+
|
| 4764 |
+
Always consult a healthcare professional before using oxymetazoline, especially if you have any
|
| 4765 |
+
underlying medical conditions, such as high blood pressure or heart disease, or are taking other
|
| 4766 |
+
medications, to ensure its safety and effectiveness for your specific situation.
|
| 4767 |
+
Introduction to Phenylephrine Nasal Spray:
|
| 4768 |
+
Phenylephrine nasal spray is a topical decongestant used to relieve nasal congestion caused by
|
| 4769 |
+
conditions such as the common cold, allergies, or sinusitis.
|
| 4770 |
+
|
| 4771 |
+
[Chapter_06_Decongestants_page5_img2.png]
|
| 4772 |
+
|
| 4773 |
+
|
| 4774 |
+
It belongs to the class of drugs known as alpha-adrenergic agonists, which work by constricting
|
| 4775 |
+
blood vessels in the nasal passages, thereby reducing swelling and congestion. Phenylephrine nasal
|
| 4776 |
+
spray is available over-the-counter and provides rapid relief from nasal congestion.
|
| 4777 |
+
Decongestants | 27
|
| 4778 |
+
|
| 4779 |
+
--- End of Page 5 ---
|
| 4780 |
+
|
| 4781 |
+
Chemical Information:
|
| 4782 |
+
● Chemical Name: Phenylephrine
|
| 4783 |
+
● Chemical Structure: Phenylephrine has the chemical formula C9H13NO2.
|
| 4784 |
+
● Its chemical structure is:
|
| 4785 |
+
|
| 4786 |
+
[Chapter_06_Decongestants_page6_img1.png]
|
| 4787 |
+
|
| 4788 |
+
|
| 4789 |
+
Uses:
|
| 4790 |
+
● Nasal Congestion: Phenylephrine nasal spray is primarily used to relieve nasal congestion
|
| 4791 |
+
associated with the common cold, allergies, sinusitis, and other upper respiratory tract
|
| 4792 |
+
infections.
|
| 4793 |
+
● Sinus Pressure: It may also help alleviate sinus pressure and discomfort caused by
|
| 4794 |
+
congestion.
|
| 4795 |
+
Stability/Storage Conditions:
|
| 4796 |
+
● Stability: Phenylephrine nasal spray is generally stable when stored properly.
|
| 4797 |
+
● Storage Conditions: It should be stored at room temperature, away from moisture, heat, and
|
| 4798 |
+
direct sunlight. Keep it out of reach of children and pets. Avoid storing it in the bathroom or
|
| 4799 |
+
kitchen, where moisture levels may be high.
|
| 4800 |
+
Safe Dose for Adults:
|
| 4801 |
+
● The recommended adult dose of phenylephrine nasal spray is typically 1 to 2 sprays into
|
| 4802 |
+
each nostril every 4 hours, not to exceed 3 doses in 24 hours.
|
| 4803 |
+
● It's essential to follow the dosage instructions provided by a healthcare professional or as
|
| 4804 |
+
indicated on the product label to avoid potential side effects or adverse reactions.
|
| 4805 |
+
Marketed Brands:
|
| 4806 |
+
● Sudafed PE Nasal Decongestant Spray
|
| 4807 |
+
● Neo-Synephrine Nasal Spray
|
| 4808 |
+
● Vicks Sinex Nasal Spray
|
| 4809 |
+
● Afrin No Drip Nasal Spray
|
| 4810 |
+
Always consult a healthcare professional before using phenylephrine nasal spray, especially if you
|
| 4811 |
+
have any underlying medical conditions, such as high blood pressure or heart disease, or are taking
|
| 4812 |
+
other medications, to ensure its safety and effectiveness for your specific situation.
|
| 4813 |
+
28 | Decongestants
|
| 4814 |
+
|
| 4815 |
+
--- End of Page 6 ---
|
| 4816 |
+
|
| 4817 |
+
FREQUENTLY ASKED QUESTIONS
|
| 4818 |
+
Question: What are decongestants?
|
| 4819 |
+
Answer: Decongestants are medications that help relieve nasal congestion by shrinking swollen
|
| 4820 |
+
blood vessels in the nasal passages, allowing for easier breathing.
|
| 4821 |
+
Question: How do decongestants work?
|
| 4822 |
+
Answer: Decongestants work by constricting blood vessels in the nasal passages, which reduces
|
| 4823 |
+
swelling and congestion, making it easier to breathe.
|
| 4824 |
+
Question: What are some common examples of decongestants?
|
| 4825 |
+
Answer: Common examples of decongestants include pseudoephedrine (Sudafed) and
|
| 4826 |
+
phenylephrine, which are available in oral tablets, liquids, and nasal sprays.
|
| 4827 |
+
Question: When should decongestants be taken?
|
| 4828 |
+
Answer: Decongestants are typically taken as needed to relieve nasal congestion due to conditions
|
| 4829 |
+
such as the common cold, allergies, or sinusitis. They are usually taken for short periods, as
|
| 4830 |
+
prolonged use can lead to rebound congestion.
|
| 4831 |
+
Question: Can decongestants be taken with other medications?
|
| 4832 |
+
Answer: Decongestants can generally be taken with other medications, but it's important to consult
|
| 4833 |
+
with a healthcare professional or pharmacist to avoid potential interactions, especially if you have
|
| 4834 |
+
underlying health conditions or are taking other medications.
|
| 4835 |
+
Question: Do decongestants have any side effects?
|
| 4836 |
+
Answer: Common side effects of decongestants may include increased heart rate, elevated blood
|
| 4837 |
+
pressure, insomnia, nervousness, and dry mouth. Prolonged use of nasal decongestant sprays can
|
| 4838 |
+
also lead to rebound congestion.
|
| 4839 |
+
Question: Can decongestants be used to treat conditions other than nasal congestion?
|
| 4840 |
+
Answer: Decongestants are primarily used to relieve nasal congestion, but they may also be used
|
| 4841 |
+
in combination with other medications to alleviate symptoms of sinus pressure or ear congestion
|
| 4842 |
+
associated with colds or allergies.
|
| 4843 |
+
Question: Are there any lifestyle changes that can help reduce the need for decongestants?
|
| 4844 |
+
Answer: Yes, staying hydrated, using a humidifier, practicing nasal saline irrigation, avoiding
|
| 4845 |
+
known allergens, and maintaining good nasal hygiene can help reduce nasal congestion and the
|
| 4846 |
+
need for decongestants.
|
| 4847 |
+
|
| 4848 |
+
Decongestants | 29
|
| 4849 |
+
|
| 4850 |
+
--- End of Page 7 ---
|
| 4851 |
+
|
MEDICINE_TXT/Chapter_07_Cough_Suppressants.txt
ADDED
|
@@ -0,0 +1,138 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
7
|
| 3 |
+
|
| 4 |
+
Cough Suppressants
|
| 5 |
+
Dr. Harshita Jain
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Cough suppressants are medications designed to alleviate coughing. They work by suppressing the
|
| 9 |
+
cough reflex in the brain. These medications are commonly used to relieve dry, hacking coughs
|
| 10 |
+
that do not produce mucus or phlegm. They can be helpful for individuals with conditions such as
|
| 11 |
+
bronchitis, colds, or the flu, where coughing can be frequent and disruptive. However, it is
|
| 12 |
+
important to use cough suppressants as directed by a healthcare professional, as they may not be
|
| 13 |
+
suitable for all types of coughs, such as those associated with chest congestion.
|
| 14 |
+
Cough suppressants are medications that reduce coughing by acting on the brain's cough reflex.
|
| 15 |
+
They are used for dry, non-productive coughs, common in conditions like colds or bronchitis.
|
| 16 |
+
Common examples of cough suppressants include:
|
| 17 |
+
1. Dextromethorphan: This is one of the most widely used cough suppressants and is available in
|
| 18 |
+
many over-the-counter cough medications.
|
| 19 |
+
2. Codeine: A prescription opioid medication that can also act as a cough suppressant.
|
| 20 |
+
3. Hydrocodone: Another opioid medication often prescribed for cough suppression, typically in
|
| 21 |
+
combination with other drugs like acetaminophen.
|
| 22 |
+
4. Benzonatate: A non-opioid cough suppressant that works by numbing the throat and lungs to
|
| 23 |
+
reduce coughing.
|
| 24 |
+
5. Diphenhydramine: While primarily an antihistamine, diphenhydramine can also have cough-
|
| 25 |
+
suppressing effects and is found in some cough medications.
|
| 26 |
+
Introduction to Dextromethorphan:
|
| 27 |
+
Dextromethorphan (DXM) is a synthetic drug classified as a cough suppressant. It is chemically
|
| 28 |
+
related to opioids but lacks significant analgesic or addictive properties when used at recommended
|
| 29 |
+
doses. Dextromethorphan is commonly used to alleviate dry, non-productive coughs associated
|
| 30 |
+
with colds, flu, and other respiratory infections. It works by suppressing the cough reflex in the
|
| 31 |
+
brain, reducing the urge to cough.
|
| 32 |
+
30 | Cough Suppressants
|
| 33 |
+
|
| 34 |
+
--- End of Page 1 ---
|
| 35 |
+
|
| 36 |
+
Chemical Information:
|
| 37 |
+
● Chemical formula: C18H25NO
|
| 38 |
+
● Molecular weight: 271.4 g/mol
|
| 39 |
+
● Chemical structure: Dextromethorphan is an analog of codeine, with a structure that includes a
|
| 40 |
+
methyl group attached to the nitrogen atom of the morphinan ring.
|
| 41 |
+
|
| 42 |
+
[Chapter_07_Cough_Suppressants_page2_img1.png]
|
| 43 |
+
|
| 44 |
+
|
| 45 |
+
Uses:
|
| 46 |
+
Dextromethorphan is primarily used as a cough suppressant. It is effective in relieving dry, hacking
|
| 47 |
+
coughs that do not produce mucus or phlegm. It is often found in over-the-counter cough and cold
|
| 48 |
+
medications, both alone and in combination with other active ingredients such as antihistamines,
|
| 49 |
+
decongestants, and expectorants.
|
| 50 |
+
Stability/Storage Conditions:
|
| 51 |
+
Dextromethorphan should be stored at room temperature, away from moisture and heat. It is
|
| 52 |
+
usually found in solid form (tablets or capsules) or liquid form (syrups). It is essential to store
|
| 53 |
+
medications containing dextromethorphan according to the instructions provided on the packaging
|
| 54 |
+
to maintain their stability and effectiveness.
|
| 55 |
+
Safe Dose for Adults:
|
| 56 |
+
The recommended dose of dextromethorphan for adults varies depending on the specific product
|
| 57 |
+
and formulation. It's crucial to follow the dosing instructions provided by the manufacturer or as
|
| 58 |
+
directed by a healthcare professional. In general, typical adult doses range from 10 mg to 30 mg
|
| 59 |
+
every 4 to 6 hours, not exceeding 120 mg in a 24-hour period. It's important not to exceed the
|
| 60 |
+
recommended dosage to avoid potential side effects or overdose.
|
| 61 |
+
Marketed Brands:
|
| 62 |
+
Dextromethorphan is available under various brand names, both alone and in combination with
|
| 63 |
+
other active ingredients. Some common brands include:
|
| 64 |
+
1. Robitussin: Trusted for generations, it offers effective relief from cough and cold symptoms,
|
| 65 |
+
restoring comfort with each dose.
|
| 66 |
+
Cough Suppressants | 31
|
| 67 |
+
|
| 68 |
+
--- End of Page 2 ---
|
| 69 |
+
|
| 70 |
+
2. Delsym: Provides long-lasting cough relief, allowing for uninterrupted rest and recovery from
|
| 71 |
+
respiratory ailments.
|
| 72 |
+
|
| 73 |
+
[Chapter_07_Cough_Suppressants_page3_img1.png]
|
| 74 |
+
|
| 75 |
+
|
| 76 |
+
3. Vicks DayQuil/NyQuil: A dynamic duo for day and night relief, offering comprehensive care
|
| 77 |
+
for cold and flu symptoms.
|
| 78 |
+
|
| 79 |
+
[Chapter_07_Cough_Suppressants_page3_img2.png]
|
| 80 |
+
|
| 81 |
+
|
| 82 |
+
4. Mucinex DM: Combines expectorant and cough suppressant properties, tackling cough and
|
| 83 |
+
congestion with a dual-action formula.
|
| 84 |
+
|
| 85 |
+
[Chapter_07_Cough_Suppressants_page3_img3.png]
|
| 86 |
+
|
| 87 |
+
|
| 88 |
+
32 | Cough Suppressants
|
| 89 |
+
|
| 90 |
+
--- End of Page 3 ---
|
| 91 |
+
|
| 92 |
+
5. Benylin: Eases cough and cold symptoms with its soothing blend, providing relief for a restful
|
| 93 |
+
night's sleep and productive days.
|
| 94 |
+
|
| 95 |
+
[Chapter_07_Cough_Suppressants_page4_img1.png]
|
| 96 |
+
|
| 97 |
+
|
| 98 |
+
These are just a few examples, and there are many other brands and generic versions available
|
| 99 |
+
worldwide. It's essential to read the product label carefully to ensure you're using a medication that
|
| 100 |
+
contains dextromethorphan and to follow the dosing instructions provided. If you are unsure about
|
| 101 |
+
which product to use or how to use it, consult with a healthcare professional.
|
| 102 |
+
FREQUENTLY ASKED QUESTIONS
|
| 103 |
+
Question: What are cough suppressants?
|
| 104 |
+
Answer: Cough suppressants are medications that help relieve coughing by inhibiting the cough reflex
|
| 105 |
+
in the throat.
|
| 106 |
+
Question: How do cough suppressants work?
|
| 107 |
+
Answer: Cough suppressants work by acting on the cough center in the brain or by numbing the throat,
|
| 108 |
+
reducing the urge to cough.
|
| 109 |
+
Question: What are some common examples of cough suppressants?
|
| 110 |
+
Answer: Common examples of cough suppressants include dextromethorphan (Robitussin DM),
|
| 111 |
+
codeine, and benzonatate (Tessalon Perles).
|
| 112 |
+
Question: When should cough suppressants be taken?
|
| 113 |
+
Answer: Cough suppressants are typically taken as needed to relieve coughing due to conditions such
|
| 114 |
+
as the common cold, bronchitis, or allergies. They are usually taken for short periods to alleviate
|
| 115 |
+
troublesome coughing episodes.
|
| 116 |
+
Question: Can cough suppressants be taken with other medications?
|
| 117 |
+
Answer: Cough suppressants can generally be taken with other medications, but it's important to
|
| 118 |
+
consult with a healthcare professional or pharmacist to avoid potential interactions, especially if you
|
| 119 |
+
have underlying health conditions or are taking other medications.
|
| 120 |
+
Cough Suppressants | 33
|
| 121 |
+
|
| 122 |
+
--- End of Page 4 ---
|
| 123 |
+
|
| 124 |
+
Question: Do cough suppressants have any side effects?
|
| 125 |
+
Answer: Common side effects of cough suppressants may include drowsiness, dizziness, nausea,
|
| 126 |
+
constipation, and in the case of codeine-containing medications, potential for addiction or respiratory
|
| 127 |
+
depression.
|
| 128 |
+
Question: Can cough suppressants be used to treat conditions other than coughing?
|
| 129 |
+
Answer: Cough suppressants are primarily used to relieve coughing, but they may also be used to
|
| 130 |
+
alleviate symptoms of sore throat or throat irritation associated with colds or allergies.
|
| 131 |
+
Question: Are there any lifestyle changes that can help reduce the need for cough suppressants?
|
| 132 |
+
Answer: Yes, staying hydrated, using a humidifier, avoiding irritants such as smoke or pollutants, and
|
| 133 |
+
practicing good respiratory hygiene can help reduce coughing and the need for cough suppressants.
|
| 134 |
+
|
| 135 |
+
34 | Cough Suppressants
|
| 136 |
+
|
| 137 |
+
--- End of Page 5 ---
|
| 138 |
+
|
MEDICINE_TXT/Chapter_08_Expectorants.txt
ADDED
|
@@ -0,0 +1,150 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
8
|
| 3 |
+
|
| 4 |
+
Expectorants
|
| 5 |
+
Mr. Rahul Kumar Ancheria
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Expectorants are medications or substances that help to thin and loosen mucus in the respiratory
|
| 9 |
+
tract, making it easier to cough up and expel. They are commonly used to relieve congestion and
|
| 10 |
+
facilitate the removal of excess mucus from the lungs and airways. Expectorants work by
|
| 11 |
+
increasing the production of respiratory tract secretions, which helps to hydrate and thin out the
|
| 12 |
+
mucus, allowing it to be expelled more easily through coughing. These medications are often used
|
| 13 |
+
to alleviate symptoms associated with respiratory conditions such as bronchitis, colds, flu, and
|
| 14 |
+
other respiratory infections.
|
| 15 |
+
Expectorants can be classified based on their mechanism of action and chemical composition. Here
|
| 16 |
+
is a classification based on mechanism of action:
|
| 17 |
+
1. Stimulating Expectorants: These expectorants work by directly stimulating the secretory
|
| 18 |
+
glands in the respiratory tract, increasing the production and expulsion of mucus. Examples
|
| 19 |
+
include:
|
| 20 |
+
● Ammonium chloride
|
| 21 |
+
● Potassium iodide
|
| 22 |
+
● Guaifenesin
|
| 23 |
+
2. Mucolytic Expectorants: Mucolytic expectorants work by breaking down the chemical
|
| 24 |
+
structure of mucus, reducing its viscosity and making it easier to expel. Examples include:
|
| 25 |
+
● N-acetylcysteine (NAC)
|
| 26 |
+
● Bromhexine
|
| 27 |
+
● Carbocisteine
|
| 28 |
+
3. Hydration Therapy: While not traditional medications, hydration therapy involves increasing
|
| 29 |
+
fluid intake to help thin out mucus and make it easier to expel.
|
| 30 |
+
General Introduction to Guaifenesin:
|
| 31 |
+
Guaifenesin, primarily classified as a stimulating expectorant, works by directly stimulating the
|
| 32 |
+
secretory glands in the respiratory tract. This action increases the production and expulsion of
|
| 33 |
+
mucus, aiding in the clearance of chest congestion associated with conditions like bronchitis, colds,
|
| 34 |
+
and flu. As an expectorant, it thins and loosens mucus in the airways, making it easier to cough up.
|
| 35 |
+
Available over-the-counter, guaifenesin is commonly found in cough and cold remedies and has
|
| 36 |
+
been in clinical use for many years due to its generally well-tolerated nature.
|
| 37 |
+
Expectorants | 35
|
| 38 |
+
|
| 39 |
+
--- End of Page 1 ---
|
| 40 |
+
|
| 41 |
+
Chemical Information:
|
| 42 |
+
● Chemical formula: C10H14O4
|
| 43 |
+
● Molecular weight: 198.22 g/mol
|
| 44 |
+
● Chemical structure: Guaifenesin is an organic compound belonging to the class of glyceryl
|
| 45 |
+
guaiacolate ethers. Its chemical structure consists of a glycerol molecule with a guaiacol
|
| 46 |
+
group attached.
|
| 47 |
+
|
| 48 |
+
[Chapter_08_Expectorants_page2_img1.png]
|
| 49 |
+
|
| 50 |
+
|
| 51 |
+
Uses:
|
| 52 |
+
Guaifenesin is primarily used to relieve chest congestion associated with respiratory conditions
|
| 53 |
+
such as the common cold, bronchitis, and other respiratory tract infections. It works by increasing
|
| 54 |
+
the volume and reducing the viscosity of respiratory tract secretions, facilitating the removal of
|
| 55 |
+
mucus through coughing. Guaifenesin is not indicated for the treatment of coughs caused by
|
| 56 |
+
smoking, asthma, or emphysema.
|
| 57 |
+
Stability/Storage Conditions:
|
| 58 |
+
Guaifenesin should be stored at room temperature, away from moisture and heat. It is typically
|
| 59 |
+
available in tablet, capsule, or liquid form (syrup). It is essential to store medications containing
|
| 60 |
+
guaifenesin according to the instructions provided on the packaging to maintain their stability and
|
| 61 |
+
effectiveness.
|
| 62 |
+
Safe Dose for Adults:
|
| 63 |
+
The recommended dose of guaifenesin for adults varies depending on the specific product and
|
| 64 |
+
formulation. It is crucial to follow the dosing instructions provided by the manufacturer or as
|
| 65 |
+
directed by a healthcare professional. In general, typical adult doses range from 200 mg to 400 mg
|
| 66 |
+
every 4 hours, not exceeding 2,400 mg in a 24-hour period. It's important not to exceed the
|
| 67 |
+
recommended dosage to avoid potential side effects or overdose.
|
| 68 |
+
Marketed Brands:
|
| 69 |
+
Guaifenesin is available under various brand names, both alone and in combination with other
|
| 70 |
+
active ingredients. Some common brands include:
|
| 71 |
+
36 | Engineering
|
| 72 |
+
|
| 73 |
+
--- End of Page 2 ---
|
| 74 |
+
|
| 75 |
+
1. Mucinex: Clears the airways with its expectorant power, offering relief from stubborn chest
|
| 76 |
+
congestion.
|
| 77 |
+
|
| 78 |
+
[Chapter_08_Expectorants_page3_img1.png]
|
| 79 |
+
|
| 80 |
+
|
| 81 |
+
2. Robitussin Chest Congestion: Targets deep-seated congestion, providing soothing relief for a
|
| 82 |
+
clearer chest.
|
| 83 |
+
3. Robitussin Mucus + Chest Congestion: Combats both mucus and chest congestion, offering
|
| 84 |
+
dual-action relief for respiratory comfort.
|
| 85 |
+
|
| 86 |
+
[Chapter_08_Expectorants_page3_img2.png]
|
| 87 |
+
|
| 88 |
+
|
| 89 |
+
4. Tussin: Provides effective relief from chest congestion, helping to ease breathing with its
|
| 90 |
+
trusted formula.
|
| 91 |
+
|
| 92 |
+
[Chapter_08_Expectorants_page3_img3.png]
|
| 93 |
+
|
| 94 |
+
|
| 95 |
+
Expectorants | 37
|
| 96 |
+
|
| 97 |
+
--- End of Page 3 ---
|
| 98 |
+
|
| 99 |
+
5. Guaifenesin LA: Long-acting relief from chest congestion, promoting clearer airways for
|
| 100 |
+
extended comfort.
|
| 101 |
+
|
| 102 |
+
[Chapter_08_Expectorants_page4_img1.png]
|
| 103 |
+
|
| 104 |
+
|
| 105 |
+
6. Luminac: Illuminates the path to respiratory relief, clearing chest congestion with its powerful
|
| 106 |
+
formula.
|
| 107 |
+
|
| 108 |
+
[Chapter_08_Expectorants_page4_img2.png]
|
| 109 |
+
|
| 110 |
+
|
| 111 |
+
These are just a few examples, and there are many other brands and generic versions available
|
| 112 |
+
worldwide. It's essential to read the product label carefully to ensure you're using a medication that
|
| 113 |
+
contains guaifenesin and to follow the dosing instructions provided.
|
| 114 |
+
FREQUENTLY ASKED QUESTIONS
|
| 115 |
+
Question: What are expectorants?
|
| 116 |
+
Answer: Expectorants are medications that help thin and loosen mucus in the airways, making it
|
| 117 |
+
easier to cough up and expel from the body.
|
| 118 |
+
Question: How do expectorants work?
|
| 119 |
+
Answer: Expectorants work by increasing the production of respiratory tract secretions, which
|
| 120 |
+
helps hydrate and loosen mucus, making it easier to clear from the airways through coughing.
|
| 121 |
+
Question: What are some common examples of expectorants?
|
| 122 |
+
Answer: Common examples of expectorants include guaifenesin (Mucinex) and potassium iodide.
|
| 123 |
+
38 | Engineering
|
| 124 |
+
|
| 125 |
+
--- End of Page 4 ---
|
| 126 |
+
|
| 127 |
+
Question: When should expectorants be taken?
|
| 128 |
+
Answer: Expectorants are typically taken as needed to relieve chest congestion and coughing
|
| 129 |
+
associated with conditions such as the common cold, bronchitis, or respiratory infections.
|
| 130 |
+
Question: Can expectorants be taken with other medications?
|
| 131 |
+
Answer: Expectorants can generally be taken with other medications, but it's important to consult
|
| 132 |
+
with a healthcare professional or pharmacist to avoid potential interactions, especially if you have
|
| 133 |
+
underlying health conditions or are taking other medications.
|
| 134 |
+
Question: Do expectorants have any side effects?
|
| 135 |
+
Answer: Common side effects of expectorants may include nausea, vomiting, stomach upset, and
|
| 136 |
+
dizziness. It's important to stay hydrated while taking expectorants to help thin mucus and reduce
|
| 137 |
+
the risk of side effects.
|
| 138 |
+
Question: Can expectorants be used to treat conditions other than chest congestion?
|
| 139 |
+
Answer: Expectorants are primarily used to relieve chest congestion and coughing, but they may
|
| 140 |
+
also be used to help clear mucus from the airways in conditions such as chronic bronchitis or cystic
|
| 141 |
+
fibrosis.
|
| 142 |
+
Question: Are there any lifestyle changes that can help reduce the need for expectorants?
|
| 143 |
+
Answer: Yes, staying hydrated, using a humidifier, avoiding irritants such as smoke or pollutants,
|
| 144 |
+
and practicing good respiratory hygiene can help reduce chest congestion and the need for
|
| 145 |
+
expectorants.
|
| 146 |
+
|
| 147 |
+
Expectorants | 39
|
| 148 |
+
|
| 149 |
+
--- End of Page 5 ---
|
| 150 |
+
|
MEDICINE_TXT/Chapter_09_Topical_Analgesics.txt
ADDED
|
@@ -0,0 +1,228 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
9
|
| 3 |
+
|
| 4 |
+
Topical Analgesics
|
| 5 |
+
Dr. Girish Kumar Vyas
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Topical analgesics are medications or substances applied directly to the skin to relieve pain and
|
| 9 |
+
discomfort in localized areas. They work by temporarily numbing the nerves in the skin or
|
| 10 |
+
reducing inflammation, thereby reducing pain signals sent to the brain. Topical analgesics come in
|
| 11 |
+
various forms, including creams, gels, patches, sprays, and ointments, and they can contain
|
| 12 |
+
different active ingredients such as lidocaine, capsaicin, menthol, or salicylates. These medications
|
| 13 |
+
are commonly used to alleviate pain associated with conditions such as muscle strains, arthritis,
|
| 14 |
+
sprains, and minor injuries. Topical analgesics offer the advantage of targeting pain at specific
|
| 15 |
+
areas, providing localized relief without the potential side effects associated with oral pain
|
| 16 |
+
medications.
|
| 17 |
+
Topical analgesics can be classified based on their active ingredients and mechanism of action.
|
| 18 |
+
Here are some examples:
|
| 19 |
+
1. Counterirritants: These topical analgesics work by producing a sensation of cold or warmth on
|
| 20 |
+
the skin, which distracts from the underlying pain. They often contain ingredients like menthol,
|
| 21 |
+
camphor, or methyl salicylate. Examples include:
|
| 22 |
+
● Icy Hot
|
| 23 |
+
● Bengay
|
| 24 |
+
● Tiger Balm
|
| 25 |
+
2. Local Anesthetics: These topical analgesics work by blocking nerve signals in the area where
|
| 26 |
+
they are applied, temporarily numbing the skin and relieving pain. Lidocaine is a common local
|
| 27 |
+
anesthetic used in topical analgesics. Examples include:
|
| 28 |
+
● Lidocaine patch (e.g., Lidoderm)
|
| 29 |
+
● Lidocaine cream (e.g., LMX)
|
| 30 |
+
3. Capsaicin Products: Capsaicin is a compound found in chili peppers that can reduce pain by
|
| 31 |
+
depleting substance P, a neurotransmitter involved in pain sensation. Capsaicin creams or patches
|
| 32 |
+
are often used for conditions such as arthritis or neuropathic pain. Examples include:
|
| 33 |
+
● Capzasin
|
| 34 |
+
● Salonpas Hot Capsicum Patch
|
| 35 |
+
40 | Topical Analgesics
|
| 36 |
+
|
| 37 |
+
--- End of Page 1 ---
|
| 38 |
+
|
| 39 |
+
4. Salicylates: Topical analgesics containing salicylates work by reducing inflammation and pain.
|
| 40 |
+
Salicylates are related to aspirin and can be absorbed through the skin. Examples include:
|
| 41 |
+
● Aspercreme
|
| 42 |
+
● Sportscreme
|
| 43 |
+
These are just a few examples, and there are many other topical analgesic products available with
|
| 44 |
+
different active ingredients and formulations. It is essential to read the product label and follow the
|
| 45 |
+
instructions provided by the manufacturer or as directed by a healthcare professional for safe and
|
| 46 |
+
effective use.
|
| 47 |
+
General Introduction to Icy Hot:
|
| 48 |
+
Icy Hot is a topical analgesic product used for relieving minor aches and pains of muscles and
|
| 49 |
+
joints. It typically contains active ingredients that produce a sensation of cold followed by a
|
| 50 |
+
sensation of warmth on the skin, which helps to distract from and alleviate pain. Icy Hot is
|
| 51 |
+
commonly used by athletes and individuals with muscle strains, sprains, arthritis, and other
|
| 52 |
+
musculoskeletal conditions.
|
| 53 |
+
Chemical Information:
|
| 54 |
+
Icy Hot is formulated with various active and inactive ingredients, including menthol, camphor,
|
| 55 |
+
and sometimes methyl salicylate. These ingredients work together to provide both cooling and
|
| 56 |
+
warming sensations to the skin, helping to relieve pain and discomfort.
|
| 57 |
+
Uses:
|
| 58 |
+
Icy Hot is applied topically to the affected area of the skin. It is commonly used to alleviate minor
|
| 59 |
+
muscle and joint pain associated with conditions such as muscle strains, sprains, arthritis, and
|
| 60 |
+
backaches. The cooling and warming sensations provided by Icy Hot help to distract from pain and
|
| 61 |
+
provide temporary relief.
|
| 62 |
+
Stability/Storage Conditions:
|
| 63 |
+
Icy Hot should be stored at room temperature, away from moisture and heat. It is typically
|
| 64 |
+
available in the form of creams, gels, patches, or sprays. It is essential to store Icy Hot products
|
| 65 |
+
according to the instructions provided on the packaging to maintain their stability and
|
| 66 |
+
effectiveness.
|
| 67 |
+
Safe Dose for Adults:
|
| 68 |
+
The recommended dose and frequency of application of Icy Hot depend on the specific product and
|
| 69 |
+
formulation. It's crucial to follow the usage instructions provided by the manufacturer or as
|
| 70 |
+
directed by a healthcare professional. Generally, Icy Hot products can be applied to the affected
|
| 71 |
+
area up to 3 to 4 times daily. It's important not to exceed the recommended dosage or frequency of
|
| 72 |
+
application to avoid potential skin irritation or other adverse effects.
|
| 73 |
+
Topical Analgesics | 41
|
| 74 |
+
|
| 75 |
+
--- End of Page 2 ---
|
| 76 |
+
|
| 77 |
+
Marketed Brands:
|
| 78 |
+
Icy Hot is a well-known brand of topical analgesic products available in various forms, including
|
| 79 |
+
creams, gels, patches, and sprays. Some specific marketed brands under the Icy Hot name include:
|
| 80 |
+
1. Icy Hot Cream: Offers a soothing blend of pain relief and cooling comfort, melting away
|
| 81 |
+
tension with its unique formula.
|
| 82 |
+
2. Icy Hot Extra Strength Pain Relieving Cream: Powerfully tackles stubborn aches and pains,
|
| 83 |
+
providing long-lasting relief for tense muscles and joints.
|
| 84 |
+
3. Icy Hot Advanced Pain Relief Cream: Elevates the standard for pain relief, offering targeted
|
| 85 |
+
care for deep-seated discomfort with a potent formula.
|
| 86 |
+
4. Icy Hot Pain Relieving Gel: Provides instant relief with its fast-acting gel formula, soothing
|
| 87 |
+
sore muscles and joints with a refreshing sensation.
|
| 88 |
+
5. Icy Hot Medicated Patch: Adheres comfortably to skin, delivering targeted relief precisely
|
| 89 |
+
where it's needed, ensuring freedom from discomfort for hours.
|
| 90 |
+
|
| 91 |
+
|
| 92 |
+
[Chapter_09_Topical_Analgesics_page3_img1.png]
|
| 93 |
+
|
| 94 |
+
|
| 95 |
+
General Introduction to Lidocaine Patch :
|
| 96 |
+
The Lidocaine patch, commonly known by its brand name Lidoderm, is a topical analgesic used for the
|
| 97 |
+
relief of localized pain. It contains the active ingredient lidocaine, a local anesthetic that works by
|
| 98 |
+
temporarily numbing the nerves in the skin, thereby reducing pain signals sent to the brain. Lidocaine
|
| 99 |
+
patches are widely used to alleviate pain associated with conditions such as post-herpetic neuralgia
|
| 100 |
+
(nerve pain following shingles), diabetic neuropathy, and other forms of localized neuropathic pain.
|
| 101 |
+
42 | Topical Analgesics
|
| 102 |
+
|
| 103 |
+
--- End of Page 3 ---
|
| 104 |
+
|
| 105 |
+
Chemical Information:
|
| 106 |
+
The Lidocaine patch contains lidocaine as its active ingredient. Lidocaine is an amide-type local
|
| 107 |
+
anesthetic that blocks nerve signals by inhibiting the influx of sodium ions into nerve cells, thereby
|
| 108 |
+
preventing the generation and conduction of nerve impulses. Each Lidocaine patch contains a specific
|
| 109 |
+
amount of lidocaine, typically ranging from 4% to 5%.
|
| 110 |
+
Uses:
|
| 111 |
+
Lidocaine patches are applied directly to the skin over the painful area. Once applied, the lidocaine in
|
| 112 |
+
the patch is absorbed through the skin and numbs the underlying nerves, providing temporary relief
|
| 113 |
+
from pain. Lidocaine patches are commonly used to manage localized pain associated with conditions
|
| 114 |
+
such as post-herpetic neuralgia, diabetic neuropathy, and musculoskeletal pain.
|
| 115 |
+
Stability/Storage Conditions:
|
| 116 |
+
Lidocaine patches should be stored at room temperature, away from moisture and heat. Each patch is
|
| 117 |
+
individually sealed in a protective pouch to maintain its stability and effectiveness. It is essential to
|
| 118 |
+
store Lidocaine patches according to the instructions provided on the packaging and to avoid exposing
|
| 119 |
+
them to extreme temperatures or humidity.
|
| 120 |
+
Safe Dose for Adults:
|
| 121 |
+
The recommended dose and duration of use of Lidocaine patches depend on the specific product and
|
| 122 |
+
formulation, as well as the individual's condition and response to treatment. It's crucial to follow the
|
| 123 |
+
usage instructions provided by the manufacturer or as directed by a healthcare professional. In general,
|
| 124 |
+
Lidocaine patches are applied to the affected area for up to 12 hours within a 24-hour period. It's
|
| 125 |
+
important not to exceed the recommended dosage or duration of use to avoid potential side effects or
|
| 126 |
+
adverse reactions.
|
| 127 |
+
Marketed Brands:
|
| 128 |
+
Lidoderm is one of the most well-known brands of Lidocaine patches available on the market. It is
|
| 129 |
+
available by prescription and is commonly prescribed by healthcare professionals for the management
|
| 130 |
+
of localized pain. Other brands of Lidocaine patches may also be available, each with its own specific
|
| 131 |
+
formulation and packaging.
|
| 132 |
+
1. Endo Pharmaceuticals Lidocaine Patch 5%: Soothes discomfort with precision, providing
|
| 133 |
+
targeted relief for localized pain.
|
| 134 |
+
2. Glenmark Pharmaceuticals Lidocaine Patch 5%: Harnesses the power of lidocaine to ease
|
| 135 |
+
pain, offering comfort with every application.
|
| 136 |
+
Topical Analgesics | 43
|
| 137 |
+
|
| 138 |
+
--- End of Page 4 ---
|
| 139 |
+
|
| 140 |
+
3. Mylan Lidocaine Patch 5%: Empowers users with a patch of relief, delivering targeted
|
| 141 |
+
comfort for sore muscles and aching joints.
|
| 142 |
+
|
| 143 |
+
[Chapter_09_Topical_Analgesics_page5_img1.png]
|
| 144 |
+
|
| 145 |
+
|
| 146 |
+
4. Teva Pharmaceuticals Lidocaine Patch 5%: Combats pain with efficacy, providing a
|
| 147 |
+
discreet solution for ongoing relief from discomfort.
|
| 148 |
+
General Introduction to Capzasin:
|
| 149 |
+
Capzasin is a topical analgesic used for the temporary relief of minor aches and pains associated with
|
| 150 |
+
arthritis, muscle strains, backaches, and other musculoskeletal conditions. It contains the active
|
| 151 |
+
ingredient capsaicin, which is derived from chili peppers and works by depleting substance P, a
|
| 152 |
+
neurotransmitter involved in transmitting pain signals to the brain. Capzasin is available over-the-
|
| 153 |
+
counter and comes in various formulations such as creams, gels, and patches.
|
| 154 |
+
Chemical Information:
|
| 155 |
+
The active ingredient in Capzasin is capsaicin, which is a naturally occurring compound found in chili
|
| 156 |
+
peppers. Capsaicin binds to and activates receptors on sensory neurons in the skin, leading to the
|
| 157 |
+
release of substance P and other neurotransmitters. This process ultimately desensitizes the nerves,
|
| 158 |
+
reducing the perception of pain.
|
| 159 |
+
Uses:
|
| 160 |
+
Capzasin is applied topically to the affected area of the skin. It works by temporarily desensitizing
|
| 161 |
+
nerve endings, thereby reducing the sensation of pain and providing relief from minor aches and pains.
|
| 162 |
+
Capzasin is commonly used for conditions such as arthritis, muscle strains, backaches, and neuropathic
|
| 163 |
+
pain.
|
| 164 |
+
44 | Topical Analgesics
|
| 165 |
+
|
| 166 |
+
--- End of Page 5 ---
|
| 167 |
+
|
| 168 |
+
Stability/Storage Conditions:
|
| 169 |
+
Capzasin products should be stored at room temperature, away from moisture and heat. They are
|
| 170 |
+
typically available in the form of creams, gels, or patches, and each product may have specific storage
|
| 171 |
+
instructions provided on the packaging. It is essential to store Capzasin products according to the
|
| 172 |
+
instructions to maintain their stability and effectiveness.
|
| 173 |
+
Safe Dose for Adults:
|
| 174 |
+
The recommended dose and frequency of application of Capzasin depend on the specific product and
|
| 175 |
+
formulation, as well as the individual's condition and response to treatment. It's crucial to follow the
|
| 176 |
+
usage instructions provided by the manufacturer or as directed by a healthcare professional. In general,
|
| 177 |
+
Capzasin products can be applied to the affected area up to 3 to 4 times daily. It's important not to
|
| 178 |
+
exceed the recommended dosage or frequency of application to avoid potential skin irritation or other
|
| 179 |
+
adverse effects.
|
| 180 |
+
Marketed Brands:
|
| 181 |
+
Capzasin is one of the most well-known brands of capsaicin-based topical analgesics available on the
|
| 182 |
+
market.
|
| 183 |
+
|
| 184 |
+
[Chapter_09_Topical_Analgesics_page6_img1.png]
|
| 185 |
+
|
| 186 |
+
|
| 187 |
+
It is available over-the-counter and can be found in various formulations such as creams, gels, and
|
| 188 |
+
patches. Other brands of capsaicin-based topical analgesics may also be available, each with its own
|
| 189 |
+
specific formulation and packaging.
|
| 190 |
+
|
| 191 |
+
Topical Analgesics | 45
|
| 192 |
+
|
| 193 |
+
--- End of Page 6 ---
|
| 194 |
+
|
| 195 |
+
FREQUENTLY ASKED QUESTIONS
|
| 196 |
+
Question: What are topical analgesics?
|
| 197 |
+
Answer: Topical analgesics are medications applied to the skin to relieve pain and discomfort in
|
| 198 |
+
specific areas of the body.
|
| 199 |
+
Question: How do topical analgesics work?
|
| 200 |
+
Answer: Topical analgesics work by blocking pain signals locally in the skin and underlying tissues,
|
| 201 |
+
providing temporary relief from pain and discomfort.
|
| 202 |
+
Question: What are some common examples of topical analgesics?
|
| 203 |
+
Answer: Common examples of topical analgesics include creams, gels, patches, and sprays containing
|
| 204 |
+
ingredients such as lidocaine, menthol, capsaicin, or NSAIDs (nonsteroidal anti-inflammatory drugs).
|
| 205 |
+
Question: When should topical analgesics be used?
|
| 206 |
+
Answer: Topical analgesics are typically used as needed to relieve pain associated with conditions
|
| 207 |
+
such as muscle strains, joint pain, arthritis, or minor injuries like bruises or sprains.
|
| 208 |
+
Question: Can topical analgesics be used with other medications?
|
| 209 |
+
Answer: Topical analgesics can generally be used with other medications, but it's important to consult
|
| 210 |
+
with a healthcare professional or pharmacist to avoid potential interactions, especially if you have
|
| 211 |
+
underlying health conditions or are taking other medications.
|
| 212 |
+
Question: Do topical analgesics have any side effects?
|
| 213 |
+
Answer: Common side effects of topical analgesics may include skin irritation, redness, itching, or
|
| 214 |
+
burning at the application site. Serious side effects are rare but may include allergic reactions or
|
| 215 |
+
systemic absorption of medication with certain ingredients.
|
| 216 |
+
Question: Can topical analgesics be used to treat conditions other than pain?
|
| 217 |
+
Answer: Topical analgesics are primarily used to relieve pain, but they may also be used to alleviate
|
| 218 |
+
symptoms of itching, burning, or inflammation associated with conditions such as insect bites,
|
| 219 |
+
sunburn, or dermatitis.
|
| 220 |
+
Question: Are there any lifestyle changes that can help reduce the need for topical analgesics?
|
| 221 |
+
Answer: Yes, practicing good posture, maintaining a healthy weight, exercising regularly, and using
|
| 222 |
+
proper body mechanics during activities can help reduce the risk of musculoskeletal pain and the need
|
| 223 |
+
for topical analgesics.
|
| 224 |
+
|
| 225 |
+
46 | Topical Analgesics
|
| 226 |
+
|
| 227 |
+
--- End of Page 7 ---
|
| 228 |
+
|
MEDICINE_TXT/Chapter_10_Laxatives.txt
ADDED
|
@@ -0,0 +1,315 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
10
|
| 3 |
+
|
| 4 |
+
Laxatives
|
| 5 |
+
Dr. Nitin Nama
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Laxatives are substances or medications used to promote bowel movements and alleviate constipation.
|
| 9 |
+
They work by increasing the frequency or ease of bowel movements, softening stools, or stimulating
|
| 10 |
+
the muscles of the intestines to move waste through the digestive tract more efficiently. Laxatives are
|
| 11 |
+
commonly used to relieve temporary constipation, promote regularity, and ease bowel movements in
|
| 12 |
+
conditions such as irritable bowel syndrome (IBS), hemorrhoids, and certain medical procedures.
|
| 13 |
+
However, it is important to use laxatives as directed by a healthcare professional and to avoid long-
|
| 14 |
+
term or excessive use, as this can lead to dependence, dehydration, electrolyte imbalances, and other
|
| 15 |
+
adverse effects.
|
| 16 |
+
Laxatives can be classified based on their mechanism of action and their specific effects on the
|
| 17 |
+
digestive system. Here are some common classifications:
|
| 18 |
+
1. Bulk-forming laxatives: These laxatives work by increasing the bulk and water content of stools,
|
| 19 |
+
which helps to stimulate bowel movements. They are usually taken with plenty of water to prevent
|
| 20 |
+
blockage in the digestive tract. Examples include psyllium husk, methylcellulose, and polycarbophil.
|
| 21 |
+
2. Stimulant laxatives: These laxatives work by stimulating the muscles of the intestines, increasing
|
| 22 |
+
the contractions and movement of waste through the digestive tract. They are often used for short-term
|
| 23 |
+
relief of constipation but may cause cramping and discomfort. Examples include bisacodyl, senna, and
|
| 24 |
+
cascara sagrada.
|
| 25 |
+
3. Osmotic laxatives: These laxatives work by drawing water into the intestines, softening stools and
|
| 26 |
+
increasing bowel movements. They are often used to relieve constipation and may be prescribed for
|
| 27 |
+
patients with certain medical conditions such as chronic constipation or hepatic encephalopathy.
|
| 28 |
+
Examples include lactulose, magnesium hydroxide (milk of magnesia), and polyethylene glycol (PEG).
|
| 29 |
+
4. Stool softeners: These laxatives work by adding moisture to stools, making them softer and easier
|
| 30 |
+
to pass. They are often recommended for individuals who need to avoid straining during bowel
|
| 31 |
+
movements, such as those recovering from surgery or childbirth. Examples include docusate sodium
|
| 32 |
+
and mineral oil.
|
| 33 |
+
Laxatives | 47
|
| 34 |
+
|
| 35 |
+
--- End of Page 1 ---
|
| 36 |
+
|
| 37 |
+
5. Lubricant laxatives: These laxatives work by coating the surface of stools, making them slippery
|
| 38 |
+
and easier to pass. They are often used for short-term relief of constipation and may be recommended
|
| 39 |
+
for individuals with painful bowel movements or anal fissures. Examples include mineral oil and
|
| 40 |
+
glycerin suppositories.
|
| 41 |
+
Methylcellulose
|
| 42 |
+
General Introduction to Methylcellulose:
|
| 43 |
+
Methylcellulose is a synthetic compound derived from cellulose; a natural polymer found in the cell
|
| 44 |
+
walls of plants. It is commonly used in pharmaceuticals, cosmetics, and various other industries due to
|
| 45 |
+
its thickening, binding, and emulsifying properties. In the context of medications, methylcellulose is
|
| 46 |
+
often used as an inactive ingredient in oral and topical formulations to improve their texture,
|
| 47 |
+
consistency, and stability.
|
| 48 |
+
Chemical Information:
|
| 49 |
+
- Chemical formula: (C6H7O2(OH)3)x(OCH3)y
|
| 50 |
+
- Molecular weight: Variable (depends on the degree of polymerization)
|
| 51 |
+
- Chemical structure: Methylcellulose is a cellulose derivative obtained by treating cellulose with
|
| 52 |
+
methyl chloride under alkaline conditions. The degree of substitution of methyl groups determines its
|
| 53 |
+
properties, such as solubility and viscosity.
|
| 54 |
+
Uses:
|
| 55 |
+
Methylcellulose has various applications in pharmaceuticals, including:
|
| 56 |
+
1. Tablet Excipient: Methylcellulose is used as a binder and disintegrant in tablet formulations to
|
| 57 |
+
ensure proper tablet cohesion and disintegration in the gastrointestinal tract.
|
| 58 |
+
2. Topical Formulations: Methylcellulose is used as a thickening agent, emulsifier, or stabilizer in
|
| 59 |
+
creams, gels, ointments, and lotions to improve their viscosity, spreadability, and texture.
|
| 60 |
+
3. Ophthalmic Solutions: Methylcellulose is used as a lubricant and viscosity-enhancing agent in eye
|
| 61 |
+
drops and ointments to improve ocular hydration and comfort.
|
| 62 |
+
Stability/Storage Conditions:
|
| 63 |
+
Methylcellulose is stable under normal storage conditions and does not require any special storage
|
| 64 |
+
considerations. It is typically found in various pharmaceutical formulations, including tablets, creams,
|
| 65 |
+
gels, and ophthalmic solutions. It is essential to store methylcellulose-containing products according to
|
| 66 |
+
the instructions provided on the packaging to maintain their stability and effectiveness.
|
| 67 |
+
48 | Laxatives
|
| 68 |
+
|
| 69 |
+
--- End of Page 2 ---
|
| 70 |
+
|
| 71 |
+
Safe Dose for Adults:
|
| 72 |
+
Since methylcellulose is not an active ingredient with pharmacological effects, it does not have a
|
| 73 |
+
specific recommended dose for adults. Instead, its use in medications is determined by the formulation
|
| 74 |
+
and concentration specified by the manufacturer. It's important to follow the usage instructions
|
| 75 |
+
provided on the product label and to consult with a healthcare professional if you have any Questions
|
| 76 |
+
or concerns about its use.
|
| 77 |
+
Marketed Brands:
|
| 78 |
+
Methylcellulose is not marketed as a standalone product but rather as an inactive ingredient in various
|
| 79 |
+
pharmaceutical formulations. It can be found in a wide range of medications, including tablets,
|
| 80 |
+
capsules, creams, gels, ointments, eye drops, and more. Some common brands that may contain
|
| 81 |
+
methylcellulose include:
|
| 82 |
+
1. Metamucil (contains methylcellulose as a bulk-forming laxative)
|
| 83 |
+
2. Refresh (contains methylcellulose in ophthalmic lubricant eye drops)
|
| 84 |
+
Doses:
|
| 85 |
+
1. Metamucil:
|
| 86 |
+
● Metamucil contains methylcellulose as a bulk-forming laxative, typically used to relieve
|
| 87 |
+
constipation and promote regularity.
|
| 88 |
+
● For adults and children 12 years and older:
|
| 89 |
+
● Start with 1 teaspoon (approximately 5 grams) mixed with 8 ounces (about 240 mL) of
|
| 90 |
+
liquid (such as water or juice) once per day.
|
| 91 |
+
● Gradually increase the dose up to 3 times per day as needed, based on individual
|
| 92 |
+
response and tolerance.
|
| 93 |
+
● It's important to mix Metamucil thoroughly with liquid and to drink it immediately after
|
| 94 |
+
mixing.
|
| 95 |
+
- For children 6 to 11 years old:
|
| 96 |
+
● Follow the dosing instructions provided by a healthcare professional or as directed on
|
| 97 |
+
the packaging.
|
| 98 |
+
Laxatives | 49
|
| 99 |
+
|
| 100 |
+
--- End of Page 3 ---
|
| 101 |
+
|
| 102 |
+
● Metamucil should be taken with a full glass of water to prevent choking or
|
| 103 |
+
gastrointestinal obstruction, and it's essential to follow the dosing instructions provided
|
| 104 |
+
on the packaging or by a healthcare professional.
|
| 105 |
+
|
| 106 |
+
[Chapter_10_Laxatives_page4_img1.png]
|
| 107 |
+
|
| 108 |
+
|
| 109 |
+
|
| 110 |
+
2. Refresh Eye Drops:
|
| 111 |
+
● Refresh contains methylcellulose as an ophthalmic lubricant, used to relieve dryness
|
| 112 |
+
and irritation of the eyes.
|
| 113 |
+
● Dosage recommendations for Refresh Eye Drops depend on the specific product and
|
| 114 |
+
formulation.
|
| 115 |
+
|
| 116 |
+
[Chapter_10_Laxatives_page4_img2.png]
|
| 117 |
+
|
| 118 |
+
|
| 119 |
+
● Follow the dosing instructions provided on the packaging or as directed by a healthcare
|
| 120 |
+
professional.
|
| 121 |
+
● Typically, 1 to 2 drops may be instilled into the affected eye(s) as needed for relief of
|
| 122 |
+
dryness or irritation.
|
| 123 |
+
● It's important to wash your hands before instilling eye drops and to avoid touching the
|
| 124 |
+
tip of the dropper to prevent contamination.
|
| 125 |
+
● If you wear contact lenses, it's recommended to remove them before using Refresh Eye
|
| 126 |
+
Drops and wait at least 15 minutes before reinserting them.
|
| 127 |
+
|
| 128 |
+
50 | Laxatives
|
| 129 |
+
|
| 130 |
+
--- End of Page 4 ---
|
| 131 |
+
|
| 132 |
+
Introduction to Bisacodyl:
|
| 133 |
+
Bisacodyl is a pharmacological agent primarily employed as a laxative, renowned for its effectiveness
|
| 134 |
+
in treating constipation and facilitating bowel movements. This compound belongs to the class of
|
| 135 |
+
stimulant laxatives, which work by stimulating the muscles of the intestines to promote bowel
|
| 136 |
+
evacuation.
|
| 137 |
+
|
| 138 |
+
[Chapter_10_Laxatives_page5_img1.png]
|
| 139 |
+
|
| 140 |
+
|
| 141 |
+
Chemical Information:
|
| 142 |
+
Chemically, bisacodyl is known as 4,4'-((2-pyridinylmethylene)bis(4,1-phenylene))bis(2,6-bis(1,1-
|
| 143 |
+
dimethylethyl)phenol)diacetate. It is a derivative of diphenylmethane and is typically administered
|
| 144 |
+
orally or rectally.
|
| 145 |
+
Uses:
|
| 146 |
+
Bisacodyl finds extensive application in the management of constipation and the regulation of bowel
|
| 147 |
+
movements. It is often prescribed to alleviate temporary constipation due to various factors, such as
|
| 148 |
+
dietary changes, medication side effects, or travel-related disruptions to regular bowel habits.
|
| 149 |
+
Additionally, it is utilized in bowel preparation protocols before certain medical procedures or
|
| 150 |
+
surgeries.
|
| 151 |
+
Stability/Storage Conditions:
|
| 152 |
+
Bisacodyl should be stored at room temperature away from light and moisture, in a tightly closed
|
| 153 |
+
container. Avoid exposing it to extreme temperatures or freezing. Proper storage ensures the stability
|
| 154 |
+
and potency of the medication over its shelf life.
|
| 155 |
+
Safe Doses for Adults:
|
| 156 |
+
The recommended dosage of bisacodyl for adults varies depending on the formulation and the
|
| 157 |
+
individual's medical condition. Generally, for oral tablets, a typical dose ranges from 5 to 15 mg once
|
| 158 |
+
daily before bedtime or as directed by a healthcare provider. For rectal suppositories, the dosage
|
| 159 |
+
typically ranges from 10 to 20 mg for adults.
|
| 160 |
+
Laxatives | 51
|
| 161 |
+
|
| 162 |
+
--- End of Page 5 ---
|
| 163 |
+
|
| 164 |
+
Marketed Brands:
|
| 165 |
+
1. Dulcolax: A gentle yet effective solution, it provides reliable relief from occasional
|
| 166 |
+
constipation, restoring comfort with ease.
|
| 167 |
+
|
| 168 |
+
[Chapter_10_Laxatives_page6_img1.png]
|
| 169 |
+
|
| 170 |
+
|
| 171 |
+
2. Correctol: Precision-crafted for digestive harmony, it offers a gentle nudge to alleviate
|
| 172 |
+
discomfort and promote regularity.
|
| 173 |
+
|
| 174 |
+
[Chapter_10_Laxatives_page6_img2.png]
|
| 175 |
+
|
| 176 |
+
|
| 177 |
+
3. Bisac-Evac: Unleashes the power of bisacodyl to encourage bowel movement, providing swift
|
| 178 |
+
relief from occasional constipation.
|
| 179 |
+
|
| 180 |
+
[Chapter_10_Laxatives_page6_img3.png]
|
| 181 |
+
|
| 182 |
+
|
| 183 |
+
52 | Laxatives
|
| 184 |
+
|
| 185 |
+
--- End of Page 6 ---
|
| 186 |
+
|
| 187 |
+
4. Doxidan: Clears the path to digestive wellness, offering dependable relief and restoring natural
|
| 188 |
+
rhythm to the body.
|
| 189 |
+
|
| 190 |
+
[Chapter_10_Laxatives_page7_img1.png]
|
| 191 |
+
|
| 192 |
+
|
| 193 |
+
5. Alophen: Nurtures digestive balance with its gentle formula, offering comfort and relief when
|
| 194 |
+
needed most.
|
| 195 |
+
|
| 196 |
+
[Chapter_10_Laxatives_page7_img2.png]
|
| 197 |
+
|
| 198 |
+
|
| 199 |
+
6. Bisa-Lax: Empowers users with gentle yet effective relief from constipation, promoting
|
| 200 |
+
digestive well-being with each dose.
|
| 201 |
+
|
| 202 |
+
[Chapter_10_Laxatives_page7_img3.png]
|
| 203 |
+
|
| 204 |
+
|
| 205 |
+
These brands may offer different formulations, such as tablets, suppositories, or liquid preparations,
|
| 206 |
+
catering to diverse patient needs and preferences.
|
| 207 |
+
General Introduction to Milk of Magnesia:
|
| 208 |
+
Milk of Magnesia is an over-the-counter medication used as an antacid and a laxative. It contains
|
| 209 |
+
magnesium hydroxide as its active ingredient and is available in liquid form for oral administration.
|
| 210 |
+
Milk of Magnesia is commonly used to relieve symptoms of heartburn, indigestion, and constipation
|
| 211 |
+
by neutralizing stomach acid and drawing water into the intestines to promote bowel movements.
|
| 212 |
+
Laxatives | 53
|
| 213 |
+
|
| 214 |
+
--- End of Page 7 ---
|
| 215 |
+
|
| 216 |
+
Chemical Information:
|
| 217 |
+
● Chemical formula: Mg(OH)2
|
| 218 |
+
● Molecular weight: 58.32 g/mol
|
| 219 |
+
● Chemical structure: Milk of Magnesia consists of magnesium ions (Mg2+) and hydroxide ions
|
| 220 |
+
(OH-) in a suspension.
|
| 221 |
+
Uses:
|
| 222 |
+
Milk of Magnesia is primarily used for two purposes:
|
| 223 |
+
1. Antacid: It works by neutralizing stomach acid to relieve symptoms of heartburn, acid
|
| 224 |
+
indigestion, and upset stomach.
|
| 225 |
+
2. Laxative: It works by drawing water into the intestines, softening the stool, and promoting
|
| 226 |
+
bowel movements to relieve constipation.
|
| 227 |
+
Stability/Storage Conditions:
|
| 228 |
+
Milk of Magnesia should be stored at room temperature, away from moisture and heat. It is typically
|
| 229 |
+
available in liquid form in bottles or containers. It is essential to store Milk of Magnesia according to
|
| 230 |
+
the instructions provided on the packaging to maintain its stability and effectiveness.
|
| 231 |
+
Safe Dose for Adults:
|
| 232 |
+
The recommended dose of Milk of Magnesia for adults varies depending on the specific product and
|
| 233 |
+
formulation, as well as the individual's condition and response to treatment. It's crucial to follow the
|
| 234 |
+
dosing instructions provided by the manufacturer or as directed by a healthcare professional. In
|
| 235 |
+
general, for the laxative effect, 30 mL to 60 mL (2 to 4 tablespoons) of Milk of Magnesia can be taken
|
| 236 |
+
orally, usually once daily or as needed for constipation relief. For antacid use, the dose may vary
|
| 237 |
+
depending on the severity of symptoms, but it's typically around 5 mL to 15 mL (1 to 3 teaspoons)
|
| 238 |
+
taken orally as needed for heartburn relief.
|
| 239 |
+
Marketed Brands:
|
| 240 |
+
Milk of Magnesia is available under various brand names, both over-the-counter and by prescription.
|
| 241 |
+
Some common brands include:
|
| 242 |
+
1. Phillips' Milk of Magnesia
|
| 243 |
+
2. Ex-Lax Milk of Magnesia
|
| 244 |
+
3. Mylanta Supreme
|
| 245 |
+
54 | Laxatives
|
| 246 |
+
|
| 247 |
+
--- End of Page 8 ---
|
| 248 |
+
|
| 249 |
+
Dose:
|
| 250 |
+
1. Phillips' Milk of Magnesia:
|
| 251 |
+
● For adults and children 12 years and older: Take 2 to 4 tablespoons (30 to 60 mL) orally, once
|
| 252 |
+
daily or as directed by a healthcare professional.
|
| 253 |
+
● For children 6 to 11 years old: Take 1 to 2 tablespoons (15 to 30 mL) orally, once daily or as
|
| 254 |
+
directed by a healthcare professional.
|
| 255 |
+
● It's important to shake the bottle well before each use, and it's typically taken on an empty
|
| 256 |
+
stomach followed by a full glass of water. Do not exceed the recommended dosage without
|
| 257 |
+
consulting a healthcare professional.
|
| 258 |
+
2. Ex-Lax Milk of Magnesia:
|
| 259 |
+
● Dosage recommendations for Ex-Lax Milk of Magnesia are similar to Phillips' Milk of
|
| 260 |
+
Magnesia, as they both contain the same active ingredient (magnesium hydroxide).
|
| 261 |
+
● Follow the dosing instructions provided on the packaging or as directed by a healthcare
|
| 262 |
+
professional.
|
| 263 |
+
● It's essential to shake the bottle well before each use and to take it on an empty stomach
|
| 264 |
+
followed by a full glass of water.
|
| 265 |
+
3. Mylanta Supreme:
|
| 266 |
+
● Mylanta Supreme is an antacid and anti-gas medication that contains ingredients such as
|
| 267 |
+
aluminum hydroxide, magnesium hydroxide, and simethicone.
|
| 268 |
+
● Dosage recommendations may vary depending on the specific symptoms being treated and the
|
| 269 |
+
individual's age and medical condition.
|
| 270 |
+
● It's important to shake the bottle well before each use, and it may be taken after meals and at
|
| 271 |
+
bedtime or as directed.
|
| 272 |
+
It's crucial to use these products as directed and to avoid exceeding the recommended dosage to
|
| 273 |
+
prevent potential side effects or complications. If you have any Questions or concerns about the
|
| 274 |
+
appropriate dosage for these laxatives, it's best to consult with a healthcare professional or pharmacist
|
| 275 |
+
for personalized advice.
|
| 276 |
+
|
| 277 |
+
Laxatives | 55
|
| 278 |
+
|
| 279 |
+
--- End of Page 9 ---
|
| 280 |
+
|
| 281 |
+
FREQUENTLY ASKED QUESTIONS
|
| 282 |
+
Question: What are laxatives?
|
| 283 |
+
Answer: Laxatives are medications or substances that help promote bowel movements and relieve
|
| 284 |
+
constipation by increasing stool frequency and softening stool consistency.
|
| 285 |
+
Question: How do laxatives work?
|
| 286 |
+
Answer: Laxatives work by stimulating bowel movements through various mechanisms, such as
|
| 287 |
+
increasing intestinal motility, softening stool, or adding bulk to stool to facilitate passage.
|
| 288 |
+
Question: What are some common examples of laxatives?
|
| 289 |
+
Answer: Common examples of laxatives include osmotic laxatives (e.g., polyethylene glycol),
|
| 290 |
+
stimulant laxatives (e.g., bisacodyl), bulk-forming laxatives (e.g., psyllium), and stool softeners (e.g.,
|
| 291 |
+
docusate sodium).
|
| 292 |
+
Question: When should laxatives be used?
|
| 293 |
+
Answer: Laxatives should be used as directed to relieve occasional constipation or to facilitate bowel
|
| 294 |
+
movements in individuals with certain medical conditions, such as irritable bowel syndrome (IBS) or
|
| 295 |
+
opioid-induced constipation.
|
| 296 |
+
Question: Can laxatives be used with other medications?
|
| 297 |
+
Answer: Laxatives can generally be used with other medications, but it's important to consult with a
|
| 298 |
+
healthcare professional or pharmacist to avoid potential interactions, especially if you have underlying
|
| 299 |
+
health conditions or are taking other medications.
|
| 300 |
+
Question: Do laxatives have any side effects?
|
| 301 |
+
Answer: Common side effects of laxatives may include abdominal cramping, bloating, gas, diarrhea,
|
| 302 |
+
electrolyte imbalances, and dependency with prolonged or excessive use.
|
| 303 |
+
Question: Can laxatives be used to treat conditions other than constipation?
|
| 304 |
+
Answer: While laxatives are primarily used to relieve constipation, certain types of laxatives, such as
|
| 305 |
+
bulk-forming laxatives or stool softeners, may also be used to manage symptoms of diarrhea or to
|
| 306 |
+
promote regular bowel movements in individuals with certain gastrointestinal disorders.
|
| 307 |
+
Question: Are there any lifestyle changes that can help reduce the need for laxatives?
|
| 308 |
+
Answer: Yes, adopting a diet high in fiber, staying hydrated, exercising regularly, and maintaining
|
| 309 |
+
regular bowel habits can help promote bowel regularity and reduce the need for laxatives in the long
|
| 310 |
+
term.
|
| 311 |
+
|
| 312 |
+
56 | Laxatives
|
| 313 |
+
|
| 314 |
+
--- End of Page 10 ---
|
| 315 |
+
|
MEDICINE_TXT/Chapter_11_Antifungals.txt
ADDED
|
@@ -0,0 +1,242 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
11
|
| 3 |
+
|
| 4 |
+
Antifungals
|
| 5 |
+
Dr. Harshita Jain
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Antifungals are a class of medications or substances designed to treat fungal infections by inhibiting
|
| 9 |
+
the growth and spread of fungi or by directly killing fungal organisms. These infections can affect
|
| 10 |
+
various parts of the body, including the skin, nails, mucous membranes, and internal organs.
|
| 11 |
+
Antifungals work through different mechanisms to combat fungal infections:
|
| 12 |
+
1. Cell Membrane Disruption: Some antifungals disrupt the integrity of fungal cell membranes,
|
| 13 |
+
which are essential for fungal survival and growth. Examples of antifungals that work by this
|
| 14 |
+
mechanism include azoles (e.g., fluconazole) and polyenes (e.g., amphotericin B).
|
| 15 |
+
2. Inhibition of Ergosterol Synthesis: Ergosterol is a vital component of fungal cell membranes.
|
| 16 |
+
Certain antifungals, such as azoles (e.g., itraconazole) and allylamines (e.g., terbinafine), inhibit the
|
| 17 |
+
synthesis of ergosterol, thereby compromising fungal cell membrane integrity.
|
| 18 |
+
3. Interference with Nucleic Acid Synthesis: Antifungals like flucytosine interfere with fungal
|
| 19 |
+
nucleic acid synthesis, inhibiting fungal replication and growth.
|
| 20 |
+
4. Disruption of Fungal Cell Wall: Echinocandins, another class of antifungals, inhibit the synthesis
|
| 21 |
+
of β-glucan, a crucial component of the fungal cell wall, leading to cell wall disruption and ultimately
|
| 22 |
+
fungal cell death.
|
| 23 |
+
Antifungals can be administered orally, topically (applied to the skin or mucous membranes), or
|
| 24 |
+
intravenously (directly into the bloodstream) depending on the type and severity of the fungal
|
| 25 |
+
infection. They play a critical role in the treatment of fungal diseases and are essential in managing
|
| 26 |
+
conditions ranging from superficial skin infections like athlete's foot to invasive systemic fungal
|
| 27 |
+
infections that can be life-threatening in immune-compromised individuals.
|
| 28 |
+
Antifungals can be classified into several categories based on their chemical structure, mechanism of
|
| 29 |
+
action, and spectrum of activity.
|
| 30 |
+
Classification:
|
| 31 |
+
1. Azoles:
|
| 32 |
+
● Mechanism of Action: Azoles inhibit the synthesis of ergosterol, a vital component of fungal
|
| 33 |
+
cell membranes, by inhibiting the enzyme lanosterol 14-alpha-demethylase.
|
| 34 |
+
● Examples: Fluconazole, Itraconazole, Ketoconazole, Voriconazole, Posaconazole.
|
| 35 |
+
● Spectrum: Broad-spectrum antifungals effective against a wide range of fungal infections,
|
| 36 |
+
including superficial and systemic infections.
|
| 37 |
+
Antifungals | 57
|
| 38 |
+
|
| 39 |
+
--- End of Page 1 ---
|
| 40 |
+
|
| 41 |
+
2. Polyenes:
|
| 42 |
+
● Mechanism of Action: Polyenes bind to ergosterol in fungal cell membranes, causing
|
| 43 |
+
membrane disruption and leakage of intracellular contents, leading to fungal cell death.
|
| 44 |
+
● Examples: Amphotericin B, Nystatin.
|
| 45 |
+
● Spectrum: Broad-spectrum antifungals used to treat serious systemic fungal infections,
|
| 46 |
+
particularly those caused by Candida and Aspergillus species.
|
| 47 |
+
3. Echinocandins:
|
| 48 |
+
● Mechanism of Action: Echinocandins inhibit the synthesis of β-glucan, a key component of
|
| 49 |
+
fungal cell walls, leading to cell wall destabilization and fungal cell death.
|
| 50 |
+
● Examples: Caspofungin, Micafungin, Anidulafungin.
|
| 51 |
+
● Spectrum: Primarily used for invasive candidiasis and aspergillosis, especially in patients who
|
| 52 |
+
are resistant to other antifungal agents.
|
| 53 |
+
4. Allylamines:
|
| 54 |
+
● Mechanism of Action: Allylamines inhibit squalene epoxidase, an enzyme involved in the
|
| 55 |
+
synthesis of ergosterol, leading to depletion of ergosterol and disruption of fungal cell
|
| 56 |
+
membranes.
|
| 57 |
+
● Examples: Terbinafine.
|
| 58 |
+
● Spectrum: Mainly used to treat dermatophyte infections such as ringworm and fungal nail
|
| 59 |
+
infections.
|
| 60 |
+
5. Flucytosine (5-Fluorocytosine):
|
| 61 |
+
● Mechanism of Action: Flucytosine is converted into 5-fluorouracil within fungal cells, which
|
| 62 |
+
interferes with fungal nucleic acid synthesis, ultimately leading to cell death.
|
| 63 |
+
● Examples: Flucytosine.
|
| 64 |
+
● Spectrum: Often used in combination with other antifungal agents for the treatment of systemic
|
| 65 |
+
fungal infections, particularly those caused by Candida species.
|
| 66 |
+
6. Topical Antifungals:
|
| 67 |
+
● These include various antifungal agents such as clotrimazole, miconazole, and econazole,
|
| 68 |
+
which are applied directly to the skin or mucous membranes to treat superficial fungal
|
| 69 |
+
infections like athlete's foot, jock itch, and vaginal yeast infections.
|
| 70 |
+
Introduction to Clotrimazole:
|
| 71 |
+
Clotrimazole is a widely used antifungal medication renowned for its efficacy in treating fungal skin
|
| 72 |
+
infections. It belongs to the class of azole antifungals and is commonly available in various
|
| 73 |
+
formulations for topical application. Clotrimazole works by inhibiting the growth and spread of fungi,
|
| 74 |
+
particularly those causing dermatophytosis (such as ringworm) and yeast infections (such as
|
| 75 |
+
candidiasis).
|
| 76 |
+
58 | Antifungals
|
| 77 |
+
|
| 78 |
+
--- End of Page 2 ---
|
| 79 |
+
|
| 80 |
+
Chemical Information:
|
| 81 |
+
Chemically, clotrimazole is known as 1-(o-chloro-α,α-diphenylbenzyl)imidazole. It is available in
|
| 82 |
+
different formulations, including creams, lotions, powders, and sprays, for topical application to the
|
| 83 |
+
affected skin areas.
|
| 84 |
+
Uses:
|
| 85 |
+
Clotrimazole is primarily indicated for the treatment of fungal skin infections, including:
|
| 86 |
+
1. Ringworm (Tinea Corporis): Fungal infection of the skin characterized by red, circular patches
|
| 87 |
+
with raised edges.
|
| 88 |
+
|
| 89 |
+
[Chapter_11_Antifungals_page3_img1.png]
|
| 90 |
+
|
| 91 |
+
|
| 92 |
+
2. Athlete's Foot (Tinea Pedis): Fungal infection affecting the skin between the toes and on the
|
| 93 |
+
soles of the feet, causing itching, redness, and peeling.
|
| 94 |
+
|
| 95 |
+
[Chapter_11_Antifungals_page3_img2.png]
|
| 96 |
+
|
| 97 |
+
|
| 98 |
+
3. Jock Itch (Tinea Cruris): Fungal infection of the groin area, leading to redness, itching, and
|
| 99 |
+
discomfort.
|
| 100 |
+
4. Yeast Infections: Clotrimazole can also be used to treat yeast infections such as vaginal
|
| 101 |
+
candidiasis (vaginal yeast infection) and oral thrush (yeast infection of the mouth and throat).
|
| 102 |
+
|
| 103 |
+
Stability/Storage Conditions:
|
| 104 |
+
Clotrimazole products should be stored at room temperature, away from moisture and heat, in a tightly
|
| 105 |
+
closed container. It is important to follow the specific storage instructions provided with the product to
|
| 106 |
+
ensure stability and efficacy. Avoid freezing clotrimazole preparations, and keep them out of reach of
|
| 107 |
+
children.
|
| 108 |
+
Antifungals | 59
|
| 109 |
+
|
| 110 |
+
--- End of Page 3 ---
|
| 111 |
+
|
| 112 |
+
Safe Dose for Adults:
|
| 113 |
+
The recommended dose and duration of treatment with clotrimazole depend on the severity and
|
| 114 |
+
location of the fungal infection. For most superficial fungal infections, clotrimazole cream or lotion is
|
| 115 |
+
typically applied to the affected area(s) two to three times daily for 2 to 4 weeks or as directed by a
|
| 116 |
+
healthcare professional. However, it is essential to follow the specific instructions provided by the
|
| 117 |
+
healthcare provider or the product labeling.
|
| 118 |
+
Marketed Brands:
|
| 119 |
+
Clotrimazole is available under various brand names, including but not limited to:
|
| 120 |
+
1. Lotrimin: Trusted for generations, it swiftly tackles fungal infections, providing soothing relief
|
| 121 |
+
and restoring skin's health.
|
| 122 |
+
|
| 123 |
+
[Chapter_11_Antifungals_page4_img1.png]
|
| 124 |
+
|
| 125 |
+
|
| 126 |
+
2. Canesten: A beacon of hope for those plagued by fungal woes, it brings comfort and clarity to
|
| 127 |
+
compromised areas.
|
| 128 |
+
|
| 129 |
+
[Chapter_11_Antifungals_page4_img2.png]
|
| 130 |
+
|
| 131 |
+
|
| 132 |
+
3. Clotrimazole-7: With a week-long regimen, it banishes fungal invaders, offering long-lasting
|
| 133 |
+
protection and peace of mind.
|
| 134 |
+
|
| 135 |
+
[Chapter_11_Antifungals_page4_img3.png]
|
| 136 |
+
|
| 137 |
+
|
| 138 |
+
60 | Antifungals
|
| 139 |
+
|
| 140 |
+
--- End of Page 4 ---
|
| 141 |
+
|
| 142 |
+
4. Gyne-Lotrimin: Tailored for feminine care, it combats discomfort with gentle efficacy,
|
| 143 |
+
restoring balance where it's needed most.
|
| 144 |
+
|
| 145 |
+
[Chapter_11_Antifungals_page5_img1.png]
|
| 146 |
+
|
| 147 |
+
|
| 148 |
+
5. Mycelex: A beacon of relief against stubborn fungal infections, it offers fast-acting comfort and
|
| 149 |
+
restores skin to its natural glory.
|
| 150 |
+
|
| 151 |
+
[Chapter_11_Antifungals_page5_img2.png]
|
| 152 |
+
|
| 153 |
+
|
| 154 |
+
These brands offer clotrimazole in different formulations and concentrations to suit the needs of
|
| 155 |
+
patients and the nature of their fungal infections. It is important to consult a healthcare professional for
|
| 156 |
+
proper diagnosis and treatment recommendations before using clotrimazole or any other antifungal
|
| 157 |
+
medication.
|
| 158 |
+
Introduction to Miconazole:
|
| 159 |
+
Miconazole is a potent antifungal medication widely recognized for its effectiveness in treating yeast
|
| 160 |
+
infections, particularly those caused by Candida species. It belongs to the azole class of antifungals and
|
| 161 |
+
is available in various formulations for topical and vaginal use. Miconazole works by inhibiting the
|
| 162 |
+
growth and spread of fungi, thereby relieving symptoms associated with yeast infections.
|
| 163 |
+
|
| 164 |
+
Antifungals | 61
|
| 165 |
+
|
| 166 |
+
--- End of Page 5 ---
|
| 167 |
+
|
| 168 |
+
Chemical Information:
|
| 169 |
+
Chemically, miconazole is known as 1-[2-(2,4-dichlorophenyl)-2-[(2,4dichlorophenyl)methoxy]ethyl]-
|
| 170 |
+
1H-imidazole. It is formulated in different forms such as creams, suppositories, powders, and oral gel
|
| 171 |
+
for topical or intravaginal application.
|
| 172 |
+
Uses:
|
| 173 |
+
Miconazole is primarily indicated for the treatment of yeast infections, including:
|
| 174 |
+
1. Vaginal Candidiasis (Vaginal Yeast Infection): Common fungal infection affecting the vagina,
|
| 175 |
+
characterized by itching, burning, vaginal discharge, and discomfort during urination or
|
| 176 |
+
intercourse.
|
| 177 |
+
2. Oral Thrush: Yeast infection of the mouth and throat, often characterized by white patches on
|
| 178 |
+
the tongue, inner cheeks, roof of the mouth, or throat, along with pain and difficulty
|
| 179 |
+
swallowing.
|
| 180 |
+
3. Skin Yeast Infections: Miconazole creams or powders can also be used to treat yeast infections
|
| 181 |
+
on the skin, such as diaper rash caused by Candida.
|
| 182 |
+
Stability/Storage Conditions:
|
| 183 |
+
Miconazole products should be stored at room temperature, away from moisture and heat, in a tightly
|
| 184 |
+
closed container. Avoid freezing miconazole preparations, and keep them out of reach of children.
|
| 185 |
+
Specific storage instructions may vary depending on the formulation and brand, so it is essential to
|
| 186 |
+
follow the directions provided with the product.
|
| 187 |
+
Safe Dose for Adults:
|
| 188 |
+
The recommended dose and duration of treatment with miconazole depend on the severity and location
|
| 189 |
+
of the yeast infection. For vaginal candidiasis, miconazole vaginal suppositories or cream are typically
|
| 190 |
+
applied intravaginally once daily for 1 to 7 days, depending on the product strength and formulation.
|
| 191 |
+
For oral thrush, miconazole oral gel is applied directly to the affected areas several times daily as
|
| 192 |
+
directed by a healthcare professional.
|
| 193 |
+
Marketed Brands:
|
| 194 |
+
Miconazole is available under various brand names, including but not limited to:
|
| 195 |
+
1. Monistat
|
| 196 |
+
2. Micatin
|
| 197 |
+
3. Femizole
|
| 198 |
+
4. Lotrimin AF
|
| 199 |
+
5. Desenex
|
| 200 |
+
These brands offer miconazole in different formulations and strengths tailored to the specific needs of
|
| 201 |
+
patients experiencing yeast infections. It is crucial to consult a healthcare provider for proper diagnosis
|
| 202 |
+
and treatment recommendations before using miconazole or any other antifungal medication.
|
| 203 |
+
62 | Antifungals
|
| 204 |
+
|
| 205 |
+
--- End of Page 6 ---
|
| 206 |
+
|
| 207 |
+
FREQUENTLY ASKED QUESTIONS
|
| 208 |
+
Question: What are antifungals?
|
| 209 |
+
Answer: Antifungals are medications used to treat fungal infections by targeting the fungi responsible
|
| 210 |
+
for the infection and inhibiting their growth or killing them.
|
| 211 |
+
Question: How do antifungals work?
|
| 212 |
+
Answer: Antifungals work by interfering with specific components of fungal cells, such as cell
|
| 213 |
+
membranes or enzymes, disrupting their function and preventing the fungi from proliferating or
|
| 214 |
+
surviving.
|
| 215 |
+
Question: What are some common examples of antifungals?
|
| 216 |
+
Answer: Common examples of antifungals include fluconazole, clotrimazole, miconazole, terbinafine,
|
| 217 |
+
and ketoconazole. They are available in various formulations, including oral tablets, creams,
|
| 218 |
+
ointments, and topical solutions.
|
| 219 |
+
Question: When should antifungals be used?
|
| 220 |
+
Answer: Antifungals should be used to treat fungal infections, including those affecting the skin (such
|
| 221 |
+
as athlete's foot or ringworm), nails, mouth (such as oral thrush), vagina (such as yeast infections), or
|
| 222 |
+
systemic infections (such as candidiasis or cryptococcal meningitis).
|
| 223 |
+
Question: Can antifungals be used with other medications?
|
| 224 |
+
Answer: Antifungals can generally be used with other medications, but it's important to consult with a
|
| 225 |
+
healthcare professional or pharmacist to avoid potential interactions, especially if you have underlying
|
| 226 |
+
health conditions or are taking other medications.
|
| 227 |
+
Question: Do antifungals have any side effects?
|
| 228 |
+
Answer: Common side effects of antifungals may include nausea, vomiting, diarrhea, abdominal pain,
|
| 229 |
+
rash, itching, or allergic reactions. Serious side effects are rare but may include liver toxicity or allergic
|
| 230 |
+
reactions.
|
| 231 |
+
Question: Can antifungals be used to prevent fungal infections?
|
| 232 |
+
Answer: Yes, antifungals may be used prophylactically in certain situations to prevent fungal
|
| 233 |
+
infections, such as in individuals with compromised immune systems (such as HIV/AIDS patients) or
|
| 234 |
+
those undergoing chemotherapy.
|
| 235 |
+
Question: Are there any lifestyle changes that can help reduce the risk of fungal infections?
|
| 236 |
+
Answer: Yes, practicing good hygiene, keeping the skin clean and dry, avoiding sharing personal
|
| 237 |
+
items such as towels or clothing, wearing breathable clothing, and avoiding prolonged exposure to
|
| 238 |
+
warm and humid environments can help reduce the risk of fungal infections.
|
| 239 |
+
Antifungals | 63
|
| 240 |
+
|
| 241 |
+
--- End of Page 7 ---
|
| 242 |
+
|
MEDICINE_TXT/Chapter_12_Acne_Medications.txt
ADDED
|
@@ -0,0 +1,264 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
12
|
| 3 |
+
|
| 4 |
+
Acne Medications
|
| 5 |
+
Mr. Rahul Kumar Ancheria
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Definition of Acne:
|
| 9 |
+
Acne is a common skin condition that occurs when hair follicles become clogged with oil (sebum) and
|
| 10 |
+
dead skin cells. It typically presents as pimples, blackheads, whiteheads, and cysts on areas of the skin
|
| 11 |
+
such as the face, neck, chest, back, and shoulders. Acne can vary in severity, from mild cases
|
| 12 |
+
characterized by occasional breakouts to more severe forms with widespread inflammation and
|
| 13 |
+
scarring.
|
| 14 |
+
Classification of Acne Medications:
|
| 15 |
+
Acne medications can be classified based on their mechanism of action and formulation. Here's a
|
| 16 |
+
classification:
|
| 17 |
+
1. Topical Retinoids:
|
| 18 |
+
● Mechanism of Action: Topical retinoids work by preventing the plugging of hair follicles and
|
| 19 |
+
promoting the turnover of skin cells, thus reducing the formation of comedones (blackheads
|
| 20 |
+
and whiteheads).
|
| 21 |
+
● Examples: Tretinoin, Adapalene, Tazarotene.
|
| 22 |
+
● Classification: Topical retinoids are classified as vitamin A derivatives and are available in
|
| 23 |
+
various formulations such as creams, gels, and lotions.
|
| 24 |
+
2. Topical Antibiotics:
|
| 25 |
+
● Mechanism of Action: Topical antibiotics reduce acne by killing acne-causing bacteria
|
| 26 |
+
(Propionibacterium acnes) and reducing inflammation.
|
| 27 |
+
● Examples: Clindamycin, Erythromycin.
|
| 28 |
+
● Classification: These medications are available as creams, gels, solutions, or foams for topical
|
| 29 |
+
application.
|
| 30 |
+
3. Benzoyl Peroxide:
|
| 31 |
+
● Mechanism of Action: Benzoyl peroxide works by killing acne-causing bacteria, reducing
|
| 32 |
+
inflammation, and unplugging blocked pores.
|
| 33 |
+
● Examples: Benzoyl peroxide.
|
| 34 |
+
● Classification: Benzoyl peroxide is available in various strengths and formulations, including
|
| 35 |
+
creams, gels, lotions, and cleansers.
|
| 36 |
+
64 | Acne Medications
|
| 37 |
+
|
| 38 |
+
--- End of Page 1 ---
|
| 39 |
+
|
| 40 |
+
4. Oral Antibiotics:
|
| 41 |
+
● Mechanism of Action: Oral antibiotics are used to reduce acne-associated inflammation and
|
| 42 |
+
control bacterial growth.
|
| 43 |
+
● Examples: Tetracycline, Doxycycline, Minocycline.
|
| 44 |
+
● Classification: Oral antibiotics are available in pill or capsule form and are typically prescribed
|
| 45 |
+
for moderate to severe acne.
|
| 46 |
+
5. Hormonal Agents:
|
| 47 |
+
● Mechanism of Action: Hormonal agents, such as oral contraceptives (birth control pills) and
|
| 48 |
+
anti-androgen medications, work by regulating hormonal fluctuations that contribute to acne
|
| 49 |
+
development.
|
| 50 |
+
● Examples: Oral contraceptives containing estrogen and progestin, Spironolactone.
|
| 51 |
+
● Classification: These medications are available as oral tablets or capsules and are commonly
|
| 52 |
+
prescribed for hormonal acne in females.
|
| 53 |
+
6. Isotretinoin (Oral Retinoid):
|
| 54 |
+
● Mechanism of Action: Isotretinoin is a powerful oral retinoid that reduces sebum production,
|
| 55 |
+
prevents the formation of acne lesions, and has anti-inflammatory properties.
|
| 56 |
+
● Examples: Isotretinoin (brand name Accutane).
|
| 57 |
+
● Classification: Isotretinoin is available in oral capsule form and is typically prescribed for
|
| 58 |
+
severe, nodular acne that has not responded to other treatments.
|
| 59 |
+
7. Combination Therapy:
|
| 60 |
+
● Mechanism of Action: Combination therapy involves using two or more acne medications with
|
| 61 |
+
complementary mechanisms of action to enhance efficacy and reduce the risk of antibiotic
|
| 62 |
+
resistance.
|
| 63 |
+
● Examples:
|
| 64 |
+
Combination
|
| 65 |
+
products
|
| 66 |
+
containing
|
| 67 |
+
benzoyl
|
| 68 |
+
peroxide
|
| 69 |
+
and
|
| 70 |
+
clindamycin,
|
| 71 |
+
Adapalene/Benzoyl Peroxide combinations.
|
| 72 |
+
● Classification: Combination therapies are available in various formulations, including creams,
|
| 73 |
+
gels, and lotions, and are prescribed based on the individual's acne severity and treatment
|
| 74 |
+
response.
|
| 75 |
+
This classification provides an overview of the main categories of acne medications and their
|
| 76 |
+
respective mechanisms of action and formulations. Treatment selection depends on factors such as
|
| 77 |
+
acne severity, skin type, medical history, and individual response to therapy, and should be guided by a
|
| 78 |
+
healthcare professional.
|
| 79 |
+
Acne Medications | 65
|
| 80 |
+
|
| 81 |
+
--- End of Page 2 ---
|
| 82 |
+
|
| 83 |
+
Introduction to Benzoyl Peroxide:
|
| 84 |
+
Benzoyl peroxide is a widely used topical medication renowned for its efficacy in treating acne
|
| 85 |
+
vulgaris, a common skin condition characterized by the formation of pimples, blackheads, whiteheads,
|
| 86 |
+
and inflammation. Benzoyl peroxide belongs to the class of organic peroxides and is available in
|
| 87 |
+
various strengths
|
| 88 |
+
for topical application. It works by reducing acne-causing
|
| 89 |
+
bacteria
|
| 90 |
+
(Propionibacterium acnes), unplugging blocked pores, and reducing inflammation associated with acne
|
| 91 |
+
lesions.
|
| 92 |
+
Chemical Information:
|
| 93 |
+
Chemically, benzoyl peroxide is represented as C14H10O4. It is available in different concentrations
|
| 94 |
+
ranging from 2.5% to 10% in various formulations such as creams, gels, lotions, and cleansers for
|
| 95 |
+
topical use.
|
| 96 |
+
Uses:
|
| 97 |
+
Benzoyl peroxide is primarily indicated for the treatment of acne vulgaris, including:
|
| 98 |
+
1. Pimples: Benzoyl peroxide helps to reduce the number and severity of pimples by killing acne-
|
| 99 |
+
causing bacteria and reducing inflammation.
|
| 100 |
+
2. Blackheads and Whiteheads: It helps to unblock pores by removing excess oil and dead skin cells,
|
| 101 |
+
thus reducing the formation of blackheads and whiteheads.
|
| 102 |
+
3. Inflammatory Acne Lesions: Benzoyl peroxide can also alleviate inflammation associated with acne
|
| 103 |
+
lesions, leading to faster healing and resolution of acne.
|
| 104 |
+
Stability/Storage Conditions:
|
| 105 |
+
Benzoyl peroxide products should be stored at room temperature, away from moisture and heat, in a
|
| 106 |
+
tightly closed container. Avoid exposing benzoyl peroxide preparations to direct sunlight or freezing
|
| 107 |
+
temperatures, as this may affect their stability and efficacy. It is important to follow the specific
|
| 108 |
+
storage instructions provided with the product to ensure optimal performance.
|
| 109 |
+
Safe Dose for Adults:
|
| 110 |
+
The recommended dose and frequency of application of benzoyl peroxide depend on the severity of
|
| 111 |
+
acne and the formulation strength. For most cases of acne, benzoyl peroxide is applied once or twice
|
| 112 |
+
daily to clean, dry skin affected by acne lesions. It is typically recommended to start with lower
|
| 113 |
+
concentrations (e.g., 2.5% or 5%) to minimize skin irritation and gradually increase the strength if
|
| 114 |
+
necessary. It is important to follow the instructions provided by a healthcare professional or the
|
| 115 |
+
product labeling.
|
| 116 |
+
|
| 117 |
+
66 | Acne Medications
|
| 118 |
+
|
| 119 |
+
--- End of Page 3 ---
|
| 120 |
+
|
| 121 |
+
Marketed Brands:
|
| 122 |
+
Benzoyl peroxide is available under various brand names, including but not limited to:
|
| 123 |
+
1. PanOxyl: Unleashes the power of benzoyl peroxide, defeating acne and restoring skin's clarity.
|
| 124 |
+
|
| 125 |
+
[Chapter_12_Acne_Medications_page4_img1.png]
|
| 126 |
+
|
| 127 |
+
|
| 128 |
+
2. Clearasil: A stalwart defender against blemishes, offering a clear path to confidence.
|
| 129 |
+
|
| 130 |
+
[Chapter_12_Acne_Medications_page4_img2.png]
|
| 131 |
+
|
| 132 |
+
|
| 133 |
+
3. Benzac: Tackles acne at its source, unveiling a complexion that is both clear and radiant.
|
| 134 |
+
|
| 135 |
+
[Chapter_12_Acne_Medications_page4_img3.png]
|
| 136 |
+
|
| 137 |
+
|
| 138 |
+
Acne Medications | 67
|
| 139 |
+
|
| 140 |
+
--- End of Page 4 ---
|
| 141 |
+
|
| 142 |
+
4. Brevoxyl: Delivers a knockout punch to stubborn acne, leaving behind a smoother, clearer
|
| 143 |
+
canvas.
|
| 144 |
+
|
| 145 |
+
[Chapter_12_Acne_Medications_page5_img1.png]
|
| 146 |
+
|
| 147 |
+
|
| 148 |
+
5. Persa-Gel: Rapid-action relief from breakouts, putting acne on notice with its potent formula.
|
| 149 |
+
These brands offer benzoyl peroxide in different formulations and concentrations to suit the needs of
|
| 150 |
+
individuals with varying degrees of acne severity and skin sensitivity. It is advisable to consult a
|
| 151 |
+
healthcare provider or dermatologist for proper diagnosis and treatment recommendations before using
|
| 152 |
+
benzoyl peroxide or any other acne medication.
|
| 153 |
+
Introduction to Salicylic Acid:
|
| 154 |
+
Salicylic acid is a well-known topical medication used primarily for its keratolytic (skin exfoliating)
|
| 155 |
+
properties and its ability to treat various skin conditions, including acne, psoriasis, and warts. It
|
| 156 |
+
belongs to the class of beta hydroxy acids (BHAs) and is derived from the bark of the willow tree or
|
| 157 |
+
synthesized chemically. Salicylic acid is available in various formulations for topical application, such
|
| 158 |
+
as creams, gels, lotions, pads, and solutions.
|
| 159 |
+
Chemical Information:
|
| 160 |
+
Chemically, salicylic acid is a monohydroxybenzoic acid with the chemical formula C7H6O3. It is a
|
| 161 |
+
colorless, crystalline organic acid that is soluble in alcohol and ether but sparingly soluble in water.
|
| 162 |
+
Salicylic acid is typically formulated as a solution in alcohol or as a cream or gel in water-miscible
|
| 163 |
+
bases for topical use.
|
| 164 |
+
Uses:
|
| 165 |
+
Salicylic acid is primarily indicated for the treatment of various skin conditions, including:
|
| 166 |
+
1. Acne: Salicylic acid helps to exfoliate the skin, unclog pores, and reduce inflammation, making it
|
| 167 |
+
effective in treating acne vulgaris. It is particularly beneficial for non-inflammatory acne lesions such
|
| 168 |
+
as blackheads and whiteheads.
|
| 169 |
+
68 | Acne Medications
|
| 170 |
+
|
| 171 |
+
--- End of Page 5 ---
|
| 172 |
+
|
| 173 |
+
2. Warts: Salicylic acid is also used for the topical treatment of common warts and plantar warts
|
| 174 |
+
(verruca plantaris). It works by softening the keratin in the wart, leading to its gradual removal.
|
| 175 |
+
3. Psoriasis: In psoriasis, salicylic acid helps to remove scales and reduce itching and inflammation
|
| 176 |
+
when applied topically to affected areas of the skin.
|
| 177 |
+
Stability/Storage Conditions:
|
| 178 |
+
Salicylic acid products should be stored at room temperature, away from moisture and heat, in a tightly
|
| 179 |
+
closed container. Avoid exposing salicylic acid preparations to direct sunlight or freezing temperatures,
|
| 180 |
+
as this may affect their stability and efficacy. It is important to follow the specific storage instructions
|
| 181 |
+
provided with the product to ensure optimal performance.
|
| 182 |
+
Safe Dose for Adults:
|
| 183 |
+
The recommended dose and frequency of application of salicylic acid depend on the severity of the
|
| 184 |
+
skin condition being treated and the formulation strength. For acne, salicylic acid is typically applied
|
| 185 |
+
once or twice daily to clean, dry skin affected by acne lesions. It is advisable to start with lower
|
| 186 |
+
concentrations (e.g., 0.5% to 2%) to minimize skin irritation and gradually increase the strength if
|
| 187 |
+
necessary. It is important to follow the instructions provided by a healthcare professional or the
|
| 188 |
+
product labeling.
|
| 189 |
+
Marketed Brands:
|
| 190 |
+
Salicylic acid is available under various brand names, including but not limited to:
|
| 191 |
+
1. Clearasil: Battles acne with precision, unveiling clearer skin with each application.
|
| 192 |
+
|
| 193 |
+
[Chapter_12_Acne_Medications_page6_img1.png]
|
| 194 |
+
|
| 195 |
+
|
| 196 |
+
Acne Medications | 69
|
| 197 |
+
|
| 198 |
+
--- End of Page 6 ---
|
| 199 |
+
|
| 200 |
+
2. Neutrogena: Harnesses science and nature, offering a gentle yet effective solution for clearer,
|
| 201 |
+
healthier skin.
|
| 202 |
+
|
| 203 |
+
[Chapter_12_Acne_Medications_page7_img1.png]
|
| 204 |
+
|
| 205 |
+
|
| 206 |
+
3. Clean & Clear: Clears the path to radiant skin, banishing blemishes with a refreshing touch.
|
| 207 |
+
|
| 208 |
+
[Chapter_12_Acne_Medications_page7_img2.png]
|
| 209 |
+
|
| 210 |
+
|
| 211 |
+
4. Stridex: Strikes down acne with each swipe, leaving behind a smoother, clearer complexion.
|
| 212 |
+
5. Oxy: Oxygenates pores, combating acne with a powerful, dermatologist-tested formula.
|
| 213 |
+
6. AcneFree: Empowers users with a comprehensive approach to acne, delivering freedom from
|
| 214 |
+
breakouts with its targeted regimen.
|
| 215 |
+
|
| 216 |
+
[Chapter_12_Acne_Medications_page7_img3.png]
|
| 217 |
+
|
| 218 |
+
|
| 219 |
+
70 | Acne Medications
|
| 220 |
+
|
| 221 |
+
--- End of Page 7 ---
|
| 222 |
+
|
| 223 |
+
These brands offer salicylic acid in different formulations and concentrations to suit the needs of
|
| 224 |
+
individuals with varying degrees of skin conditions. It is advisable to consult a healthcare provider or
|
| 225 |
+
dermatologist for proper diagnosis and treatment recommendations before using salicylic acid or any
|
| 226 |
+
other skincare medication.
|
| 227 |
+
FREQUENTLY ASKED QUESTION
|
| 228 |
+
Question: What are some common over-the-counter acne medications?
|
| 229 |
+
Answer: Common over-the-counter acne medications include benzoyl peroxide, salicylic acid, and
|
| 230 |
+
sulfur-based treatments. These medications work by targeting acne-causing bacteria, unclogging pores,
|
| 231 |
+
and reducing inflammation.
|
| 232 |
+
Question: How does benzoyl peroxide work to treat acne?
|
| 233 |
+
Answer: Benzoyl peroxide works by killing acne-causing bacteria on the skin's surface, reducing
|
| 234 |
+
inflammation, and helping to unclog pores. It is available in various strengths, formulations, and
|
| 235 |
+
application methods, such as gels, creams, and washes.
|
| 236 |
+
Question: What is salicylic acid, and how does it help with acne?
|
| 237 |
+
Answer: Salicylic acid is a beta hydroxy acid that exfoliates the skin, helping to unclog pores, reduce
|
| 238 |
+
inflammation, and prevent new acne breakouts. It is commonly found in acne cleansers, toners, and
|
| 239 |
+
spot treatments.
|
| 240 |
+
Question: Are there any potential side effects of using acne medications?
|
| 241 |
+
Answer: Some potential side effects of acne medications include dryness, redness, peeling, irritation,
|
| 242 |
+
and increased sensitivity to sunlight. It's essential to start with lower concentrations and gradually
|
| 243 |
+
increase use to minimize adverse reactions.
|
| 244 |
+
Question: How long does it typically take to see results from acne medications?
|
| 245 |
+
Answer: The time it takes to see results from acne medications varies depending on the severity of
|
| 246 |
+
acne and the chosen treatment. While some people may see improvement within a few weeks, it may
|
| 247 |
+
take several months of consistent use to achieve significant results.
|
| 248 |
+
Question: Can acne medications be used together for better results?
|
| 249 |
+
Answer: Yes, acne medications can often be used together to target different aspects of acne, such as
|
| 250 |
+
bacteria, inflammation, and pore clogging. However, it's essential to use them as directed and consult
|
| 251 |
+
with a healthcare professional to ensure compatibility and effectiveness.
|
| 252 |
+
Question: Are acne medications safe to use during pregnancy or while breastfeeding?
|
| 253 |
+
Answer: Some acne medications, such as topical retinoids and oral antibiotics, may not be safe during
|
| 254 |
+
pregnancy or breastfeeding. It's crucial to consult with a healthcare provider before using any acne
|
| 255 |
+
treatment during these times to ensure the safety of both the mother and the baby.
|
| 256 |
+
Question: What should I do if over-the-counter acne medications aren't effective?
|
| 257 |
+
Answer: If over-the-counter acne medications aren't providing the desired results, it's recommended to
|
| 258 |
+
consult with a dermatologist. They can assess your skin condition, prescribe stronger medications if
|
| 259 |
+
necessary, or recommend alternative treatments, such as prescription-strength retinoids or oral
|
| 260 |
+
medications like isotretinoin.
|
| 261 |
+
Acne Medications | 71
|
| 262 |
+
|
| 263 |
+
--- End of Page 8 ---
|
| 264 |
+
|
MEDICINE_TXT/Chapter_13_Motion_Sickness_Medications.txt
ADDED
|
@@ -0,0 +1,233 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
13
|
| 3 |
+
|
| 4 |
+
Motion Sickness Medications
|
| 5 |
+
Dr. Girish Kumar Vyas
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Motion sickness, also known as travel sickness or kinetosis, is a condition characterized by a
|
| 9 |
+
combination of symptoms such as nausea, vomiting, dizziness, sweating, and general discomfort that
|
| 10 |
+
occurs when an individual is exposed to motion or movement. It commonly arises during travel in
|
| 11 |
+
vehicles such as cars, boats, airplanes, trains, or amusement park rides, but can also occur during other
|
| 12 |
+
activities involving motion, such as virtual reality experiences or swinging on a swing.
|
| 13 |
+
The underlying cause of motion sickness is believed to involve a mismatch between sensory input
|
| 14 |
+
received by the brain from the vestibular system (inner ear), visual system (eyes), and proprioceptive
|
| 15 |
+
system (muscles and joints). When the brain receives conflicting signals from these sensory systems
|
| 16 |
+
regarding the body's position and movement, it can lead to confusion and the development of motion
|
| 17 |
+
sickness symptoms.
|
| 18 |
+
For example, when traveling in a car, the inner ear senses motion, but the eyes may perceive a
|
| 19 |
+
stationary environment, such as reading a book or looking at a smartphone. This discrepancy between
|
| 20 |
+
sensory inputs can trigger motion sickness symptoms in susceptible individuals. Similarly, on a boat or
|
| 21 |
+
airplane, the sensation of motion may not match what the eyes perceive, leading to motion sickness.
|
| 22 |
+
Factors that can increase the likelihood of experiencing motion sickness include:
|
| 23 |
+
1. Individual Sensitivity: Some individuals are more prone to motion sickness than others, with
|
| 24 |
+
susceptibility varying widely among people.
|
| 25 |
+
2. Type of Motion: Certain types of motion, such as rocking or swaying, may be more likely to induce
|
| 26 |
+
motion sickness than others.
|
| 27 |
+
3. Visual Factors: Activities that involve focusing on nearby objects or screens, rather than looking
|
| 28 |
+
into the distance, can exacerbate motion sickness.
|
| 29 |
+
4. Environmental Conditions: Rough seas, turbulent air, or winding roads can increase the severity of
|
| 30 |
+
motion sickness symptoms.
|
| 31 |
+
5. Duration of Exposure: Prolonged exposure to motion, such as on long car rides or boat trips, can
|
| 32 |
+
increase the likelihood of developing motion sickness.
|
| 33 |
+
While motion sickness is typically temporary and resolves once the motion stops, it can cause
|
| 34 |
+
significant discomfort and inconvenience for affected individuals. Management strategies for motion
|
| 35 |
+
sickness include medications, such as antihistamines or scopolamine, as well as non-pharmacological
|
| 36 |
+
approaches like acupressure bands or avoiding triggering activities.
|
| 37 |
+
72 | Motion Sickness Medications
|
| 38 |
+
|
| 39 |
+
--- End of Page 1 ---
|
| 40 |
+
|
| 41 |
+
Motion Sickness Medications:
|
| 42 |
+
Motion sickness medications are pharmaceutical agents used to prevent or alleviate the symptoms of
|
| 43 |
+
motion sickness, a condition characterized by nausea, vomiting, dizziness, and sweating, which can
|
| 44 |
+
occur during motion or travel. These medications work by targeting the underlying mechanisms that
|
| 45 |
+
contribute to motion sickness, such as disturbances in the vestibular system or the central nervous
|
| 46 |
+
system.
|
| 47 |
+
Motion sickness medications can be classified into several categories based on their mechanism of
|
| 48 |
+
action:
|
| 49 |
+
1. Antihistamines: Antihistamines, such as dimenhydrinate (Dramamine), diphenhydramine
|
| 50 |
+
(Benadryl), and meclizine (Bonine, Dramamine Less Drowsy), are commonly used to prevent
|
| 51 |
+
and treat motion sickness. They work by blocking histamine receptors in the brain, reducing
|
| 52 |
+
stimulation of the vestibular system and alleviating symptoms of nausea and vomiting.
|
| 53 |
+
2. Scopolamine: Scopolamine is an anticholinergic medication available in transdermal patch
|
| 54 |
+
form (e.g., Transderm Scop). It works by blocking the action of acetylcholine in the brain,
|
| 55 |
+
thereby reducing vestibular system activity and decreasing motion sickness symptoms. The
|
| 56 |
+
patch is typically applied behind the ear at least 4 hours before travel and provides continuous
|
| 57 |
+
release of medication for up to 3 days.
|
| 58 |
+
3. PhosphorylatedCarbohydrates: Phosphorylated carbohydrates, such
|
| 59 |
+
as ginger and
|
| 60 |
+
acupressure bands, are alternative remedies used to alleviate motion sickness symptoms.
|
| 61 |
+
Ginger is believed to reduce nausea and vomiting by acting on the gastrointestinal tract and
|
| 62 |
+
central nervous system. Acupressure bands apply pressure to specific points on the wrist,
|
| 63 |
+
purportedly reducing nausea and vomiting associated with motion sickness.
|
| 64 |
+
4. PrescriptionMedications: In severe cases of motion sickness, prescription medications such as
|
| 65 |
+
promethazine (Phenergan), ondansetron (Zofran), and scopolamine oral tablets may be
|
| 66 |
+
prescribed. These medications work through various mechanisms to alleviate nausea and
|
| 67 |
+
vomiting, providing relief for individuals who do not respond to over-the-counter remedies.
|
| 68 |
+
Motion sickness medications are commonly used by individuals who experience symptoms during
|
| 69 |
+
travel by car, boat, airplane, or other modes of transportation. It is important to follow the dosing
|
| 70 |
+
instructions provided by healthcare professionals or the product labeling when using these medications
|
| 71 |
+
to ensure safety and efficacy. Additionally, individuals with certain medical conditions or taking other
|
| 72 |
+
medications should consult a healthcare provider before using motion sickness medications to avoid
|
| 73 |
+
potential interactions or adverse effects.
|
| 74 |
+
Motion Sickness Medications | 73
|
| 75 |
+
|
| 76 |
+
--- End of Page 2 ---
|
| 77 |
+
|
| 78 |
+
Introduction to Dimenhydrinate (Dramamine):
|
| 79 |
+
Dimenhydrinate, commonly marketed under the brand name Dramamine, is a medication primarily
|
| 80 |
+
used to prevent and treat motion sickness, including symptoms such as nausea, vomiting, and dizziness
|
| 81 |
+
associated with various forms of motion, such as traveling by car, boat, or airplane. It belongs to the
|
| 82 |
+
class of antihistamines with antiemetic properties, meaning it works by blocking histamine receptors in
|
| 83 |
+
the brain and inner ear, reducing the signals that trigger nausea and vomiting.
|
| 84 |
+
Uses:
|
| 85 |
+
Dimenhydrinate is indicated for the prevention and treatment of motion sickness, including:
|
| 86 |
+
1. Nausea and Vomiting: Dimenhydrinate helps alleviate symptoms of nausea and vomiting
|
| 87 |
+
associated with motion sickness, making it particularly useful for individuals prone to travel-related
|
| 88 |
+
discomfort.
|
| 89 |
+
2. Dizziness and Vertigo: Dimenhydrinate can also help reduce feelings of dizziness and vertigo
|
| 90 |
+
induced by motion, providing relief for those experiencing imbalance or spatial disorientation during
|
| 91 |
+
travel.
|
| 92 |
+
Stability/Storage Conditions:
|
| 93 |
+
Dimenhydrinate products should be stored at room temperature, away from moisture and heat, in a
|
| 94 |
+
tightly closed container. Avoid exposing dimenhydrinate tablets or liquid formulations to direct
|
| 95 |
+
sunlight or extreme temperatures, as this may affect their stability and potency. It is essential to follow
|
| 96 |
+
the specific storage instructions provided with the product to ensure optimal performance.
|
| 97 |
+
Safe Dose for Adults:
|
| 98 |
+
The recommended dose of dimenhydrinate for adults varies depending on the individual's age, weight,
|
| 99 |
+
and the severity of motion sickness symptoms. Typically, for the prevention of motion sickness, adults
|
| 100 |
+
may take 50 to 100 mg of dimenhydrinate orally every 4 to 6 hours as needed, up to a maximum daily
|
| 101 |
+
dose of 400 mg. For the treatment of acute symptoms, a similar dosage regimen can be followed.
|
| 102 |
+
However, it is crucial to consult a healthcare professional for personalized dosing recommendations,
|
| 103 |
+
especially for individuals with underlying medical conditions or taking other medications.
|
| 104 |
+
Marketed Brands:
|
| 105 |
+
Dimenhydrinate is available under various brand names, including but not limited to:
|
| 106 |
+
74 | Motion Sickness Medications
|
| 107 |
+
|
| 108 |
+
--- End of Page 3 ---
|
| 109 |
+
|
| 110 |
+
1. Dramamine: Soothes motion sickness with a gentle touch, calming nausea's turbulent waves,
|
| 111 |
+
ensuring smooth sailing ahead.
|
| 112 |
+
|
| 113 |
+
[Chapter_13_Motion_Sickness_Medications_page4_img1.png]
|
| 114 |
+
|
| 115 |
+
|
| 116 |
+
2. Gravol: Allies against queasiness, offering relief for travelers and unsettled stomachs alike,
|
| 117 |
+
restoring tranquility on the journey.
|
| 118 |
+
|
| 119 |
+
[Chapter_13_Motion_Sickness_Medications_page4_img2.png]
|
| 120 |
+
|
| 121 |
+
|
| 122 |
+
3. Dinate: A trusted aid, easing digestive discomfort with its gentle formula, promoting harmony
|
| 123 |
+
within.
|
| 124 |
+
4. Dimate: Calming the storm within, it provides respite from digestive disturbances, restoring
|
| 125 |
+
equilibrium to the body.
|
| 126 |
+
5. Triptone: Offering serenity amidst turbulence, it quells the tumult of unsettled stomachs,
|
| 127 |
+
bringing peace to troubled waters.
|
| 128 |
+
These brands offer dimenhydrinate in different formulations, such as tablets, chewable tablets, and
|
| 129 |
+
liquid solutions, catering to the diverse preferences and needs of individuals seeking relief from motion
|
| 130 |
+
sickness symptoms. It is advisable to consult a healthcare provider before using dimenhydrinate or any
|
| 131 |
+
other medication, especially if you have any medical conditions or are taking other medications.
|
| 132 |
+
Motion Sickness Medications | 75
|
| 133 |
+
|
| 134 |
+
--- End of Page 4 ---
|
| 135 |
+
|
| 136 |
+
Introduction to Meclizine:
|
| 137 |
+
Meclizine is a medication commonly used to prevent and treat symptoms of motion sickness, vertigo,
|
| 138 |
+
and nausea. It belongs to the class of antihistamines with antiemetic properties, meaning it works by
|
| 139 |
+
blocking histamine receptors in the brain, particularly in the vestibular system, which controls balance
|
| 140 |
+
and spatial orientation. Meclizine is often prescribed or available over-the-counter under various brand
|
| 141 |
+
names for the relief of motion sickness and related symptoms.
|
| 142 |
+
Uses:
|
| 143 |
+
Meclizine is indicated for the prevention and treatment of several conditions, including:
|
| 144 |
+
1. Motion Sickness: Meclizine is highly effective in preventing and alleviating symptoms of motion
|
| 145 |
+
sickness, such as nausea, vomiting, and dizziness, associated with various forms of travel, including
|
| 146 |
+
car rides, boat trips, and airplane flights.
|
| 147 |
+
2. Vertigo: Meclizine is also used to manage vertigo, a sensation of spinning or dizziness, often
|
| 148 |
+
associated with inner ear disorders such as benign paroxysmal positional vertigo (BPPV) or
|
| 149 |
+
labyrinthitis.
|
| 150 |
+
3. Nausea and Vomiting: Meclizine can help reduce symptoms of nausea and vomiting caused by
|
| 151 |
+
motion sickness or other factors, providing relief for individuals experiencing gastrointestinal
|
| 152 |
+
discomfort.
|
| 153 |
+
Stability/Storage Conditions:
|
| 154 |
+
Meclizine products should be stored at room temperature, away from moisture and heat, in a tightly
|
| 155 |
+
closed container. Avoid exposing meclizine tablets or liquid formulations to direct sunlight or extreme
|
| 156 |
+
temperatures, as this may affect their stability and potency. It is important to follow the specific storage
|
| 157 |
+
instructions provided with the product to ensure optimal performance.
|
| 158 |
+
Safe Dose for Adults:
|
| 159 |
+
The recommended dose of meclizine for adults varies depending on the individual's age, weight, and
|
| 160 |
+
the severity of symptoms. Typically, for the prevention of motion sickness, adults may take 25 to 50
|
| 161 |
+
mg of meclizine orally one hour before travel, with a maximum daily dose of 100 mg. For the
|
| 162 |
+
treatment of acute symptoms, a similar dosage regimen can be followed. However, it is crucial to
|
| 163 |
+
consult a healthcare professional for personalized dosing recommendations, especially for individuals
|
| 164 |
+
with underlying medical conditions or taking other medications.
|
| 165 |
+
Marketed Brands:
|
| 166 |
+
1. Dramamine Less Drowsy: Sail through your travels with confidence using Dramamine Less
|
| 167 |
+
Drowsy, providing effective motion sickness relief without the unwanted side effects of drowsiness.
|
| 168 |
+
76 | Motion Sickness Medications
|
| 169 |
+
|
| 170 |
+
--- End of Page 5 ---
|
| 171 |
+
|
| 172 |
+
2. Bonine: Enjoy every moment of your adventure without the distraction of motion sickness, thanks to
|
| 173 |
+
Bonine's reliable and non-drowsy formula.
|
| 174 |
+
|
| 175 |
+
[Chapter_13_Motion_Sickness_Medications_page6_img1.png]
|
| 176 |
+
|
| 177 |
+
|
| 178 |
+
3. Antivert: Whether it's a road trip or a cruise, trust Antivert to keep motion sickness at bay, allowing
|
| 179 |
+
you to focus on the journey ahead.
|
| 180 |
+
|
| 181 |
+
[Chapter_13_Motion_Sickness_Medications_page6_img2.png]
|
| 182 |
+
|
| 183 |
+
|
| 184 |
+
4. Meclizine HCI: Find relief from nausea and dizziness with Meclizine HCI, a trusted remedy for
|
| 185 |
+
motion sickness that lets you stay alert and active.
|
| 186 |
+
5. Meclozine: Take control of motion sickness with Meclozine, providing fast-acting relief so you can
|
| 187 |
+
stay on course and enjoy the ride without interruption.
|
| 188 |
+
These brands offer meclizine in different formulations, such as tablets, chewable tablets, and liquid
|
| 189 |
+
solutions, catering to the diverse preferences and needs of individuals seeking relief from motion
|
| 190 |
+
sickness, vertigo, and related symptoms. It is advisable to consult a healthcare provider before using
|
| 191 |
+
meclizine or any other medication, especially if you have any medical conditions or are taking other
|
| 192 |
+
medications.
|
| 193 |
+
|
| 194 |
+
Motion Sickness Medications | 77
|
| 195 |
+
|
| 196 |
+
--- End of Page 6 ---
|
| 197 |
+
|
| 198 |
+
FREQUENTLY ASKED QUESTION
|
| 199 |
+
Question: What are motion sickness medications?
|
| 200 |
+
Answer: Motion sickness medications are treatments used to alleviate symptoms of motion sickness,
|
| 201 |
+
including nausea, vomiting, dizziness, and sweating, caused by motion or movement.
|
| 202 |
+
Question: How do motion sickness medications work?
|
| 203 |
+
Answer: Motion sickness medications work by acting on the inner ear or the central nervous system to
|
| 204 |
+
reduce sensory input and minimize the mismatch between visual and vestibular signals that contribute
|
| 205 |
+
to motion sickness symptoms.
|
| 206 |
+
Question: What are some common examples of motion sickness medications?
|
| 207 |
+
Answer: Common examples of motion sickness medications include dimenhydrinate (Dramamine),
|
| 208 |
+
meclizine (Bonine), scopolamine patches, and ginger supplements.
|
| 209 |
+
Question: When should motion sickness medications be used?
|
| 210 |
+
Answer: Motion sickness medications should be used before exposure to motion or travel, such as
|
| 211 |
+
before boarding a boat, plane, car, or amusement park ride, to prevent or alleviate symptoms of motion
|
| 212 |
+
sickness.
|
| 213 |
+
Question: Can motion sickness medications be used with other medications?
|
| 214 |
+
Answer: Motion sickness medications can generally be used with other medications, but it's essential
|
| 215 |
+
to consult with a healthcare professional or pharmacist to avoid potential interactions, especially if you
|
| 216 |
+
have underlying health conditions or are taking other medications.
|
| 217 |
+
Question: Do motion sickness medications have any side effects?
|
| 218 |
+
Answer: Common side effects of motion sickness medications may include drowsiness, dry mouth,
|
| 219 |
+
blurred vision, constipation, or urinary retention, especially with antihistamine-based medications like
|
| 220 |
+
dimenhydrinate.
|
| 221 |
+
Question: Can motion sickness medications be used for other conditions?
|
| 222 |
+
Answer: While motion sickness medications are primarily used to prevent or alleviate symptoms of
|
| 223 |
+
motion sickness, certain medications, such as meclizine, may also be used to manage symptoms of
|
| 224 |
+
vertigo or dizziness associated with inner ear disorders.
|
| 225 |
+
Question: Are there any lifestyle changes that can help reduce the need for motion sickness
|
| 226 |
+
medications?
|
| 227 |
+
Answer: Yes, avoiding triggers of motion sickness, such as reading while in motion, sitting in the front
|
| 228 |
+
seat of a vehicle, focusing on a fixed point in the distance, staying hydrated, and avoiding heavy or
|
| 229 |
+
greasy meals before travel, can help reduce the risk of motion sickness and the need for medications.
|
| 230 |
+
78 | Motion Sickness Medications
|
| 231 |
+
|
| 232 |
+
--- End of Page 7 ---
|
| 233 |
+
|
MEDICINE_TXT/Chapter_14_Anti_Diarrheals.txt
ADDED
|
@@ -0,0 +1,183 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
14
|
| 3 |
+
|
| 4 |
+
Anti-Diarrheal
|
| 5 |
+
Dr. Nitin Nama
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Diarrhea is a common gastrointestinal condition characterized by frequent, loose, and watery bowel
|
| 9 |
+
movements. It occurs when the intestines fail to adequately absorb fluid or when excess fluid is
|
| 10 |
+
secreted into the bowel, resulting in the passage of loose or liquid stools. Diarrhea can be acute, lasting
|
| 11 |
+
for a short duration, or chronic, persisting for weeks or months. It is often accompanied by symptoms
|
| 12 |
+
such as abdominal cramps, bloating, urgency, and nausea.
|
| 13 |
+
Diarrhea can have various causes, including:
|
| 14 |
+
1. Infections: Viral, bacterial, or parasitic infections of the gastrointestinal tract, such as norovirus,
|
| 15 |
+
Salmonella, Escherichia coli (E. coli), or Giardia, can lead to acute infectious diarrhea.
|
| 16 |
+
2. Food Poisoning: Consuming contaminated food or water containing harmful bacteria, viruses, or
|
| 17 |
+
toxins can result in foodborne illness and acute diarrhea.
|
| 18 |
+
3. Medications: Certain medications, such as antibiotics, laxatives, and some cancer treatments, can
|
| 19 |
+
disrupt the balance of gut bacteria or stimulate bowel movements, leading to diarrhea as a side effect.
|
| 20 |
+
4. Dietary Factors: Excessive consumption of certain foods or beverages, such as spicy foods, dairy
|
| 21 |
+
products, caffeine, or artificial sweeteners, can irritate the digestive tract and trigger diarrhea.
|
| 22 |
+
5. Underlying Conditions: Chronic diarrhea may be a symptom of underlying medical conditions,
|
| 23 |
+
including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, lactose
|
| 24 |
+
intolerance, or gastrointestinal infections.
|
| 25 |
+
Anti-diarrheal medications are pharmaceutical agents used to alleviate symptoms of diarrhea by
|
| 26 |
+
slowing down the movement of the intestines, reducing fluid secretion, and increasing the absorption
|
| 27 |
+
of water and electrolytes. These medications help restore normal bowel function, decrease stool
|
| 28 |
+
frequency, and provide relief from diarrhea-related discomfort.
|
| 29 |
+
Common types of anti-diarrheal medications include:
|
| 30 |
+
1. Loperamide (Imodium): Loperamide is an opioid receptor agonist that acts directly on the
|
| 31 |
+
intestinal muscles to slow down bowel movements and increase stool consistency. It is available over-
|
| 32 |
+
the-counter and by prescription in various formulations, including tablets, capsules, and liquid
|
| 33 |
+
solutions.
|
| 34 |
+
Anti-Diarrheals | 79
|
| 35 |
+
|
| 36 |
+
--- End of Page 1 ---
|
| 37 |
+
|
| 38 |
+
2. Bismuth Subsalicylate: Bismuth subsalicylate is an antacid and anti-inflammatory agent that coats
|
| 39 |
+
the gastrointestinal tract, reducing inflammation and absorption of fluid and toxins. It is commonly
|
| 40 |
+
found in over-the-counter medications such as Pepto-Bismol.
|
| 41 |
+
|
| 42 |
+
[Chapter_14_Anti_Diarrheals_page2_img1.png]
|
| 43 |
+
|
| 44 |
+
|
| 45 |
+
3. Diphenoxylate/Atropine (Lomotil): Diphenoxylate is an opioid receptor agonist similar to
|
| 46 |
+
loperamide, while atropine is included to discourage misuse and overdose. This combination
|
| 47 |
+
medication slows intestinal motility and reduces diarrhea symptoms.
|
| 48 |
+
|
| 49 |
+
[Chapter_14_Anti_Diarrheals_page2_img2.png]
|
| 50 |
+
|
| 51 |
+
|
| 52 |
+
4. Codeine: Codeine, an opioid analgesic, can also be used as an anti-diarrheal agent by slowing down
|
| 53 |
+
bowel movements and increasing absorption in the intestines. However, due to its potential for
|
| 54 |
+
dependence and respiratory depression, it is less commonly prescribed for diarrhea.
|
| 55 |
+
|
| 56 |
+
[Chapter_14_Anti_Diarrheals_page2_img3.png]
|
| 57 |
+
|
| 58 |
+
|
| 59 |
+
Anti-diarrheal medications are generally safe when used as directed but should not be used for
|
| 60 |
+
prolonged periods without medical supervision, especially in cases of infectious diarrhea or underlying
|
| 61 |
+
medical conditions. It is essential to consult a healthcare professional before using anti-diarrheals,
|
| 62 |
+
especially if you have severe diarrhea, fever, blood in stools, or other concerning symptoms.
|
| 63 |
+
80 | Anti-Diarrheals
|
| 64 |
+
|
| 65 |
+
--- End of Page 2 ---
|
| 66 |
+
|
| 67 |
+
Introduction to Loperamide (Imodium):
|
| 68 |
+
Loperamide, commonly marketed under the brand name Imodium, is a medication primarily used to
|
| 69 |
+
treat diarrhea, including acute diarrhea and chronic diarrhea associated with conditions such as irritable
|
| 70 |
+
bowel syndrome (IBS) and inflammatory bowel disease (IBD). It belongs to the class of medications
|
| 71 |
+
known as antidiarrheals, which work by slowing down the movement of the intestines and reducing the
|
| 72 |
+
frequency and volume of bowel movements. Loperamide is available over-the-counter and by
|
| 73 |
+
prescription in various formulations, including tablets, capsules, and liquid solutions.
|
| 74 |
+
Uses:
|
| 75 |
+
Loperamide is indicated for the treatment of several conditions related to diarrhea, including:
|
| 76 |
+
1. Acute Diarrhea: Loperamide is highly effective in reducing the frequency and severity of acute
|
| 77 |
+
diarrhea episodes caused by viral or bacterial infections, food poisoning, or other gastrointestinal
|
| 78 |
+
disturbances.
|
| 79 |
+
2. Chronic Diarrhea: Loperamide can also be used to manage chronic diarrhea associated with
|
| 80 |
+
conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or other
|
| 81 |
+
gastrointestinal disorders, providing relief from frequent and watery stools.
|
| 82 |
+
3. Traveler's Diarrhea: Loperamide is commonly used as a preventive measure or treatment for
|
| 83 |
+
traveler'sdiarrhea, a condition caused by consuming contaminated food or water during travel to
|
| 84 |
+
foreign countries or regions with poor sanitation.
|
| 85 |
+
Stability/Storage Conditions:
|
| 86 |
+
Loperamide products should be stored at room temperature, away from moisture and heat, in a tightly
|
| 87 |
+
closed container. Avoid exposing loperamide tablets or liquid formulations to direct sunlight or
|
| 88 |
+
extreme temperatures, as this may affect their stability and potency. It is important to follow the
|
| 89 |
+
specific storage instructions provided with the product to ensure optimal performance.
|
| 90 |
+
Safe Dose for Adults:
|
| 91 |
+
The recommended dose of loperamide for adults varies depending on the individual's age, weight, and
|
| 92 |
+
the severity of diarrhea symptoms. Typically, for the treatment of acute diarrhea, adults may take an
|
| 93 |
+
initial dose of 4 mg (two tablets or capsules) followed by 2 mg (one tablet or capsule) after each loose
|
| 94 |
+
stool, with a maximum daily dose of 16 mg. For the management of chronic diarrhea, a similar dosage
|
| 95 |
+
regimen can be followed, but it is essential to consult a healthcare professional for personalized dosing
|
| 96 |
+
recommendations, especially for individuals with underlying medical conditions or taking other
|
| 97 |
+
medications.
|
| 98 |
+
|
| 99 |
+
Anti-Diarrheals | 81
|
| 100 |
+
|
| 101 |
+
--- End of Page 3 ---
|
| 102 |
+
|
| 103 |
+
Marketed Brands:
|
| 104 |
+
Loperamide is available under various brand names, including but not limited to:
|
| 105 |
+
1. Imodium: Tackle that upset stomach swiftly with Imodium, your reliable companion for on-
|
| 106 |
+
the-go relief from diarrhea.
|
| 107 |
+
|
| 108 |
+
[Chapter_14_Anti_Diarrheals_page4_img1.png]
|
| 109 |
+
|
| 110 |
+
|
| 111 |
+
2. Kaopectate Anti-Diarrheal: When unexpected discomfort strikes, trust Kaopectate Anti-
|
| 112 |
+
Diarrheal for fast-acting relief and gentle support for your digestive system.
|
| 113 |
+
|
| 114 |
+
[Chapter_14_Anti_Diarrheals_page4_img2.png]
|
| 115 |
+
|
| 116 |
+
|
| 117 |
+
3. Diamode: Don't let diarrhea derail your plans; keep Diamode handy for effective relief and get
|
| 118 |
+
back to feeling your best in no time.
|
| 119 |
+
|
| 120 |
+
[Chapter_14_Anti_Diarrheals_page4_img3.png]
|
| 121 |
+
|
| 122 |
+
|
| 123 |
+
82 | Anti-Diarrheals
|
| 124 |
+
|
| 125 |
+
--- End of Page 4 ---
|
| 126 |
+
|
| 127 |
+
4. Pepto Diarrhea Control: Experience relief you can count on with Pepto Diarrhea Control,
|
| 128 |
+
offering fast and soothing action for those inconvenient moments.
|
| 129 |
+
|
| 130 |
+
[Chapter_14_Anti_Diarrheals_page5_img1.png]
|
| 131 |
+
|
| 132 |
+
|
| 133 |
+
5. Lopex: Say goodbye to discomfort with Lopex, your go-to solution for rapid relief from
|
| 134 |
+
diarrhea, allowing you to seize the day with confidence.
|
| 135 |
+
|
| 136 |
+
[Chapter_14_Anti_Diarrheals_page5_img2.png]
|
| 137 |
+
|
| 138 |
+
|
| 139 |
+
These brands offer loperamide in different formulations, such as tablets, capsules, and liquid solutions,
|
| 140 |
+
catering to the diverse preferences and needs of individuals seeking relief from acute or chronic
|
| 141 |
+
diarrhea. It is advisable to consult a healthcare provider before using loperamide or any other
|
| 142 |
+
medication, especially if you have any medical conditions or are taking other medications.
|
| 143 |
+
FREQUENTLY ASKED QUESTIONS
|
| 144 |
+
Question: What are anti-diarrheals?
|
| 145 |
+
Answer: Anti-diarrheals are medications used to alleviate symptoms of diarrhea by slowing down
|
| 146 |
+
bowel movements and reducing the frequency and liquidity of stools.
|
| 147 |
+
Question: How do anti-diarrheals work?
|
| 148 |
+
Answer: Anti-diarrheals work through various mechanisms, including slowing down intestinal
|
| 149 |
+
motility, increasing water absorption from the intestines, and reducing inflammation in the digestive
|
| 150 |
+
tract.
|
| 151 |
+
Question: What are some common examples of anti-diarrheals?
|
| 152 |
+
Answer: Common examples of anti-diarrheal medications include loperamide (Imodium), bismuth
|
| 153 |
+
subsalicylate (Pepto-Bismol), and diphenoxylate/atropine (Lomotil).
|
| 154 |
+
Anti-Diarrheals | 83
|
| 155 |
+
|
| 156 |
+
--- End of Page 5 ---
|
| 157 |
+
|
| 158 |
+
Question: When should anti-diarrheals be used?
|
| 159 |
+
Answer: Anti-diarrheals should be used to treat acute episodes of diarrhea, such as those caused by
|
| 160 |
+
viral infections, bacterial infections, or dietary indiscretions, as well as to alleviate symptoms of
|
| 161 |
+
chronic diarrhea associated with conditions such as irritable bowel syndrome (IBS) or inflammatory
|
| 162 |
+
bowel disease (IBD).
|
| 163 |
+
Question: Can anti-diarrheals be used with other medications?
|
| 164 |
+
Answer: Anti-diarrheals can generally be used with other medications, but it's essential to consult with
|
| 165 |
+
a healthcare professional or pharmacist to avoid potential interactions, especially if you have
|
| 166 |
+
underlying health conditions or are taking other medications.
|
| 167 |
+
Question: Do anti-diarrheals have any side effects?
|
| 168 |
+
Answer: Common side effects of anti-diarrheal medications may include constipation, bloating,
|
| 169 |
+
abdominal cramps, nausea, or dizziness. Serious side effects are rare but may include toxic megacolon
|
| 170 |
+
or paralytic ileus, especially with prolonged or excessive use.
|
| 171 |
+
Question: Can anti-diarrheals be used for other conditions?
|
| 172 |
+
Answer: While anti-diarrheals are primarily used to treat diarrhea, certain medications, such as
|
| 173 |
+
bismuth subsalicylate, may also be used to alleviate symptoms of indigestion, heartburn, or nausea.
|
| 174 |
+
Question: Are there any lifestyle changes that can help reduce the need for anti-diarrheals?
|
| 175 |
+
Answer: Yes, staying hydrated, following a bland diet, avoiding foods and beverages that can
|
| 176 |
+
exacerbate diarrhea (such as caffeine, dairy products, and fatty or spicy foods), practicing good
|
| 177 |
+
hygiene, and managing stress levels can help reduce the risk of diarrhea and the need for anti-diarrheal
|
| 178 |
+
medications.
|
| 179 |
+
|
| 180 |
+
84 | Anti-Diarrheals
|
| 181 |
+
|
| 182 |
+
--- End of Page 6 ---
|
| 183 |
+
|
MEDICINE_TXT/Chapter_15_Oral_Rehydration_Solutions.txt
ADDED
|
@@ -0,0 +1,242 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
15
|
| 3 |
+
|
| 4 |
+
Oral Rehydration Solutions
|
| 5 |
+
Dr. Harshita Jain
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Hydration: Hydration refers to the process of maintaining adequate fluid balance in the body by
|
| 9 |
+
consuming enough water and electrolytes to meet the body's needs. Water is essential for various
|
| 10 |
+
physiological functions, including regulating body temperature, transporting nutrients and waste
|
| 11 |
+
products, lubricating joints, and supporting cellular function. Adequate hydration is crucial for overall
|
| 12 |
+
health and well-being.
|
| 13 |
+
Factors that influence hydration include fluid intake, fluid loss through urine, sweat, and respiration, as
|
| 14 |
+
well as environmental conditions such as temperature and humidity. Dehydration can occur when fluid
|
| 15 |
+
loss exceeds fluid intake, leading to an imbalance in body fluids and electrolytes. It is important to
|
| 16 |
+
maintain proper hydration levels by drinking fluids regularly, especially during physical activity, hot
|
| 17 |
+
weather, illness, or other situations that increase fluid loss.
|
| 18 |
+
Dehydration: Dehydration occurs when the body loses more fluids and electrolytes than it takes in,
|
| 19 |
+
resulting in an imbalance in body fluids and electrolyte concentrations. This can lead to various
|
| 20 |
+
symptoms and health complications, ranging from mild to severe, depending on the degree of
|
| 21 |
+
dehydration and the underlying cause. Symptoms of dehydration may include thirst, dry mouth, dark-
|
| 22 |
+
colored urine, fatigue, dizziness, confusion, rapid heartbeat, and reduced urine output.
|
| 23 |
+
|
| 24 |
+
[Chapter_15_Oral_Rehydration_Solutions_page1_img1.png]
|
| 25 |
+
|
| 26 |
+
|
| 27 |
+
Causes of dehydration may include inadequate fluid intake, excessive sweating, vomiting, diarrhea,
|
| 28 |
+
fever, prolonged exposure to hot or dry environments, and certain medical conditions such as diabetes
|
| 29 |
+
Oral Rehydration Solutions | 85
|
| 30 |
+
|
| 31 |
+
--- End of Page 1 ---
|
| 32 |
+
|
| 33 |
+
or kidney disease. Prompt recognition and treatment of dehydration are essential to prevent
|
| 34 |
+
complications and restore fluid balance in the body.
|
| 35 |
+
Rehydration: Rehydration is the process of replenishing fluid and electrolyte levels in the body to
|
| 36 |
+
restore proper hydration status. It involves consuming fluids and electrolytes to replace those lost
|
| 37 |
+
through sweating, urination, vomiting, diarrhea, or other causes of dehydration. Rehydration is
|
| 38 |
+
essential for maintaining normal bodily functions and preventing complications associated with
|
| 39 |
+
dehydration.
|
| 40 |
+
Methods of rehydration may include drinking water, oral rehydration solutions (ORS), consuming
|
| 41 |
+
electrolyte-rich beverages (such as sports drinks), and, in severe cases of dehydration, receiving
|
| 42 |
+
intravenous fluids administered by healthcare professionals. The choice of rehydration method depends
|
| 43 |
+
on the severity of dehydration, the underlying cause, and the individual's overall health condition.
|
| 44 |
+
Oral rehydration solutions (ORS):Oral rehydration solutions (ORS) are specially formulated
|
| 45 |
+
solutions containing a precise balance of water, sugars (such as glucose or sucrose), and electrolytes
|
| 46 |
+
(such as sodium, potassium, and chloride). ORS are designed to rapidly replenish fluids and
|
| 47 |
+
electrolytes lost during diarrhea, vomiting, or excessive sweating, helping to prevent or treat
|
| 48 |
+
dehydration.
|
| 49 |
+
ORS are typically recommended for individuals with mild to moderate dehydration, especially children
|
| 50 |
+
and adults with acute diarrhea caused by infections or other gastrointestinal conditions. They are
|
| 51 |
+
available over-the-counter and come in pre-packaged sachets or ready-to-use liquid form. ORS are
|
| 52 |
+
easy to administer and are generally safe and effective when used as directed.
|
| 53 |
+
ORS work by facilitating the absorption of water and electrolytes in the intestines, promoting fluid
|
| 54 |
+
retention and restoring proper hydration status. They are a cost-effective and lifesaving intervention for
|
| 55 |
+
preventing dehydration-related complications, particularly in resource-limited settings and during
|
| 56 |
+
outbreaks of diarrheal diseases. It is essential to follow the instructions for preparing and administering
|
| 57 |
+
ORS correctly, especially in cases involving infants, children, or individuals with severe dehydration
|
| 58 |
+
or other medical conditions.
|
| 59 |
+
Electrolyte Solutions for Dehydration
|
| 60 |
+
Dehydration is a common condition characterized by an inadequate intake or excessive loss of fluids
|
| 61 |
+
and electrolytes from the body. It can occur due to various factors such as diarrhea, vomiting,
|
| 62 |
+
excessive sweating, fever, or inadequate fluid intake. Electrolyte solutions are specifically formulated
|
| 63 |
+
to replenish fluids and essential electrolytes lost during dehydration, restoring proper hydration status
|
| 64 |
+
and electrolyte balance.
|
| 65 |
+
86 | Oral Rehydration Solutions
|
| 66 |
+
|
| 67 |
+
--- End of Page 2 ---
|
| 68 |
+
|
| 69 |
+
Composition of Electrolyte Solutions:
|
| 70 |
+
Electrolyte solutions typically contain a precise balance of water, electrolytes, and carbohydrates to
|
| 71 |
+
facilitate rapid rehydration and electrolyte replacement. Key components of electrolyte solutions
|
| 72 |
+
include:
|
| 73 |
+
1. Water: Water serves as the solvent for electrolytes and facilitates the absorption and distribution of
|
| 74 |
+
nutrients and electrolytes throughout the body.
|
| 75 |
+
2. Electrolytes: Electrolytes are minerals with an electric charge that play crucial roles in maintaining
|
| 76 |
+
fluid balance, regulating nerve and muscle function, and supporting various physiological processes.
|
| 77 |
+
Common electrolytes found in electrolyte solutions include:
|
| 78 |
+
- Sodium (Na+)
|
| 79 |
+
- Potassium (K+)
|
| 80 |
+
- Chloride (Cl-)
|
| 81 |
+
- Bicarbonate (HCO3-)
|
| 82 |
+
- Magnesium (Mg2+)
|
| 83 |
+
- Calcium (Ca2+)
|
| 84 |
+
These electrolytes are essential for maintaining proper hydration, nerve conduction, muscle
|
| 85 |
+
contraction, and acid-base balance in the body.
|
| 86 |
+
3. Carbohydrates: Carbohydrates, such as glucose or sucrose, are often included in electrolyte
|
| 87 |
+
solutions to provide a source of energy and facilitate the absorption of water and electrolytes in the
|
| 88 |
+
intestines.
|
| 89 |
+
Types of Electrolyte Solutions:
|
| 90 |
+
There are several types of electrolyte solutions available for the management of dehydration, each
|
| 91 |
+
tailored to specific needs and clinical situations:
|
| 92 |
+
1. Oral Rehydration Solutions (ORS): ORS are specially formulated solutions containing water,
|
| 93 |
+
electrolytes, and carbohydrates designed to prevent and treat dehydration caused by diarrhea, vomiting,
|
| 94 |
+
or excessive sweating. They are available in standard, reduced osmolarity, hypotonic, and rice-based
|
| 95 |
+
formulations, providing options for different age groups and clinical scenarios.
|
| 96 |
+
2. Intravenous (IV) Fluids: IV fluids are administered directly into the bloodstream through a vein,
|
| 97 |
+
providing rapid hydration and electrolyte replacement in cases of severe dehydration or inability to
|
| 98 |
+
tolerate oral fluids. IV fluids may contain various electrolyte concentrations, such as normal saline
|
| 99 |
+
(0.9% sodium chloride), lactated Ringer's solution, or dextrose-containing solutions, depending on the
|
| 100 |
+
patient's condition and fluid needs.
|
| 101 |
+
Oral Rehydration Solutions | 87
|
| 102 |
+
|
| 103 |
+
--- End of Page 3 ---
|
| 104 |
+
|
| 105 |
+
3. Pediatric Electrolyte Solutions:Pediatric electrolyte solutions are specifically formulated for
|
| 106 |
+
infants and children to address their unique fluid and electrolyte requirements. These solutions are
|
| 107 |
+
available in various flavors and concentrations to improve palatability and compliance in pediatric
|
| 108 |
+
patients.
|
| 109 |
+
4. Sports Drinks: Sports drinks contain water, electrolytes (mainly sodium and potassium), and
|
| 110 |
+
carbohydrates (e.g., glucose, sucrose) and are designed to replenish fluids and electrolytes lost during
|
| 111 |
+
physical activity or exercise. While not typically used for medical rehydration purposes, sports drinks
|
| 112 |
+
may be beneficial for mild dehydration in individuals engaging in strenuous physical activities.
|
| 113 |
+
Uses of Electrolyte Solutions:
|
| 114 |
+
Electrolyte solutions are used for various purposes in the management of dehydration, including:
|
| 115 |
+
Prevention and Treatment of Dehydration: Electrolyte solutions, particularly ORS, are used to
|
| 116 |
+
prevent and treat dehydration caused by diarrhea, vomiting, fever, or excessive sweating. They help
|
| 117 |
+
restore fluid and electrolyte balance, alleviate symptoms, and prevent complications associated with
|
| 118 |
+
dehydration.
|
| 119 |
+
Management of Gastrointestinal Conditions: Electrolyte solutions are beneficial in managing
|
| 120 |
+
gastrointestinal conditions such as gastroenteritis, food poisoning, inflammatory bowel disease (IBD),
|
| 121 |
+
and irritable bowel syndrome (IBS), which can lead to fluid and electrolyte imbalances.
|
| 122 |
+
Rehydration During Illness: Electrolyte solutions are essential for rehydrating individuals who are
|
| 123 |
+
unable to tolerate solid foods or oral fluids due to illness, surgery, or medical procedures. They provide
|
| 124 |
+
a safe and effective way to deliver fluids and electrolytes directly into the body, promoting recovery
|
| 125 |
+
and preventing complications.
|
| 126 |
+
Electrolyte solutions play a critical role in the management of dehydration by replenishing fluids and
|
| 127 |
+
essential electrolytes lost during various clinical conditions. Whether administered orally or
|
| 128 |
+
intravenously, these solutions provide rapid rehydration, restore electrolyte balance, and support
|
| 129 |
+
overall health and well-being. It is essential to use electrolyte solutions appropriately, under the
|
| 130 |
+
guidance of healthcare professionals, to ensure optimal hydration and prevent complications associated
|
| 131 |
+
with dehydration.
|
| 132 |
+
Marketed Brands:
|
| 133 |
+
1. Pedialyte: Pedialyte is a popular ORS formulation designed for infants, children, and adults to
|
| 134 |
+
prevent dehydration caused by diarrhea, vomiting, or fever.
|
| 135 |
+
88 | Oral Rehydration Solutions
|
| 136 |
+
|
| 137 |
+
--- End of Page 4 ---
|
| 138 |
+
|
| 139 |
+
|
| 140 |
+
[Chapter_15_Oral_Rehydration_Solutions_page5_img1.png]
|
| 141 |
+
|
| 142 |
+
|
| 143 |
+
2. Gatorade: Gatorade is a sports drink that serves as an ORS for rehydrating individuals
|
| 144 |
+
engaged in strenuous physical activities or exercise.
|
| 145 |
+
|
| 146 |
+
[Chapter_15_Oral_Rehydration_Solutions_page5_img2.png]
|
| 147 |
+
|
| 148 |
+
|
| 149 |
+
3. DripDrop ORS:DripDrop ORS is a medical-grade oral rehydration solution formulated to
|
| 150 |
+
rapidly replenish fluids and electrolytes lost during dehydration.
|
| 151 |
+
|
| 152 |
+
[Chapter_15_Oral_Rehydration_Solutions_page5_img3.png]
|
| 153 |
+
|
| 154 |
+
|
| 155 |
+
Oral Rehydration Solutions | 89
|
| 156 |
+
|
| 157 |
+
--- End of Page 5 ---
|
| 158 |
+
|
| 159 |
+
4. Enfalyte:Enfalyte is an ORS specifically designed for infants and young children to prevent
|
| 160 |
+
and treat dehydration caused by diarrhea, vomiting, or fever.
|
| 161 |
+
|
| 162 |
+
[Chapter_15_Oral_Rehydration_Solutions_page6_img1.png]
|
| 163 |
+
|
| 164 |
+
|
| 165 |
+
5. Oral Rehydration Salts (ORS): ORS packets are pre-packaged formulations containing a
|
| 166 |
+
precise mixture of electrolytes and glucose in powder form, widely used in both clinical and
|
| 167 |
+
home settings.
|
| 168 |
+
|
| 169 |
+
[Chapter_15_Oral_Rehydration_Solutions_page6_img2.png]
|
| 170 |
+
|
| 171 |
+
|
| 172 |
+
6. CeraLyte:CeraLyte is an ORS formulation containing electrolytes such as sodium, potassium,
|
| 173 |
+
and chloride, as well as rice-based carbohydrates for improved absorption and tolerance.
|
| 174 |
+
|
| 175 |
+
[Chapter_15_Oral_Rehydration_Solutions_page6_img3.png]
|
| 176 |
+
|
| 177 |
+
|
| 178 |
+
|
| 179 |
+
7. Hydralyte:Hydralyte is an ORS solution available in various formats, including ready-to-drink
|
| 180 |
+
liquids, effervescent tablets, and ice blocks, suitable for adults and children.
|
| 181 |
+
90 | Oral Rehydration Solutions
|
| 182 |
+
|
| 183 |
+
--- End of Page 6 ---
|
| 184 |
+
|
| 185 |
+
|
| 186 |
+
8. ReVital Electrolyte Solution: ReVital Electrolyte Solution is an ORS designed to restore
|
| 187 |
+
hydration and electrolyte balance in individuals with dehydration caused by diarrhea, vomiting,
|
| 188 |
+
or excessive sweating.
|
| 189 |
+
|
| 190 |
+
9. ORS-L: ORS-L is a low-osmolarity oral rehydration solution containing a reduced
|
| 191 |
+
concentration of glucose and electrolytes, suitable for preventing dehydration in children and
|
| 192 |
+
adults.
|
| 193 |
+
|
| 194 |
+
[Chapter_15_Oral_Rehydration_Solutions_page7_img1.png]
|
| 195 |
+
|
| 196 |
+
|
| 197 |
+
|
| 198 |
+
10. World Health Organization (WHO) Oral Rehydration Solution: The WHO Oral
|
| 199 |
+
Rehydration Solution is a standard ORS formulation recommended by the World Health
|
| 200 |
+
Organization for the treatment of dehydration caused by diarrhea in children and adults
|
| 201 |
+
worldwide.
|
| 202 |
+
FREQUENTLY ASKED QUESTIONS
|
| 203 |
+
Question: What are oral rehydration solutions (ORS)?
|
| 204 |
+
Answer: Oral rehydration solutions (ORS) are specially formulated fluids containing electrolytes and
|
| 205 |
+
carbohydrates designed to replenish fluids and electrolytes lost during episodes of dehydration,
|
| 206 |
+
particularly due to diarrhea or vomiting.
|
| 207 |
+
Question: How do oral rehydration solutions work?
|
| 208 |
+
Answer: ORS works by replacing lost fluids and electrolytes, such as sodium, potassium, and glucose,
|
| 209 |
+
to restore the body's electrolyte balance and promote rehydration.
|
| 210 |
+
Question: What are some common examples of oral rehydration solutions?
|
| 211 |
+
Answer: Common examples of oral rehydration solutions include commercially available products
|
| 212 |
+
such as Pedialyte, Rehydralyte, and Infalyte, as well as homemade solutions made with ingredients like
|
| 213 |
+
salt, sugar, and water.
|
| 214 |
+
Question: When should oral rehydration solutions be used?
|
| 215 |
+
Answer: ORS should be used to prevent or treat dehydration caused by conditions such as diarrhea,
|
| 216 |
+
vomiting, excessive sweating, or fever, especially in infants, young children, or individuals at risk of
|
| 217 |
+
dehydration.
|
| 218 |
+
Oral Rehydration Solutions | 91
|
| 219 |
+
|
| 220 |
+
--- End of Page 7 ---
|
| 221 |
+
|
| 222 |
+
Question: Can oral rehydration solutions be used with other medications?
|
| 223 |
+
Answer: Oral rehydration solutions can generally be used with other medications, but it's essential to
|
| 224 |
+
consult with a healthcare professional or pharmacist to ensure compatibility and effectiveness,
|
| 225 |
+
especially if you have underlying health conditions or are taking other medications.
|
| 226 |
+
Question: Do oral rehydration solutions have any side effects?
|
| 227 |
+
Answer: Oral rehydration solutions are generally safe when used as directed, but consuming large
|
| 228 |
+
amounts may lead to electrolyte imbalances, especially in individuals with certain health conditions
|
| 229 |
+
such as kidney disease or heart failure.
|
| 230 |
+
Question: Can oral rehydration solutions be used for other conditions?
|
| 231 |
+
Answer: While ORS is primarily used to prevent or treat dehydration due to diarrhea or vomiting, it
|
| 232 |
+
may also be used to rehydrate individuals during periods of fluid loss due to excessive sweating, fever,
|
| 233 |
+
or heat exhaustion.
|
| 234 |
+
Question: Are there any lifestyle changes that can help reduce the need for oral rehydration solutions?
|
| 235 |
+
Answer: Yes, practicing good hygiene, consuming a balanced diet, staying hydrated, avoiding
|
| 236 |
+
contaminated food and water, and seeking prompt medical attention for conditions such as diarrhea or
|
| 237 |
+
vomiting can help reduce the risk of dehydration and the need for oral rehydration solutions.
|
| 238 |
+
|
| 239 |
+
92 | Oral Rehydration Solutions
|
| 240 |
+
|
| 241 |
+
--- End of Page 8 ---
|
| 242 |
+
|
MEDICINE_TXT/Chapter_16_Sleep_Aids.txt
ADDED
|
@@ -0,0 +1,251 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
CHAPTER
|
| 2 |
+
16
|
| 3 |
+
|
| 4 |
+
Sleep Aids
|
| 5 |
+
Mr. Rahul Kumar Ancheria
|
| 6 |
+
|
| 7 |
+
|
| 8 |
+
Sleep aids, also known as hypnotics or sleep medications, are pharmaceutical agents used to promote
|
| 9 |
+
sleep or improve the quality and duration of sleep in individuals with sleep disturbances or insomnia.
|
| 10 |
+
These medications work by targeting various pathways in the brain involved in regulating sleep-wake
|
| 11 |
+
cycles, neurotransmitter activity, and relaxation of the central nervous system.
|
| 12 |
+
Sleep aids can be classified into different categories based on their mechanism of action, duration of
|
| 13 |
+
action, and route of administration. Common types of sleep aids include:
|
| 14 |
+
1. Sedative-Hypnotics: Sedative-hypnotic medications, such as benzodiazepines (e.g., temazepam,
|
| 15 |
+
triazolam) and non-benzodiazepine receptor agonists (e.g., zolpidem, zaleplon, eszopiclone), act on
|
| 16 |
+
gamma-aminobutyric acid (GABA) receptors in the brain to induce sedation, reduce anxiety, and
|
| 17 |
+
promote sleep onset. These medications are typically used for short-term treatment of insomnia.
|
| 18 |
+
2. Melatonin Receptor Agonists: Melatonin receptor agonists (e.g., ramelteon, tasimelteon) target
|
| 19 |
+
melatonin receptors in the brain's suprachiasmatic nucleus, which regulates the body's circadian
|
| 20 |
+
rhythm and sleep-wake cycle. These medications mimic the effects of the natural hormone melatonin,
|
| 21 |
+
promoting sleep initiation and regulating sleep patterns.
|
| 22 |
+
3. Antidepressants: Some antidepressant medications, particularly those in the selective serotonin
|
| 23 |
+
reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) classes, may be
|
| 24 |
+
prescribed off-label for the treatment of insomnia, especially when co-occurring with depression or
|
| 25 |
+
anxiety disorders. Examples include trazodone, amitriptyline, and doxepin.
|
| 26 |
+
4. Antihistamines: Certain over-the-counter antihistamine medications, such as diphenhydramine
|
| 27 |
+
(Benadryl), doxylamine (Unisom), and promethazine, possess sedating properties and are occasionally
|
| 28 |
+
used as sleep aids due to their ability to induce drowsiness.
|
| 29 |
+
5. Herbal Supplements: Herbal supplements like valerian root, chamomile, and passionflower are
|
| 30 |
+
believed to have mild sedative effects and may be used as natural sleep aids. However, the efficacy and
|
| 31 |
+
safety of these supplements for treating insomnia vary, and more research is needed to establish their
|
| 32 |
+
effectiveness.
|
| 33 |
+
Sleep Aids | 93
|
| 34 |
+
|
| 35 |
+
--- End of Page 1 ---
|
| 36 |
+
|
| 37 |
+
It is important to note that while sleep aids can be effective in the short term for managing sleep
|
| 38 |
+
disturbances, they are not intended for long-term use due to the risk of tolerance, dependence, and
|
| 39 |
+
potential adverse effects. Additionally, lifestyle modifications, cognitive-behavioral therapy for
|
| 40 |
+
insomnia (CBT-I), and addressing underlying medical or psychological conditions are important
|
| 41 |
+
components of comprehensive sleep management approaches. Individuals considering the use of sleep
|
| 42 |
+
aids should consult with a healthcare professional to determine the most appropriate treatment options
|
| 43 |
+
based on their specific needs and circumstances.
|
| 44 |
+
Some examples of OTC medications available for sleep aids:
|
| 45 |
+
1. Diphenhydramine (Benadryl): Diphenhydramine is an antihistamine medication that is
|
| 46 |
+
available OTC and is commonly used for its sedative effects. It can help induce drowsiness and
|
| 47 |
+
promote sleep onset. However, it may cause drowsiness the next day and is not recommended
|
| 48 |
+
for long-term use.
|
| 49 |
+
|
| 50 |
+
[Chapter_16_Sleep_Aids_page2_img1.png]
|
| 51 |
+
|
| 52 |
+
|
| 53 |
+
2. Doxylamine (Unisom): Doxylamine is another antihistamine medication available OTC that is
|
| 54 |
+
used as a sleep aid. Similar to diphenhydramine, it can help with sleep initiation, but it may also
|
| 55 |
+
cause drowsiness and potential next-day drowsiness.
|
| 56 |
+
|
| 57 |
+
[Chapter_16_Sleep_Aids_page2_img2.png]
|
| 58 |
+
|
| 59 |
+
|
| 60 |
+
[Chapter_16_Sleep_Aids_page2_img3.png]
|
| 61 |
+
|
| 62 |
+
|
| 63 |
+
[Chapter_16_Sleep_Aids_page2_img4.png]
|
| 64 |
+
|
| 65 |
+
|
| 66 |
+
[Chapter_16_Sleep_Aids_page2_img5.png]
|
| 67 |
+
|
| 68 |
+
|
| 69 |
+
[Chapter_16_Sleep_Aids_page2_img6.png]
|
| 70 |
+
|
| 71 |
+
|
| 72 |
+
[Chapter_16_Sleep_Aids_page2_img7.png]
|
| 73 |
+
|
| 74 |
+
|
| 75 |
+
[Chapter_16_Sleep_Aids_page2_img8.png]
|
| 76 |
+
|
| 77 |
+
|
| 78 |
+
[Chapter_16_Sleep_Aids_page2_img9.png]
|
| 79 |
+
|
| 80 |
+
|
| 81 |
+
[Chapter_16_Sleep_Aids_page2_img10.png]
|
| 82 |
+
|
| 83 |
+
|
| 84 |
+
[Chapter_16_Sleep_Aids_page2_img11.png]
|
| 85 |
+
|
| 86 |
+
|
| 87 |
+
[Chapter_16_Sleep_Aids_page2_img12.png]
|
| 88 |
+
|
| 89 |
+
|
| 90 |
+
[Chapter_16_Sleep_Aids_page2_img13.png]
|
| 91 |
+
|
| 92 |
+
|
| 93 |
+
[Chapter_16_Sleep_Aids_page2_img14.png]
|
| 94 |
+
|
| 95 |
+
|
| 96 |
+
[Chapter_16_Sleep_Aids_page2_img15.png]
|
| 97 |
+
|
| 98 |
+
|
| 99 |
+
[Chapter_16_Sleep_Aids_page2_img16.png]
|
| 100 |
+
|
| 101 |
+
|
| 102 |
+
94 | Sleep Aids
|
| 103 |
+
|
| 104 |
+
--- End of Page 2 ---
|
| 105 |
+
|
| 106 |
+
3. Melatonin Supplements: Melatonin is a hormone naturally produced by the body that
|
| 107 |
+
regulates the sleep-wake cycle. Melatonin supplements are available OTC and are commonly
|
| 108 |
+
used to help regulate sleep patterns, particularly for individuals experiencing jet lag or shift
|
| 109 |
+
work-related sleep disturbances.
|
| 110 |
+
|
| 111 |
+
[Chapter_16_Sleep_Aids_page3_img1.png]
|
| 112 |
+
|
| 113 |
+
|
| 114 |
+
4. Valerian Root: Valerian root is an herbal supplement that has been used for centuries as a
|
| 115 |
+
natural remedy for insomnia and anxiety. It is believed to have mild sedative effects and can
|
| 116 |
+
help promote relaxation and improve sleep quality. Valerian root supplements are available
|
| 117 |
+
OTC in various forms, including capsules, tablets, and teas.
|
| 118 |
+
|
| 119 |
+
[Chapter_16_Sleep_Aids_page3_img2.png]
|
| 120 |
+
|
| 121 |
+
|
| 122 |
+
|
| 123 |
+
5. Chamomile Tea: Chamomile is an herb that has been traditionally used as a natural remedy for
|
| 124 |
+
insomnia and anxiety. Chamomile tea is caffeine-free and contains compounds that may
|
| 125 |
+
promote relaxation and sleepiness. It is commonly consumed before bedtime to help induce
|
| 126 |
+
sleep.
|
| 127 |
+
|
| 128 |
+
[Chapter_16_Sleep_Aids_page3_img3.png]
|
| 129 |
+
|
| 130 |
+
|
| 131 |
+
Sleep Aids | 95
|
| 132 |
+
|
| 133 |
+
--- End of Page 3 ---
|
| 134 |
+
|
| 135 |
+
6. Lavender Supplements or Essential Oil: Lavender is known for its calming and soothing
|
| 136 |
+
properties. Lavender supplements or essential oil can be used OTC to promote relaxation and
|
| 137 |
+
improve sleep quality. Some people find that inhaling lavender essential oil or using it in
|
| 138 |
+
aromatherapy diffusers before bedtime can help induce sleep.
|
| 139 |
+
|
| 140 |
+
[Chapter_16_Sleep_Aids_page4_img1.png]
|
| 141 |
+
|
| 142 |
+
|
| 143 |
+
7. Magnesium Supplements: Magnesium is a mineral that plays a role in regulating
|
| 144 |
+
neurotransmitters and promoting relaxation. Magnesium supplements are available OTC and
|
| 145 |
+
may help improve sleep quality, particularly in individuals with low magnesium levels.
|
| 146 |
+
|
| 147 |
+
[Chapter_16_Sleep_Aids_page4_img2.png]
|
| 148 |
+
|
| 149 |
+
|
| 150 |
+
It is important to note that while OTC sleep aids can be effective for short-term use in managing sleep
|
| 151 |
+
disturbances, they are not intended for long-term use without consulting a healthcare professional.
|
| 152 |
+
Additionally, individuals should be cautious about potential interactions with other medications or
|
| 153 |
+
medical conditions and should follow recommended dosages and usage instructions. If sleep problems
|
| 154 |
+
persist or worsen, it's important to seek medical advice for proper evaluation and treatment.
|
| 155 |
+
Diphenhydramine as a Sleeping Aid:
|
| 156 |
+
Diphenhydramine is a first-generation antihistamine medication commonly used as a sleep aid due to
|
| 157 |
+
its sedative effects. It is available over-the-counter (OTC) and is widely used to help individuals with
|
| 158 |
+
difficulty falling asleep or staying asleep. Diphenhydramine is also found in various allergy
|
| 159 |
+
medications, where its primary purpose is to relieve symptoms such as itching, sneezing, and runny
|
| 160 |
+
nose caused by allergic reactions.
|
| 161 |
+
96 | Sleep Aids
|
| 162 |
+
|
| 163 |
+
--- End of Page 4 ---
|
| 164 |
+
|
| 165 |
+
|
| 166 |
+
[Chapter_16_Sleep_Aids_page5_img1.png]
|
| 167 |
+
|
| 168 |
+
|
| 169 |
+
Mechanism of Action:
|
| 170 |
+
Diphenhydramine exerts its sedative effects by antagonizing histamine receptors in the brain,
|
| 171 |
+
particularly H1 receptors. Histamine is a neurotransmitter involved in regulating wakefulness and
|
| 172 |
+
arousal. By blocking histamine receptors, diphenhydramine reduces the activity of wake-promoting
|
| 173 |
+
pathways in the brain, leading to drowsiness and facilitating sleep onset.
|
| 174 |
+
Pharmacokinetics:
|
| 175 |
+
After oral administration, diphenhydramine is rapidly absorbed from the gastrointestinal tract and
|
| 176 |
+
reaches peak blood levels within 1 to 2 hours. It has a relatively short half-life of approximately 4 to 6
|
| 177 |
+
hours, meaning its sedative effects may wear off relatively quickly compared to other sleep
|
| 178 |
+
medications. Diphenhydramine is metabolized primarily in the liver and excreted in the urine.
|
| 179 |
+
Indications for Use:
|
| 180 |
+
Diphenhydramine is indicated for the temporary relief of occasional sleeplessness or insomnia. It is
|
| 181 |
+
commonly used by individuals who have difficulty falling asleep or staying asleep, as well as those
|
| 182 |
+
experiencing jet lag or shift work-related sleep disturbances. Diphenhydramine may also be used as an
|
| 183 |
+
adjunctive therapy in the management of allergic conditions that co-occur with sleep disturbances,
|
| 184 |
+
such as allergic rhinitis or urticaria.
|
| 185 |
+
Dosage and Administration:
|
| 186 |
+
The recommended dosage of diphenhydramine for sleep varies depending on factors such as age,
|
| 187 |
+
weight, and individual response to the medication. Typically, adults may take 25 to 50 mg of
|
| 188 |
+
diphenhydramine orally 30 minutes to one hour before bedtime. It is important to follow the dosing
|
| 189 |
+
instructions provided on the product label or as directed by a healthcare professional to avoid
|
| 190 |
+
exceeding the recommended dosage.
|
| 191 |
+
Precautions and Considerations:
|
| 192 |
+
While diphenhydramine can be effective in promoting sleep, there are several precautions and
|
| 193 |
+
considerations to keep in mind:
|
| 194 |
+
● Diphenhydramine may cause drowsiness and impair cognitive and motor function, particularly
|
| 195 |
+
the morning after use. Individuals should avoid activities requiring mental alertness or
|
| 196 |
+
coordination, such as driving or operating heavy machinery, until they know how the
|
| 197 |
+
medication affects them.
|
| 198 |
+
● Long-term use of diphenhydramine as a sleep aid is not recommended due to the risk of
|
| 199 |
+
tolerance, dependence, and potential adverse effects, including dry mouth, blurred vision,
|
| 200 |
+
constipation, and urinary retention.
|
| 201 |
+
Sleep Aids | 97
|
| 202 |
+
|
| 203 |
+
--- End of Page 5 ---
|
| 204 |
+
|
| 205 |
+
● Diphenhydramine may interact with other medications, including sedatives, tranquilizers, and
|
| 206 |
+
monoamine oxidase inhibitors (MAOIs), increasing the risk of additive sedative effects or
|
| 207 |
+
adverse reactions. It is essential to consult a healthcare professional before using
|
| 208 |
+
diphenhydramine concurrently with other medications.
|
| 209 |
+
● Individuals with certain medical conditions, such as narrow-angle glaucoma, urinary retention,
|
| 210 |
+
prostate enlargement, asthma, or chronic obstructive pulmonary disease (COPD), should use
|
| 211 |
+
diphenhydramine with caution and under medical supervision.
|
| 212 |
+
Diphenhydramine is a widely used OTC medication for the management of occasional sleeplessness or
|
| 213 |
+
insomnia. Its sedative effects make it effective in promoting sleep onset and improving sleep quality in
|
| 214 |
+
individuals with sleep disturbances. However, it is essential to use diphenhydramine cautiously,
|
| 215 |
+
following recommended dosages and precautions, and to seek medical advice if sleep problems persist
|
| 216 |
+
or worsen. Additionally, lifestyle modifications and behavioral interventions should be considered as
|
| 217 |
+
part of a comprehensive approach to managing sleep disorders.
|
| 218 |
+
FREQUENTLY ASKED QUESTIONS
|
| 219 |
+
Question: What are sleep aids?
|
| 220 |
+
Answer: Sleep aids are medications or supplements designed to promote sleep or alleviate insomnia by
|
| 221 |
+
inducing drowsiness, reducing anxiety, or improving sleep quality.
|
| 222 |
+
Question: How do sleep aids work?
|
| 223 |
+
Answer: Sleep aids work through various mechanisms, including enhancing the activity of
|
| 224 |
+
neurotransmitters involved in sleep regulation, such as gamma-aminobutyric acid (GABA), serotonin,
|
| 225 |
+
or melatonin, and suppressing wakefulness-promoting neurotransmitters.
|
| 226 |
+
Question: What are some common examples of sleep aids?
|
| 227 |
+
Answer: Common examples of sleep aids include over-the-counter medications such as
|
| 228 |
+
diphenhydramine (found in products like Benadryl or Tylenol PM), doxylamine (found in Unisom),
|
| 229 |
+
prescription medications like zolpidem (Ambien), eszopiclone (Lunesta), or melatonin supplements.
|
| 230 |
+
Question: When should sleep aids be used?
|
| 231 |
+
Answer: Sleep aids should be used to treat short-term insomnia or occasional sleep disturbances, as
|
| 232 |
+
well as to alleviate symptoms of anxiety or jet lag that may affect sleep quality.
|
| 233 |
+
Question: Can sleep aids be used with other medications?
|
| 234 |
+
Answer: Sleep aids can generally be used with other medications, but it's essential to consult with a
|
| 235 |
+
healthcare professional or pharmacist to avoid potential interactions, especially if you have underlying
|
| 236 |
+
health conditions or are taking other medications.
|
| 237 |
+
Question: Do sleep aids have any side effects?
|
| 238 |
+
Answer: Common side effects of sleep aids may include drowsiness, dizziness, confusion, headache,
|
| 239 |
+
dry mouth, or gastrointestinal disturbances. Some medications may also have more serious side effects,
|
| 240 |
+
such as sleepwalking or sleep-related behaviors.
|
| 241 |
+
Question: Can sleep aids be used for other conditions?
|
| 242 |
+
Answer: While sleep aids are primarily used to promote sleep or alleviate insomnia, certain
|
| 243 |
+
medications, such as antihistamines, may also be used to relieve symptoms of allergies or colds.
|
| 244 |
+
Question: Are there any lifestyle changes that can help reduce the need for sleep aids?
|
| 245 |
+
Answer: Yes, practicing good sleep hygiene, such as maintaining a regular sleep schedule, creating a
|
| 246 |
+
relaxing bedtime routine, avoiding stimulants like caffeine or nicotine before bedtime, and creating a
|
| 247 |
+
comfortable sleep environment, can help improve sleep quality and reduce the need for sleep aids.
|
| 248 |
+
98 | Sleep Aids
|
| 249 |
+
|
| 250 |
+
--- End of Page 6 ---
|
| 251 |
+
|